(TOP (NP (NP (NN Induction)) (PP (IN of) (NP (JJ cytokine) (NN expression))) (PP (IN in) (NP (NNS leukocytes))) (PP (IN by) (NP (NP (VBG binding)) (PP (IN of) (NP (JJ thrombin-stimulated) (NNS platelets))))) (. .)))
(TOP (NP (NP (NN BACKGROUND)) (: :) (S (VP (VBN Activated) (S (NP (NNS platelets)) (VP (VBP tether) (CC and) (VBP activate) (NP (JJ myeloid) (NNS leukocytes)))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (JJ potential) (NN relevance)) (PP (IN of) (NP (NP (DT this) (NN mechanism)) (PP (IN in) (NP (NP (JJ acute) (JJ myocardial) (NN infarction)) (PRN (-LRB- -LRB-) (NP (NNP AMI)) (-RRB- -RRB-)))))))))) (, ,) (NP (PRP we)) (VP (VBD examined) (NP (JJ cytokine) (NN induction)) (PP (IN by) (NP (NP (JJ leukocyte-platelet) (NN adhesion)) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ leukocyte-platelet) (NNS conjugates))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP AMI))))))))) (. .)))
(TOP (NP (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (NP (PRP We)) (VP (VBD obtained) (NP (JJ peripheral) (JJ venous) (NN blood) (NNS samples)) (PP (IN in) (NP (CD 20) (NNS patients))) (PP (IN with) (NP (NNP AMI))) (PP (IN before) (CC and) (NP (JJ daily))) (PP (IN for) (NP (CD 5) (NNS days))) (PP (PP (IN after) (NP (NP (JJ direct) (JJ percutaneous) (JJ transluminal) (JJ coronary) (NN angioplasty)) (PRN (-LRB- -LRB-) (NP (NNP PTCA)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (CD 20) (NNS patients)) (VP (VBG undergoing) (NP (JJ elective) (NNP PTCA)))))))) (. .)))
(TOP (S (PP (IN Throughout) (NP (DT the) (NN study) (NN period))) (, ,) (NP (NP (NP (JJ CD41) (NN immunofluorescence)) (PP (IN of) (NP (NNS leukocytes)))) (PRN (-LRB- -LRB-) (NP (NN flow) (NN cytometry)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (NP (VBN increased) (JJ leukocyte-platelet) (NN adhesion)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP AMI))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN control) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ mean) (JJ +/-) (NN SE)) (PP (IN of) (NP (JJ fluorescence) (NNP -LSB-) (NNS channels) (NNP -RSB-))) (PP (IN before) (NP (NNP PTCA)))) (: :) (NP (NP (CD 77)) (PP (NN +/-) (NP (CD 16))) (PP (IN versus) (NP (NP (CD 35)) (PP (NN +/-) (NP (CD 9))))))) (: ;) (S (NP (NNP P)) (VP (SYM =) (NP (CD .003)))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN vitro))) (, ,) (NP (JJ thrombin-stimulated) (JJ fixed) (NNS platelets)) (VP (VBN bound) (PP (TO to) (NP (NNS neutrophils) (CC and) (NNS monocytes)))) (. .)))
(TOP (S (PP (IN Within) (NP (CD 2) (NNS hours))) (, ,) (NP (DT this)) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN increased) (NN mRNA)) (PP (IN for) (NP (NP (NP (NN interleukin)) (PRN (-LRB- -LRB-) (NP (NNP IL)) (-RRB- -RRB-))) (, ,) (NP (CD 1) (NN beta)) (, ,) (NP (NN IL-8)) (, ,) (CC and) (NP (NP (JJ monocyte) (NN chemoattractant) (NN protein)) (PRN (-LRB- -LRB-) (NP (NNP MCP)) (-RRB- -RRB-)) (NP (NP (CD -1)) (PP (IN in) (NP (JJ unfractionated) (NNS leukocytes)))))))))) (. .)))
(TOP (S (PP (IN After) (NP (CD 4) (NNS hours))) (, ,) (S (NP (NP (JJ IL-1) (NN beta)) (CC and) (NP (NP (NN IL-8) (NN concentration)) (PP (IN of) (NP (DT the) (JJ cell-free) (NN supernatant))))) (VP (VBD had) (VP (VBN increased) (PP (IN by) (NP (CD 268))) (NP (QP (CD +/-) (CD 36)) (NN %))))) (CC and) (S (NP (NP (NP (NP (CD 210) (NN +/-)) (NP (CD 7) (NN %))) (, ,) (ADVP (RB respectively)) (, ,)) (CC and) (NP (JJ cellular) (NN MCP-1) (NN content))) (VP (VBD had) (VP (VBN increased) (PP (IN by) (NP (CD 170) (NN +/-))) (NP (CD 8) (NN %))))) (. .)))
(TOP (S (NP (NP (NN Addition)) (PP (IN of) (NP (NP (VBN activated) (NNS platelets)) (PP (TO to) (NP (JJ adherent) (NNS monocytes)))))) (VP (VP (VBD had) (NP (DT a) (JJ similar) (NN effect))) (CC and) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (JJ nuclear) (NN factor-kappa) (NN B) (NN activation)))))) (. .)))
(TOP (S (NP (NP (NNP Inhibition)) (PP (IN of) (NP (VBG binding))) (PP (IN by) (NP (JJ anti-P) (NN selectin) (NNS antibodies)))) (VP (VBD reduced) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (VBN activated) (NNS platelets)) (PP (IN on) (NP (JJ cytokine) (NN production))))))) (. .)))
(TOP (NP (NP (NNS CONCLUSIONS)) (: :) (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP AMI))))) (, ,) (NP (JJ leukocyte-platelet) (NN adhesion)) (VP (VBZ is) (VP (VBN increased)))) (. .)))
(TOP (S (S (VP (VBG Binding) (PP (IN of) (NP (VBN activated) (NNS platelets))))) (VP (VBZ induces) (NP (NP (NP (JJ IL-1) (NN beta)) (, ,) (NP (NN IL-8)) (, ,)) (CC and) (NP (NP (NN MCP-1)) (PP (IN in) (NP (NNS leukocytes)))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ leukocyte-platelet) (NN adhesion)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS responses)) (PP (IN in) (NP (NNP AMI))))))))))) (. .)))
(TOP (NP (NP (NP (JJ Defective) (NN survival)) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NP (NNS thymocytes)) (PP (IN in) (NP (JJ transgenic) (NNS mice))))))) (VP (VBG expressing) (NP (NP (DT a) (ADJP (RB catalytically) (JJ inactive)) (NN form)) (PP (IN of) (NP (JJ Ca2+/calmodulin-dependent) (NN protein) (NN kinase) (NNP IV))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN generated) (NP (NP (JJ transgenic) (NNS mice)) (SBAR (WHNP (WDT that)) (S (VP (VBP express) (NP (NP (DT a) (ADJP (RB catalytically) (JJ inactive)) (NN form)) (PP (IN of) (NP (NP (JJ Ca2+/calmodulin-dependent) (NN protein) (NN kinase) (NNP IV)) (PRN (-LRB- -LRB-) (NP (NNP CaMKIV)) (-RRB- -RRB-))))) (PP (ADVP (RB specifically)) (IN in) (NP (JJ thymic) (NNP T) (NNS cells))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (DT this) (NN protein)))) (VP (VBZ results) (PP (IN in) (NP (DT a) (ADJP (RB markedly) (VBN reduced)) (JJ thymic) (NN cellularity))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (DT the) (VBG remaining) (NNS cells)))) (VP (VBZ is) (ADJP (RB normal)) (PP (VBN based) (PP (IN on) (NP (NP (NN evaluation)) (PP (IN of) (NP (DT the) (NNP CD4) (CC and) (NNP CD8) (NN cell) (NN surface) (NNS antigens))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN used) (S (VP (TO to) (VP (VB gauge) (NP (NNP T) (NN cell) (NN development)))))))))))))))) (. .)))
(TOP (S (NP (NP (VBN Isolated) (JJ thymic) (NNP T) (NNS cells)) (PP (IN from) (NP (DT the) (JJ transgenic) (NNS mice)))) (ADVP (RB also)) (VP (VBP show) (NP (NP (DT a) (ADJP (RB dramatically) (VBN decreased)) (NN survival) (NN rate)) (SBAR (WHADVP (WRB when)) (S (VP (VBN evaluated) (PP (IN in) (NP (NN culture))) (PP (IN under) (NP (NP (NNS conditions)) (SBAR (WHNP (WDT that)) (S (VP (VBP do) (RB not) (VP (VB favor) (NP (NN activation))))))))))))) (. .)))
(TOP (S (SBAR (WHADVP (WRB When)) (S (VP (VBN challenged) (PP (IN with) (NP (NP (DT an) (VBG activating) (NN stimulus)) (PP (JJ such) (IN as) (NP (NP (NN alpha-CD3)) (CC or) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NN phorbol) (NN ester)) (CC plus) (NP (NN ionophore)))))))))))) (, ,) (NP (DT the) (NNS cells)) (VP (VBP are) (VP (ADVP (RB severely)) (VBN compromised) (PP (IN in) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB produce) (NP (NP (DT the) (JJ cytokine) (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP (NP (NN Reduction)) (PP (IN of) (NP (NN IL-2) (NN production)))) (VP (VBZ is) (ADJP (JJ secondary) (PP (TO to) (NP (DT the) (NN inability) (S (VP (TO to) (VP (VP (VB phosphorylate) (NP (NP (DT the) (NNP cAMP) (NN response) (NN element)) (VP (VBG binding) (NP (NP (NN protein)) (, ,) (NP (NNP CREB)) (, ,))))) (CC and) (VP (VB induce) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ immediate) (JJ early) (NNS genes)) (PP (JJ such) (IN as) (NP (NNP Fos) (NNP B))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN required) (S (VP (TO to) (VP (VB transactivate) (NP (DT the) (NN IL-2) (NN promoter)))))))))))))))))))) (. .)))
(TOP (S (SBAR (IN Because) (S (S (NP (JJ transgene) (NN expression)) (VP (VBD was) (VP (VBN regulated) (PP (IN by) (NP (NP (DT the) (JJ proximal) (NN promoter)) (PP (IN of) (NP (DT the) (JJ murine) (NN lck) (NN gene)))))))) (CC and) (S (NP (DT this) (NN promoter)) (VP (VBZ is) (VP (VBN inactivated) (PP (IN in) (NP (NP (NNP T) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP exit) (NP (DT the) (NN thymus)))))))))))) (, ,) (NP (DT the) (JJ mutant) (NNP hCaMKIV)) (VP (VBZ is) (RB not) (ADJP (JJ present) (PP (IN in) (NP (JJ peripheral) (NNP T) (NNS cells))))) (. .)))
(TOP (S (ADVP (RB Consequently)) (, ,) (NP (NP (NNP T) (VBZ lymphocytes)) (ADJP (JJ present) (PP (IN in) (NP (DT the) (NN spleen))))) (VP (MD can) (VP (VB be) (VP (VBN activated) (ADVP (RB normally)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT either) (NN stimulus)) (VP (VBD mentioned) (ADVP (IN above))))))) (, ,) (S (VP (VBG demonstrating) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (JJ inactive) (NNP CaMKIV))) (PP (IN on) (NP (NN activation)))) (VP (VBP are) (ADJP (JJ reversible)))))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NNP CaMKIV)) (VP (MD may) (VP (VB represent) (NP (NP (DT a) (ADJP (RB physiologically) (JJ relevant)) (NNP CREB) (NN kinase)) (PP (IN in) (NP (NNP T) (NNS cells)))))))) (CC and) (SBAR (IN that) (S (NP (DT the) (NN enzyme)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN required) (S (VP (TO to) (VP (VB ensure) (NP (NP (JJ normal) (NN expansion)) (PP (IN of) (NP (NP (NNP T) (NNS cells)) (PP (IN in) (NP (DT the) (NN thymus))))))))))))))) (. .)))
(TOP (S (SBAR (IN Whereas) (S (NP (NP (DT the) (NN pathway)) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (JJ latter) (NN role))))) (VP (VBZ is) (ADVP (RB yet)) (S (VP (TO to) (VP (VB be) (VP (VBN elucidated)))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB include) (NP (NNP CREB) (NN phosphorylation))))))) (. .)))
(TOP (S (NP (DT The) (NN class) (NNP II) (NN trans-activator) (NNP CIITA)) (VP (VBZ interacts) (PP (IN with) (NP (DT the) (JJ TBP-associated) (NN factor) (NN TAFII32)))) (. .)))
(TOP (S (NP (NP (DT The) (NN class) (NNP II) (NNP trans-activator)) (PRN (-LRB- -LRB-) (NP (NNP CIITA)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT the) (JJ main) (JJ transcriptional) (NN co-activator)) (PP (IN for) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP MHC) (NN class) (NNP II) (NNS proteins))))))) (. .)))
(TOP (S (NP (PRP$ Its) (JJ N-terminal) (CD 125) (JJ amino) (NNS acids)) (VP (VBP function) (PP (IN as) (NP (DT an) (JJ independent) (JJ transcriptional) (NN activation) (NN domain)))) (. .)))
(TOP (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (NP (DT the) (JJ primary) (JJ amino) (NN acid) (NN sequence)) (PP (IN of) (NP (DT the) (NN activation) (NN domain)))))) (VP (VBP predict) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (CD three) (NNS alpha-helices)) (, ,) (NP (NP (DT each)) (PP (IN with) (NP (NP (DT a) (JJ high) (NN proportion)) (PP (IN of) (NP (JJ acidic) (NNS residues)))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (JJ site-directed) (NNS mutagenesis)))) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (CD two)) (PP (IN of) (NP (DT these) (VBN predicted) (NNS alpha-helices)))) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NP (JJ full) (JJ transcriptional) (NN activation)) (PP (IN by) (NP (NNP CIITA)))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT a) (NNP CIITA) (NN protein)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT both) (JJ functional) (NNS alpha-helices)) (VP (VBP have) (VP (VBN been) (VP (VBN deleted))))))) (VP (NNS displays) (NP (DT a) (JJ dominant) (JJ negative) (NN phenotype))) (. .)))
(TOP (S (NP (NP (DT This) (NN activation) (NN domain)) (PP (IN of) (NP (NNP CIITA)))) (VP (NNS interacts) (PP (IN with) (NP (NP (DT the) (CD 32) (NN kDa) (NN subunit)) (PP (IN of) (NP (NP (DT the) (JJ general) (NN transcription) (NN complex) (NNP TFIID)) (, ,) (NP (NNP TAFII32))))))) (. .)))
(TOP (S (NP (NP (JJ Decreased) (JJ transcriptional) (NN activation)) (PP (IN by) (NP (NP (JJ N-terminal) (NNS deletions)) (PP (IN of) (NP (NNP CIITA)))))) (VP (VBZ is) (VP (VBN correlated) (ADVP (RB directly)) (PP (IN with) (NP (NP (PRP$ their) (VBN reduced) (VBG binding)) (PP (TO to) (NP (NNP TAFII32))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NNS interactions)) (PP (IN between) (NP (NNP TAFII32) (CC and) (NNP CIITA)))) (VP (VBP are) (ADJP (JJ responsible) (PP (IN for) (NP (NP (NN activation)) (PP (IN of) (NP (NN class) (NNP II) (NNS genes)))))))))) (. .)))
(TOP (NP (NP (JJ Specific) (JJ complex) (NN formation)) (PP (IN between) (NP (NP (DT the) (NN type) (NNP II)) (SBAR (S (NP (JJ bare) (NN lymphocyte)) (VP (VBD syndrome-associated) (NP (NNS transactivators) (NNP CIITA) (CC and) (NNP RFX5))))))) (. .)))
(TOP (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (ADJP (JJ defective) (PP (IN in) (NP (NP (DT the) (CD five) (NN complementation) (NNS groups)) (VP (VBN identified) (PP (IN in) (NP (DT the) (NN class))) (NP (NP (JJ II-negative) (JJ bare) (NN lymphocyte) (NN syndrome)) (CC or) (NP (JJ corresponding) (NN laboratory) (NNS mutants)))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN cloned)))) (. .)))
(TOP (S (NP (CD One) (NN gene)) (VP (VBZ encodes) (NP (NP (DT a) (NN protein)) (, ,) (NP (NNP RFX5)) (, ,)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (NP (NP (DT a) (NN member)) (PP (IN of) (NP (NP (DT the) (NNP RFX) (NN family)) (PP (IN of) (NP (NNP DNA) (VBG binding) (NNS proteins)))))))))) (. .)))
(TOP (S (S (NP (NP (DT The) (JJ other)) (, ,) (NP (NNP CIITA)) (, ,)) (VP (VBZ encodes) (NP (DT a) (JJ large) (NN protein)) (PP (IN with) (NP (DT a) (VBN defined) (JJ acidic) (JJ transcriptional) (NN activation) (NN domain))))) (: ;) (S (NP (DT this) (NN protein)) (VP (VBZ does) (RB not) (VP (VB interact) (PP (IN with) (NP (NNP DNA)))))) (. .)))
(TOP (S (NP (NP (NN Expression) (NNS plasmids)) (VP (VBG encoding) (NP (NP (NNS regions)) (PP (IN of) (NP (NNP RFX5))) (VP (VBD fused) (PP (TO to) (NP (DT the) (NNP GAL4) (NNP DNA) (VBG binding) (NN domain))))))) (VP (VBD activated) (NP (NN transcription)) (PP (IN from) (NP (NP (DT a) (NN reporter) (VB construct)) (VP (VBG containing) (NP (NP (NNP GAL4) (NNS sites)) (PP (IN in) (NP (NP (DT a) (NN cotransfection) (NN assay)) (PP (IN in) (NP (DT the) (NNP Raji) (JJ human) (NN B) (NN cell) (NN line)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (DT these) (NNS plasmids)) (VP (VBD produced) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN in) (NP (JJ HeLa) (NNS cells)))) (PP (ADVP (RB only)) (IN in) (NP (NP (NP (NN conjunction)) (PP (IN with) (NP (NN interferon) (NN gamma) (NN stimulation)))) (, ,) (NP (NP (DT a) (NN condition)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NN expression)) (PP (IN of) (NP (DT both) (NNP CIITA) (CC and) (NN class) (NNP II) (JJ major) (NN histocompatibility) (NN complex) (NN surface) (NNS proteins)))) (VP (VBP are) (ADJP (JJ induced.)))))))))))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (DT these) (NNS plasmids)) (VP (VBD were) (RB not) (ADJP (JJ active)) (PP (IN in) (NP (NP (NNP RJ2.2.5)) (, ,) (NP (NP (DT an)) (PP (IN in) (NP (NP (NN vitro) (JJ mutagenized) (NN derivative)) (PP (IN of) (NP (NNP Raji))))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT both) (NNS copies)) (PP (IN of) (NP (NNP CIITA)))) (VP (VBP are) (ADJP (JJ defective))))))))) (. .)))
(TOP (S (NP (NP (JJ Transcriptional) (NN activation)) (PP (IN by) (NP (DT the) (NNP RFX5) (NN fusion) (NN protein)))) (VP (MD could) (VP (VB be) (VP (VBN restored) (PP (IN in) (NP (NNP RJ2.2.5))) (PP (IN by) (NP (NN cotransfection))) (PP (IN with) (NP (DT a) (NNP CIITA) (NN expression) (NN plasmid)))))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (NP (NP (DT a) (JJ direct) (NN interaction)) (PP (IN between) (NP (NNP RFX5) (CC and) (NNP CIITA)))) (VP (VBD was) (VP (VBN detected) (PP (IN with) (NP (DT the) (NN yeast) (JJ two-hybrid) (CC and) (JJ far-Western) (NN blot) (NNS assays))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NNP RFX5)) (VP (MD can) (VP (VB activate) (NP (NN transcription)) (PP (ADVP (RB only)) (IN in) (NP (NP (NN cooperation)) (PP (IN with) (NP (NNP CIITA))))))) (. .)))
(TOP (S (NP (NNP RFX5) (CC and) (NNP CIITA)) (VP (VBP associate) (S (VP (TO to) (VP (VB form) (NP (NP (DT a) (NN complex)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG activating) (NP (NN transcription)) (PP (IN from) (NP (NN class) (NNP II) (JJ major) (NN histocompatibility) (NN complex) (NNS promoters)))))))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (DT this) (NN complex))) (, ,) (NP (NN promoter) (NN specificity)) (VP (VBZ is) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN DNA) (VBG binding) (NN domain)) (PP (IN of) (NP (NNP RFX5)))))))) (CC and) (S (NP (DT the) (JJ general) (NN transcription) (NN apparatus)) (VP (VBZ is) (VP (VBN recruited) (PP (IN by) (NP (NP (DT the) (JJ acidic) (NN activation) (NN domain)) (PP (IN of) (NP (NNP CIITA)))))))) (. .)))
(TOP (S (S (NP (NN CCAAT/enhancer) (VBG binding) (NN protein) (NN epsilon)) (VP (VBZ is) (ADJP (RB preferentially) (JJ up-regulated)) (PP (IN during) (NP (JJ granulocytic) (NN differentiation))))) (CC and) (S (NP (PRP$ its) (JJ functional) (NN versatility)) (VP (VBZ is) (VP (VBN determined) (PP (IN by) (NP (NP (JJ alternative) (NN use)) (PP (IN of) (NP (NP (NNS promoters)) (CC and) (NP (NN differential) (NN splicing))))))))) (. .)))
(TOP (S (NP (NNP CCAAT/enhancer) (JJ binding) (NN protein) (PRN (-LRB- -LRB-) (NNP C/EBP) (-RRB- -RRB-)) (NN epsilon)) (VP (VP (VBZ is) (NP (NP (DT a) (ADJP (RB recently) (VBN cloned)) (NN member)) (PP (IN of) (NP (NP (DT the) (NNP C/EBP) (NN family)) (PP (IN of) (NP (NN transcription) (NNS factors))))))) (CC and) (VP (VBZ is) (VP (VBN expressed) (PP (ADVP (RB exclusively)) (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (JJ hematopoietic) (NN origin)))))))) (. .)))
(TOP (S (NP (DT The) (JJ human) (NNP C/EBPepsilon) (NN gene)) (VP (VBZ is) (VP (VBN transcribed) (PP (IN by) (NP (NP (CD two) (JJ alternative) (NNS promoters)) (, ,) (NP (NNP Palpha)) (CC and) (NP (NNP Pbeta)))))) (. .)))
(TOP (S (NP (NP (DT A) (NN combination)) (PP (IN of) (NP (NP (NN differential) (NN splicing)) (CC and) (NP (NP (NN alternative) (NN use)) (PP (IN of) (NP (NNS promoters))))))) (VP (VBZ generates) (NP (NP (CD four) (NNP mRNA) (NNS isoforms)) (, ,) (PP (IN of) (NP (NP (CD 2.6) (NN kb)) (CC and) (NP (NP (CD 1.3-1.5) (NN kb)) (PP (IN in) (NP (NN size)))))))) (. .)))
(TOP (S (NP (DT These) (NNS transcripts)) (VP (MD can) (VP (VB encode) (NP (NP (CD three) (NNS proteins)) (PP (IN of) (NP (NP (JJ calculated) (JJ molecular) (NN mass) (CD 32.2) (NNP kDa)) (, ,) (NP (CD 27.8) (NNP kDa)) (, ,) (CC and) (NP (CD 14.3) (NN kDa))))))) (. .)))
(TOP (S (ADVP (RB Accordingly)) (, ,) (NP (NP (JJ Western) (NNS blots)) (PP (IN with) (NP (NP (NNS antibodies) (JJ specific)) (PP (IN for) (NP (DT the) (JJ DNA-binding) (NN domain))))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ common) (PP (TO to) (NP (DT all) (NNS forms))))))) (, ,)) (VP (VB identify) (NP (JJ multiple) (NNS proteins))) (. .)))
(TOP (S (NP (NNP C/EBPepsilon) (NNP mRNA)) (VP (VBD was) (VP (ADVP (RB greatly)) (VBN induced) (PP (IN during) (PP (IN in) (NP (NP (NN vitro) (JJ granulocytic) (NN differentiation)) (PP (IN of) (NP (JJ human) (JJ primary) (NN CD34-LRB-+-RRB-) (NNS cells)))))))) (. .)))
(TOP (S (NP (NP (JJ Retinoic) (NN acid) (NN treatment)) (PP (IN of) (NP (NNP HL60) (JJ promyelocytic) (NN leukemia) (NNS cells))) (PP (IN for) (NP (CD 24) (NN hr)))) (VP (VBD induced) (NP (NNP C/EBPepsilon) (NNP mRNA) (NNS levels)) (PP (IN by) (NP (CD 4-fold))) (, ,) (SBAR (IN while) (S (NP (VBN prolonged) (NN treatment)) (VP (ADVP (RB gradually)) (VBN reduced) (NP (NNP mRNA) (NN expression)) (PP (TO to) (NP (NN pretreatment) (NNS levels))))))) (. .)))
(TOP (S (NP (NP (JJ Transient) (NN transfection) (NNS experiments)) (PP (IN with) (NP (NN expression) (NNS vectors))) (PP (IN for) (NP (NP (CD two)) (PP (IN of) (NP (DT the) (NNS isoforms)))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT the) (JJ 32.2-kDa) (NN protein)) (VP (VBZ is) (NP (NP (DT an) (NN activator)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (JJ granulocyte) (JJ colony-stimulating) (NN factor) (NN receptor) (NN promoter)))))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ 14.3-kDa) (NN protein)) (VP (VBZ is) (RB not)))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NNP C/EBPepsilon)) (VP (VP (VBZ is) (VP (VBN regulated) (PP (IN in) (NP (DT a) (JJ complex) (NN fashion))))) (CC and) (VP (MD may) (VP (VB play) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (JJ myeloid) (NN differentiation)))))))))))) (. .)))
(TOP (NP (NP (JJ Transcriptional) (NN activity)) (CC and) (NP (NP (JJ constitutive) (JJ nuclear) (NN localization)) (PP (IN of) (NP (DT the) (NNP ETS) (NN protein) (NN Elf-1)))) (. .)))
(TOP (S (NP (NN Elf-1)) (VP (VBZ is) (NP (NP (DT a) (JJ lymphoid-specific) (NN transcription) (NN factor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ belongs) (PP (TO to) (NP (DT the) (NNP ETS) (NN protein) (NN family)))))))) (. .)))
(TOP (S (NP (PRP It)) (VP (MD can) (VP (NN bind) (PP (TO to) (NP (NN DNA) (NN target) (NNS sequences))) (PP (IN within) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ cytokine) (NNS genes))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP demonstrate) (SBAR (DT that) (S (NP (NN Elf-1)) (VP (VBZ is) (VP (ADVP (RB constitutively)) (VBN localized) (PP (IN in) (NP (NP (DT the) (NN nucleus)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ amino) (NNS acids)) (NP (CD 86-265))))))))))))))))) (. .)))
(TOP (S (NP (NP (NN Analysis)) (PP (IN of) (NP (JJ Gal4-Elf-1) (NN fusion) (NNS proteins)))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (JJ N-terminal) (CD 86) (JJ amino) (NNS acids)) (PP (IN of) (NP (NN Elf-1)))) (VP (VBP contain) (NP (NP (DT a) (JJ transcriptional) (NN activation) (NN domain)) (, ,) (SBAR (WHNP (NP (DT the) (NN activity)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBZ is) (VP (VBN attenuated) (PP (IN by) (NP (DT an) (JJ internal) (NN repression) (NN domain)))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (JJ Elf-1)) (VP (VP (NNS interacts) (ADVP (RB specifically)) (PP (IN with) (NP (DT the) (NNP E74) (NN target) (NN sequence)))) (CC and) (VP (MD can) (VP (VB stimulate) (NP (NP (NN transcription)) (VP (VBN driven) (PP (IN by) (NP (NP (DT the) (NNP E74) (NN site)) (ADJP (JJ independent) (PP (IN of) (NP (JJ mitogenic) (VBG signaling))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NNP Elf-1)) (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB stimulate) (NP (NP (NN gene) (NN transcription)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN development) (CC and) (NN activity)) (PP (IN of) (NP (NNS lymphocytes)))))))))))))))) (. .)))
(TOP (S (NP (NNP Histamine)) (VP (VBZ modulates) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNS c-fos)))) (PP (IN through) (NP (JJ cyclic) (NNP AMP) (NN production))) (PP (IN via) (NP (NP (DT the) (NNP H2) (NN receptor)) (PP (IN in) (NP (DT the) (JJ human) (JJ promonocytic) (NN cell) (NN line) (NNP U937)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN histamine)) (CC and) (NP (PRP$ its) (NNS agonists)))) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS c-fos)) (CC and) (NP (JJ c-myc) (NNS proto-oncogenes))))))) (PP (IN at) (NP (NP (DT the) (ADJP (JJ transcriptional) (CC and) (JJ translational)) (NNS levels)) (PP (IN in) (NP (DT the) (JJ human) (JJ promonocytic) (NNP U937) (NN cell) (NN line)))))) (. .)))
(TOP (S (NP (NNP Histamine)) (VP (ADVP (RB transiently)) (VBD increased) (NP (UCP (JJ cAMP) (CC and) (JJ c-fos)) (NN expression)) (PP (IN through) (NP (NN H2) (NNS receptors)))) (. .)))
(TOP (S (S (NP (NNP Dibutyryl) (NNP cAMP)) (ADVP (RB also)) (VP (VBD increased) (NP (JJ c-fos) (NN mRNA) (CC and) (NN protein)))) (, ,) (CC and) (S (NP (NNS levels)) (VP (VBD remained) (VP (VBN elevated) (PP (ADVP (RB even)) (IN after) (NP (NP (CD 12) (NN hr)) (PP (IN of) (NP (NN treatment)))))))) (. .)))
(TOP (S (NP (NP (NN Dose-dependence) (NNS studies)) (VP (VBG using) (NP (NN histamine) (CC and) (NN dimaprit)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NNP EC50) (NNS values)) (PP (IN for) (NP (NP (NNP cAMP) (NN production)) (CC and) (NP (JJ c-fos) (NN increase))))) (VP (VBD were) (ADJP (JJ similar))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNP cAMP)) (VP (MD might) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (JJ c-fos) (NN induction))) (PP (IN via) (NP (NNP H2) (NNS receptors))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (NNS studies)) (VP (VBD carried) (PRT (RP out)) (S (VP (VBG using) (NP (NP (NNP H7)) (, ,) (NP (DT a) (NN protein) (NN kinase) (NNP A/protein) (FW kinase) (NNP C) (NN inhibitor)) (, ,)) (NP (VBD blocked) (JJ c-fos) (NN induction)))) (, ,) (SBAR (IN whereas) (S (NP (DT no) (NN effect)) (VP (VBD was) (VP (VBN observed) (PP (IN with) (NP (NP (NN bisindolylmaleimide)) (, ,) (NP (DT a) (JJ specific) (NN protein) (NN kinase) (NNP C) (NN inhibitor))))))))) (. .)))
(TOP (S (NP (NP (DT No) (NN modification)) (PP (IN of) (NP (JJ c-myc) (NN expression)))) (VP (MD could) (VP (VB be) (VP (VBN detected) (PP (IN on) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN histamine)) (CC or) (NP (PRP$ its) (NNS analogues))))))))) (. .)))
(TOP (S (ADVP (RB Nevertheless)) (, ,) (NP (NN dibutyryl) (NNP cAMP)) (VP (VBD induced) (NP (NP (DT a) (NN down-regulation)) (PP (IN of) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (DT this) (NN proto-oncogene))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN dibutyryl) (NNP cAMP)) (VP (VBD inhibited) (NP (NN cell) (NN growth)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (, ,) (SBAR (IN whereas) (S (NP (NN histamine)) (VP (VBD failed) (S (VP (TO to) (VP (VB affect) (NP (NP (NN proliferation) (CC and) (NN differentiation)) (PP (IN of) (NP (NNP U937) (NNS cells))))))))))) (. .)))
(TOP (S (NP (NP (NNS Cells)) (VP (VBN pretreated) (PP (IN with) (NP (NN dimaprit))))) (VP (VBD showed) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NNP cAMP) (NN response)) (PP (TO to) (NP (NP (JJ subsequent) (NN addition)) (PP (IN of) (NP (NN H2) (NNS agonists)))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NNP cAMP) (NN response)) (PP (TO to) (NP (NN prostaglandin) (NN E2)))) (VP (VBD remained) (ADJP (JJ unaltered)))))) (. .)))
(TOP (S (NP (NP (DT This) (RB homologous) (NN mechanism)) (PP (IN of) (NP (NN H2) (NN receptor) (NN desensitization)))) (VP (VBD was) (ADJP (NP (NN time)) (JJ dependent))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (DT that) (S (NP (NN histamine)) (VP (VP (VBZ activates) (NP (NP (JJ several) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN differentiation))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP cAMP)) (CC and) (NP (JJ c-fos) (NN production))))))))) (, ,) (CC but) (VP (VBZ fails) (S (VP (TO to) (VP (VB promote) (NP (NP (NN differentiation)) (PP (IN of) (NP (NNP U937) (NNS cells))))))) (, ,) (PP (ADVP (RB apparently)) (JJ due) (PP (TO to) (NP (NP (DT the) (JJ rapid) (NN desensitization)) (PP (IN of) (NP (NN H2) (NNS receptors))))))))))) (. .)))
(TOP (S (NP (JJ Human) (NNS cytomegalovirus)) (VP (VBZ induces) (NP (JJ interleukin-8) (NN production)) (PP (IN by) (NP (NP (DT a) (JJ human) (JJ monocytic) (NN cell) (NN line)) (, ,) (NP (CD THP-1)) (, ,))) (PP (IN through) (S (VP (VBG acting) (ADVP (RB concurrently)) (PP (IN on) (NP (NP (NP (NN AP-1-)) (CC and) (NP (JJ NF-kappaB-binding) (NNS sites))) (PP (IN of) (NP (DT the) (JJ interleukin-8) (NN gene))))))))) (. .)))
(TOP (S (NP (NNP Cytomegalovirus) (PRN (-LRB- -LRB-) (NNP CMV) (-RRB- -RRB-)) (NN infection)) (VP (VBD induced) (NP (JJ interleukin-8) (PRN (-LRB- -LRB-) (NN IL-8) (-RRB- -RRB-)) (NN gene) (NN transcription)) (PP (IN in) (NP (NP (DT a) (JJ human) (JJ monocytic) (NN cell) (NN line)) (, ,) (NP (NN THP-1) (NNS cells)) (, ,))) (S (VP (VBG leading) (PP (TO to) (NP (NN IL-8) (NN secretion)))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ functional) (NN analysis)) (PP (IN of) (NP (DT the) (NN IL-8) (NN gene)))) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT both) (NNP AP-1-) (CC and) (NNP NF-kappaB) (JJ factor-binding) (NNS elements)) (VP (VBD were) (VP (VBN involved) (PP (IN in) (S (VP (VBG conferring) (NP (DT the) (NN responsiveness)) (PP (TO to) (NP (NNP CMV))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NNP CMV)) (VP (VBD induced) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NNP NF-kappaB) (CC and) (NNP AP-1) (NNS complexes)))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP CMV)) (VP (VBZ activates) (NP (DT these) (JJ transcriptional) (NNS factors)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NN IL-8) (NN gene) (NN expression))))))))) (. .)))
(TOP (NP (NP (NP (JJ Concomitant) (NN downregulation)) (PP (IN of) (NP (NP (NNP IgH) (CD 3') (NN enhancer) (NN activity)) (CC and) (NP (JJ c-myc) (NN expression)))) (PP (IN in) (NP (DT a) (NN plasmacytoma) (LS x) (JJ fibroblast) (NN environment)))) (: :) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NN dysregulation)) (PP (IN of) (NP (VBN translocated) (JJ c-myc)))))) (. .)))
(TOP (S (NP (NP (NN Regulation)) (PP (IN of) (NP (JJ immunoglobulin) (JJ heavy) (NN chain) (PRN (-LRB- -LRB-) (NNP IgH) (-RRB- -RRB-)) (NN gene) (NN expression)))) (VP (VBZ is) (VP (VBN controlled) (PP (IN by) (NP (NP (NP (DT a) (NNP B) (JJ cell-specific) (NN promoter)) (, ,) (NP (JJ intronic) (NN enhancer)) (CC and) (NP (JJ additional) (NNP B) (JJ cell-specific) (NN enhancer) (NNS elements))) (VP (VBN identified) (ADVP (RB recently)) (PP (IN in) (NP (NP (DT the) (CD 3') (NN end)) (PP (IN of) (NP (DT the) (NNP IgH) (NN locus)))))))))) (. .)))
(TOP (S (S (NP (NP (NP (CD One)) (PP (IN of) (NP (DT the) (JJ latter) (NNS elements)))) (, ,) (NP (DT the) (NNP IgH) (CD 3') (NN enhancer)) (, ,)) (VP (VBZ is) (PP (IN of) (NP (JJ particular) (NN interest))))) (: :) (S (NP (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (PRP it)) (VP (VBZ is) (ADJP (NNP B) (JJ cell-specific) (CC and) (JJ active)) (PP (ADVP (RB only)) (IN in) (NP (JJ late) (NNP B) (NN cell) (NN development))))) (: ;) (S (S (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (PP (IN in) (NP (NN rodent) (NNS plasmacytomas))) (CC and) (PP (IN in) (NP (NP (DT some) (JJ human) (NNP Burkitt) (POS 's)) (NNS lymphomas))) (SBAR (S (NP (PRP it)) (VP (VBZ is) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (NN locus) (NN control) (NN region)) (PRN (-LRB- -LRB-) (NP (NNP LCR)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (NN deregulation)) (PP (IN of) (NP (DT the) (JJ c-myc) (NN oncogene))))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN translocation)) (PP (IN into) (NP (DT the) (NNP IgH) (NN locus))))))))))))))))))) (: ;) (CC and) (S (NP (-LRB- -LRB-) (CD 3) (-RRB- -RRB-)) (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP control) (S (NP (JJ Ig) (NN gene) (NN class)) (VP (NN switch) (NP (NN recombination)))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN used) (NP (DT a) (JJ somatic) (NN cell) (NN hybridization) (NN approach)) (S (VP (TO to) (VP (ADVP (RB genetically)) (VB analyse) (NP (NP (NN regulation)) (PP (IN of) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (NNP IgH) (CD 3') (NN enhancer))))))))))) (. .)))
(TOP (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN mouse) (CD MPC11) (NN plasmacytoma) (NNS cells)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NNP IgH) (CD 3') (NN enhancer)) (VP (VBZ is) (ADJP (JJ active))))) (, ,)) (VP (VBP are) (VP (VBN fused) (PP (IN with) (NP (NNS fibroblasts))))))) (, ,) (NP (NN Ig) (NN expression)) (VP (VBZ is) (VP (VBN extinguished) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN transcription))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (PP (IN in) (NP (DT a) (NNP MPC11) (NN plasmacytoma) (LS x) (JJ fibroblast) (NN environment))) (, ,) (NP (DT the) (NNP IgH) (CD 3') (NN enhancer)) (VP (VBZ is) (ADJP (RB transcriptionally) (JJ inactive)))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (VBG binding)) (PP (IN of) (NP (JJ several) (NNP B) (JJ cell-specific) (NN transcription) (NNS factors))) (, ,) (ADJP (JJ essential) (PP (IN for) (NP (NNP IgH) (CD 3') (NN enhancer) (NN activity)))) (, ,)) (VP (VBZ is) (VP (VP (VBG lacking)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB explain) (NP (CD 3') (NN enhancer) (NN inactivity)))))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (VBG binding)) (PP (IN of) (NP (NNS repressors)))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN excluded))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (JJ high) (NN expression) (NN level)) (PP (IN of) (NP (JJ c-myc))) (, ,) (ADJP (JJ characteristic) (PP (IN of) (NP (NP (DT the) (JJ parental) (NNP MPC11) (NNS cells)) (VP (VBG carrying) (NP (DT the) (JJ t-LRB-12;15-RRB-) (NN translocation)))))) (, ,)) (VP (VBZ is) (ADJP (JJ down-regulated) (PP (IN in) (NP (DT the) (NNS hybrids))) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (JJ unfused) (NNS fibroblasts))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN inactivation)) (PP (IN of) (NP (DT the) (NNP IgH) (CD 3') (NN enhancer)))) (VP (VBZ is) (NP (NP (DT a) (JJ multifactorial) (NN process)) (VP (VBG affecting) (NP (NP (JJ several) (NN transcription) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP control) (NP (NP (DT the) (ADJP (JJ cell-specific) (CC and) (JJ developmental)) (NN activity)) (PP (IN of) (NP (DT the) (NN enhancer))))))))))) (. .)))
(TOP (NP (NP (NP (NN Construction)) (CC and) (NP (NP (JJ biological) (NN characterization)) (PP (IN of) (NP (NP (DT an) (JJ interleukin-12) (NN fusion) (NN protein)) (PRN (-LRB- -LRB-) (NN Flexi-12) (-RRB- -RRB-)))))) (: :) (NP (NP (NN delivery)) (PP (TO to) (NP (NP (JJ acute) (JJ myeloid) (JJ leukemic) (NNS blasts)) (VP (VBG using) (NP (JJ adeno-associated) (NN virus)))))) (. .)))
(TOP (S (NP (NP (NN Interleukin-12)) (PRN (-LRB- -LRB-) (NP (NN IL-12)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (NN cytokine)) (SBAR (WHNP (IN that)) (S (VP (VP (NNS exhibits) (NP (NP (JJ pleiotropic) (NNS effects)) (PP (IN on) (NP (NP (NNS lymphocytes)) (CC and) (NP (JJ natural) (NN killer) (NNS cells)))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (NP (NN promise)) (PP (IN for) (NP (NP (DT the) (NN immunotherapy)) (PP (IN of) (NP (NN cancer))))))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (DT the) (JJ immune) (JJ costimulatory) (NN molecule) (NNP B7.1) (CC and) (NNP IL-12)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ synergistic) (PP (IN for) (NP (NNP T) (NN cell) (NN activation)))))))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG transfecting) (NP (NN tumor) (NNS cells)) (PP (IN with) (NP (DT both) (NP (NNP IL-12)) (CC and) (NP (NNP B7.1) (NNP cDNAs))))))) (, ,) (NP (NP (PRP it))) (VP (MD may) (VP (VB be) (ADJP (JJ possible)) (S (VP (TO to) (VP (VB use) (NP (DT these) (VBN modified) (NNS targets)) (PP (IN as) (NP (NNS vaccines)))))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ major) (NN obstacle)) (PP (IN in) (S (VP (VBG designing) (NP (DT a) (NN vector))))) (S (VP (TO to) (VP (VB deliver) (NP (DT these) (NNS genes)))))) (VP (NNS results) (PP (IN from) (NP (NP (DT the) (NN structure)) (PP (IN of) (NP (NN IL-12)))))) (. .)))
(TOP (S (NP (JJ Functional) (NN IL-12)) (VP (VBZ is) (NP (NP (DT a) (NN heterodimer)) (VP (VBN composed) (PP (IN of) (NP (NP (CD two) (JJ distinct) (NNS subunits)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN encoded) (PP (IN by) (NP (JJ separate) (NNS genes))) (PP (IN on) (NP (JJ different) (NNS chromosomes)))))))))))) (. .)))
(TOP (S (NP (NP (NN Production)) (PP (IN of) (NP (JJ functional) (NN IL-12)))) (VP (VBZ requires) (NP (NP (DT the) (VBN coordinated) (NN expression)) (PP (IN of) (NP (DT both) (NNS genes))))) (. .)))
(TOP (S (NP (DT This)) (VP (VBZ presents) (NP (NP (NP (JJ several) (NNS problems)) (PP (IN in) (NP (NNS vectors)))) (, ,) (NP (NP (RB particularly) (DT those)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (JJ additional) (NNS genes)) (, ,) (NP (CC either) (NP (DT a) (JJ co-stimulatory) (NN gene)) (CC or) (NP (DT a) (JJ selectable) (NN marker))) (, ,)) (VP (VBP are) (VP (VBN inserted)))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN constructed) (NP (NP (DT a) (JJ single) (NN cDNA)) (SBAR (WHNP (WDT that)) (S (VP (VBZ encodes) (NP (NP (DT a) (JJ single-chain) (NN protein)) (, ,) (VP (VBN called) (S (NP (NN Flexi-12)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ retains) (NP (NP (NP (DT all)) (PP (IN of) (NP (NP (DT the) (JJ biological) (NNS characteristics)) (PP (IN of) (NP (JJ recombinant) (NN IL-12)))))) (PRN (-LRB- -LRB-) (NN rIL-12) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (NP (DT The) (JJ monomeric) (NN polypeptide) (NN Flexi-12)) (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VP (VB induce) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (NN phytohemagglutinin) (PRN (-LRB- -LRB-) (NNP PHA) (-RRB- -RRB-)) (NNS blasts))))) (, ,) (VP (VBP induce) (S (NP (NNP PHA) (NNS blasts)) (VP (TO to) (VP (VB secrete) (NP (NP (NN interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-))))))) (CC and) (VP (ADVP (RB additionally)) (, ,) (PP (IN by) (NP (NN preincubation))) (, ,) (VB enhance) (NP (NP (DT the) (NN killing)) (PP (IN of) (NP (NP (CD K562) (NNS targets)) (PP (IN by) (NP (NNS PBLs)))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS phenomena)) (VP (VBP are) (PP (IN in) (NP (NP (DT a) (JJ dose-dependent) (NN manner)) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT that)) (VP (VBN seen) (PP (IN with) (NP (NN rIL-12)))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (ADVP (RB also)) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (JJ tyrosine) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NNP STAT) (CD 4) (NN transcription) (NN factor))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ unique) (PP (TO to) (NP (DT the) (NN IL-12) (VBG signaling) (NN pathway)))))))))))) (, ,)) (VP (VBZ occurs) (PP (IN with) (NP (NN Flexi-12))) (PP (IN at) (NP (NP (NNS levels)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN seen) (PP (IN with) (NP (NN rIL-12)))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VP (VBN packaged) (NN Flexi-12) (PP (IN into) (NP (NP (DT a) (JJ recombinant) (JJ adeno-associated) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP AAV)) (-RRB- -RRB-))))) (CC and) (VP (VBD used) (NP (DT this) (NN vector)) (S (VP (TO to) (VP (VB infect) (NP (JJ acute) (JJ myeloid) (NN leukemic) (PRN (-LRB- -LRB-) (NNP AML) (-RRB- -RRB-)) (NNS blasts)))))))) (. .)))
(TOP (S (NP (VBN Infected) (NNP AML) (NNS blasts)) (VP (VBD produced) (NP (NP (QP (IN between) (CD 2) (CC and) (CD 6)) (NN ng)) (PP (IN of) (NP (NP (NN IL-12/10) (PRN (-LRB- -LRB-) (CD 6) (-RRB- -RRB-)) (NNS cells)) (PP (IN per) (NP (NP (NN ml)) (PP (IN per) (NP (CD 48) (NN hr))))))))) (. .)))
(TOP (S (NP (DT These) (NNS studies)) (ADVP (RB also)) (VP (VBP confirm) (SBAR (IN that) (S (NP (NNP AAV)) (VP (VBZ is) (NP (NP (DT an) (JJ efficient) (NN delivery) (NN vehicle)) (PP (IN for) (NP (NP (NNS cytokines)) (PP (TO to) (NP (JJ leukemic) (NNS cells)))))))))) (. .)))
(TOP (S (NP (NP (NP (JJ Direct) (NN analysis)) (PP (IN of) (NP (DT these) (VBN modified) (NNS cells)))) (VP (VBG acting) (PP (IN as) (NP (NN tumor) (NNS vaccines))))) (VP (VBZ is) (ADJP (JJ underway))) (. .)))
(TOP (S (NP (NNP ETS1) (, ,) (NNP NFkappaB) (CC and) (NNP AP1)) (VP (ADVP (RB synergistically)) (VBP transactivate) (NP (DT the) (JJ human) (NNP GM-CSF) (NN promoter))) (. .)))
(TOP (S (NP (NP (NN Activation)) (PP (IN of) (NP (NN helper) (NN T) (NNS cells)))) (VP (NNS results) (PP (IN in) (S (VP (VBP coordinate) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS cytokines)) (VP (VBN involved) (PP (IN in) (NP (NP (NN differentiation) (, ,) (NN proliferation) (CC and) (NN activation)) (PP (IN of) (NP (DT the) (JJ haematopoietic) (NN system))))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Granulocyte-macrophage) (NN colony) (VBG stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NN GM-CSF) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (CD one) (JJ such) (NN cytokine)) (, ,) (SBAR (WHNP (WP$ whose) (VBN increased) (NN expression)) (S (VP (NNS results) (ADVP (RB mostly)) (PP (IN from) (NP (NP (NNS increases)) (PP (IN in) (NP (NN transcription)))))))))) (. .)))
(TOP (S (NP (NP (JJ Cis-acting) (NNS elements)) (PP (IN with) (NP (NNP NFkappaB) (, ,) (NNP AP1) (CC and) (JJ ETS-like) (JJ binding) (NNS motifs)))) (VP (VP (VBP have) (VP (VBN been) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NN promoter) (NN region)) (PP (IN of) (NP (DT the) (NNP GM-CSF) (NN gene)))))))) (, ,) (CC and) (VP (VBP are) (ADJP (ADJP (JJ important)) (CC or) (ADJP (JJ essential) (PP (IN for) (NP (JJ transcriptional) (NN activity))))) (PP (VBG following) (NP (NNP T) (NN cell) (NN activation))))) (. .)))
(TOP (S (NP (CD ETS1)) (VP (VBZ is) (NP (NP (DT a) (NN transcription) (NN factor)) (PP (IN of) (NP (DT the) (NNP ETS) (NN family))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (NNP T) (NNS cells))))))))) (. .)))
(TOP (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN shown) (SBAR (IN that) (S (NP (NNP ETS1)) (VP (MD can) (VP (VB transactivate) (NP (NNP GM-CSF)) (PP (IN in) (NP (NNP Jurkat) (NNP T) (NNS cells)))))))))) (, ,) (CC but) (S (SBAR (RB only) (IN after) (S (NP (DT the) (NNS cells)) (VP (VBP have) (VP (VBN been) (VP (VBN stimulated) (PP (IN by) (NP (NN treatment))) (PP (IN with) (NP (NNP PMA) (CC and) (NN ionomycin)))))))) (, ,) (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP mimic) (NP (NNP T) (NN cell) (NN activation))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (NP (PRP we)) (VP (VBD proposed) (SBAR (IN that) (S (NP (NP (NNP ETS1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN expressed) (ADVP (RB constitutively)) (PP (IN in) (NP (NNP Jurkat) (NNS cells))))))) (, ,)) (VP (MD may) (VP (VB act) (PP (IN in) (NP (NP (NN concert)) (PP (IN with) (NP (NNP PMA/ionomycin) (JJ inducible) (NNS factors)))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP ETS1)) (VP (MD can) (VP (VB transactivate) (SBAR (S (NP (DT a) (JJ GM-CSF) (NN reporter)) (VP (VBP construct) (PP (IN in) (NP (JJ unstimulated) (NNP Jurkat) (NNS cells)))))) (, ,) (S (VP (VBG providing) (SBAR (IN that) (S (NP (DT either) (NNP NFkappaB) (CC or) (NNP AP1) (NN transcription) (NNS factors)) (VP (VBP are) (VP (VBN supplied) (PP (IN by) (NP (NN co-transfection)))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP confirm) (SBAR (IN that) (S (NP (NP (VBG binding)) (PP (IN of) (NP (NP (JJ endogenous) (NNP NFkappaB)) (CC and) (NP (NNP AP1))))) (VP (VBZ is) (VP (VBN induced) (PP (VBG following) (NP (NP (NNP PMA/ionomycin) (NN treatment)) (PP (IN of) (NP (NNP T) (NNS cells)))))))))) (. .)))
(TOP (S (S (NP (NP (NNP Transactivation)) (PP (IN by) (NP (NNP ETS1) (, ,) (NNP NFkappaB) (CC and) (NNP AP1)))) (VP (VBZ is) (ADJP (JJ synergistic)))) (, ,) (CC and) (S (NP (NP (NN mutation)) (PP (IN of) (NP (DT the) (JJ individual) (JJ binding) (NNS sites)))) (VP (VBZ reveals) (SBAR (IN that) (S (NP (NP (DT the) (JJ transcriptional) (NNS activities)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (VBP are) (ADJP (JJ interdependent))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ constitutive) (NNP ETS1)) (, ,) (CC and) (NP (NP (JJ inducible) (NNP NFkappaB)) (CC and) (NP (NNP AP1))) (, ,)) (VP (VBP cooperate) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJR higher) (NN order) (JJ transcriptional) (NN complex)) (PP (IN in) (NP (VBN activated) (NNP T) (NNS cells))))))))))) (. .)))
(TOP (S (NP (NP (NNP Relief)) (PP (IN of) (NP (NN cyclin)))) (NP (DT A) (NN gene)) (VP (JJ transcriptional) (ADVP (NN inhibition)) (PP (IN during) (NP (NP (NN activation)) (PP (IN of) (NP (JJ human) (JJ primary) (NNP T) (NNS lymphocytes))))) (PP (IN via) (NP (NNP CD2) (CC and) (NNP CD28) (NN adhesion) (NNS molecules)))) (. .)))
(TOP (S (NP (NNP Cyclin) (NNP A) (NN transcription)) (VP (VBZ is) (NP (NP (NN cell) (NN cycle)) (VP (VP (VBN regulated)) (CC and) (VP (VBN induced) (PP (IN by) (NP (NN cell) (JJ proliferative) (NNS signals))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB understand) (NP (NP (DT the) (NNS mechanisms)) (VP (VBD underlined) (PP (IN in) (NP (NP (DT this) (NN regulation)) (PP (IN in) (NP (JJ normal) (JJ human) (NNS cells)))))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN analysed) (PP (IN in) (NP (NP (JJ vivo) (JJ protein-DNA) (NNS interactions)) (PP (IN at) (NP (NP (DT the) (NNP Cyclin) (NNP A) (VBZ locus)) (PP (IN in) (NP (JJ primary) (NNP T) (NNS lymphocytes))))))))) (. .)))
(TOP (S (NP (NP (NN Stimulation)) (PP (IN of) (NP (JJ purified) (NNP T) (NNS lymphocytes))) (PP (IN by) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (JJ monoclonal) (NNS antibodies))) (VP (VBN directed) (PP (IN at) (NP (NNP CD2) (CC and) (NNP CD28) (NN adhesion) (NNS molecules))))))) (VP (VBZ gives) (NP (NN rise)) (PP (TO to) (NP (DT a) (JJ long) (JJ lasting) (NN proliferation))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ accessory) (NNS cells)))))) (. .)))
(TOP (S (NP (NNP Cyclin) (NNP A)) (VP (VBD was) (VP (VBN observed) (PP (IN after) (NP (NP (CD 4) (NNS days)) (PP (IN of) (NP (NN costimulation))) (PP (IN with) (NP (JJ anti) (NNP CD2) (NNP +) (NNP CD28))))) (SBAR (IN whereas) (S (NP (NP (NN stimulation)) (PP (IN by) (NP (NP (JJ anti) (NNP CD2)) (CC or) (NP (NNP anti) (NNP CD28)))) (ADVP (RB alone))) (VP (VBD was) (RB not) (ADJP (JJ effective))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN vivo))) (NP (JJ genomic) (NNP DMS) (NN footprinting)) (VP (VP (VBD revealed) (ADVP (RB upstream) (PP (IN of) (NP (DT the) (JJ major) (NN transcription) (NN initiation) (NNS sites))))) (, ,) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD three)) (NN protein) (VBG binding) (NNS sites)) (, ,) (SBAR (WHNP (WHNP (CD two)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD were) (ADJP (RB constitutively) (JJ occupied))))))))) (. .)))
(TOP (S (NP (PRP They)) (VP (NN bind) (PP (IN in) (NP (NN vitro))) (NP (ADJP (RB respectively) (JJ ATF-1) (CC and) (JJ NF-Y)) (NNS proteins))) (. .)))
(TOP (S (NP (DT The) (JJ third) (NN site)) (VP (VBD was) (VP (VBN occupied) (PP (PP (IN in) (NP (JJ quiescent) (NNS cells))) (CC or) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN stimulated) (PP (IN by) (NP (NP (JJ anti) (NNP CD2)) (CC or) (NP (NP (NNP anti) (NNP CD28)) (ADVP (RB alone))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ mitogenic) (NN combination)) (PP (IN of) (NP (FW anti) (FW CD2) (FW +) (FW anti) (NNP CD28)))) (VP (VBD released) (NP (DT the) (NN footprint)) (SBAR (IN as) (S (NP (NNS cells)) (VP (VBD were) (VP (VBN committed) (PP (TO to) (NP (NN proliferation)))))))) (. .)))
(TOP (S (S (ADJP (JJ Consistent) (PP (IN with) (NP (NNS theses) (NNS results))))) (, ,) (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN prepared) (PP (IN from) (NP (JJ quiescent) (NNS cells))))) (VP (VBD formed) (NP (NP (DT a) (JJ specific) (NN complex)) (PP (IN with) (NP (DT this) (NN element)))) (, ,) (SBAR (IN whereas) (S (NP (NP (NNS extracts)) (VP (VBN prepared) (PP (IN from) (NP (NP (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (FW anti) (FW CD2) (FW +) (FW anti) (NNP CD28)))))))) (VP (VBD failed) (S (VP (TO to) (VP (VB do) (SBAR (RB so) (IN after) (S (NP (NNS cells)) (VP (VBD entered) (NP (DT a) (JJ proliferative) (NN state)))))))))))) (. .)))
(TOP (S (NP (NP (JJ Molecular) (NN cloning)) (CC and) (NP (NP (NN characterization)) (PP (IN of) (NP (DT a) (NAC (NNP cDNA) (, ,) (NNP CHEMR1) (, ,)))))) (VP (VBG encoding) (NP (DT a) (NN chemokine) (NN receptor)) (PP (IN with) (NP (NP (DT a) (NN homology)) (PP (TO to) (NP (NP (DT the) (JJ human) (NNP C-C) (NN chemokine) (NN receptor)) (, ,) (NP (NN CCR-4))))))) (. .)))
(TOP (S (NP (NNS Chemokines)) (VP (VBP refer) (PP (TO to) (NP (NP (DT a) (ADJP (RB rapidly) (VBG expanding)) (NN family)) (PP (IN of) (NP (NP (JJ small) (NNS cytokines)) (SBAR (WHNP (WP$ whose) (JJ primary) (NN function)) (S (VP (VBZ is) (NP (NP (NN recruitment)) (PP (IN of) (NP (NP (NNS leukocytes)) (PP (TO to) (NP (JJ inflammatory) (NNS sites)))))))))))))) (. .)))
(TOP (S (NP (DT These)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (NN bind) (PP (TO to) (NP (NP (JJ seven-transmembrane-domain)) (VP (VBG containing) (NP (NNS receptors)))))))))) (. .)))
(TOP (S (NP (NP (NP (DT A) (JJ cDNA) (NN clone)) (, ,) (NP (NNP CHEMR1)) (, ,)) (VP (VBG resembling) (NP (DT the) (JJ typical) (NNP G) (JJ protein-coupled) (NN receptor))) (, ,)) (VP (VBD was) (VP (VBN isolated) (PP (IN from) (NP (DT a) (NN mouse) (JJ cytotoxic) (NNP T-lymphocyte) (PRN (-LRB- -LRB-) (NNP CTL) (-RRB- -RRB-)) (NN library))))) (. .)))
(TOP (S (NP (NP (JJ Northern) (NN blot) (NN analysis)) (PP (IN in) (NP (NN mouse) (NN cell) (NNS lines)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (PRP$ its) (NN expression)) (VP (VBZ is) (VP (VBN found) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS cells))) (, ,) (PP (VBG including) (NP (NP (NNP T) (NNS cells)) (, ,) (NP (NN B) (NNS cells)) (, ,) (CC and) (NP (NNS macrophages))))))))))) (. .)))
(TOP (S (NP (DT The) (NNP CHEMR1) (NN gene) (NNP Scya3r2)) (VP (VBZ is) (NP (NP (DT a) (JJ single-copy) (NN gene)) (SBAR (WHNP (WP$ whose) (JJ open) (NN reading) (NN frame)) (S (VP (MD may) (VP (VB be) (PP (IN in) (NP (NP (DT a) (JJ single) (NN exon) (CC and) (NNS maps)) (PP (TO to) (NP (NP (DT the) (JJ distal) (NN region)) (PP (IN of) (NP (NN mouse) (NNP Chr) (CD 9))) (SBAR (WHADVP (WRB where)) (S (NP (NP (DT the) (NN mouse) (NN macrophage) (JJ inflammatory) (NN protein-1alpha) (PRN (-LRB- -LRB-) (NN MIP-1alpha) (-RRB- -RRB-)) (NN receptor) (NN gene) (NNP Scya3r)) (CC and) (NP (CD two) (JJ related) (NNP C-C) (NN chemokine) (JJ receptor-like) (NNS genes))) (VP (VBP reside)))))))))))))) (. .)))
(TOP (S (NP (JJ Amino) (NN acid) (NN sequence) (NN comparison)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NNP CHEMR1)) (VP (VBZ is) (ADJP (NP (CD 84) (NN %)) (JJ identical) (PP (TO to) (NP (JJ human) (NN CCR-4)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NNP CHEMR1)) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (NP (DT a) (NN mouse) (NN CCR-4))))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Binding) (NNS assays)) (VP (VBG using) (NP (JJ 125I-labeled) (NN C-C) (NNS chemokines)) (PP (IN in) (NP (JJ mammalian) (NNS cells))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NNP CHEMR1)) (VP (VBD did) (RB not) (VP (NN bind) (NP (NN MIP-1alpha) (, ,) (NNP RANTES) (, ,) (CC or) (NN MIP-1beta)) (, ,) (SBAR (IN whereas) (S (NP (NNP CCR-1)) (VP (VBZ binds) (NP (NNP MIP-1alpha) (CC and) (NNP RANTES)))))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NN result)) (VP (VBZ is) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (VBN reported) (NNS properties)) (PP (IN of) (NP (JJ human) (NN CCR-4))))))) (. .)))
(TOP (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP CHEMR1)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN receptor)) (PP (IN for) (NP (NP (JJ unidentified) (NNP C-C) (NN chemokine)) (CC or) (NP (NP (DT a) (JJ low-affinity) (NN receptor)) (PP (IN for) (NP (NN MIP-1alpha)))))))))))) (. .)))
(TOP (NP (NP (JJ Biphasic) (NN control)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NN activation))) (VP (VBN induced) (PP (IN by) (NP (NP (NP (DT the) (VBG triggering)) (PP (IN of) (NP (JJ HLA-DR) (NNS antigens)))) (VP (VBN expressed) (PP (IN on) (NP (NN B) (NNS cells))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN regulation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NN activation))) (PP (VBG following) (NP (NP (DT the) (VBG triggering)) (PP (IN of) (NP (JJ HLA-DR) (NNS antigens))) (PP (IN by) (NP (NNP mAb) (NNP L243)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PP (IN at) (NP (NP (JJ various) (NNS times)) (PP (IN in) (NP (NNP Raji) (NNS cells)))))))) (. .)))
(TOP (S (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBD demonstrated) (NP (NP (DT a) (JJ strong) (NN increase)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NNP DNA))) (VP (VBG binding) (PP (IN after) (S (VP (VBG triggering) (PP (IN of) (NP (JJ HLA-DR) (NNS antigens))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (JJ TNF-alpha-activity) (VBG neutralizing) (NNS antibodies)))) (, ,) (NP (DT the) (NNS authors)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN upregulation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB depend) (, ,) (PP (IN at) (NP (JJ later) (NN time) (NN point))) (, ,) (PP (IN on) (NP (NP (DT an) (JJ autocrine) (NN effect)) (PP (IN of) (NP (JJ TNF-alpha) (JJ secreted))))) (PP (NN following) (S (VP (VBG triggering) (PP (IN of) (NP (JJ HLA-DR) (NNS antigens)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (JJ TNF-alpha) (NN independent)) (PP (IN in) (NP (DT the) (JJ early) (NN time) (NN point)))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN upregulation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (JJ binding) (NN activity)))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP (NP (DT the) (VBG triggering)) (PP (IN of) (NP (NP (VBN selected) (NNS epitopes)) (PP (IN of) (NP (JJ HLA-DR) (NNS antigens))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN fact))) (, ,) (NP (NP (NNP mAb) (NNP L243)) (CC but) (RB not) (NP (DT the) (JJ staphylococcal) (NNS superantigens)) (, ,) (NP (NP (JJ staphylococcal) (JJ exotoxin) (JJ toxic) (NN shock) (NN syndrome)) (NP (ADJP (JJ toxin-I) (CC or) (JJ staphylococcal)) (NN enterotoxin) (NNP B))) (, ,)) (VP (VBP regulate) (NP (DT the) (NNP NF-kappa) (NNP B) (JJ binding) (NN activity))) (. .)))
(TOP (S (NP (NP (JJ Anti-Ehrlichia) (NN chaffeensis) (NN antibody)) (VP (VBN complexed) (PP (IN with) (NP (NNP E.) (NN chaffeensis))))) (VP (VBZ induces) (NP (NP (JJ potent) (JJ proinflammatory) (NN cytokine) (NNP mRNA) (NN expression)) (PP (IN in) (NP (JJ human) (NNS monocytes)))) (PP (IN through) (NP (NP (JJ sustained) (NN reduction)) (PP (IN of) (NP (NP (NN IkappaB-alpha) (CC and) (NN activation)) (PP (IN of) (NP (NNP NF-kappaB)))))))) (. .)))
(TOP (S (NP (NNP Ehrlichia) (NN chaffeensis)) (VP (VBZ is) (NP (NP (DT an) (JJ obligatory) (JJ intracellular) (NN bacterium)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ infects) (NP (NNS monocytes) (CC and) (NNS macrophages))) (CC and) (VP (VBZ is) (NP (NP (DT the) (JJ etiologic) (NN agent)) (PP (IN of) (NP (NP (JJ human) (NN ehrlichiosis)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))))))))) (. .)))
(TOP (S (NP (PRP$ Our) (JJ previous) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN exposure)) (PP (IN of) (NP (JJ human) (NNS monocytes))) (PP (TO to) (NP (NNP E.) (NN chaffeensis)))) (VP (VBZ induces) (NP (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ interleukin-1beta) (ADJP (PRN (-LRB- -LRB-) (NN IL-1beta) (-RRB- -RRB-)) (, ,) (NN IL-8) (, ,) (CC and) (NN IL-10)) (NNS genes)) (PP (IN in) (NP (NN vitro)))))) (CC but) (RB not) (NP (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))))) (CC and) (NP (NNP IL-6) (NNP mRNAs)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ anti-E.) (NN chaffeensis) (NN antibody)) (VP (VBN complexed) (PP (IN with) (NP (NP (NNP E.) (NNS chaffeensis)) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ major) (JJ proinflammatory) (NNS cytokines)) (PP (IN in) (NP (JJ human) (NNS monocytes))))))))))))) (VP (VBD was) (VP (VBN examined))) (. .)))
(TOP (S (S (NP (JJ Human) (JJ monocytic) (NN cell) (NN line) (NN THP-1)) (VP (VBD was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP E.) (NNS chaffeensis)) (SBAR (WHNP (WDT which)) (S (VP (VBD had) (VP (VBN been) (VP (VBN preincubated) (PP (IN with) (NP (JJ human) (JJ anti-E.) (NN chaffeensis) (NN serum))) (PP (IN for) (NP (CD 2) (NN h))))))))))))) (, ,) (CC and) (S (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN cytokine) (NNS mRNAs)))) (VP (VBD were) (VP (VBN evaluated) (PP (IN by) (NP (JJ competitive) (JJ reverse) (NN transcription-PCR)))))) (. .)))
(TOP (NP (NP (JJ Anti-E.) (NN chaffeensis) (NN antibody)) (VP (VBN complexed) (PP (IN with) (NP (NNP E.) (NNS chaffeensis))) (NP (NP (ADJP (RB significantly) (VBN enhanced)) (NNP mRNA) (NN expression)) (PP (IN of) (NP (NN IL-1beta)))) (PP (IN in) (NP (JJ THP-1) (NNS cells)))) (. .)))
(TOP (S (NP (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NNP TNF-alpha)))) (CC and) (NP (NNP IL-6) (NNP mRNAs))) (VP (VBD was) (ADVP (RB also)) (VP (VBN induced))) (. .)))
(TOP (S (NP (NP (DT The) (NNS levels)) (PP (IN of) (NP (NP (NP (JJ secreted) (NN IL-1beta)) (, ,) (NP (NNP TNF-alpha)) (, ,)) (CC and) (NP (NNP IL-6)))) (PP (IN during) (NP (NP (CD 24) (NN h)) (PP (IN of) (NP (NN stimulation)))))) (VP (VBD were) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NNP Escherichia) (NNS coli) (NN lipopolysaccharide))) (PP (IN at) (NP (CD 1) (NN microg/ml)))))))) (. .)))
(TOP (S (NP (NP (NNP Fab) (NN fragment)) (PP (IN of) (NP (JJ anti-E.) (NN chaffeensis) (NN immunoglobulin) (NNP G))) (VP (VBD complexed) (PP (IN with) (NP (NNP E.) (NNS chaffeensis))))) (VP (VBD did) (RB not) (VP (VB induce) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (CD three) (NNS cytokines)))) (, ,) (S (VP (VBG indicating) (SBAR (SBAR (IN that) (S (NP (JJ ehrlichial) (VBG binding)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NNP IL-1beta) (NNP mRNA) (NN expression))))))) (CC and) (SBAR (IN that) (S (NP (NP (VBG binding)) (PP (IN of) (NP (DT the) (JJ immune) (NN complex))) (PP (TO to) (NP (DT the) (NNP Fc) (NN gamma) (NN receptor)))) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (NP (NNP TNF-alpha)) (CC and) (NP (NNP IL-6) (NNP mRNA) (NN expression))) (CC and) (NP (VBD enhanced) (NNP IL-1beta) (NNP mRNA) (NN expression))))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ prolonged) (NN degradation)) (PP (IN of) (NP (NP (NN IkappaB-alpha) (CC and) (NN activation)) (PP (IN of) (NP (NNP NF-kappaB)))))) (VP (VBD were) (VP (VBN demonstrated) (PP (IN in) (NP (NP (CD THP-1) (NNS cells)) (VP (VBN exposed) (PP (TO to) (NP (NP (JJ anti-E.) (NN chaffeensis) (NN serum)) (CC and) (NP (NNP E.) (NNS chaffeensis))))))))) (. .)))
(TOP (S (NP (DT This) (NN result)) (VP (VBZ implies) (SBAR (DT that) (S (NP (NP (NN development)) (PP (IN of) (NP (JJ anti-E.) (NN chaffeensis) (NN antibody))) (PP (IN in) (NP (NNS patients)))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ major) (JJ proinflammatory) (NNS cytokines)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB play) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NP (NN ehrlichiosis)) (CC and) (NP (JJ immune) (NNS responses))))))) (PP (TO to) (NP (PRP it)))))))))))))))) (. .)))
(TOP (S (NP (JJ S-allyl) (NN cysteine)) (VP (VBZ inhibits) (NP (NP (NN activation)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PP (IN in) (NP (JJ human) (NNP T) (NNS cells))))))) (. .)))
(TOP (S (NP (JJ Reactive) (NN oxygen) (NNS species)) (VP (VBP are) (ADJP (VBN involved) (PP (IN in) (NP (NP (NN signal) (NN transduction) (NNS pathways)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NNP B) (PRN (-LRB- -LRB-) (NNP NF-kappa) (NNP B) (-RRB- -RRB-)) (NN activation)) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN gene) (NN transcription))))))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD reported) (SBAR (IN that) (S (NP (NP (DT a) (JJ garlic) (NN compound)) (, ,) (NP (NP (JJ S-allyl) (NN cysteine)) (PRN (-LRB- -LRB-) (NP (NNP SAC)) (-RRB- -RRB-))) (, ,)) (VP (VBZ protects) (NP (JJ bovine) (JJ pulmonary) (NN artery) (JJ endothelial) (NNS cells)) (PP (IN from) (NP (NP (JJ oxidant) (NN injury)) (VP (VBN induced) (PP (IN by) (NP (NP (NN hydrogen) (NN peroxide)) (PRN (-LRB- -LRB-) (NP (CD H2O2)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD determined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP SAC))) (PP (IN on) (NP (NP (NNP NF-kappa) (NNP B) (NN activation)) (PP (IN in) (NP (NP (JJ human) (NNP T) (NNS lymphocytes)) (PRN (-LRB- -LRB-) (NP (NN Jurkat) (NNS cells)) (-RRB- -RRB-)))))) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))) (CC and) (NP (NNP H2O2))))))) (. .)))
(TOP (S (NP (NP (NNP Activated) (NNP NF-kappa) (NNP B)) (PP (IN in) (NP (JJ nuclear) (NNS extracts)))) (VP (VBD was) (VP (VBN measured) (PP (IN by) (NP (NP (DT an) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)) (VP (VBG using) (NP (JJ 32P-labeled) (NN probe))))))) (. .)))
(TOP (S (NP (NNP SAC)) (VP (ADVP (RB consistently)) (VBD exhibited) (NP (NP (DT a) (JJ dose-dependent) (NN inhibition)) (PP (IN of) (NP (NP (NNP NF-kappa) (NNP B) (NN activation)) (VP (VBN induced) (PP (IN by) (NP (DT both) (NNP TNF-alpha) (CC and) (NNP H2O2)))))))) (. .)))
(TOP (S (NP (NP (NNP Supershift)) (PP (IN with) (NP (NP (JJ specific) (NNS antibodies)) (PP (TO to) (NP (NNP NF-kappa) (NNP B) (NNS subunits)))))) (VP (VBD confirmed) (SBAR (IN that) (S (NP (DT the) (JJ inducible) (JJ retarded) (NNS bands)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (ADJP (NNP EMSA) (CC and) (JJ p65-p50)) (NN heterodimer)) (PP (IN of) (NP (DT the) (NNP NF-kappa) (NNP B/Rel) (NN protein))))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP SAC)) (VP (MD may) (VP (VB act) (PP (IN via) (NP (NP (JJ antioxidant) (NNS mechanisms)) (SBAR (S (VP (TO to) (VP (VB block) (NP (NP (NNP NF-kappa) (NNP B) (NN activation)) (PP (IN in) (NP (NNP Jurkat) (NNS cells))))))))))))))) (. .)))
(TOP (NP (NP (NN Effect)) (PP (IN of) (NP (NN adenovirus) (CD 2))) (PP (IN on) (NP (NP (JJ cellular) (NN gene) (NN activation)) (PP (IN in) (NP (JJ blood-derived) (NNS monocytes) (CC and) (NNS macrophages))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN adenovirus) (ADJP (CD 2) (PRN (-LRB- -LRB-) (NN Ad2) (-RRB- -RRB-))) (NN infection))) (PP (IN on) (NP (NP (JJ human) (NNS monocytes)) (CC and) (NP (JJ monocyte-derived) (NNS macrophages))))) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (NP (NN expression)) (PP (IN of) (NP (NNP TNF-alpha)))) (CC and) (NP (NNP IL-1) (NN beta)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NNS monocytes))) (, ,) (NP (DT the) (NN virus)) (VP (VBD was) (VP (VBN bound) (PP (TO to) (NP (DT the) (NN surface))) (PP (IN without) (S (VP (VBG being) (VP (VBN internalized))))))) (. .)))
(TOP (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NNP Ad2)) (VP (VBD was) (VP (VBN internalized) (PP (IN by) (NP (NNS macrophages))))) (. .)))
(TOP (S (NP (NP (DT No) (NN virus) (NN replication)) (CC and) (NP (NP (DT no) (NN transcription)) (PP (IN of) (NP (DT the) (JJ Ad2) (JJ early) (NNS genes))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (DT either)) (PP (IN of) (NP (DT the) (NNS cells))))))) (. .)))
(TOP (S (NP (JJ Ad2) (NN infection)) (VP (VBD induced) (NP (NP (JJ transient) (NN increase)) (PP (IN in) (NP (NP (DT the) (NNP mRNA) (NNS levels)) (PP (IN for) (NP (NP (NNP TNF-alpha)) (CC and) (NP (NNP IL-1) (NN beta)))))) (PP (PP (IN in) (NP (DT both) (NNS monocytes))) (CC and) (PP (IN in) (NP (NNS macrophages))))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NNS kinetics)) (PP (IN of) (NP (DT the) (NN transcription)))) (VP (VBD was) (ADJP (RB slightly) (JJ different)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN production)) (PP (IN of) (NP (DT both) (NNS cytokines))) (, ,) (VP (VBN measured) (PP (IN by) (NP (NNP ELISA) (NNS tests)))) (, ,)) (VP (VBD was) (VP (VBN enhanced) (PP (IN in) (NP (NNS monocytes))))) (. .)))
(TOP (S (PP (IN In) (NP (NNS macrophages))) (, ,) (NP (NP (DT a) (JJ slight) (NN enhancement)) (PP (IN of) (NP (JJ TNF-alpha) (NN production)))) (VP (VBD was) (VP (VBN seen) (, ,) (SBAR (IN whereas) (S (NP (JJ IL-1) (NN beta)) (VP (VBD was) (RB not) (VP (VBN detected))))))) (. .)))
(TOP (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ cellular) (NNS genes)) (VP (MD might) (VP (VB be) (VP (VBN activated) (PP (IN by) (NP (JJ Ad2) (NN virus) (NN infection))) (PP (IN in) (NP (NP (JJ nonpermissive) (NNS cells)) (SBAR (WHADVP (WRB where)) (S (NP (DT no) (JJ viral) (NN gene) (NNS products)) (VP (MD could) (VP (VB be) (VP (VBN detected)))))))))))))) (. .)))
(TOP (S (NP (NP (NN AP-1)) (VP (VBN derived) (PP (IN from) (NP (JJ mature) (NNS monocytes) (CC and) (NNS astrocytes))))) (VP (ADVP (RB preferentially)) (VBZ interacts) (PP (IN with) (NP (DT the) (NNP HTLV-I) (NN promoter) (NN central) (CD 21) (NN bp) (NN repeat)))) (. .)))
(TOP (S (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (DT the) (JJ cellular) (NN transcription) (NNS factors)) (VP (VBG interacting) (PP (IN with) (NP (NP (DT the) (JJ human) (NNP T) (NN cell) (JJ lymphotropic) (NN virus) (NN type)) (NP (NP (PRP I)) (PRN (-LRB- -LRB-) (NP (NNP HTLV-I)) (-RRB- -RRB-))))) (NP (NP (JJ long) (NN terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NNP LTR)) (-RRB- -RRB-))))))) (VP (VBZ is) (ADJP (JJ essential) (PP (TO to) (S (VP (VBG dissecting) (NP (NP (DT the) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (JJ viral) (NN transcription)))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (ADJP (JJ pertinent) (PP (TO to) (NP (NP (DT the) (ADJP (JJ oncogenic) (CC and) (JJ neuropathogenic)) (NNS processes)) (VP (VBN associated) (PP (IN with) (NP (NNP HTLV-I) (NN infection))) (PP (IN in) (NP (DT both) (NP (DT the) (ADJP (JJ immune) (CC and) (JJ nervous)) (NNS systems)))))))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Electrophoretic) (NN mobility) (NN shift)) (PRN (-LRB- -LRB-) (NP (NNP EMS)) (-RRB- -RRB-)) (NP (NP (NNS analyses)) (VP (VBG utilizing) (NP (NNS oligonucleotides)) (ADVP (RB homologous)) (PP (TO to) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (CD 21) (NN bp) (NN repeat) (NNS elements)))))))) (VP (VBD reacted) (PP (IN with) (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN derived) (PP (IN from) (NP (NP (NN cell) (NNS lines)) (PP (IN of) (NP (ADJP (JJ lymphocytic) (, ,) (JJ monocytic) (, ,) (JJ neuronal) (, ,) (CC and) (JJ glial)) (NN cell) (NN origin)))))))) (SBAR (S (VP (VBP have) (VP (VBN demonstrated) (NP (NP (NN differential)) (ADJP (VBG binding) (PP (IN of) (NP (JJ cellular) (NNS factors))))) (PP (TO to) (NP (NP (DT the) (CD three) (CD 21) (NN bp) (NNS repeats)) (PRN (-LRB- -LRB-) (NP (CD 1-4)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP (NP (NNP ATF/CREB) (CC and) (NNP Sp) (NN family) (NNS members)) (VP (VBN interacted) (PP (IN with) (NP (NP (DT the) (CD 21) (NN bp) (NNS repeats)) (SBAR (S (VP (TO to) (VP (VB form) (NP (NP (JJ DNA-protein) (NNS complexes)) (ADJP (JJ common) (PP (TO to) (NP (DT all) (NN cell) (NNS types))))))))))))) (VP (VBD examined)) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (DT a) (JJ unique) (JJ DNA-protein) (NN complex)) (VP (VBD was) (VP (VBN detected) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN promoter) (NN central) (CD 21) (NN bp) (NN repeat)) (VP (VBD was) (VP (VBN reacted) (PP (IN with) (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN derived) (PP (IN from) (NP (CC either) (NP (DT the) (NNP U-373) (NNP MG) (NN glioblastoma) (NN cell) (NN line)) (CC or) (NP (DT the) (JJ THP-1) (JJ mature) (JJ monocytic) (NN cell) (NN line))))))))))))) (. .)))
(TOP (S (PP (VBN Based) (PP (IN on) (NP (JJ nucleotide) (NN sequence) (NNS requirements) (CC and) (NN immunoreactivity)))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT this) (JJ DNA-protein) (NN complex)) (VP (VBZ is) (VP (VBN comprised) (PP (IN of) (NP (DT the) (JJ AP-1) (NNS components) (, ,) (NNP Fos) (CC and) (NNP Jun)))))))) (. .)))
(TOP (S (NP (NP (DT An) (JJ acute) (NN myeloid) (NN leukemia) (NN gene)) (, ,) (NP (NNP AML1)) (, ,)) (VP (VBZ regulates) (NP (NP (JJ transcriptional) (NN activation)) (CC and) (NP (JJ hemopoietic) (JJ myeloid) (NN cell) (NN differentiation))) (ADVP (RB antagonistically)) (PP (IN by) (NP (CD two) (JJ alternative) (JJ spliced) (NNS forms)))) (. .)))
(TOP (S (NP (NP (DT The) (NNP AML1) (NN gene)) (PP (IN on) (NP (NN chromosome) (CD 21)))) (VP (VBZ is) (VP (VP (VBN disrupted) (PP (IN in) (NP (NP (DT the) (NN -LRB-8;21-RRB--LRB-q22;q22-RRB-) (CC and) (NN -LRB-3;21-RRB--LRB-q26;q22-RRB-) (NNS translocations)) (VP (VBN associated) (PP (IN with) (NP (JJ myelogenous) (NNS leukemias))))))) (CC and) (VP (VBZ encodes) (NP (DT a) (JJ DNA-binding) (NN protein))))) (. .)))
(TOP (S (PP (IN From) (NP (NNP AML1) (NN gene))) (, ,) (NP (NP (CD two) (JJ representative) (NNS forms)) (PP (IN of) (NP (NP (NNS proteins)) (, ,) (NP (NNP AML1a)) (CC and) (NP (NNP AML1b))))) (, ,) (VP (VBP are) (VP (VBN produced) (PP (IN by) (NP (DT an) (JJ alternative) (NN splicing))))) (. .)))
(TOP (S (S (NP (DT Both) (NNS forms)) (VP (VBP have) (NP (JJ DNA-binding) (NN domain)))) (, ,) (CC but) (S (NP (NNP AML1a)) (VP (VBZ lacks) (NP (NP (DT a) (JJ putative) (JJ transcriptional) (NN activation) (NN domain)) (SBAR (WHNP (WDT which)) (S (NP (NNP AML1b)) (VP (VBZ has))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NP (NNP AML1a)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB solely)) (VP (VBZ has) (NP (NP (DT no) (NNS effects)) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN regulator))))))) (, ,)) (VP (ADVP (RB dominantly)) (VBZ suppresses) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN by) (NP (NNP AML1b))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (JJ AML1a)) (VP (NNS exhibits) (NP (NP (DT the) (JJR higher) (NN affinity)) (PP (IN for) (NP (NNP DNA-binding))) (PP (IN than) (NP (NNP AML1b))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (NP (NP (DT a) (JJ dominant) (JJ negative) (NN form)) (PP (IN of) (NP (NP (NNP AML1)) (, ,) (NP (NNP AML1a)) (, ,)))) (VP (ADVP (RB totally)) (VBD suppressed) (NP (NP (JJ granulocytic) (NN differentiation)) (VP (ADVP (RB otherwise)) (VBN induced) (PP (IN by) (NP (JJ granulocyte) (JJ colony-stimulating) (NN factor))) (SBAR (WHADVP (WRB when)) (S (NP (NNP AML1a)) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (JJ 32Dc13) (JJ murine) (JJ myeloid) (NNS cells)))))))))) (. .)))
(TOP (S (NP (NP (JJ Such) (NN differentiation) (NN block)) (PP (IN by) (NP (NNP AML1a)))) (VP (VBD was) (VP (VBN canceled) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN overexpression)) (PP (IN of) (NP (NNP AML1b))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (ADVP (RB strongly)) (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (ADJP (RB transcriptionally) (JJ active)) (NN form)) (PP (IN of) (NP (NNP AML1)))) (VP (VBZ is) (ADJP (JJ essential) (PP (IN for) (NP (DT the) (JJ myeloid) (NN cell) (NN differentiation)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT an) (JJ altered) (NN expression) (NN level)) (PP (IN of) (NP (CD AML1))) (PP (IN along) (PP (IN with) (NP (NP (DT the) (JJ myeloid) (NN differentiation)) (PP (IN in) (NP (JJ several) (JJ hemopoietic) (NN cell) (NNS lines)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT these) (NNS cases))) (, ,) (ADVP (IN at) (JJS least)) (, ,) (NP (DT the) (NNP AML1) (NN expression) (NN level)) (VP (VBZ is) (NP (NP (DT a) (JJ potential) (NN regulator)) (PP (IN for) (NP (JJ myeloid) (NN cell) (NN differentiation))))) (. .)))
(TOP (S (PP (IN Of) (NP (DT the) (JJ GATA-binding) (NNS proteins))) (, ,) (NP (RB only) (NN GATA-4)) (ADVP (RB selectively)) (VP (VBZ regulates) (NP (DT the) (JJ human) (NN IL-5) (NN gene) (NN promoter)) (PP (IN in) (NP (NP (NN IL-5) (VBG producing) (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (VBP express) (NP (JJ multiple) (JJ GATA-binding) (NNS proteins)))))))) (. .)))
(TOP (S (NP (NP (NN Interleukin-5)) (PRN (-LRB- -LRB-) (NP (NN IL-5)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VP (VBN produced) (PP (IN by) (NP (NNP T) (NNS lymphocytes)))) (CC and) (VP (VBN known) (S (VP (TO to) (VP (VB support) (NP (NP (NN B) (NN cell) (NN growth)) (CC and) (NP (NP (JJ eosinophilic) (NN differentiation)) (PP (IN of) (NP (DT the) (NN progenitor) (NNS cells))))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NP (NN ATL-16T) (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (VBP express) (NP (NNP IL-5) (NNP mRNA)))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN identified) (NP (NP (DT a) (NN region)) (, ,) (PP (IN within) (NP (DT the) (JJ human) (NN IL-5) (NN gene) (NN promoter))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ regulates) (NP (NN IL-5) (NN gene) (NN transcription)))))))) (. .)))
(TOP (S (NP (DT This) (JJ cis-acting) (NN sequence)) (VP (VP (VBZ contains) (NP (NP (DT the) (NN core) (VBG binding) (NN motif)) (, ,) (NP (NNP -LRB-A/T-RRB-GATA-LRB-A/G-RRB-)) (, ,) (PP (IN for) (NP (JJ GATA-binding) (NN family) (NNS proteins))))) (CC and) (VP (ADVP (RB thus)) (VBZ suggests) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (DT these) (NN family) (NNS members)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VP (VBP describe) (NP (NP (DT the) (NN cloning)) (PP (IN of) (NP (NP (JJ human) (NN GATA-4)) (PRN (-LRB- -LRB-) (NN hGATA-4) (-RRB- -RRB-)))))) (CC and) (VP (VBP show) (SBAR (DT that) (S (NP (NN hGATA-4)) (ADVP (RB selectively)) (VP (VBZ interacts) (PP (IN with) (NP (NP (DT the) (CD -70) (NNP GATA) (NN site)) (PP (IN within) (NP (DT the) (NNP IL-5) (JJ proximal) (NN promoter) (NN region)))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NN promoter) (NN deletion) (CC and) (NN mutation) (NNS analyses))) (, ,) (NP (PRP we)) (VP (VBD established) (NP (DT this) (NN region)) (PP (IN as) (NP (DT a) (JJ positive) (JJ regulatory) (NN element)))) (. .)))
(TOP (S (NP (NN Cotransfection) (NNS experiments)) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT both) (NNP hGATA-4) (CC and) (NNP PMA/A23187) (NN stimulation)) (VP (VBP are) (ADJP (JJ necessary)) (PP (IN for) (NP (DT the) (NNP IL-5) (NN promoter) (NN activation))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN requirement)) (PP (IN of) (NP (NP (DT another) (JJ regulatory) (NN element)) (VP (VBN called) (S (NP (NNP CLE0)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ lies) (NP (NP (JJ downstream)) (PP (IN of) (NP (DT the) (CD -70) (NNP GATA) (NN site))))))) (, ,)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN demonstrated))) (. .)))
(TOP (S (S (NP (NN ATL-16T) (NNS cells)) (VP (VBP express) (NP (NP (NNP mRNA)) (PP (IN of) (NP (NP (CD three) (JJ GATA-binding) (NNS proteins)) (, ,) (NP (NN hGATA-2) (, ,) (NN hGATA-3) (CC and) (NN hGATA-4))))))) (, ,) (CC and) (S (NP (NP (DT each)) (PP (IN of) (NP (PRP them)))) (VP (VBZ has) (NP (DT a) (NN potential) (S (VP (TO to) (VP (NN bind) (PP (TO to) (NP (DT the) (NN consensus) (NNP -LRB-A/T-RRB-GATA-LRB-G/A-RRB-) (NN motif))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (S (VP (VBG using) (NP (NNP ATL-16T) (JJ nuclear) (VBP extract)))) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (SBAR (DT that) (S (NP (NN GATA-4)) (VP (VBZ is) (NP (NP (DT the) (RB only) (JJ GATA-binding) (NN protein)) (SBAR (WHNP (WDT that)) (S (VP (VBZ forms) (NP (NP (JJ specific) (JJ DNA-protein) (NN complex)) (PP (IN with) (NP (DT the) (CD -70) (NNP GATA) (NN site)))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)) (PP (IN with) (NP (NP (NNS extracts)) (PP (IN of) (NP (NP (NNP COS) (NNS cells)) (VP (VBG expressing) (NP (JJ GATA-binding) (NNS proteins)))))))) (VP (VBD showed) (SBAR (DT that) (S (NP (NN GATA-4)) (VP (VBZ has) (NP (NP (DT the) (JJS highest) (JJ binding) (NN affinity)) (PP (TO to) (NP (NP (DT the) (CD -70) (NNP GATA) (NN site)) (PP (IN among) (NP (DT the) (CD three) (JJ GATA-binding) (NNS proteins)))))))))) (. .)))
(TOP (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NN transactivation) (NN ability)) (VP (VBD was) (VP (VBN compared) (PP (IN among) (NP (DT the) (CD three))))))) (, ,) (NP (NNP GATA-4)) (VP (VBD showed) (NP (DT the) (JJS highest) (NN activity))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT the) (JJ selective) (NN role)) (PP (IN of) (NP (NN GATA-4))) (PP (IN in) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NN IL-5) (NN gene))) (PP (IN in) (NP (NP (DT a) (NN circumstance)) (SBAR (WHADVP (WRB where)) (S (NP (NP (JJ multiple) (NNS members)) (PP (IN of) (NP (DT the) (JJ GATA-binding) (NNS proteins)))) (VP (VBP are) (VP (VBN expressed))))))))))) (. .)))
(TOP (S (NP (NP (VBN Increased) (NN expression)) (PP (IN of) (NP (NNP Gs-LRB-alpha-RRB-)))) (VP (VBZ enhances) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (JJ adenylyl) (NN cyclase) (NN signal) (NN transduction) (NN cascade))))) (. .)))
(TOP (S (NP (NP (NN Expression)) (PP (IN of) (NP (NP (DT the) (JJ stimulatory) (NNP G) (NN protein)) (, ,) (NP (NNP G-LRB-S-RRB-alpha)) (, ,)))) (VP (MD can) (VP (VB vary) (PP (PP (IN over) (NP (NP (DT a) (JJ 3-fold) (NN range)) (PP (IN in) (NP (JJ human) (NNS tissues))))) (CC and) (PP (IN in) (NP (JJ rodent) (JJ central) (JJ nervous) (NN system)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN fact))) (, ,) (NP (NP (DT the) (NN offspring)) (PP (IN of) (NP (NNS alcoholics)))) (VP (VBP have) (NP (NP (JJR higher) (NNS levels)) (PP (IN of) (NP (JJ G-LRB-S-RRB-alpha) (NN expression))) (PP (IN in) (NP (JJ certain) (NNS tissues)))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN offspring)) (PP (IN of) (NP (NNS nonalcoholics))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN research)))) (VP (VBD was) (S (VP (TO to) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (DT a) (JJ causal) (NN relationship)) (VP (VBZ exists) (PP (IN between) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NN G-LRB-S-RRB-alpha) (CC and) (NN induction)) (PP (IN of) (NP (DT the) (JJ adenylyl) (NN cyclase) (PRN (-LRB- -LRB-) (NNP AC) (-RRB- -RRB-)) (NN cascade))))))))))))))))) (. .)))
(TOP (S (NP (DT The) (NN methodology)) (VP (VBD employed) (NP (NP (JJ transient) (NN transfection)) (PP (IN of) (NP (NNP HEK) (CD 293) (NNS cells)))) (PP (IN with) (NP (NP (DT a) (NN cDNA)) (PP (IN for) (NP (NP (DT the) (JJ 52-kDa) (NN form)) (PP (IN of) (NP (NN G-LRB-S-RRB-alpha))) (PP (IN under) (NP (NP (NN regulation)) (PP (IN by) (NP (JJ inducible) (NN metallothionein) (NNS promoters)))))))))) (. .)))
(TOP (S (NP (NNS Transfectants)) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (VBG varying) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 0-125) (NNP microM)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NN zinc) (NN sulfate)) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (DT a) (JJ 3-fold) (NN range)) (PP (IN of) (NP (JJ membrane) (JJ G-LRB-S-RRB-alpha) (NN expression))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN range)) (PP (IN of) (NP (JJ G-LRB-S-RRB-alpha) (NN expression))) (VP (VBD produced))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB mimic) (NP (NP (DT a) (ADJP (RB physiologically) (JJ relevant)) (NN spectrum)) (PP (IN of) (NP (JJ G-LRB-S-RRB-alpha) (NN expression))) (PP (IN in) (NP (NP (NNS membranes)) (VP (VBN derived) (PP (IN from) (NP (NP (JJ human) (NNS tissues)) (CC and) (NP (NN rat) (NN brain))))))))))))) (. .)))
(TOP (S (NP (PRP It)) (VP (VBD was) (VP (VBN observed) (UCP (SBAR (IN that) (S (NP (NP (NN induction)) (PP (IN of) (NP (JJ G-LRB-S-RRB-alpha) (NN expression)))) (VP (VBD increased) (S (ADJP (JJ constitutive)))))) (CONJP (RB as) (RB well) (IN as)) (VP (VBN stimulated) (NP (NNP cAMP) (NN accumulation)))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN induction)) (PP (IN of) (NP (JJ G-LRB-S-RRB-alpha) (NN expression)))) (VP (VBN increased) (NP (NP (NNS events)) (ADJP (JJ distal) (PP (TO to) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NNP cAMP))) (PP (VBG including) (NP (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor)))) (, ,) (NP (NP (JJ cAMP) (NN response) (NN element)) (NP (NP (VBG binding) (NN protein)) (CC and) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (JJ cAMP-dependent) (NN reporter) (NNS genes))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN summary))) (, ,) (NP (DT these) (NNS studies)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (JJ G-LRB-S-RRB-alpha) (NN expression)))) (VP (VBZ has) (NP (NP (DT a) (JJ marked) (NN impact)) (PP (IN on) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN activity)) (PP (IN of) (NP (DT the) (NNP AC) (NN cascade))))) (PP (IN from) (NP (DT the) (NN membrane))) (PP (IN through) (PP (TO to) (NP (DT the) (NN nucleus))))))))))) (. .)))
(TOP (S (NP (PRP It)) (VP (VBZ is) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (NNS individuals)) (SBAR (WHNP (WP who)) (S (VP (VBP differ) (PP (IN in) (NP (JJ G-LRB-S-RRB-alpha) (NN expression))))))) (VP (MD may) (ADVP (RB also)) (VP (VB differ) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ certain) (JJ cAMP-dependent) (NNS genes))))))))))) (. .)))
(TOP (S (NP (NP (NN Expression)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (PP (IN during) (NP (NN sodium) (NN phenylacetate)))))) (VP (VBD induced) (NP (JJ erythroid) (NN differentiation)) (PP (IN in) (NP (CD K562) (NNS cells)))) (. .)))
(TOP (S (PP (IN During) (NP (NP (CD 15) (NNS days)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (CD K562) (NNS cells)) (PP (IN with) (NP (NN sodium) (NN phenylacetate))))))))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT the) (JJ cellular) (NN hemoglobin) (NN concentration))) (PP (IN with) (NP (NP (DT a) (JJ similar) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ gamma-globin) (NNP mRNA))))))))) (. .)))
(TOP (S (NP (JJ Morphological) (NNS studies)) (VP (VBD demonstrated) (NP (NP (JJ characteristic) (NNS features)) (PP (IN of) (NP (JJ erythroid) (NN differentiation) (CC and) (NN maturation))))) (. .)))
(TOP (S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (NP (EX there)) (VP (VBD was) (SBAR (S (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NN cell) (NN surface)))))))) (VP (VBZ antigenes) (NP (NP (NNP CD33)) (, ,) (NP (NNP CD34)) (, ,) (NP (NNP CD45)) (, ,) (NP (NNP CD71)) (CC and) (NP (NNP glycophorin) (NNP A))))))) (. .)))
(TOP (S (ADVP (RB Likewise)) (, ,) (NP (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ erythroid) (NN transcription) (NNS factors) (NNP GATA-1) (, ,) (NNP GATA-2) (, ,) (NNP NF-E2) (, ,) (NNP SCL) (CC and) (NNP RBTN2)))))) (, ,) (NP (NP (DT all)) (VP (VBN expressed) (PP (IN in) (NP (JJ untreated) (NNP K562) (NNS cells))))) (, ,)) (VP (VBD did) (RB not) (VP (VB increase) (PP (IN during) (NP (NN sodium) (NN phenylacetate))) (S (VP (VBD induced) (NP (JJ erythroid) (NN differentiation)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (DT the) (JJ nuclear) (NNS factors) (JJ Evi-1) (CC and) (JJ c-myb))) (, ,) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (JJ erythroid) (NN differentiation)))))) (, ,)) (VP (VBD did) (RB not) (VP (VB decrease))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP conclude) (SBAR (DT that) (S (NP (NP (NN sodium) (JJ phenylacetate) (NN treatment)) (PP (IN of) (NP (NNP K562) (NNS cells)))) (VP (VP (VBZ increases) (NP (JJ gamma-globin) (NN mRNA))) (CC and) (VP (VBZ induces) (NP (NN cell) (NN maturation)) (SBAR (IN as) (S (VP (VBN judged) (PP (IN by) (NP (NN morphology))) (PP (IN without) (S (VP (VBG affecting) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ erythroid) (NN transcription) (NNS factors)) (, ,) (SBAR (WHNP (WHNP (DT some)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ beta-like) (NN globin) (NNS genes))))))))))))))))))))))))))) (. .)))
(TOP (NP (NP (JJ Glucocorticoid) (NNS receptors)) (PP (PP (IN in) (NP (NP (JJ human) (JJ peripheral) (NN blood) (NN mononuclear) (NNS cells)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NN age))))))) (CC and) (PP (TO to) (NP (NN sport) (NN activity)))) (. .)))
(TOP (S (NP (NP (JJ Glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NNP GR) (-RRB- -RRB-))) (VP (VP (VBP are) (NP (JJ ubiquitous) (NNS molecules))) (CC and) (VP (VBP are) (ADJP (JJ present)) (PP (PP (ADVP (RB also)) (IN in) (NP (DT the) (NN hippocampus))) (CC and) (PP (IN in) (NP (JJ several) (JJ other) (ADJP (JJ nervous) (CC and) (JJ immune)) (NNS tissues)))))) (. .)))
(TOP (S (NP (NP (JJ Peripheral) (NN blood) (NN mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP PBMCs)) (-RRB- -RRB-))) (VP (VBP are) (NP (NP (DT a) (JJ good) (NN model)) (PP (IN for) (NP (NP (NNS studies)) (PP (IN of) (NP (NNP GR))) (PP (IN in) (NP (NNS humans))))))) (. .)))
(TOP (S (NP (NNS Glucocorticoids)) (VP (VP (VBP are) (ADJP (JJ important) (PP (IN for) (S (VP (VBG maintaining) (NP (NP (JJ cellular)) (CC and) (NP (JJ humoral) (NN homeostasis)))))))) (CC and) (VP (VBP are) (NP (NP (JJ key) (NNS mediators)) (PP (IN of) (NP (JJ neuroendocrine-immune) (JJ regulatory) (NNS interactions)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN increase)) (PP (IN of) (NP (NN cortisol)))) (VP (VP (VBZ is) (ADJP (JJ immunosuppressive))) (CC and) (VP (VBZ reduces) (NP (NNP GR) (NN concentration)) (PP (DT both) (IN in) (NP (ADJP (JJ nervous) (CC and) (JJ immune)) (NNS systems))))) (. .)))
(TOP (S (NP (NP (NN Variation)) (PP (IN of) (NP (NP (NNS glucocorticoids)) (PP (IN in) (NP (JJ healthy) (VBN aged) (NNS subjects) (CC and) (NNS athletes)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown)))) (. .)))
(TOP (S (S (VP (VBN Prompted) (PP (IN by) (NP (DT these) (NNS results))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN investigated) (PP (IN in) (NP (NN man))) (NP (NP (DT a) (JJ possible) (NN relationship)) (PP (IN between) (NP (NP (NNP GR) (VBG binding) (NN capacity)) (PP (PP (IN in) (NP (DT the) (NNS PBMCs) (CC and) (NN age))) (, ,) (PP (IN in) (NP (NP (NN relation)) (PP (ADVP (RB also)) (TO to) (NP (NP (NN plasma) (NN testosterone)) (CC and) (NP (NN cortisol)))))))))))) (. .)))
(TOP (S (NP (DT The) (JJ same) (NNS parameters)) (VP (VBP have) (VP (VBN been) (VP (VBN examined) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NN soccer) (NNS players))))) (PP (IN for) (NP (NP (NN comparison)) (PP (IN with) (NP (DT the) (JJ sedentary) (NN group)))))))) (. .)))
(TOP (S (NP (NNP GR) (JJ binding) (NN capacity)) (VP (VBD was) (ADJP (ADJP (ADJP (ADJP (ADJP (JJR higher)) (PP (IN in) (NP (JJR younger) (NNS subjects)))) (PP (IN than) (PP (IN in) (NP (JJR older) (NNS ones))))) (, ,) (CC and) (ADJP (ADJP (JJR lower))) (PP (IN in) (NP (NP (DT the) (NN group)) (PP (IN of) (NP (NNS athletes)))))) (PP (IN than) (PP (IN in) (NP (DT the) (ADJP (JJR younger) (CC and) (JJR older)) (JJ sedentary) (NNS subjects)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ sedentary) (NN group))) (NP (DT a) (JJ negative) (NN correlation)) (VP (VBD was) (ADJP (JJ present) (PP (IN between) (NP (NP (NNP GR) (VBG binding) (NN capacity)) (CC and) (NP (NN age)))))) (. .)))
(TOP (S (S (NP (NN Plasma) (NN cortisol)) (VP (VP (VBD was) (ADJP (JJR higher))) (CC and) (VP (VB testosterone) (ADVP (JJR lower)) (PP (IN in) (NP (DT the) (NNS athletes)))))) (: ;) (S (NP (PRP they)) (VP (VBD were) (ADVP (RB negatively)) (VP (VP (VBN correlated) (PP (IN in) (NP (NNS athletes)))) (CC and) (VP (ADVP (RB positively)) (VBN correlated) (PP (IN in) (NP (DT the) (JJ sedentary) (NNS subjects))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNS results)) (PP (IN for) (NP (NNS athletes)))) (VP (VBP agree) (PP (IN with) (NP (PRP$ their) (JJR lower) (JJ anabolic/catabolic) (NN balance)))) (. .)))
(TOP (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NP (JJ reduced) (NNP GR) (NNS levels)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NN age) (CC and) (NN sport) (NN activity)))))))) (VP (MD could) (VP (VB involve) (NP (NP (DT a) (NN loss)) (CC or) (NP (NP (DT an) (NN involution)) (PP (IN of) (NP (NN receptor) (NN synthesis))))))) (. .)))
(TOP (S (ADVP (RB However)) (NP (NP (JJ other) (NNS possibilities)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ altered) (NN distribution)) (PP (PP (IN of) (NP (NP (JJ lymphocyte) (NNS subpopulations)) (PP (IN with) (NP (JJ different) (NN receptor) (NNS concentrations))))) (CC and) (PP (IN with) (NP (JJ different) (NN cytokine) (NN production)))))) (, ,)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN excluded)))) (. .)))
(TOP (S (NP (JJ Several) (JJ neuroendocrine-immune) (NNS interactions)) (VP (MD could) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (JJ reduced) (NNP GR) (NNS levels)) (PP (IN with) (NP (NP (NN age) (CC and) (NN sport) (NN activity)) (PP (IN in) (NP (NN man)))))))))) (. .)))
(TOP (NP (NP (NN Rescue)) (PP (IN by) (NP (NP (NNS cytokines)) (PP (IN of) (NP (JJ apoptotic) (NN cell) (NN death))))) (VP (VBN induced) (PP (IN by) (NP (NP (NN IL-2) (NN deprivation)) (PP (IN of) (NP (JJ human) (JJ antigen-specific) (NNP T) (NN cell) (NNS clones)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN control)) (PP (IN of) (NP (NP (NN cell) (NN survival)) (CC and) (NP (NN cell) (NN death))))) (VP (VBZ is) (PP (IN of) (NP (NP (JJ central) (NN importance)) (PP (IN in) (NP (NP (NNS tissues)) (PP (IN with) (NP (NP (JJ high) (NN cell) (NN turnover)) (PP (JJ such) (IN as) (NP (DT the) (JJ lymphoid) (NN system)))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNS cytokines)) (PP (IN on) (NP (NP (JJ IL-2) (JJ deprivation-induced) (NN apoptosis)) (PP (IN of) (NP (JJ human) (JJ antigen-specific) (NNP T) (NN helper) (NNS clones)))))))) (PP (IN with) (NP (JJ different) (JJ cytokine) (NN production) (NNS profiles))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT that) (NN IL-2)) (, ,) (NP (NP (NN interferon-alpha)) (PRN (-LRB- -LRB-) (NP (NN IFN-alpha)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ IFN-beta) (VBN inhibited) (NN IL-2) (NN deprivation) (NN apoptosis)) (PP (IN in) (NP (NNP Th0) (, ,) (NNP Th1) (, ,) (CC and) (JJ Th2) (NNS clones)))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD found) (SBAR (DT that) (S (NP (NN IL-2)) (VP (VBZ protects) (NP (NNP T) (NN cell) (NNS clones)) (PP (IN from) (NP (NP (NN IL-2) (NN deprivation) (NN apoptosis)) (VP (VBG accompanying) (NP (NP (JJ active) (NN proliferation)) (CC and) (NP (NP (JJ enhanced) (NN expression)) (PP (IN of) (NP (NNP P53) (, ,) (NNP Rb) (CC and) (NNP Bcl-xL) (NNS proteins)))))))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP IFN-alpha/beta)) (VP (VBD rescued) (NP (NNP T) (NN cell) (NNS clones)) (PP (IN from) (NP (NP (NN apoptosis)) (PP (IN without) (NP (JJ active) (NN proliferation))))))) (, ,) (CC and) (S (NP (NP (NN expression)) (PP (IN of) (NP (NP (JJ apoptosis-associated) (NNS proteins)) (VP (VBN tested))))) (ADVP (RB so) (RB far)) (VP (VBD was) (ADJP (JJ unaffected)))) (. .)))
(TOP (S (NP (DT This)) (VP (MD may) (VP (VB be) (ADJP (JJ due) (PP (TO to) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (NNP T) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NN IL-2))))) (VP (VBD contained) (NP (NP (DT those)) (VP (VBN located) (PP (IN in) (NP (NP (NNP S) (CD +) (NNP G2/M) (NNS phases)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ vast) (NN majority)) (PP (IN of) (NP (NP (NNP T) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NNP IFN-alpha/beta))))))) (VP (VBD were) (VP (VBN located) (PP (IN in) (NP (NNP G0/G1) (NN phase))))))))))))))) (. .)))
(TOP (S (NP (NNP IFN-alpha/beta)) (ADVP (RB specifically)) (VP (VP (VBD induced) (NP (JJ tyrosine) (NN phosphorylation))) (CC and) (VP (NN translocation) (PP (IN into) (NP (NP (NN nucleus)) (PP (IN of) (NP (NP (NN signal) (NNS transducers)) (CC and) (NP (NP (NNS activators)) (PP (IN of) (NP (NN transcription) (PRN (-LRB- -LRB-) (NNP STAT) (-RRB- -RRB-)) (CD 2) (NN protein)))))))) (PP (IN in) (NP (DT the) (NNP T) (NN cell) (NNS clones))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN over-expression)) (PP (IN of) (NP (CD STAT2))) (PP (IN by) (NP (NP (NN transfection)) (PP (IN of) (NP (DT the) (NNP cDNA)))))) (VP (VBD prevented) (NP (NP (NN apoptosis)) (PP (IN of) (NP (DT the) (NNP T) (NN cell) (NNS clones))))) (. .)))
(TOP (S (NP (PRP$ Our) (JJ present) (NN study)) (VP (NNS shows) (SBAR (WDT that) (S (S (VP (VP (VBP IFN-alpha)) (CC and) (VP (VBP -beta)))) (VP (VB mediate) (NP (JJ anti-apoptotic) (NN effect)) (PP (IN through) (NP (JJ other) (NNS pathways))) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NP (NN IL-2)) (PP (IN in) (NP (NN growth) (NN factor) (NN deprivation) (NN apoptosis))))))))))) (. .)))
(TOP (S (NP (NP (JJ Lipopolysaccharide) (NN induction)) (PP (IN of) (NP (DT the) (NN tumor)))) (VP (VBZ necrosis) (NP (JJ factor-alpha) (NN promoter)) (PP (IN in) (NP (JJ human) (JJ monocytic) (NNS cells)))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN by) (NP (ADJP (JJ Egr-1) (, ,) (JJ c-Jun) (, ,) (CC and) (JJ NF-kappaB)) (NN transcription) (NNS factors))) (. .)))
(TOP (S (NP (NP (NNS Biosynthesis)) (PP (IN of) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NN TNF-alpha) (-RRB- -RRB-))))) (VP (VBZ is) (ADVP (RB predominantly)) (PP (IN by) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ monocytic) (NN lineage)))))) (. .)))
(TOP (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ various) (JJ cis-acting) (JJ regulatory) (NNS elements))) (PP (IN in) (NP (NP (DT the) (NN lipopolysaccharide) (PRN (-LRB- -LRB-) (NNP LPS) (-RRB- -RRB-)) (NN induction)) (PP (IN of) (NP (DT the) (JJ human) (JJ TNF-alpha) (NN promoter))) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (JJ monocytic) (NN lineage))))))))) (. .)))
(TOP (S (NP (NP (JJ Functional) (NN analysis)) (PP (IN of) (NP (JJ monocytic) (JJ THP-1) (NNS cells)))) (VP (VBN transfected) (PP (IN with) (NP (NP (NNS plasmids)) (VP (VBG containing) (NP (NP (JJ various) (NNS lengths)) (PP (IN of) (NP (NP (NP (JJ TNF-alpha) (NN promoter) (VBD localized) (NN enhancer) (NNS elements)) (PP (IN in) (NP (DT a) (NN region)))) (PRN (-LRB- -LRB-) (NP (NP (CD -182)) (PP (TO to) (NP (NP (CD -37) (NN base) (NNS pairs)) (PRN (-LRB- -LRB-) (NN bp) (-RRB- -RRB-))))) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (VP (VBN required) (PP (IN for) (NP (NP (JJ optimal) (NN transcription)) (PP (IN of) (NP (DT the) (JJ TNF-alpha) (NN gene))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP LPS)))))))))))))))) (. .)))
(TOP (S (S (NP (CD Two) (NNS regions)) (VP (VBD were) (VP (VBN identified)))) (: :) (S (S (NP (NP (NN region) (PRP I)) (PRN (-LRB- -LRB-) (NP (QP (CD -182) (TO to) (CD -162)) (NN bp)) (-RRB- -RRB-))) (VP (VBD contained) (NP (DT an) (VBG overlapping) (NN Sp1/Egr-1) (NN site)))) (, ,) (CC and) (S (NP (NP (NN region) (NNP II)) (PRN (-LRB- -LRB-) (NP (NP (CD -119)) (PP (TO to) (NP (CD -88)))) (-RRB- -RRB-))) (VP (VBD contained) (NP (NP (NNP CRE) (CC and) (NNP NF-kappaB)) (PRN (-LRB- -LRB-) (VP (VBN designated) (S (NP (NNP kappaB3)))) (-RRB- -RRB-))) (NP (NNS sites))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ unstimulated) (NN THP-1)) (, ,) (NP (JJ CRE-binding) (NN protein)) (CC and) (, ,) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (, ,))) (NP (JJ c-Jun) (NNS complexes)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (NN bind) (PP (TO to) (NP (DT the) (NNP CRE) (NN site)))))))) (. .)))
(TOP (S (NP (NNP LPS) (NN stimulation)) (VP (VBD increased) (NP (NP (DT the) (JJ binding)) (PP (IN of) (NP (JJ c-Jun-containing) (NNS complexes))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP LPS) (NN stimulation)) (VP (VBD induced) (NP (NP (DT the) (VBG binding)) (PP (IN of) (NP (JJ cognate) (JJ nuclear) (NNS factors))) (PP (TO to) (NP (NP (DT the) (NNP Egr-1) (CC and) (NNP kappaB3) (NNS sites)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (VP (VBN identified) (PP (IN as) (ADJP (JJ Egr-1) (CC and) (JJ p50/p65))) (, ,) (ADVP (RB respectively)))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNP CRE) (CC and) (NNP kappaB3) (NNS sites)) (PP (IN in) (NP (NN region) (NNP II))) (ADVP (RB together))) (VP (VBD conferred) (NP (JJ strong) (NNP LPS) (NN responsiveness)) (PP (TO to) (NP (DT a) (JJ heterologous) (NN promoter))) (, ,) (SBAR (IN whereas) (S (ADVP (RB individually)) (NP (PRP they)) (VP (VBD failed) (S (VP (TO to) (VP (VB provide) (NP (JJ transcriptional) (NN activation))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (S (VP (VBG increasing) (NP (NP (DT the) (NN spacing)) (PP (IN between) (NP (NP (DT the) (NNP CRE)) (CC and) (NP (DT the) (JJ kappaB3) (NNS sites))))) (NP (ADJP (RB completely) (VBN abolished)) (NNP LPS) (NN induction)))) (, ,) (VP (VBG suggesting) (NP (NP (DT a) (JJ cooperative) (NN interaction)) (PP (IN between) (NP (JJ c-Jun) (NNS complexes) (CC and) (NNS p50/p65))))) (. .)))
(TOP (S (NP (DT These) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ maximal) (NNP LPS) (NN induction)) (PP (IN of) (NP (DT the) (JJ TNF-alpha) (NN promoter)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ concerted) (NN participation)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD two)) (JJ separate) (JJ cis-acting) (JJ regulatory) (NNS elements)))))))))) (. .)))
(TOP (S (NP (NP (JJ Inducible) (NN expression)) (CC and) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN coactivator) (NNP BOB.1/OBF.1))) (PP (IN in) (NP (NNP T) (NNS cells) (NNP -LSB-))))) (VP (VBP see) (S (NP (NNS comments)) (ADJP (NN -RSB-))))))
(TOP (S (NP (NNP BOB.1/OBF.1)) (VP (VBZ is) (NP (NP (DT a) (JJ transcriptional) (NN coactivator)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VP (ADVP (RB constitutively)) (VBN expressed) (PP (IN in) (NP (NN B) (NNS cells)))) (CC and) (VP (NNS interacts) (PP (IN with) (NP (DT the) (ADJP (NNP Oct1) (CC and) (NNP Oct2)) (NN transcription) (NNS factors)))))))))) (. .)))
(TOP (SINV (PP (IN Upon) (NP (NP (NN activation)) (PP (IN of) (NP (NP (NNP Jurkat) (NNP T) (NNS cells)) (CC and) (NP (NP (JJ primary) (JJ murine) (NNS thymocytes)) (PP (IN with) (NP (NP (JJ phorbol) (NNS esters)) (CC and) (NP (JJ ionomycin) (, ,) (JJ BOB.1/OBF.1) (NN expression) (CC and) (NN transactivation) (NN function))))))))) (VP (VBD were) (VP (VBN induced))) (. .)))
(TOP (S (S (NP (NNP BOB.1/OBF.1)) (VP (VBD was) (VP (VBN phosphorylated) (PP (IN at) (NP (NNP Ser184))) (PP (DT both) (PP (IN in) (NP (NN vivo))) (CC and) (PP (IN in) (NP (NN vitro))))))) (, ,) (CC and) (S (NP (DT this) (NN modification)) (VP (VBD was) (VP (VBN required) (PP (IN for) (NP (JJ inducible) (NN activation)))))) (. .)))
(TOP (S (NP (NP (NN Mutation)) (PP (IN of) (NP (NNP Ser184)))) (ADVP (RB also)) (VP (VBD diminished) (NP (NN transactivation) (NN function)) (PP (IN in) (NP (NNP B) (NNS cells))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT the) (VBG activating) (NN phosphorylation)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ inducible) (PP (IN in) (NP (NNP T) (NNS cells)))))))) (VP (VBZ is) (ADJP (RB constitutively) (JJ present)) (PP (IN in) (NP (NNP B) (NNS cells))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NNP BOB.1/OBF.1)) (VP (VBZ is) (NP (NP (DT a) (JJ transcriptional) (NN coactivator)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (ADVP (RB critically)) (VBN regulated) (PP (IN by) (NP (NP (JJ posttranslational) (NNS modifications)) (SBAR (S (VP (TO to) (VP (VB mediate) (NP (NN cell) (JJ type-specific) (NN gene) (NN expression)))))))))))))) (. .)))
(TOP (NP (NP (NNS Cytokines)) (: :) (NP (NP (JJ shared) (NNS receptors)) (, ,) (NP (JJ distinct) (NNS functions))) (. .)))
(TOP (S (S (SBAR (IN That) (S (NP (NP (DT the) (NN signal) (NN transduction) (NNS pathways)) (VP (VBN used) (PP (IN by) (NP (DT the) (NNS cytokines) (NN IL-2) (CC and) (NN IL-15))))) (VP (VBP are) (ADJP (JJ identical))))) (VP (MD would) (VP (VB suggest) (SBAR (IN that) (S (NP (DT these) (NNS cytokines)) (VP (VBP have) (NP (NP (JJ redundant) (NNS roles)) (PP (IN in) (NP (JJ lymphoid) (NN development)))))))))) (: ;) (S (ADVP (RB instead)) (, ,) (NP (NN IL-2)) (VP (VBZ is) (NP (NP (DT the) (NN guardian)) (PP (IN of) (NP (JJ thymus-derived) (NNP T-cell) (NN homeostasis)))) (, ,) (SBAR (IN while) (S (NP (NN interleukin-15)) (VP (VBZ promotes) (NP (NP (JJ extrathymic) (NN development)) (PP (IN of) (NP (NNP T) (CC and) (NNP NK) (NNS cells))))))))) (. .)))
(TOP (NP (NP (NP (NNP Association)) (PP (IN between) (NP (NP (NN expression)) (PP (IN of) (NP (NP (JJ intercellular) (NN adhesion) (NN molecule-1) (CC and) (NN integration)) (PP (IN of) (NP (JJ human) (NNP T-cell-leukemia) (NN virus)))))))) (NP (NP (NN type) (CD 1)) (PP (IN in) (NP (JJ adult) (JJ T-cell) (NN leukemia) (NNS cells)))) (. .)))
(TOP (S (NP (NP (PRP It))) (VP (VBZ is) (VP (VBN known) (SBAR (IN that) (S (NP (NP (DT the) (NN expression) (NNS levels)) (PP (IN of) (NP (NP (JJ intercellular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN ICAM-1)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ adult) (NNP T) (NN cell) (NN leukemia) (PRN (-LRB- -LRB-) (NNP ATL) (-RRB- -RRB-)) (NNS cells)))))) (VP (VBP are) (ADJP (JJ high)) (, ,) (SBAR (IN whereas) (S (NP (NP (DT those)) (PP (IN in) (NP (JJ T-lymphoid) (NNS cells)))) (VP (VBP are) (RB not))))))))) (. .)))
(TOP (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP influence) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ ICAM-1) (NNS molecules)))))))))))) (, ,) (NP (NP (JJ Northern) (NN blot) (NN analysis)) (SBAR (S (VP (TO to) (VP (VB measure) (NP (NP (DT the) (NN expression) (NN level)) (PP (IN of) (NP (NP (JJ ICAM-1) (NNS mRNAs)) (CC and) (NP (JJ Southern) (NN blot) (NN hybridization))))) (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NN integration)) (PP (IN of) (NP (JJ human) (NNP T-cell-leukemia) (NN virus) (NN type) (CD 1) (PRN (-LRB- -LRB-) (NN HTLV-1) (-RRB- -RRB-)) (NNS provirus)))))))))))) (VP (VBD were) (VP (VBN done))) (. .)))
(TOP (S (NP (NP (DT The) (NNS levels)) (PP (IN of) (NP (NP (NNP ICAM-1) (NNP mRNA) (NN expression)) (PP (IN of) (NP (NNP ATL) (NNS cells)))))) (VP (VBD were) (ADJP (ADJP (RB generally) (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (JJ T-lymphoid) (NNS cells))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (NP (JJ ILT-mat) (NNS cells)) (CC and) (NP (NN ATL16T-LRB---RRB-) (NNS cells))) (, ,) (SBAR (IN although) (S (NP (PRP they)) (VP (VBD were) (NP (NNP ATL) (NNS cells))))) (, ,) (VP (VBD showed) (NP (NP (ADJP (RB rather) (JJ low)) (NN surface) (NN ICAM-1) (NN expression)) (CC and) (NP (NNP ICAM-1) (NNP mRNA) (NN expression)))) (. .)))
(TOP (S (NP (JJ Southern) (NN blot) (NN hybridization)) (VP (VBD showed) (SBAR (IN that) (S (NP (QP (RB only) (CD two) (CC and) (CD four)) (NNS bands)) (VP (VBD were) (VP (VBN found) (PP (IN in) (NP (NNP ILT-mat) (CC and) (NNP ATL16T-LRB---RRB-) (NNS cells))) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (IN whereas) (S (NP (CD &gt;) (CD 10) (NNS bands)) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (JJ other) (NNP ATL) (NNS cells)))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (S (SBAR (IN that) (S (NP (NP (JJ monoclonal) (NN integration)) (PP (IN of) (NP (NNP HTLV-1)))) (VP (VBZ provirus) (PP (TO to) (NP (NP (NP (DT the) (NN genome)) (PP (IN of) (NP (NNP T) (NN cell)))) (, ,) (ADVP (RB especially)) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN integration) (NNS sites)))) (, ,)))))) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS factors)) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (JJ ICAM-1) (NNS molecules)))))))))))) (. .)))
(TOP (NP (NP (NN Role)) (PP (IN of) (NP (NP (DT the) (NN X2) (NN box)) (PP (IN in) (NP (VBN activated) (NN transcription))) (PP (IN from) (NP (DT the) (NNP DRA) (NN promoter))) (PP (IN in) (NP (NNP B) (NNS cells))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NP (DT the) (JJ evolutionary) (JJ conserved) (NN X2) (NN box)) (PP (IN in) (NP (NP (DT the) (NN promoter)) (PP (IN of) (NP (DT the) (NNP HLA-DRA) (NN gene)))))))) (PP (IN from) (NP (NP (DT the) (JJ human) (JJ major) (NN histocompatibility) (NN complex)) (PRN (-LRB- -LRB-) (NP (NNP MHC)) (-RRB- -RRB-)))) (PP (IN in) (S (VP (VBG resting) (CC and) (VBN activated) (NP (NN B) (NNS cells)))))) (. .)))
(TOP (S (NP (NP (NN NF-X2)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ contains) (NP (NP (NNS members)) (PP (IN of) (NP (NP (DT the) (NN AP-1/ATF/CREB) (NNS families)) (PP (IN of) (NP (NN transcription) (NNS factors))))))))) (, ,)) (VP (NNS interacts) (PP (IN with) (NP (NP (DT the) (NN X2) (NN box)) (PRN (-LRB- -LRB-) (NP (NN 5'-TGCGTCA-3')) (-RRB- -RRB-)))) (PP (IN from) (NP (NP (NNS positions)) (NP (NP (CD -97)) (PP (TO to) (NP (CD -91))) (PP (IN in) (NP (DT the) (NNP DRA) (NN promoter))))))) (. .)))
(TOP (S (PP (IN In) (S (VP (VBG resting) (NP (NNP Raji) (NNS cells))))) (, ,) (NP (NP (JJ little)) (PP (TO to) (NP (NP (DT no) (VBG binding)) (PP (TO to) (NP (DT the) (NNP X2) (NN box)))))) (VP (VBD was) (VP (VBN observed))) (. .)))
(TOP (S (PP (IN In) (NP (JJ sharp) (NN contrast))) (, ,) (PP (IN in) (NP (NP (NN B) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (FW phorbol) (FW ester) (NNP 12-O-tetradecanoylphorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NNP TPA)) (-RRB- -RRB-))))))) (, ,) (NP (NP (JJ strong) (NNS interactions)) (PP (IN between) (NP (NP (DT the) (NNP X2) (NN box) (CC and) (NN NF-X2)) (VP (VBG containing) (NP (NNS c-Fos)))))) (VP (VBD were) (VP (VBN observed))) (. .)))
(TOP (S (S (SBAR (IN As) (S (VP (VBN determined) (PP (IN by) (NP (NP (JJ transient) (NN expression)) (CC and) (NP (NNP RNA) (NNS analyses))))))) (, ,) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (NN protein) (NN kinase) (NNP C)) (PRN (-LRB- -LRB-) (NP (NNP PKC)) (-RRB- -RRB-))))) (ADVP (RB also)) (VP (VBN increased) (NP (NP (NNS rates)) (PP (IN of) (NP (NN transcription)))) (PP (IN from) (NP (DT the) (JJ wild-type) (NNP DRA) (NN promoter))))) (CC but) (S (RB not) (PP (IN from) (NP (DT a) (NNP DRA) (NN promoter) (NN bearing))) (VP (VBD clustered) (NP (NP (NN point) (NNS mutations)) (PP (IN in) (NP (DT the) (NNP X2) (NN box)))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP (NP (DT the) (NN co-expression)) (PP (IN with) (NP (DT a) (JJ dominant) (JJ negative) (NNS c-Fos)))) (VP (VBD abolished) (NP (NP (DT the) (NN responsiveness)) (PP (TO to) (NP (NNP TPA))))))) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (VBN activated) (NN transcription)) (PP (IN of) (NP (DT the) (NNP DRA) (NN gene)))) (VP (VBZ depends) (PP (IN on) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (DT the) (NNP X2) (NN box) (CC and) (NN NF-X2)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ contains) (NP (NNS c-Fos))))))))))))) (. .)))
(TOP (S (NP (NP (NN Transcription) (NN factor) (VBG binding) (NNS sites)) (ADJP (JJ downstream) (PP (IN of) (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (NN transcription) (NN start) (NN site))))) (VP (VBP are) (ADJP (JJ important) (PP (IN for) (NP (NN virus) (NN infectivity))))) (. .)))
(TOP (S (SBAR (WHADVP (WRB When)) (S (ADJP (RB transcriptionally) (JJ active)))) (, ,) (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus) (PRN (-LRB- -LRB-) (NNP HIV) (-RRB- -RRB-)) (NN promoter)) (VP (VBZ contains) (NP (NP (DT a) (JJ nucleosome-free) (NN region)) (VP (VBG encompassing) (NP (DT both) (NP (DT the) (NN promoter/enhancer) (NN region)) (CC and) (NP (NP (DT a) (JJ large) (NN region)) (PRN (-LRB- -LRB-) (ADJP (NP (NP (CD 255) (NNS nucleotides)) (VP (VBP -LSB-) (RB nt))) (JJ -RSB-)) (-RRB- -RRB-)) (ADJP (JJ downstream) (PP (IN of) (NP (DT the) (NN transcription) (NN start) (NN site))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN identified) (NP (NP (JJ new) (VBG binding) (NNS sites)) (PP (IN for) (NP (NP (NP (NN transcription) (NNS factors)) (ADJP (JJ downstream) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN start) (NN site)) (PRN (-LRB- -LRB-) (NP (RB nt) (NP (NP (CD 465)) (PP (TO to) (NP (CD 720))))) (-RRB- -RRB-)))))) (: :) (NP (NP (NP (CD three) (NNP AP-1) (NNS sites)) (PRN (-LRB- -LRB-) (NP (NP (NN I) (, ,) (NNP II)) (, ,) (CC and) (NP (NNP III))) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (JJ AP3-like) (NN motif)) (PRN (-LRB- -LRB-) (NP (NN AP3-L)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ downstream) (JJ binding) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP DBF)) (-RRB- -RRB-)) (NP (NN site)) (, ,) (CC and) (NP (VBN juxtaposed) (JJ Sp1) (NNS sites)))))))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (SBAR (IN that) (S (NP (DT the) (NNP DBF) (NN site)) (VP (VBZ is) (NP (NP (DT an) (JJ interferon-responsive) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP IRF)) (-RRB- -RRB-)) (VP (VBG binding) (NP (NN site))))))) (CC and) (SBAR (IN that) (S (NP (DT the) (NNP AP3-L) (NN motif)) (VP (VBZ binds) (S (NP (DT the) (JJ T-cell-specific) (NN factor)) (ADJP (NN NF-AT)))))))) (. .)))
(TOP (S (NP (NP (NNS Mutations)) (SBAR (WHNP (WDT that)) (S (VP (VBP abolish) (NP (NP (DT the) (VBG binding)) (PP (IN of) (NP (DT each) (NN factor)))) (PP (TO to) (NP (PRP$ its) (JJ cognate) (NN site))))))) (VP (VBP are) (VP (VBN introduced) (PP (IN in) (NP (NP (DT an) (JJ infectious) (NNP HIV-1) (JJ molecular) (NN clone)) (SBAR (S (VP (TO to) (VP (VB study) (NP (NP (PRP$ their) (NN effect)) (PP (IN on) (NP (NNP HIV-1) (NN transcription) (CC and) (NN replication)))))))))))) (. .)))
(TOP (S (NP (NP (NP (JJ Individual) (NN mutation)) (PP (IN of) (NP (DT the) (NNP DBF) (CC or) (NNP AP3-L) (NN site)))) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (JJ double) (NN mutation) (NN AP-1-LRB-III-RRB-/AP3-L))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NNP HIV-1) (NN replication)) (PP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ wild-type) (NN virus)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS proviruses)) (VP (VBG carrying) (NP (NP (NNS mutations)) (PP (IN in) (NP (DT the) (JJ Sp1) (NNS sites)))))) (VP (VBD were) (ADJP (RB totally) (JJ defective)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NN replication)))))) (. .)))
(TOP (S (NP (NN Virus) (NN production)) (VP (VBD occurred) (PP (IN with) (NP (NP (ADJP (RB slightly) (VBN delayed)) (NNS kinetics)) (PP (IN for) (NP (NP (NNS viruses)) (VP (VBG containing) (NP (NP (JJ combined) (NNS mutations)) (PP (PP (IN in) (NP (NP (DT the) (NNP AP-1-LRB-III-RRB-)) (, ,) (NP (NNP AP3-L)) (, ,) (CC and) (NP (NNP DBF) (NNS sites)))) (CC and) (PP (IN in) (NP (DT the) (NNP AP3-L) (CC and) (NNP DBF-sites)))))))))) (, ,) (SBAR (IN whereas) (S (NP (NNS viruses)) (VP (VBN mutated) (PP (PP (IN in) (NP (DT the) (NNP AP-1-LRB-I,II,III-RRB-) (CC and) (NNP AP3-L) (NNS sites))) (CC and) (PP (IN in) (NP (NP (DT the) (NNP AP-1-LRB-I,II,III-RRB-) (, ,) (NNP AP3-L) (, ,) (CC and) (NNP DBF) (NNS sites)) (VP (VBD exhibited) (NP (DT a) (ADJP (RB severely) (JJ defective)) (JJ replicative) (NN phenotype)))))))))) (. .)))
(TOP (S (NP (DT No) (JJ RNA-packaging) (NN defect)) (VP (MD could) (VP (VB be) (VP (VBN measured) (PP (IN for) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ mutant) (NNS viruses)) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (NN quantification)) (PP (IN of) (NP (PRP$ their) (NNP HIV) (NN genomic) (NNP RNA))))))))))))))) (. .)))
(TOP (S (NP (NP (NNP Measurement)) (PP (IN of) (NP (NP (DT the) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (DT the) (NNP HIV-1) (NN promoter))) (PP (IN after) (NP (NP (JJ transient) (NN transfection)) (PP (PP (IN of) (NP (DT the) (NNP HIV-1) (NN provirus) (NN DNA))) (CC or) (PP (IN of) (NP (JJ long) (NN terminal) (NN repeat-luciferase) (NNS constructs))))))))) (VP (VBD showed) (NP (NP (DT a) (JJ positive) (NN correlation)) (PP (IN between) (NP (NP (DT the) (NN transcriptional)) (CC and) (NP (NP (DT the) (NN replication) (NNS defects)) (PP (IN for) (NP (JJS most) (NNS mutants)))))))) (. .)))
(TOP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor-kappa) (NN B)) (PP (IN in) (NP (JJ cytokine) (NN gene) (NN regulation))))) (. .)))
(TOP (S (NP (NN Transcription) (NNS factors)) (VP (VBP are) (NP (NP (JJ DNA-binding) (NNS proteins)) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (NN gene) (NN expression))))))) (. .)))
(TOP (S (NP (NP (NNP Nuclear) (NNP factor-kappa) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP NF-kappa) (NNP B)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ critical) (NN transcription) (NN factor)) (PP (IN for) (NP (NP (JJ maximal) (NN expression)) (PP (IN of) (NP (JJ many) (NNS cytokines))))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ inflammatory) (NNS diseases))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (JJ adult) (JJ respiratory) (NN distress) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NNP ARDS)) (-RRB- -RRB-))) (CC and) (NP (NN sepsis) (NN syndrome)))))))))))) (. .)))
(TOP (S (NP (NP (NN Activation) (CC and) (NN regulation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))) (VP (VBP are) (VP (ADVP (RB tightly)) (VBN controlled) (PP (IN by) (NP (NP (NP (DT a) (NN group)) (PP (IN of) (NP (JJ inhibitory) (NNS proteins)))) (PRN (-LRB- -LRB-) (S (NP (PRP I)) (VP (VBP kappa) (NP (NNP B)))) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBP sequester) (NP (NNP NF-kappa) (NNP B)) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (JJ immune/inflammatory) (NN effector) (NNS cells)))))))))))) (. .)))
(TOP (S (S (NP (NNP NF-kappa) (NNP B) (NN activation)) (VP (VBZ involves) (NP (VBN signaled) (NN phosphorylation) (, ,) (NN ubiquitination)))) (, ,) (CC and) (S (NP (NP (NN proteolysis)) (PP (IN of) (NP (PRP I)))) (VP (VBP kappa) (NP (NNP B)))) (. .)))
(TOP (S (NP (NNP Liberated) (NNP NF-kappa) (NNP B)) (VP (VBZ migrates) (PP (TO to) (NP (NP (DT the) (NN nucleus)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (PRP it)) (VP (VP (VBZ binds) (PP (TO to) (NP (JJ specific) (NN promoter) (NNS sites)))) (CC and) (VP (NNS activates) (NP (NN gene) (NN transcription))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN activation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))) (VP (VBZ initiates) (NP (NP (DT both) (ADJP (JJ extracellular) (CC and) (JJ intracellular)) (JJ regulatory) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP result) (PP (IN in) (NP (NP (NN autoregulation)) (PP (IN of) (NP (DT the) (JJ inflammatory) (NN cascade))))) (PP (IN through) (NP (NP (NN modulation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NN activation)))))))))) (. .)))
(TOP (S (ADVP (RB Recently)) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN linked) (PP (TO to) (NP (NNP ARDS)))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (JJ critical) (JJ proximal) (NN step)) (PP (IN in) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NP (JJ neutrophilic) (NN inflammation)) (PP (IN in) (NP (NN animal) (NNS models))))))))))))))) (. .)))
(TOP (S (NP (NP (NNP Activation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))) (VP (MD can) (VP (VB be) (VP (VBN inhibited) (PP (IN in) (NP (NN vivo))) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNS antioxidants)) (, ,) (NP (NNS corticosteroids)) (, ,) (CC and) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN endotoxin) (NN tolerance))))))))))) (. .)))
(TOP (S (NP (NP (NN Identification)) (PP (IN of) (NP (NP (ADJP (RBR more) (JJ specific) (CC and) (JJ efficacious)) (NNS inhibitors)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NN activation)))))) (VP (MD might) (VP (VB prove) (ADJP (JJ beneficial) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ cytokine-mediated) (JJ inflammatory) (NNS diseases)))))))) (. .)))
(TOP (NP (NP (NP (JJ Pancreatic) (NN islet) (NN expression) (NNS studies)) (CC and) (NP (NP (JJ polymorphic) (NN DNA) (NNS markers)) (PP (IN in) (NP (DT the) (NNS genes))))) (ADJP (VP (VBG encoding) (NP (JJ hepatocyte) (JJ nuclear) (NN factor-3alpha))) (, ,) (ADJP (JJ -3beta)) (, ,) (ADJP (JJ -3gamma) (, ,) (JJ -4gamma) (, ,) (CC and) (CD -6))) (. .)))
(TOP (S (NP (NP (DT The) (NNS genes)) (VP (VBG encoding) (NP (DT the) (ADJP (RB functionally) (VBN related)) (JJ hepatocyte) (JJ nuclear) (NNS factors)) (ADJP (JJ HNF-1alpha) (CC and) (JJ HNF-4alpha)))) (VP (NN play) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (JJ normal) (JJ pancreatic) (JJ beta-cell) (NN function))))) (. .)))
(TOP (S (NP (NP (NNS Mutations)) (PP (IN in) (NP (DT these) (JJ liver-enriched) (NN transcription) (NNS factors)))) (VP (VBP result) (PP (IN in) (NP (NP (CD two) (NNS forms)) (PP (IN of) (NP (NP (NP (NP (JJ early-onset) (NN type) (CD 2) (NN diabetes)) (PRN (-LRB- -LRB-) (NP (NP (JJ maturity-onset) (NN diabetes)) (PP (IN of) (NP (DT the) (JJ young) (NNP -LSB-) (NNP MODY) (NNP -RSB-)))) (-RRB- -RRB-))) (, ,) (NP (NNP MODY3)) (CC and) (NP (NNP MODY1))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ impaired) (JJ glucose-stimulated) (NN insulin) (NN secretion)) (, ,) (NP (JJ early) (NN disease) (NN onset)) (, ,) (CC and) (NP (JJ autosomal) (JJ dominant) (NN inheritance))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ transcriptional) (NN hierarchy)) (PP (IN of) (NP (NNS HNFs)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (JJ other) (NNS proteins)) (PP (IN of) (NP (DT the) (JJ regulatory) (NN cascade)))) (VP (MD might) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (JJ other) (NNS forms)) (PP (IN of) (NP (NP (NNP MODY)) (CC and/or) (NP (JJ late-onset) (NN type) (CD 2) (NN diabetes)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (ADJP (JJ HNF-3alpha) (, ,) (JJ -3beta) (, ,) (JJ -3gamma) (, ,) (JJ -4gamma) (, ,) (CC and) (CD -6)) (VP (VBP are) (VP (VBN expressed) (PP (IN in) (NP (JJ pancreatic) (NNS beta-cells)))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN identification) (CC and) (NN characterization)) (PP (IN of) (NP (NP (NP (JJ simple) (NN tandem) (NN repeat) (NN DNA) (NNS polymorphisms)) (PP (IN in) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (S (ADJP (JJ HNF-3alpha) (, ,) (JJ -3beta) (, ,) (JJ -3gamma) (, ,) (JJ -4gamma) (, ,) (CC and) (CD -6))))))) (CC and) (NP (NP (DT the) (NN mapping)) (PP (IN of) (NP (NNP HNF-6))) (PP (TO to) (NP (NP (NN chromosome) (NNS bands)) (ADJP (JJ 15q21.1-21.2) (PP (IN by) (NP (NP (NN fluorescence)) (PP (IN in) (NP (NN situ) (NN hybridization))))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS markers)) (VP (MD will) (VP (VB be) (ADJP (JJ useful) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ genetic) (NN variation))) (PP (IN in) (NP (DT these) (NNS genes))) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN type) (CD 2) (NN diabetes)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN vivo) (NN footprinting))) (CC and) (S (NP (NP (JJ mutational) (NN analysis)) (PP (IN of) (NP (DT the) (JJ proximal) (NNP CD19) (NN promoter)))) (VP (VBP reveal) (NP (NP (NP (JJ important) (NNS roles)) (PP (IN for) (NP (DT an) (JJ SP1/Egr-1) (JJ binding) (NN site)))) (CC and) (NP (NP (DT a) (NN novel) (NN site)) (VP (VBD termed) (S (NP (DT the) (NNP PyG) (NN box)))))))) (. .)))
(TOP (S (NP (CD CD19) (NN expression)) (VP (VBZ begins) (PP (IN at) (NP (NP (DT the) (JJ pro-B) (NN cell) (NN stage)) (PP (IN of) (NP (NN B) (NN cell) (NN development)))))) (. .)))
(TOP (SBAR (IN As) (S (NP (JJ such) (PRP it)) (VP (VBZ serves) (PP (IN as) (NP (DT a) (JJ good) (NN prototype))) (PP (IN for) (NP (NP (NNP B) (JJ cell-specific) (NNS genes)) (SBAR (WHNP (WP$ whose) (NN expression)) (S (VP (VBZ begins) (ADVP (RB shortly)) (PP (IN after) (NP (NN lineage) (NN commitment)))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB understand) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBG controlling) (NP (NNP CD19) (NN gene) (NN expression))))))) (, ,) (NP (PRP we)) (VP (VP (VBD isolated)) (CC and) (VP (ADVP (RB functionally)) (VBD characterized) (NP (DT the) (NNP CD19) (NN promoter)) (S (VP (VBG using) (PRT (IN in)) (NP (NP (NN vivo) (NN footprinting)) (, ,) (NP (NN gel) (NN shift) (NNS assays)) (, ,) (CC and) (NP (NN transfection) (NNS studies))))))) (. .)))
(TOP (S (NP (NP (NN Reporter) (NNS constructs)) (VP (VBG spanning) (NP (NP (NNS portions)) (PP (IN of) (NP (DT the) (NN promoter)))))) (VP (VBD identified) (NP (NP (DT a) (NN region)) (PP (IN between) (NP (NP (CD -85) (CC and) (CD -200)) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (NN reporter) (NN gene) (NN activity)) (PP (IN in) (NP (JJ lymphoid) (NNS cells))))))))))))) (. .)))
(TOP (SINV (PP (IN In) (NP (NN vivo) (NN footprinting))) (VP (VBD identified)) (NP (NP (JJ protected) (NNS regions)) (PP (IN over) (NP (NP (DT the) (JJ known) (JJ high) (NN affinity) (NN B) (NN cell) (JJ lineage-specific) (NN activator) (NN protein) (PRN (-LRB- -LRB-) (NNP BSAP) (-RRB- -RRB-)) (NN site)) (, ,) (NP (DT the) (JJ low) (NN affinity) (NNP BSAP) (NN site)) (, ,) (NP (NP (DT a) (JJ SP1/Egr-1) (NN site)) (VP (VBD termed) (S (NP (DT the) (NNP CD19) (NNP GC) (NN box))))) (, ,) (CC and) (NP (NP (CD two) (NN novel) (NNS sites)) (VP (VBD named) (S (NP (DT the) (NNP AT) (NN box) (CC and) (NN PyG) (NN box)))))))) (. .)))
(TOP (NP (NP (NP (NNP Phorbol) (NN ester) (NN treatment)) (PP (IN of) (NP (DT a) (JJ pre-B) (NN cell) (NN line) (JJ up-regulated) (NNP CD19) (NN expression)))) (, ,) (VP (VBN induced) (NP (NNP Egr-1))) (, ,) (CC and) (VP (VBD enhanced) (NP (DT the) (NN footprint)) (PP (IN over) (NP (DT the) (NNP GC) (NN box)))) (. .)))
(TOP (S (NP (JJ Gel) (NN shift) (NNS assays)) (VP (VBD demonstrated) (S (NP (NNP SP1) (CC and) (NNP Egr-1)) (VP (VBG binding) (PP (TO to) (NP (DT the) (NNP CD19) (NNP GC) (NN box))))) (, ,) (SBAR (IN while) (S (NP (JJ unknown) (JJ nuclear) (NNS proteins)) (VP (VBD bound) (NP (NP (DT the) (NNP PyG)) (CC and) (NP (NNP AT) (NNS boxes))))))) (. .)))
(TOP (S (NP (NP (NNS Mutations)) (PP (PP (IN in) (NP (DT the) (NNP AT) (NN box))) (CC or) (PP (IN in) (NP (DT the) (NNP BSAP) (NNS sites))))) (VP (VBD did) (RB not) (VP (VB affect) (SBAR (S (NP (NNP CD19) (NN reporter)) (VP (VBP construct) (NP (NN activity)) (, ,) (SBAR (IN while) (S (S (NP (NP (DT a) (NN mutation)) (PP (IN of) (NP (DT the) (NNP GC) (NN box)))) (VP (VBD reduced) (NP (PRP it)) (ADVP (RB modestly)))) (, ,) (CC and) (S (NP (DT a) (NNP PyG) (NN box) (NN mutation)) (VP (VBD reduced) (NP (PRP it)) (ADVP (RB dramatically))))))))))) (. .)))
(TOP (S (NP (NNP BSAP)) (VP (VBD failed) (S (VP (TO to) (VP (VB trans-activate) (NP (NNP CD19) (NN promoter) (NNS constructs)) (PP (IN in) (NP (NP (NN B) (NNS cells)) (CC or) (NP (JJ non-B) (NNS cells))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (NN cis) (NNS elements)) (PP (JJ such) (IN as) (NP (DT the) (NNP PyG) (CC and) (NNP GC) (NNS boxes)))) (VP (VBP are) (ADVP (RB also)) (ADJP (JJ necessary) (PP (IN for) (NP (JJ high) (NN level) (NNP CD19) (NN promoter) (NN expression)))))))))) (. .)))
(TOP (NP (NP (DT A) (JJ conserved) (JJ tissue-specific) (NN structure)) (PP (IN at) (NP (NP (DT a) (JJ human) (JJ T-cell) (NN receptor)) (NP (JJ beta-chain) (NN core) (NN promoter)))) (. .)))
(TOP (S (NP (DT The) (NNP T-cell) (NN receptor) (PRN (-LRB- -LRB-) (NNP TCR) (-RRB- -RRB-)) (JJ beta-chain) (NNS promoters)) (VP (VBP have) (VP (VBN been) (VP (VBN characterized) (PP (IN as) (NP (NP (JJ nonstructured) (JJ basal) (NNS promoters)) (SBAR (WHNP (WDT that)) (S (VP (VBP carry) (NP (DT a) (JJ single) (JJ conserved) (JJ ubiquitous) (JJ cyclic) (JJ AMP-responsive) (NN element)))))))))) (. .)))
(TOP (S (NP (NP (PRP$ Our) (NN investigation)) (PP (IN of) (NP (DT the) (JJ human) (NNP TCR) (NN beta) (NN gene)))) (VP (VBZ uncovers) (NP (DT a) (ADJP (ADJP (RB surprisingly) (JJ complex)) (CC and) (ADJP (JJ tissue-specific))) (NN structure)) (PP (IN at) (NP (DT the) (NNP TCR) (NNP Vbeta) (CD 8.1) (NN promoter)))) (. .)))
(TOP (S (NP (NP (NP (DT The) (NN core)) (PP (IN of) (NP (DT the) (NN promoter)))) (PRN (-LRB- -LRB-) (NP (NP (NNS positions)) (NP (NP (CD -42)) (PP (TO to) (NP (CD +11))))) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN recognized) (PP (PP (IN by) (NP (NP (DT the) (JJ lymphoid) (JJ cell-specific) (NN transcription) (NNS factors)) (NP (NNP Ets-1) (, ,) (NNP LEF1) (, ,) (CC and) (NNP AML1)))) (CONJP (RB as) (RB well) (IN as)) (PP (IN by) (NP (NNP CREB/ATF-1)))) (, ,) (SBAR (IN as) (S (VP (VBZ is) (VP (VBN demonstrated) (PP (IN in) (NP (NP (NN gel) (NN shift)) (CC and) (NP (NN footprinting) (NNS experiments)))))))))) (. .)))
(TOP (S (PP (IN With) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NNP LEF1))))) (, ,) (NP (DT these) (NNS factors)) (VP (VBP activate) (NP (NN transcription)) (PP (IN in) (NP (NNP T) (NNS cells)))) (. .)))
(TOP (S (NP (NP (VBG Binding) (NNS sites)) (PP (IN at) (NP (DT the) (NN core) (NN region)))) (VP (VBP show) (NP (NP (JJ little) (NN conservation)) (PP (IN with) (NP (NN consensus) (NNS sites))))) (. .)))
(TOP (S (ADVP (RB Nonetheless)) (, ,) (VP (NP (NP (NNP CREB)) (, ,) (NP (NNP Ets-1)) (, ,) (CC and) (NP (NNP AML1) (NN bind))) (CC and) (VP (VBP activate) (ADVP (RB cooperatively))) (CC and) (ADVP (RB very) (RB efficiently)) (PP (IN through) (NP (NP (DT the) (JJ nonconsensus) (JJ binding) (NNS sites)) (PP (IN at) (NP (DT the) (NN core) (NN promoter) (NN region)))))) (. .)))
(TOP (S (NP (JJ Moderate) (JJ ubiquitous) (NN activation)) (VP (VBZ is) (VP (ADVP (RBR further)) (VBN induced) (PP (IN by) (NP (NP (NNP CREB/ATF)) (CC and) (NP (NNP Sp1) (NNS factors)))) (PP (IN through) (NP (JJ proximal) (JJ upstream) (NNS elements))))) (. .)))
(TOP (S (NP (DT The) (JJ tissue-specific) (NN core) (NN promoter) (NN structure)) (VP (VBZ is) (ADVP (RB apparently)) (VP (VBN conserved) (PP (IN in) (NP (NP (JJ other) (ADJP (RB T-cell-specifically) (VBN expressed)) (NNS genes)) (PP (JJ such) (IN as) (NP (DT the) (NNP CD4) (NN gene))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT both) (NP (DT the) (NN enhancer)) (CC and) (NP (DT the) (NN promoter))) (VP (VBP have) (NP (NP (DT a) (JJ complex) (JJ tissue-specific) (NN structure)) (SBAR (WHNP (WP$ whose) (JJ functional) (NN interplay)) (S (VP (VBZ potentiates) (NP (JJ T-cell-specific) (NN transcription)))))))))) (. .)))
(TOP (S (NP (NP (JJ Opposite) (NNS effects)) (PP (IN of) (NP (NP (NP (DT the) (JJ acute) (JJ promyelocytic) (NN leukemia) (JJ PML-retinoic) (NN acid) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NNP RAR) (NN alpha)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP PLZF-RAR) (NN alpha) (NN fusion) (NNS proteins)) (PP (IN on) (NP (JJ retinoic) (NN acid))))))) (VP (NN signalling)) (. .)))
(TOP (S (NP (NP (NN Fusion) (NNS proteins)) (VP (VBG involving) (NP (NP (NP (DT the) (JJ retinoic) (NN acid) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NNP RAR) (NN alpha)) (-RRB- -RRB-))) (CC and) (NP (DT the) (NNP PML) (CC or) (NNP PLZF) (JJ nuclear) (NN protein))))) (VP (VBP are) (NP (NP (DT the) (JJ genetic) (NNS markers)) (PP (IN of) (NP (NP (JJ acute) (JJ promyelocytic) (NNS leukemias)) (PRN (-LRB- -LRB-) (NP (NNPS APLs)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (S (NP (NP (NNS APLs)) (PP (IN with) (NP (NP (DT the) (NNP PML-RAR) (NN alpha)) (CC or) (NP (DT the) (NNP PLZF-RAR) (NN alpha) (NN fusion) (NN protein))))) (VP (VBP are) (ADJP (RB phenotypically) (JJ indistinguishable)) (SBAR (IN except) (IN that) (S (NP (PRP they)) (VP (VBP differ) (PP (IN in) (NP (NP (PRP$ their) (NN sensitivity)) (PP (TO to) (NP (JJ retinoic) (NN acid) (PRN (-LRB- -LRB-) (NNP RA) (-RRB- -RRB-)) (JJ -induced) (NN differentiation)))))))))) (: :) (S (S (NP (NN PML-RAR) (NN alpha) (NNS blasts)) (VP (VBP are) (ADJP (JJ sensitive) (PP (TO to) (NP (NNP RA)))))) (CC and) (S (NP (NNS patients)) (VP (VBP enter) (NP (NN disease) (NN remission)) (PP (IN after) (NP (NNP RA) (NN treatment))) (, ,) (SBAR (IN while) (S (NP (NP (NNS patients)) (PP (IN with) (NP (NN PLZF-RAR) (NN alpha)))) (VP (VBP do) (RB not))))))) (. .)))
(TOP (S (S (NP (NP (PRP We)) (ADVP (RB here))) (VP (VBP report) (SBAR (DT that) (FRAG (NP (PRN (-LRB- -LRB-) (FW i) (-RRB- -RRB-)) (PP (IN like) (NP (NN PML-RAR) (NN alpha) (NN expression))) (, ,) (NP (NP (NP (NN PLZF-RAR) (NN alpha) (NN expression) (NNS blocks) (NN terminal) (NN differentiation)) (PP (IN of) (NP (NP (JJ hematopoietic) (NN precursor) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NNP U937) (CC and) (NNP HL-60)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ different) (NNS stimuli)))))) (PRN (-LRB- -LRB-) (NP (NP (NN vitamin) (NN D3)) (, ,) (S (VP (VBG transforming) (NP (NN growth) (NN factor) (NNS beta1))))) (, ,) (CC and) (NP (NN dimethyl) (NN sulfoxide)))) (-RRB- -RRB-)) (: ;) (NP (NP (PRN (-LRB- -LRB-) (NN ii) (-RRB- -RRB-)) (NN PML-RAR) (NN alpha)) (, ,) (CC but) (RB not) (NP (NN PLZF-RAR) (NN alpha))) (, ,) (VP (VP (VBZ increases) (NP (NP (NNP RA) (NN sensitivity)) (PP (IN of) (NP (JJ hematopoietic) (NN precursor) (NNS cells))))) (CC and) (VP (VBZ restores) (NP (NP (NNP RA) (NN sensitivity)) (PP (IN of) (NP (JJ RA-resistant) (JJ hematopoietic) (NNS cells)))))))))) (: ;) (S (S (PRN (-LRB- -LRB-) (NP (NN iii)) (-RRB- -RRB-)) (NP (NP (NN PML-RAR) (NN alpha)) (CC and) (NP (NN PLZF-RAR) (NN alpha))) (VP (VBP have) (NP (JJ similar) (NNP RA) (JJ binding) (NNS affinities)))) (: ;) (CC and) (PRN (-LRB- -LRB-) (S (NP (NP (NN iv) (-RRB- -RRB-)) (NP (NN PML-RAR) (NN alpha))) (VP (VBZ enhances) (NP (NP (DT the) (NNP RA) (NN response)) (PP (IN of) (NP (NP (NNP RA) (NN target) (NNS genes)) (PRN (-LRB- -LRB-) (NP (NP (DT those)) (PP (IN for) (NP (NP (NNP RAR) (NN beta)) (, ,) (NP (NNP RAR) (NN gamma)) (, ,) (CC and) (NP (NN transglutaminase) (NN type) (NNP II) (NNP -LSB-) (NNP TGase) (NNP -RSB-))))) (-RRB- -RRB-)))) (PP (IN in) (NP (NN vivo)))))) (, ,)) (SBAR (IN while) (S (NP (NNP PLZF-RAR) (NN alpha) (NN expression)) (VP (VBZ has) (NP (NP (NP (RB either) (DT no) (NN effect)) (PRN (-LRB- -LRB-) (NP (NNP RAR) (NN beta)) (-RRB- -RRB-))) (CC or) (NP (NP (DT an) (JJ inhibitory) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (NNP RAR) (NN gamma)) (CC and) (NP (NN type) (NNP II) (NNP TGase))) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NP (NNP PML-RAR) (NN alpha)) (CC and) (NP (NN PLZF-RAR) (NN alpha))) (VP (VBP have) (NP (NP (JJ similar) (PRN (-LRB- -LRB-) (JJ inhibitory) (-RRB- -RRB-)) (NNS effects)) (PP (IN on) (NP (NP (JJ RA-independent) (NN differentiation)) (CC and) (NP (NP (JJ opposite) (PRN (-LRB- -LRB-) (ADJP (JJ stimulatory) (CC or) (JJ inhibitory)) (-RRB- -RRB-)) (NNS effects)) (PP (IN on) (NP (JJ RA-dependent) (NN differentiation)))))))))) (CC and) (SBAR (IN that) (S (NP (PRP they)) (VP (VBP behave) (PP (IN in) (NP (NN vivo))) (PP (IN as) (NP (NP (JJ RA-dependent) (NNS enhancers)) (CC or) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (JJ RA-responsive) (NNS genes)))))) (, ,) (ADVP (RB respectively))))))) (. .)))
(TOP (S (NP (NP (PRP$ Their) (JJ different) (NNS activities)) (PP (IN on) (NP (DT the) (NNP RA) (NN signalling) (NN pathway)))) (VP (MD might) (VP (VB underlie) (NP (NP (DT the) (JJ different) (NNS responses)) (PP (IN of) (NP (NP (NN PML-RAR) (NN alpha)) (CC and) (NP (NN PLZF-RAR) (NN alpha) (NNS APLs)))) (PP (TO to) (NP (NNP RA) (NN treatment)))))) (. .)))
(TOP (S (NP (DT The) (NNP PLZF-RAR) (NN alpha) (NN fusion) (NN protein)) (VP (VBZ contains) (NP (NP (DT an) (ADJP (RB approximately) (JJ 120-amino-acid)) (JJ N-terminal) (NN motif)) (PRN (-LRB- -LRB-) (VP (VBN called) (S (NP (DT the) (NNP POZ) (NN domain)))) (-RRB- -RRB-)) (, ,) (SBAR (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADVP (RB also)) (VP (VBN found) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NN zinc) (NN finger) (NNS proteins)) (CC and) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NN poxvirus) (NNS proteins)))))))))))) (CC and) (SBAR (WHNP (WDT which)) (S (VP (VBZ mediates) (NP (JJ protein-protein) (NNS interactions)))))))) (. .)))
(TOP (S (NP (NP (NN Deletion)) (PP (IN of) (NP (DT the) (NNP PLZF) (NNP POZ) (NN domain)))) (VP (ADVP (RB partially)) (VBD abrogated) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN PLZF-RAR) (NN alpha))) (PP (PP (IN on) (NP (JJ RA-induced) (NN differentiation))) (CC and) (PP (IN on) (NP (JJ RA-mediated) (NN type) (NNP II) (NNP TGase) (NN up-regulation))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (JJ POZ-mediated) (NN protein) (NNS interactions)) (VP (MD might) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ inhibitory) (JJ transcriptional) (NNS activities)) (PP (IN of) (NP (NN PLZF-RAR) (NN alpha))))))))))))) (. .)))
(TOP (NP (NP (NP (NN Induction)) (PP (IN of) (NP (JJ human) (NN immunodeficiency) (NN virus)))) (VP (NN type) (NP (CD 1) (NN expression)) (PP (IN in) (NP (JJ monocytic) (NNS cells))) (PP (IN by) (NP (NP (NNP Cryptococcus) (NNPS neoformans)) (CC and) (NP (NNP Candida) (NNS albicans))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP (NN candidiasis) (CC and) (NN cryptococcosis)) (VP (VBP are) (ADJP (JJ common)) (PP (IN in) (NP (NP (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP HIV)) (-RRB- -RRB-)) (NP (JJ -infected) (NNS persons))))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNP Cryptococcus) (NNPS neoformans)) (CC and) (NP (NNP Candida) (NNS albicans)))) (PP (IN on) (NP (NNP HIV) (NN expression))) (PP (IN in) (NP (JJ monocytic) (NNS cells)))) (VP (VBD was) (VP (VBN examined))) (. .)))
(TOP (S (NP (NP (NN Stimulation)) (PP (IN of) (NP (NP (DT the) (ADJP (RB latently) (JJ HIV-infected)) (JJ myelomonocytic) (NN cell) (NN line) (NN OM-10.1)) (PP (IN with) (NP (NP (NNP C.) (NNPS neoformans)) (CC and) (NP (NNP C.) (NNS albicans)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (VBN pooled) (JJ human) (NN serum)))))))) (VP (VBD caused) (NP (NP (DT a) (JJ ratio-dependent) (NN increase)) (PP (IN in) (NP (NNP HIV) (NN production))))) (. .)))
(TOP (S (NP (NP (NNP Induction)) (PP (IN of) (NP (NNP HIV))) (PP (IN by) (NP (NNP C.) (NNS neoformans)))) (VP (VBD was) (VP (VBN enhanced) (PP (IN by) (NP (JJ anti-capsular) (NN antibody))) (, ,) (SBAR (IN while) (S (NP (NP (NN induction)) (PP (IN by) (NP (DT both) (NNS organisms)))) (VP (VBD was) (VP (VBN inhibited) (PP (IN by) (NP (JJ anti-TNF-alpha) (NN antibody))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ THP-1) (NNS cells)) (VP (VBN transfected) (PP (IN with) (NP (NNP HIV) (NN plasmid) (NNS constructs)))))) (, ,) (NP (DT both) (NNS organisms)) (VP (VBD induced) (NP (NN transcription)) (PP (IN from) (NP (NP (DT the) (NNP HIV) (JJ long) (NN terminal) (NN repeat)) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (ADJP (JJ dependent) (PP (IN on) (NP (JJ intact) (JJ NF-kappaB) (JJ binding) (NNS sequences)))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (NNP C.) (NNPS neoformans)) (CC and) (NP (NNP C.) (NNS albicans))) (VP (VBP enhance) (NP (NNP HIV) (NN expression)) (PP (IN in) (NP (JJ monocytic) (NNS cells))) (PP (IN through) (NP (DT a) (ADJP (JJ TNF-alpha-) (CC and) (JJ NF-kappaB-dependent)) (NN mechanism)))) (. .)))
(TOP (S (PP (IN In) (NP (JJ HIV-infected) (NNS patients))) (, ,) (NP (JJ such) (NN enhancement)) (VP (VP (MD may) (VP (ADVP (RB further)) (VB impair) (NP (NN host) (NN immunity)))) (CC and) (VP (MD could) (VP (VB accelerate) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNP HIV) (NN disease))))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ human) (NN homologue)) (PP (IN of) (NP (DT the) (NNP Drosophila) (NNP Toll) (NN protein)))) (VP (VBZ signals) (SBAR (S (NP (NP (NN activation)) (PP (IN of) (NP (JJ adaptive) (NN immunity) (NNP -LSB-)))) (VP (VBP see) (S (NP (NNS comments)) (ADJP (NN -RSB-)))))))))
(TOP (S (NP (NP (NN Induction)) (PP (IN of) (NP (DT the) (JJ adaptive) (JJ immune) (NN response)))) (VP (VBZ depends) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ co-stimulatory) (NNS molecules) (CC and) (NNS cytokines))))) (PP (IN by) (NP (JJ antigen-presenting) (NNS cells)))) (. .)))
(TOP (S (NP (NP (DT The) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP control) (NP (NP (DT the) (JJ initial) (NN induction)) (PP (IN of) (NP (DT these) (NNS signals))) (PP (IN upon) (NP (NN infection)))))))) (VP (VBP are) (VP (ADVP (RB poorly)) (VBN understood))) (. .)))
(TOP (S (NP (NP (PRP It))) (VP (VBZ has) (VP (VBN been) (VP (VBN proposed) (SBAR (IN that) (S (NP (PRP$ their) (NN expression)) (VP (VBZ is) (VP (VBN controlled) (PP (IN by) (NP (NP (DT the) (ADJP (JJ non-clonal) (, ,) (CC or) (NN innate) (, ,)) (NN component)) (PP (IN of) (NP (NP (NN immunity)) (SBAR (WHNP (WDT that)) (S (VP (VBD preceded) (PP (IN in) (NP (NN evolution))) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT an) (JJ adaptive) (JJ immune) (NN system)) (PP (IN in) (NP (NNS vertebrates)))))))))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP report) (ADVP (RB here)) (NP (NP (DT the) (NN cloning) (CC and) (NN characterization)) (PP (IN of) (NP (NP (DT a) (JJ human) (NN homologue)) (PP (IN of) (NP (NP (DT the) (NNP Drosophila) (NN toll) (NN protein)) (PRN (-LRB- -LRB-) (NP (NNP Toll)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB induce) (NP (NP (DT the) (JJ innate) (JJ immune) (NN response)) (PP (IN in) (NP (NN adult) (NNP Drosophila)))))))))))))))))) (. .)))
(TOP (S (PP (IN Like) (NP (NNP Drosophila) (NNP Toll))) (, ,) (NP (JJ human) (NNP Toll)) (VP (VBZ is) (NP (NP (DT a) (NN type)) (SBAR (S (NP (PRP I)) (VP (VBP transmembrane) (NP (NN protein)) (PP (IN with) (NP (NP (NP (DT an) (JJ extracellular) (NN domain)) (VP (VBG consisting) (PP (IN of) (NP (DT a) (JJ leucine-rich) (NN repeat) (PRN (-LRB- -LRB-) (NNP LRR) (-RRB- -RRB-)) (NN domain))))) (, ,) (CC and) (NP (NP (DT a) (JJ cytoplasmic) (NN domain)) (PP (ADVP (RB homologous)) (TO to) (NP (NP (DT the) (JJ cytoplasmic) (NN domain)) (PP (IN of) (NP (DT the) (JJ human) (NN interleukin) (PRN (-LRB- -LRB-) (NNP IL) (-RRB- -RRB-)) (JJ -1) (NN receptor))))))))))))) (. .)))
(TOP (S (NP (DT Both) (NP (NNP Drosophila) (NNP Toll)) (CC and) (NP (DT the) (JJ IL-1) (NN receptor))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB signal) (PP (IN through) (NP (DT the) (NNP NF-kappaB) (NN pathway)))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT a) (ADJP (RB constitutively) (JJ active)) (JJ mutant)) (PP (IN of) (NP (JJ human) (NNP Toll))) (VP (VBD transfected) (PP (IN into) (NP (JJ human) (NN cell) (NNS lines))))) (VP (MD can) (VP (VB induce) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (NNP NF-kappaB)) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ NF-kappaB-controlled) (NNS genes)))))) (PP (IN for) (NP (NP (NP (DT the) (JJ inflammatory) (NNS cytokines) (NN IL-1)) (, ,) (NP (NN IL-6) (CC and) (NN IL-8)) (, ,)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ co-stimulatory) (NN molecule) (NNP B7.1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ naive) (NNP T) (NNS cells)))))))))))))))))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (JJ B-cell) (NN commitment)) (PP (PP (TO to) (NP (NN plasma) (NNS cells))) (CC or) (PP (TO to) (NP (NN memory) (NN B) (NNS cells)))))) (. .)))
(TOP (S (PP (IN During) (NP (JJ humoral) (JJ immune) (NNS responses))) (, ,) (NP (JJ B-lymphocyte) (NN activation)) (VP (VBZ is) (VP (VBN followed) (PP (IN by) (NP (NP (NN differentiation)) (PP (IN along) (NP (CC either) (NP (DT the) (NN plasma) (NN cell) (NN pathway)) (CC or) (NP (DT the) (NN memory) (JJ B-cell) (NN pathway)))))))) (. .)))
(TOP (S (NP (JJ Recent) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN CD40-CD40) (NN ligand)) (, ,) (NP (NN OX-OX40) (NN ligand)) (, ,) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NNS cytokines)))) (CC and) (NP (JJ intracellular) (JJ transcriptional) (NNS factors))) (VP (MD may) (DT all) (VP (VBP contribute) (PP (TO to) (NP (JJ B-lymphocyte) (NN differentiation) (NN control)))))))) (. .)))
(TOP (S (NP (NP (DT A) (VBN shortened) (NN life) (NN span)) (PP (IN of) (NP (NNP EKLF-/-) (NN adult) (NNS erythrocytes))) (, ,) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN deficiency)) (PP (IN of) (NP (JJ beta-globin) (NNS chains)))))) (, ,)) (VP (VBZ is) (VP (VBN ameliorated) (PP (IN by) (NP (JJ human) (NN gamma-globin) (NNS chains))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (RB homologous) (NN recombination)))) (, ,) (NP (DT both) (NP (NP (NNP EKLF) (NNS alleles)) (PP (IN in) (NP (JJ murine) (JJ embryonic) (NN stem) (PRN (-LRB- -LRB-) (NNP ES) (-RRB- -RRB-)) (NNS cells))))) (VP (VBD were) (VP (VBN inactivated))) (. .)))
(TOP (S (NP (DT These) (NNP EKLF-/-) (NNP ES) (NNS cells)) (VP (VBD were) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG undergoing) (PP (IN in) (NP (NN vitro) (NN differentiation))) (S (VP (TO to) (VP (VB form) (NP (NP (JJ definitive) (JJ erythroid) (NNS colonies)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (NN size) (CC and) (NN number))) (PP (TO to) (NP (NP (DT those)) (VP (VBN formed) (PP (IN by) (NP (JJ wild-type) (NNP ES) (NNS cells))))))))))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (S (NP (DT the) (NNP EKLF-/-) (NNS colonies)) (VP (VBD were) (ADJP (RB poorly) (VBN hemoglobinized)))) (CC and) (S (NP (NP (VBN enucleated) (NNS erythrocytes)) (PP (IN in) (NP (DT these) (NNS colonies)))) (VP (VBD contained) (NP (JJ numerous) (NNP Heinz) (NNS bodies)))) (. .)))
(TOP (S (NP (VB Reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction) (PRN (-LRB- -LRB-) (NN RT-PCR) (-RRB- -RRB-)) (NNS analyses)) (VP (VBD revealed) (SBAR (DT that) (S (NP (NN adult) (CC and) (JJ embryonic) (NN globin) (NNS genes)) (VP (VBD were) (VP (ADVP (RB appropriately)) (VBN regulated) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (JJ beta) (NN h1-globin)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD continued) (S (VP (TO to) (VP (VB be) (VP (VBN expressed) (PP (IN at) (NP (DT a) (ADJP (RB very) (JJ low)) (NN level))))))))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN ratio)) (PP (IN of) (NP (JJ adult) (JJ beta-globin/alpha-globin) (NN mRNA))) (PP (IN in) (NP (DT the) (JJ mutant) (NNP ES) (NNS cells)))) (VP (VBD was) (NP (NP (CD 1/15)) (PP (IN of) (NP (DT that)))) (PP (IN in) (NP (JJ wild-type) (NNP ES) (NNS cells)))) (. .)))
(TOP (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNP EKLF-/-) (NNS cells)) (VP (VBD were) (VP (VBN injected) (PP (IN into) (NP (NNS blastocysts))))))) (, ,) (NP (PRP they)) (VP (VBD did) (RB not) (VP (VB contribute) (PP (IN at) (NP (NP (DT a) (JJ detectable) (NN level)) (PP (TO to) (NP (NP (DT the) (JJ mature) (JJ erythrocyte) (NN compartment)) (PP (IN of) (NP (DT the) (JJ chimeric) (NNS animals))))) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (NN analysis)) (PP (IN of) (NP (NP (NN glucose) (NN phosphate)) (ADJP (JJ isomerase-1) (PRN (-LRB- -LRB-) (JJ GPI-1) (-RRB- -RRB-)) (NP (NP (NNS isozymes) (CC and) (NNS hemoglobins)) (SBAR (WHNP (WDT that)) (S (VP (VBP distinguish) (NP (NNP ES) (JJ cell-derived) (NNS erythrocytes)) (PP (IN from) (NP (NN host) (JJ blastocyst-derived) (NNS erythrocytes))))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ semiquantitative) (NNP RT-PCR) (NN analysis)) (PP (IN of) (NP (NNP RNA))) (PP (IN from) (NP (NP (NNS reticulocytes)) (PP (IN of) (NP (DT the) (JJ same) (JJ chimeric) (NNS animals)))))) (VP (VBD suggested) (SBAR (IN that) (S (NP (DT the) (NNP ES) (JJ cell-derived) (NNS reticulocytes)) (VP (VBD were) (ADJP (JJ present)) (PP (IN at) (NP (NP (DT a) (NN level)) (PP (IN of) (NP (QP (CD 6) (NN %) (TO to) (CD 8) (NN %)))))))))) (. .)))
(TOP (S (NP (DT This)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (DT the) (NNP EKLF-/-) (NNS erythrocytes)) (PP (IN in) (NP (NN adult) (NNS animals)))) (VP (MD must) (VP (VB be) (ADJP (JJ short-lived)) (, ,) (PP (ADVP (RB apparently)) (JJ due) (PP (TO to) (NP (NP (DT the) (NN imbalance)) (PP (IN of) (NP (FW beta-) (FW versus) (JJ alpha-globin) (NNS chains)))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (NN precipitation)) (PP (IN of) (NP (NP (JJ excess) (JJ alpha-globin) (NNS chains)) (SBAR (S (VP (TO to) (VP (VB form) (NP (NNP Heinz) (NNS bodies))))))))))))))))) (. .)))
(TOP (S (S (ADJP (JJ Consistent) (PP (IN with) (NP (DT this) (NN hypothesis))))) (, ,) (NP (DT the) (JJ short) (NN life) (NN span)) (VP (VBD was) (VP (VBN ameliorated) (PP (IN by) (NP (NP (NN introduction)) (PP (IN into) (NP (NP (DT the) (NNP EKLF-/-) (NNP ES) (NNS cells)) (PP (IN of) (NP (DT a) (JJ human) (JJ LCR/gamma-globin) (NN gene))))) (, ,) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP ES) (JJ cell-derived) (NNS reticulocytes)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ mature) (NNS erythrocytes)) (PP (IN in) (NP (NP (DT the) (NN blood)) (PP (IN of) (NP (DT the) (JJ chimeric) (NNS animals))))))))))))))) (. .)))
(TOP (NP (NP (NN Induction)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NNP B/Rel) (JJ nuclear) (NN activity)) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes))) (PP (IN by) (NP (JJ anti-HLA) (NN class) (PRP I) (JJ monoclonal) (NNS antibodies))))) (. .)))
(TOP (S (NP (NP (JJ Monoclonal) (NNS antibodies)) (PP (IN against) (NP (NP (NP (DT either) (ADJP (JJ monomorphic) (CC or) (JJ polymorphic)) (NNS determinants)) (PP (IN of) (NP (NN class) (NN I) (NN antigen))) (VP (VBN induced) (PP (IN in) (NP (NNP PBMC))))) (CC and) (NP (ADJP (RB highly) (VBN purified)) (NNP T))))) (VP (VBZ lymphocytes) (NP (NP (DT the) (JJ nuclear) (NN activity)) (PP (IN of) (NP (NNP NF-kappa) (NNP B/Rel) (NNS complexes))))) (. .)))
(TOP (S (NP (DT These)) (VP (VBD included) (NP (DT both) (NP (QP (CD p50/p50) (CC and) (CD p50/p65)) (NNS dimers)) (, ,) (VP (VBN recognized) (PP (IN by) (NP (NP (JJ specific) (NNS antibodies)) (PP (IN in) (NP (NNP EMSA)))))))) (. .)))
(TOP (S (S (NP (DT The) (VBN induced) (NNS complexes)) (VP (VBD were) (ADJP (JJ detectable)) (PP (IN in) (NP (NP (NNS extracts)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBN incubated) (PP (IN with) (NP (NP (JJ anti-class) (PRP I) (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NNP mAb)) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 1.5) (NN h)))))))))) (: ;) (S (NP (DT the) (NN induction)) (VP (VP (VBD was) (ADJP (JJ maximal)) (PP (IN at) (NP (CD 5) (NN h))) (, ,) (S (ADJP (JJ persistent) (PP (IN at) (NP (CD 16) (NN h)))))) (CC and) (VP (ADVP (DT no) (RBR longer)) (JJ observed) (PP (IN at) (NP (CD 40) (NN h)))))) (. .)))
(TOP (S (S (NP (DT The) (NNP mAb)) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP (NNP NF-kappa) (NNP B/Rel) (JJ nuclear) (NN activity)) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN incubated) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ 3,4-dichloroisocoumarin))))))))))))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (PRP I)))) (VP (VBP kappa) (NP (JJ B-alpha) (NN degradation))) (. .)))
(TOP (S (ADVP (RB Together)) (, ,) (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN class) (NN I)) (VP (VBG triggering))) (VP (MD can) (VP (VB induce) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NNP NF-kappa) (NNP B/Rel) (JJ nuclear) (NN activity)) (PP (IN in) (NP (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes)))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG modulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN regulated) (PP (IN by) (NP (DT these) (NN transcription) (NNS factors)))))))))))))) (. .)))
(TOP (S (NP (NNP EBF) (CC and) (NNP E47)) (VP (VBP collaborate) (S (VP (TO to) (VP (VB induce) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ endogenous) (JJ immunoglobulin) (JJ surrogate) (NN light) (NN chain) (NNS genes)))))))) (. .)))
(TOP (S (NP (NP (NP (NNP Early) (NNP B) (NN cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP EBF)) (-RRB- -RRB-))) (CC and) (NP (NNP E47))) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (JJ transcriptional) (NN control)) (PP (IN of) (NP (JJ early) (NNP B) (NN lymphocyte) (NN differentiation)))))) (. .)))
(TOP (S (PP (IN With) (NP (NP (DT the) (NN aim)) (PP (IN of) (S (VP (VBG identifying) (NP (JJ genetic) (NNS targets)) (PP (IN for) (NP (DT these) (NN transcription) (NNS factors)))))))) (, ,) (NP (PRP we)) (ADVP (RB stably)) (VP (VBD transfected) (NP (NP (NNS cDNAs)) (VP (VP (VBG encoding) (NP (NP (NNP EBF)) (CC or) (NP (NP (DT a) (JJ covalent) (NN homodimer)) (PP (IN of) (NP (NNP E47)))))) (, ,) (ADVP (RB individually) (CC or) (RB together)) (, ,))) (PP (IN into) (NP (NP (JJ immature) (JJ hematopoietic) (JJ Ba/F3) (NNS cells)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP lack) (NP (DT both) (NNS factors)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN combination))) (, ,) (NP (NNP EBF) (CC and) (NNP E47)) (VP (VBP induce) (NP (NP (JJ efficient) (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ endogenous) (JJ immunoglobulin) (JJ surrogate) (NN light) (NN chain) (NNS genes)) (, ,) (NP (CD lambda5)) (CC and) (NP (NNP VpreB))))) (, ,) (SBAR (IN whereas) (S (NP (JJ other) (JJ pre-B) (JJ cell-specific) (NNS genes)) (VP (VBP remain) (ADJP (JJ silent)))))) (. .)))
(TOP (S (NP (RB Multiple) (ADJP (RB functionally) (JJ important)) (UCP (NNP EBF) (CC and) (NNP E47)) (VBG binding) (NNS sites)) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (DT the) (CD lambda5) (NN promoter/enhancer) (NN region))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (CD lambda5)) (VP (VBZ is) (NP (NP (DT a) (JJ direct) (JJ genetic) (NN target)) (PP (IN for) (NP (DT these) (NN transcription) (NNS factors))))))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP EBF) (CC and) (NNP E47)) (VP (VBP synergize) (S (VP (TO to) (VP (VB activate) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NP (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP define) (NP (NP (DT an) (JJ early) (NN stage)) (PP (IN of) (NP (DT the) (NNP B) (NN cell) (NN lineage))))))))))))))))))) (. .)))
(TOP (NP (NP (JJ Nuclear) (NNS levels)) (PP (IN of) (NP (JJ NF-kappaB) (NN correlate))) (PP (IN with) (NP (NP (JJ syncytium-forming) (NN capacity)) (PP (IN of) (NP (CD 8e51) (NNS cells))))) (, ,) (VP (VBG expressing) (NP (DT a) (JJ defective) (NNP HIV) (NN virus))) (. .)))
(TOP (S (NP (NP (DT The) (JJ double) (NN NF-kappaB) (NN site)) (VP (VBN identified) (PP (IN in) (NP (NP (NP (DT the) (NNP LTR)) (PP (IN of) (NP (DT the) (JJ human) (NN immunodeficiency) (JJ virus-1)))) (PRN (-LRB- -LRB-) (NP (NNP HIV-1)) (-RRB- -RRB-)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB be) (ADJP (JJ necessary)) (PP (IN for) (NP (JJ efficient) (JJ viral) (NN transcription))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (NP (PRP we)) (VP (VBP present) (NP (NP (DT the) (NN characterisation)) (PP (IN of) (NP (NP (JJ NF-kappaB) (NNS subunits)) (VP (VBN engaged) (PP (IN in) (NP (NP (NNS complexes)) (VP (VBG binding) (PP (TO to) (NP (NP (DT the) (NNP HIV-1) (NNP NF-kappaB) (NN site)) (PP (IN in) (NP (JJ human) (JJ 8e51) (NNS T-cells))))))))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBP harbour) (NP (DT a) (JJ defective) (NNP HIV-1))))))))) (. .)))
(TOP (S (NP (QP (IN At) (JJS least) (CD four)) (JJ different) (JJ specific) (NN NF-kappaB) (NNS complexes)) (VP (VBP are) (ADJP (JJ present)) (PP (IN in) (NP (NP (DT the) (NN nucleus)) (PP (IN of) (NP (DT these) (NNS cells)))))) (. .)))
(TOP (S (PP (IN With) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ specific) (NNS antibodies))))) (NP (PRP we)) (VP (VBP have) (VP (VBN determined) (NP (NP (DT the) (NN composition)) (PP (IN of) (NP (NP (DT each) (NN complex)) (VP (VBG using) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)))))))) (. .)))
(TOP (S (NP (DT The) (NNS results)) (VP (VBP show) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ several) (NNP NF-kappaB) (NN family) (NNS members)))) (, ,) (PP (IN with) (S (NP (DT the) (VBG transactivating) (NNP RelA)) (VP (VBG being) (VP (VBN engaged) (PP (IN in) (NP (JJ multiple) (NNS complexes)))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN importance)) (PP (IN of) (NP (JJ NF-kappaB) (NNS complexes))) (PP (IN in) (NP (JJ viral) (NNS functions)))) (VP (VBZ has) (VP (VBN been) (VP (VBN established) (S (VP (VBG comparing) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ NF-kappaB) (JJ DNA-binding) (NNS complexes)))) (PP (IN with) (NP (NP (JJ syncytia-forming) (NN activity)) (PP (IN of) (NP (JJ 8e51) (NNS cells)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN fact))) (, ,) (NP (NP (JJ 8e51) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBD had) (ADVP (RB almost)) (VP (VBN lost) (NP (PRP$ their) (JJ syncytia-forming) (NN capacity))))))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB contain) (NP (NP (QP (IN at) (JJS least) (CD 10) (NNS times)) (ADJP (RBR less) (JJ active)) (JJ NF-kappaB) (JJ DNA-binding) (NN complex)) (PP (IN than) (NP (DT the) (ADJP (RB actively) (NN fusing)) (NNS cells))))))))) (. .)))
(TOP (S (NP (DT The) (NN correlation)) (VP (VBZ is) (ADJP (JJ specific)) (SBAR (IN as) (S (NP (NP (DT the) (NN level)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD three)) (JJ other) (NN transcription) (NNS factors)))) (VP (VBD did) (RB not) (VP (VB change)))))) (. .)))
(TOP (NP (NP (JJ Differential) (NN interaction)) (PP (IN of) (NP (NP (JJ nuclear) (NNS factors)) (PP (IN with) (NP (DT the) (JJ leukocyte-specific) (JJ pp52) (NN promoter))) (PP (IN in) (NP (NNP B) (CC and) (NNP T) (NNS cells))))) (. .)))
(TOP (S (NP (DT The) (JJ leukocyte-specific) (, ,) (JJ cytoskeleton-binding) (NN pp52) (PRN (-LRB- -LRB-) (NN LSP-1) (, ,) (NN WP-34) (-RRB- -RRB-)) (NN protein)) (VP (VBZ is) (VP (ADVP (RB widely)) (VBN expressed) (PP (IN in) (NP (NP (JJ multiple) (NN leukocyte) (NNS lineages)) (, ,) (PP (VBG including) (NP (NP (NNP B) (CC and) (NNP T) (NNS lymphocytes)) (, ,) (NP (NNS granulocytes)) (, ,) (CC and) (NP (NNS macrophages)))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD detected) (NP (NP (DT a) (JJ tissue-specific) (NN promoter)) (VP (VBG preceding) (NP (NP (DT the) (NN exon)) (VP (VBG encoding) (NP (NP (DT the) (NNP N) (NN terminus)) (PP (IN of) (NP (DT the) (FW pp52) (FW leukocyte) (NN protein))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT the) (JJ functional) (NN characterization)) (PP (IN of) (NP (NP (DT this) (NN promoter) (CC and) (NN identification)) (PP (IN of) (NP (NP (DT the) (NNS factors)) (PP (IN in) (NP (NP (NNP B) (CC and) (NNP T) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (PRP$ its) (NN activity))))))))))))) (. .)))
(TOP (S (NP (DT The) (JJ pp52) (NN promoter)) (VP (VBZ contains) (NP (NP (DT an) (NN initiator)) (VP (VBG specifying) (NP (NP (NP (DT the) (JJ unique) (CD 5') (NN terminus)) (PP (IN of) (NP (FW pp52) (FW mRNA)))) (, ,) (NP (NP (NN tandem) (NNS pairs)) (PP (IN of) (NP (NNP Ets) (CC and) (NNP SP1) (NNS motifs)))) (, ,) (CC and) (NP (DT a) (JJ lone) (NNP C/EBP) (NN motif)))))) (. .)))
(TOP (S (NP (PDT All) (DT these) (NNS motifs)) (VP (VP (VBP are) (ADJP (JJ essential))) (CC and) (VP (ADVP (RB collectively)) (VB control) (NP (JJ transcriptional) (NN activity)))) (. .)))
(TOP (S (NP (NP (NNP DNA) (VBG binding) (NNS studies)) (CC and) (NP (JJ Ab) (NN supershift) (NNS assays))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (JJ different) (NNS combinations)) (PP (IN of) (NP (NP (NNS factors)) (VP (JJ interact) (PP (IN with) (NP (DT these) (NNS motifs))) (PP (IN in) (NP (NNP B) (NNS cells))))))) (VP (VBP vs) (NP (NNP T) (NNS cells)))))) (. .)))
(TOP (S (NP (DT The) (NNP Ets) (NNS motifs)) (VP (VBP are) (VP (ADVP (RB preferentially)) (VBN bound) (PP (IN by) (NP (NP (NN PU-1)) (PP (IN in) (NP (NN B) (NN cell) (VBZ extracts))) (PP (IN from) (NP (NP (DT all) (NNS stages)) (PP (IN of) (NP (NN development))))))) (, ,) (SBAR (IN whereas) (S (NP (DT a) (JJ different) (NNP Ets) (NN family) (NN member)) (VP (VBZ reacts) (PP (IN with) (NP (NP (DT these) (NNS motifs)) (PP (IN in) (NP (NNP T) (NN cell) (NNS extracts)))))))))) (. .)))
(TOP (S (NP (DT The) (NNP C/EBP) (NN motif)) (VP (VP (VBZ is) (VP (VBN bound) (PP (IN by) (NP (NP (NN Ig/EBP-1)) (PP (IN in) (NP (JJ pre-B) (NN cell) (CC and) (NN T) (NN cell) (NNS extracts))))))) (, ,) (CC but) (VP (VBZ is) (VP (VBN replaced) (PP (IN by) (NP (NP (JJ nuclear) (NN factor-IL-6beta)) (CC or) (NP (NP (DT a) (JJ nuclear) (JJ factor-IL-6beta-Ig/EBP-1) (NN heterodimer)) (PP (IN in) (NP (NN plasmacytoma) (NN cell) (NNS extracts))))))))) (. .)))
(TOP (S (PP (IN Despite) (NP (NP (PRP$ its) (JJ reported) (NN role)) (PP (IN as) (NP (NP (DT a) (JJ negative) (NN regulator)) (PP (IN of) (NP (NN transcription))))))) (, ,) (NP (NN Ig/EBP-1)) (VP (VBZ appears) (S (VP (TO to) (VP (VB exert) (NP (NP (DT a) (JJ stimulatory) (NN effect)) (PP (IN on) (NP (DT this) (NN promoter)))))))) (. .)))
(TOP (S (NP (DT These) (NNS findings)) (VP (VP (VBP reveal) (NP (NP (DT the) (NNS features)) (VP (VBG controlling) (NP (DT the) (JJ pp52) (NN promoter)) (PP (IN in) (NP (NNP B) (CC and) (NNP T) (NNS cells)))))) (CC and) (VP (VB provide) (NP (DT the) (NN foundation)) (PP (IN for) (S (VP (VBG determining) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT this) (NN promoter))) (PP (IN in) (NP (JJ other) (JJ leukocyte) (NNS lineages))))))))) (. .)))
(TOP (NP (NP (JJ Synthetic) (NNS glucocorticoids)) (SBAR (WHNP (WDT that)) (S (VP (VBP dissociate) (NP (NP (NN transactivation)) (CC and) (NP (JJ AP-1) (NN transrepression) (NN exhibit) (JJ antiinflammatory) (NN activity))) (PP (IN in) (NP (NN vivo)))))) (. .)))
(TOP (S (NP (NP (DT Some)) (PP (IN of) (NP (DT the) (ADJP (RBS most) (JJ potent)) (ADJP (JJ antiinflammatory) (CC and) (JJ immunosuppressive)) (NNS agents)))) (VP (VBP are) (NP (JJ synthetic) (NNS glucocorticoids))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (JJ major) (NN side) (NNS effects)) (VP (ADVP (RB severely)) (VBP limit) (NP (PRP$ their) (JJ therapeutic) (NN use))) (. .)))
(TOP (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (VBN improved) (JJ glucocorticoid-based) (NNS drugs)))) (VP (MD will) (VP (VB require) (NP (NP (DT the) (NN separation)) (PP (IN of) (ADJP (JJ beneficial) (PP (IN from) (NP (JJ deleterious) (NNS effects)))))))) (. .)))
(TOP (S (NP (NP (CD One) (NN possibility)) (PP (IN toward) (NP (DT this) (NN goal)))) (VP (VBZ is) (S (VP (TO to) (VP (VB try) (S (VP (TO to) (VP (VB dissociate) (NP (NP (CD two) (JJ main) (NNS activities)) (PP (IN of) (NP (NP (NNS glucocorticoids)) (, ,) (PP (FW i.e.) (NP (NN transactivation) (CC and) (NN transrepression))))))))))))) (. .)))
(TOP (S (S (VP (VBG Screening) (PP (IN of) (NP (NP (DT a) (NN library)) (PP (IN of) (NP (NP (NNS compounds)) (VP (VBG using) (NP (NP (NN transactivation)) (CC and) (NP (JJ AP-1) (NN transrepression) (NNS models))) (PP (IN in) (NP (ADJP (RB transiently) (VBN transfected)) (NNS cells)))))))))) (VP (VBD identified) (NP (NP (JJ dissociated) (NNS glucocorticoids)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP exert) (NP (NP (JJ strong) (JJ AP-1) (NN inhibition)) (CC but) (NP (NP (JJ little)) (CC or) (NP (DT no) (NN transactivation))))))))) (. .)))
(TOP (S (ADVP (RB Importantly)) (, ,) (PP (IN despite) (NP (JJ high) (NN ligand) (VBG binding) (NN affinity))) (, ,) (NP (NP (DT the) (JJ prototypic) (JJ dissociated) (NN compound)) (, ,) (NP (NNP RU24858)) (, ,)) (VP (VP (VBD acted) (PP (IN as) (NP (DT a) (JJ weak) (NN agonist)))) (CC and) (VP (VBD did) (RB not) (VP (ADVP (RB efficiently)) (VB antagonize) (NP (NP (JJ dexamethasone-induced) (NN transcription)) (PP (IN in) (NP (JJ transfected) (NNS cells))))))) (. .)))
(TOP (S (NP (JJ Similar) (NNS results)) (VP (VBD were) (VP (VBN obtained) (PP (IN in) (NP (JJ hepatic) (NNP HTC) (NNS cells))) (PP (IN for) (NP (NP (DT the) (NN transactivation)) (PP (IN of) (NP (NP (DT the) (JJ endogenous) (JJ tyrosine) (JJ amino) (NN transferase) (NN gene)) (PRN (-LRB- -LRB-) (NP (NNP TAT)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS enzymes)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ glucocorticoid-dependent) (NN stimulation)) (PP (IN of) (NP (NN neoglucogenesis)))))))))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB investigate) (SBAR (IN whether) (S (NP (JJ dissociated) (NNS glucocorticoids)) (VP (VBD retained) (NP (NP (DT the) (ADJP (JJ antiinflammatory) (CC and) (JJ immunosuppressive)) (NN potential)) (PP (IN of) (NP (JJ classic) (NNS glucocorticoids)))))))))) (, ,) (NP (NP (JJ several)) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo) (NNS models))))) (VP (VBD were) (VP (VBN used))) (. .)))
(TOP (S (ADVP (RB Indeed)) (, ,) (NP (NP (NN secretion)) (PP (IN of) (NP (DT the) (JJ proinflammatory) (NN lymphokine) (NN interleukin-1beta)))) (VP (VBD was) (VP (ADVP (RB severely)) (VBN inhibited) (PP (IN by) (NP (NP (JJ dissociated) (NNS glucocorticoids)) (PP (IN in) (NP (JJ human) (JJ monocytic) (NNP THP) (CD 1) (NNS cells))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (PP (IN in) (NP (NP (CD two)) (PP (IN in) (NP (NN vivo) (NNS models))))) (, ,) (NP (DT these) (NNS compounds)) (VP (VBD exerted) (NP (NP (DT an) (ADJP (JJ antiinflammatory) (CC and) (JJ immunosuppressive)) (NN activity)) (ADJP (ADJP (RB as) (JJ potent)) (PP (IN as) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ classic) (NN glucocorticoid) (NN prednisolone)))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (MD may) (VP (VP (VB lead) (PP (TO to) (NP (NP (DT an) (NN improvement)) (PP (IN of) (NP (ADJP (JJ antiinflammatory) (CC and) (JJ immunosuppressive)) (NNS therapies)))))) (CC and) (VP (VB provide) (NP (NP (DT a) (NN novel) (NN concept)) (PP (IN for) (NP (NN drug) (NN discovery))))))) (. .)))
(TOP (S (NP (NN Activation)) (VP (NN domain) (NP (NP (NNS requirements)) (PP (IN for) (NP (NP (NN disruption)) (PP (IN of) (NP (NNP Epstein-Barr) (NN virus) (NN latency))) (PP (IN by) (NP (NNP ZEBRA))))))) (. .)))
(TOP (S (NP (NP (NN Latent) (NN infection)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN by) (NP (NP (NNP Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP EBV)) (-RRB- -RRB-))))) (VP (MD can) (VP (VB be) (VP (VBN disrupted) (PP (IN by) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NNP EBV) (NNP ZEBRA) (NN protein)))))))) (. .)))
(TOP (S (NP (NP (NNP ZEBRA)) (, ,) (NP (DT a) (JJ transcriptional) (NN activator)) (, ,)) (VP (VBZ initiates) (NP (DT the) (NNP EBV) (JJ lytic) (NN cascade)) (PP (IN by) (S (VP (VBG activating) (NP (JJ viral) (NN gene) (NN expression)))))) (. .)))
(TOP (S (NP (NNP ZEBRA)) (VP (VP (VBZ is) (ADVP (RB also)) (ADJP (JJ indispensable) (PP (IN for) (NP (JJ viral) (NN replication))))) (CC and) (VP (NNS binds) (ADVP (RB directly)) (PP (TO to) (NP (NP (DT the) (NNP EBV) (JJ lytic) (NN origin)) (PP (IN of) (NP (NN replication))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNS studies)) (VP (VBD described))) (VP (ADVP (RB herein)) (VB demonstrate) (SBAR (IN that) (FRAG (NP (DT the) (NN activation) (NN domain))))) (. .)))
(TOP (S (NP (NNP ZEBRA) (NN activation)) (VP (MD can) (VP (VB be) (VP (VBN replaced) (PP (IN by) (NP (DT a) (ADJP (ADJP (JJ heterologous) (JJ acidic)) (, ,) (ADJP (JJ proline-rich) (, ,) (CC or) (JJ glutamine-rich))) (NN activation) (NN domain)))))) (. .)))
(TOP (S (NP (NNP ZEBRA) (NN activation) (NN domain) (NN swap) (NNS constructs)) (VP (VBP retain) (NP (NP (NNP ZEBRA) (POS 's)) (JJ native) (NNS abilities)) (S (VP (VP (TO to) (VP (VB activate) (NP (JJ specific) (NNP EBV) (NNS promoters)))) (, ,) (VP (TO to) (VP (VB disrupt) (NP (NNP EBV) (NN latency)))) (, ,) (CC and) (VP (TO to) (VP (VB stimulate) (NP (NN replication)) (PP (IN at) (NP (DT the) (NNP EBV) (JJ lytic) (NN origin)))))))) (. .)))
(TOP (S (NP (NP (JJ Additional) (NN work)) (, ,) (VP (VBG employing) (NP (NP (ADJP (JJ sequential) (CC and) (JJ internal)) (NNS deletions)) (PP (IN of) (NP (NP (NNP ZEBRA) (POS 's)) (JJ N-terminal) (NN activation) (NN domain))))) (, ,)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (PRP$ its) (JJ separate) (NNS activities)) (VP (VP (VP (VBP are) (RB not) (ADJP (JJ attributable) (PP (TO to) (NP (JJ specific) (NNS subdomains))))) (CC but) (VP (VBP are) (VP (VBN spread) (PP (IN throughout) (NP (PRP$ its) (NNP N) (NN terminus)))))) (CC and) (ADVP (RB therefore)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN inactivated) (PP (IN by) (S (VP (VBG deleting) (NP (JJ localized) (NNS regions)))))))))))) (. .)))
(TOP (S (NP (JJ Transcription) (NN factor) (NN GATA-3)) (VP (VBZ is) (VP (VP (ADVP (RB differentially)) (VBN expressed) (PP (IN in) (NP (JJ murine) (ADJP (JJ Th1) (CC and) (JJ Th2)) (NNS cells)))) (CC and) (VP (VBZ controls) (NP (NP (JJ Th2-specific) (NN expression)) (PP (IN of) (NP (DT the) (JJ interleukin-5) (NN gene))))))) (. .)))
(TOP (S (NP (NP (NN Interleukin-5)) (PRN (-LRB- -LRB-) (NP (NN IL-5)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN produced) (PP (PP (IN by) (NP (NNP CD4-LRB-+-RRB-) (NNP T) (NN helper) (CD 2) (PRN (-LRB- -LRB-) (NN Th2) (-RRB- -RRB-)) (NNS cells))) (, ,) (CC but) (RB not) (PP (IN by) (NP (JJ Th1) (NNS cells)))))))) (, ,)) (VP (VBZ plays) (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NN eosinophilia)) (PP (IN in) (NP (NN asthma)))))))) (. .)))
(TOP (S (PP (IN Despite) (NP (VBG increasing) (NN evidence) (SBAR (IN that) (S (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (JJ many) (NNS diseases)))) (VP (VBZ is) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN ratio)) (PP (IN of) (NP (NP (NP (DT the) (CD two) (NNS subsets)) (PP (IN of) (NP (NNP CD4-LRB-+-RRB-) (NNP T) (NN helper) (NNS cells)))) (, ,) (NP (NNP Th1) (CC and) (NNP Th2)))))))))))) (, ,) (NP (NP (DT the) (JJ molecular) (NN basis)) (PP (IN for) (NP (JJ Th1-) (CC and) (JJ Th2-specific) (NN gene) (NN expression)))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN elucidated)))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD established) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN for) (NP (DT the) (NN transcription) (NN factor) (NN GATA-3))) (PP (IN in) (NP (NP (NN IL-5) (NN promoter) (NN activation)) (PP (IN in) (NP (NP (NN EL-4) (NNS cells)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP express) (NP (DT both) (JJ Th1-) (CC and) (JJ Th2-type) (NNS cytokines))))))))))) (. .)))
(TOP (S (NP (NP (PRP$ Our) (NNS studies)) (VP (VBN reported) (ADVP (RB here)))) (VP (VBP demonstrate) (SBAR (DT that) (S (NP (NN GATA-3)) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NN IL-5) (NN gene))))) (PP (IN in) (NP (JJ bona) (JJ fide) (JJ Th2) (NNS cells)))))))) (. .)))
(TOP (S (SBAR (IN Whereas) (S (NP (NP (NNS mutations)) (PP (IN in) (NP (DT the) (NNP GATA-3) (NN site)))) (VP (VBD abolished) (NP (NP (ADJP (JJ antigen-) (CC or) (JJ cAMP-stimulated)) (NN IL-5) (NN promoter) (NN activation)) (PP (IN in) (NP (JJ Th2) (NNS cells))))))) (, ,) (NP (NP (JJ ectopic) (NN expression)) (PP (IN of) (NP (NP (NN GATA-3)) (PP (PP (IN in) (NP (JJ Th1) (NNS cells))) (CC or) (PP (IN in) (NP (DT a) (JJ non-lymphoid) (, ,) (JJ non-IL-5-producing) (NN cell) (NN line))))))) (VP (VBD activated) (NP (DT the) (NN IL-5) (NN promoter))) (. .)))
(TOP (S (S (PP (IN During) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (NP (JJ naive) (NNP CD4-LRB-+-RRB-) (NNP T) (NNS cells)) (VP (VBN isolated) (PP (IN from) (NP (NNP T) (NN cell) (NN receptor) (JJ transgenic) (NNS mice)))))))) (, ,) (NP (JJ GATA-3) (NN gene) (NN expression)) (VP (VP (VBD was) (ADJP (JJ up-regulated) (PP (IN in) (S (VP (VBG developing) (NP (JJ Th2) (NNS cells))))))) (, ,) (CC but) (VP (VBD was) (ADJP (JJ down-regulated) (PP (IN in) (NP (JJ Th1) (NNS cells))))))) (, ,) (CC and) (S (NP (NP (JJ antigen-) (CC or) (JJ cAMP-activated) (JJ Th2) (NNS cells)) (PRN (-LRB- -LRB-) (CC but) (RB not) (NP (JJ Th1) (NNS cells)) (-RRB- -RRB-))) (VP (VBD expressed) (NP (DT the) (JJ GATA-3) (NN protein)))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NNP GATA-3)) (VP (MD may) (VP (VB play) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (DT the) (NN balance)))) (PP (IN between) (NP (NP (ADJP (JJ Th1) (CC and) (JJ Th2)) (NNS subsets)) (PP (IN in) (NP (JJ immune) (NNS responses))))))) (. .)))
(TOP (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ GATA-3) (NN activity)))) (VP (VBZ has) (NP (NP (JJ therapeutic) (NN potential)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN asthma)) (CC and) (NP (JJ other) (JJ hypereosinophilic) (NNS diseases)))))))) (. .)))
(TOP (S (NP (NN Transcription)) (VP (NNS factors) (PP (IN in) (NP (JJ immune-mediated) (NN disease)))) (. .)))
(TOP (S (NP (NP (DT A) (JJ large) (NN amount)) (PP (IN of) (NP (NP (JJ detailed) (NN information)) (PP (IN about) (NP (NP (NP (DT the) (JJ intracellular) (NNS proteins)) (VP (VBG regulating) (NP (NNP NF-kappa) (NNP B) (NN activation)))) (CC and) (NP (NP (DT the) (JJ cellular) (NN response)) (PP (TO to) (NP (NNP NF-kappa) (NNP B) (NN activation))))))))) (VP (VBZ has) (VP (VBN emerged) (ADVP (RB recently)))) (. .)))
(TOP (S (NP (NP (JJ Several) (JJ small) (NNS molecules)) (, ,) (NP (DT an) (JJ antisense) (NN oligonucleotide)) (, ,) (CC and) (NP (NP (NN gene) (JJ therapeutic) (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (JJ NF-kappa) (NN b) (NN activation))))))) (VP (VBP have) (VP (VBN been) (VP (VBN described)))) (. .)))
(TOP (S (PP (IN Despite) (NP (DT this))) (, ,) (NP (EX there)) (VP (VBP are) (ADVP (RB still)) (NP (JJ significant) (NNS gaps)) (PP (IN in) (NP (NP (PRP$ our) (NN understanding)) (PP (IN of) (NP (NP (DT this) (NN process)) (CC and) (NP (PRP$ its) (NNS consequences))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN characterization)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (VP (ADVP (RB selectively)) (VBG regulating) (NP (JJ cytokine) (NN production)) (PP (IN by) (NP (NNP CD4+) (NNP T) (NN cell) (NNS subsets))))))) (VP (VBZ is) (PP (IN at) (NP (DT a) (ADJP (RB very) (JJ early)) (NN stage)))) (. .)))
(TOP (S (NP (CD Three) (VBG interacting) (NNS proteins)) (VP (VBP have) (ADVP (RB recently)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB contribute) (PP (TO to) (NP (NP (JJ subset-restricted) (NN expression)) (PP (IN of) (NP (DT the) (NN IL-4) (NN gene))))))))))) (. .)))
(TOP (S (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ other) (NNS elements)) (VP (VBG regulating) (NP (NN IL-4) (NN gene) (NN expression)))))) (, ,) (ADVP (RB however)) (, ,) (CC and) (S (NP (NP (DT the) (JJ relative) (NN importance)) (PP (IN of) (NP (DT these) (ADJP (RB recently) (VBN identified)) (NNS proteins)))) (VP (VBZ has) (ADVP (RB yet)) (S (VP (TO to) (VP (VB be) (VP (VBN determined))))))) (. .)))
(TOP (S (NP (JJ alpha-Tocopheryl) (NN succinate)) (VP (VBZ inhibits) (NP (JJ monocytic) (NN cell) (NN adhesion)) (PP (TO to) (NP (JJ endothelial) (NNS cells))) (PP (IN by) (S (VP (VBG suppressing) (NP (NNP NF-kappa) (NNP B) (NN mobilization)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN adherence)) (PP (IN of) (NP (NNS monocytes))) (PP (TO to) (NP (VBN activated) (NN endothelium)))) (VP (VBZ is) (NP (NP (DT an) (JJ early) (NN event)) (PP (IN in) (NP (NN atherogenesis))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP (NNS antioxidants)) (VP (VBP have) (VP (VBN been) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ antiatherosclerotic) (NN potential))))))))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ alpha-tocopherol) (PRN (-LRB- -LRB-) (NNP TCP) (-RRB- -RRB-))) (CC and) (NP (NP (PRP$ its) (NX (NX (NN acetate)) (CC and) (NX (JJ succinate) (NNS esters)))) (PP (IN on) (NP (NP (JJ monocyte) (NN adhesion)) (PP (TO to) (NP (NP (JJ cytokine-stimulated) (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP HUVEC)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP (JJ Endothelial) (NNS cells)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP TCP)) (, ,) (NP (NP (JJ alpha-tocopherol) (NN acetate)) (PRN (-LRB- -LRB-) (NP (NNP TCP) (NN acetate)) (-RRB- -RRB-))) (, ,)) (CC or) (NP (NP (JJ alpha-tocopheryl) (NN succinate)) (PRN (-LRB- -LRB-) (NP (NNP TCP) (NN succinate)) (-RRB- -RRB-))))) (PP (IN before) (NP (NP (NP (NP (NN stimulation)) (PP (IN with) (NP (NN tumor) (NN necrosis) (NN factor-alpha)))) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (: ;) (NP (NP (CD 10) (NNP U/ml)) (, ,) (NP (CD 6) (NN h))) (-RRB- -RRB-))) (CC or) (NP (NP (JJ interleukin-1) (NN beta)) (PRN (-LRB- -LRB-) (NP (JJ IL-1) (NN beta)) (: ;) (NP (CD 10) (NNP U/ml)) (, ,) (NP (CD 6) (NN h)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (S (NP (NP (JJ Cytokine-stimulated) (NN cell) (NN surface) (NN expression)) (PP (IN of) (NP (JJ vascular) (NN cell)))) (VP (NN adhesion) (ADJP (JJ molecule-1) (PRN (-LRB- -LRB-) (NNP VCAM-1) (, ,) (NNP CD106) (-RRB- -RRB-))))) (CC and) (S (NP (NP (NP (NNP E-selectin)) (PRN (-LRB- -LRB-) (NP (NNP ELAM-1)) (, ,) (NP (NNP CD62E)) (-RRB- -RRB-))) (, ,) (CC but) (RB not) (PP (IN of) (NP (NP (JJ intercellular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NNP ICAM-1)) (, ,) (NP (NNP CD54)) (-RRB- -RRB-)))) (, ,)) (VP (VBD was) (ADJP (ADJP (ADJP (JJ time-)) (CC and) (ADJP (JJ dose-))) (VP (ADVP (RB dependently)) (VBN inhibited) (PP (PP (IN by) (NP (NNP TCP) (NN succinate))) (CC but) (RB not) (PP (IN by) (NP (NNP TCP) (CC or) (NNP TCP) (VBP acetate)))))))) (. .)))
(TOP (S (NP (NP (NNP TCP) (NN succinate)) (PRN (-LRB- -LRB-) (NP (CD 200) (NNP microM)) (, ,) (NP (CD 24) (NN h)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NNP TNF-induced) (NNP VCAM-1) (CC and) (NNP E-selectin) (NN expression)) (PP (PP (IN from) (NP (NP (DT a) (JJ specific) (JJ mean) (NN fluorescence) (NN intensity)) (PP (IN of) (NP (QP (CD 151) (CD +/-) (CD 28) (TO to) (CD 12) (CD +/-) (CD 4)) (NNS channels))))) (CC and) (PP (IN from) (NP (NP (QP (CD 225) (CD +/-) (CD 38) (TO to) (CD 79) (CD +/-) (CD 21)) (NNS channels)) (, ,) (ADVP (RB respectively)))))) (. .)))
(TOP (S (NP (NP (NNP Succinate)) (ADVP (RB alone))) (VP (VBD had) (NP (DT no) (NN effect))) (. .)))
(TOP (S (NP (JJ Decreased) (NN adhesion) (NN molecule) (NN expression)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (JJ monocytic) (NN cell) (NN adhesion))))))) (. .)))
(TOP (S (NP (NP (NP (FW TCP) (FW succinate)) (PRN (-LRB- -LRB-) (NP (NNP 20) (NNP microM)) (, ,) (NP (CD 72) (NN h)) (-RRB- -RRB-))) (, ,) (CC but) (NP (NP (RB not) (NNP TCP)) (PRN (-LRB- -LRB-) (NP (CD 200) (NNP microM)) (, ,) (NP (CD 72) (NN h)) (-RRB- -RRB-))) (, ,)) (VP (VBN reduced) (NP (NNP U-937) (NN cell) (NN adhesion)) (PP (TO to) (NP (NP (JJ TNF-alpha-stimulated)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNP U/ml)) (, ,) (NP (CD 6) (NN h)) (-RRB- -RRB-)) (NP (NNP HUVEC)))) (PP (PP (IN by) (NP (NP (CD 30) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP P) (VBD &lt;) (CD 0.025)) (-RRB- -RRB-)))) (CC and) (PP (TO to) (NP (NNP IL-1) (VBD beta-stimulated) (NNP HUVEC)))) (PP (IN by) (NP (NP (CD 56) (NN %)) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD &lt;) (NP (CD 0.010)))) (-RRB- -RRB-))))) (. .)))
(TOP (S (NP (NP (JJ Electrophoretic) (JJ mobility-shift) (NNS assays)) (PP (IN of) (NP (NNP HUVEC) (JJ nuclear) (NNS proteins)))) (VP (VBD revealed) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ TNF-alpha-stimulated) (JJ nuclear) (NN factor-kappa) (NNP B) (PRN (-LRB- -LRB-) (NNP NF-kappa) (NNP B) (-RRB- -RRB-)) (NN activation))) (PP (IN after) (NP (NP (NN pretreatment)) (PP (IN of) (NP (NNP HUVEC))))) (PP (PP (IN with) (NP (NNP TCP) (NN succinate))) (CC but) (RB not) (PP (IN with) (NP (NP (NNP TCP)) (, ,) (NP (NNP TCP) (VBP acetate)) (, ,) (CC or) (NP (NP (VB succinate)) (ADVP (RB alone)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT the) (NN vitamin) (NN E) (JJ derivative) (NNP TCP) (NN succinate)) (VP (VBZ prevents) (NP (JJ monocytic) (NN cell) (NN adhesion)) (PP (TO to) (NP (JJ cytokine-stimulated) (JJ endothelial) (NNS cells))) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B))))))) (, ,) (S (VP (ADVP (RB further)) (VBG emphasizing) (NP (NP (DT the) (JJ antiatherosclerotic) (NN potential)) (PP (IN of) (NP (NN lipid) (JJ soluble) (NNS antioxidants)))))))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (JJ inosine-5'-monophosphate) (NN dehydrogenase) (NN type) (NNP II) (NN gene) (NN expression))) (PP (IN in) (NP (JJ human) (NNP T) (NNS cells))) (. .)))
(TOP (NP (NP (NN Role)) (PP (IN for) (NP (DT a) (JJ novel) (CD 5') (JJ palindromic) (NN octamer) (NN sequence))) (. .)))
(TOP (S (NP (NP (NN Expression)) (PP (IN of) (NP (NP (DT the) (NN gene)) (VP (VBG encoding) (NP (NP (JJ human) (JJ inosine-5'-monophosphate) (NN dehydrogenase) (PRN (-LRB- -LRB-) (NNP IMPDH) (-RRB- -RRB-)) (NN type) (NNP II)) (, ,) (NP (NP (DT an) (NN enzyme)) (VP (VBG catalyzing) (NP (NP (DT the) (JJ rate-limiting) (NN step)) (PP (IN in) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (JJ guanine) (NNS nucleotides)))))))) (, ,)))))) (VP (VP (VBZ is) (VP (VBN increased) (ADJP (ADVP (RBR more) (IN than)) (JJ 10-fold) (PP (IN in) (NP (VBN activated) (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes)))))) (CC and) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NNP T) (NN cell) (NN activation)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (JJ 5'-regulatory) (NNS sequences)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ important) (PP (IN for) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT this) (NN gene))) (PP (IN in) (NP (NNP T) (NNS cells)))))))))))) (. .)))
(TOP (S (NP (NP (NNP DNase) (NNP I) (NN mapping)) (PP (IN of) (NP (JJ genomic) (NN DNA)))) (VP (VBD identified) (NP (NP (DT a) (JJ hypersensitive) (NN element)) (PP (IN near) (NP (DT the) (NN transcription) (NN initiation) (NN site))))) (. .)))
(TOP (S (S (NP (NP (JJ Fine) (NN mapping)) (PP (IN by) (PP (IN in) (NP (NN vivo) (NN footprinting))))) (VP (VBD demonstrated) (NP (NP (CD five) (NN transcription) (NN factor)) (VP (VBG binding) (NP (NP (NNS sites)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN occupied) (PP (IN in) (NP (DT both) (S (VP (VBG resting) (CC and) (VBN activated) (NP (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes))))))))))))))) (: ;) (S (NP (DT these)) (VP (VBP are) (NP (NP (NN tandem) (NNP CRE) (NNS motifs)) (, ,) (NP (DT a) (JJ Sp1) (NN site)) (, ,) (NP (DT an) (VBG overlapping) (NN Egr-1/Sp1) (NN site)) (, ,) (CC and) (NP (NP (DT a) (JJ novel) (JJ palindromic) (NN octamer) (NN sequence)) (PRN (-LRB- -LRB-) (NP (NNP POS)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP (DT The) (NN tandem) (NNP CRE) (CC and) (NNP POS) (NNS sites)) (VP (VBP are) (PP (IN of) (NP (JJ major) (JJ functional) (NN importance))) (SBAR (IN as) (S (VP (VBN judged) (PP (IN by) (NP (ADJP (JJ mutational) (CC and) (JJ electrophoretic)) (NN mobility) (NN shift) (NNS analyses))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP provide) (NP (NN evidence) (SBAR (DT that) (S (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ human) (NNP IMPDH) (NN type) (NNP II) (NN gene)))) (VP (VBZ is) (VP (ADVP (RB predominantly)) (VBN regulated) (PP (IN by) (NP (NP (DT the) (JJ nuclear) (NNS factors) (NN ATF-2)) (CC and) (NP (DT an) (ADJP (RB as) (RB yet)) (JJ unidentified) (JJ POS-binding) (NN protein)))))))))) (. .)))
(TOP (S (NP (JJ Additional) (JJ major) (JJ protein-DNA) (NNS interactions)) (VP (VBP do) (RB not) (VP (VB occur) (PP (IN within) (NP (DT the) (NN promoter) (NN region))) (PP (IN after) (NP (NNP T) (NN lymphocyte) (NN activation))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (NN requirement)) (PP (IN for) (NP (NP (JJ additional) (JJ protein-protein) (NNS interactions)) (CC and/or) (NP (NP (JJ post-translational) (NNS modifications)) (PP (IN of) (NP (JJ pre-bound) (NN transcription) (NNS factors))) (SBAR (S (VP (TO to) (VP (VB account) (PP (IN for) (NP (NP (DT the) (JJ observed) (NN increase)) (PP (IN in) (NP (NNP IMPDH) (NN type) (NNP II) (NN gene) (NN expression))))))))))))))))) (. .)))
(TOP (NP (NP (JJ Transcriptional) (NN regulation)) (PP (IN during) (NP (NN myelopoiesis))) (. .)))
(TOP (S (NP (NP (DT The) (VBN coordinated) (NN production)) (PP (IN of) (NP (NP (DT all) (NN blood) (NNS cells)) (PP (IN from) (NP (DT a) (JJ common) (NN stem) (NN cell)))))) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB highly) (JJ regulated)) (NN process)) (VP (VBG involving) (NP (NP (JJ successive) (NNS stages)) (PP (IN of) (NP (NN commitment) (CC and) (NN differentiation))))))) (. .)))
(TOP (S (PP (PP (IN From) (NP (NP (NP (NNS analyses)) (PP (IN of) (NP (NNS mice)))) (ADJP (JJ deficient) (PP (IN in) (NP (NN transcription) (NN factor) (NNS genes)))))) (CC and) (PP (IN from) (NP (NP (DT the) (NNS characterizations)) (PP (IN of) (NP (NP (NN chromosome) (NNS breakpoints)) (PP (IN in) (NP (JJ human) (NNS leukemias)))))))) (, ,) (NP (NP (PRP it))) (VP (VBZ has) (VP (VBN become) (ADJP (JJ evident)) (SBAR (IN that) (S (NP (NN transcription) (NNS factors)) (VP (VBP are) (NP (NP (JJ important) (NNS regulators)) (PP (IN of) (NP (NN hematopoiesis))))))))) (. .)))
(TOP (S (PP (IN During) (NP (NP (NN myelopoiesis)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ includes) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (ADJP (JJ granulocytic) (CC and) (JJ monocytic)) (NNS lineages))))))))) (, ,) (NP (NP (NN transcription) (NNS factors)) (PP (IN from) (NP (JJ several) (NNS families)))) (VP (VP (VBP are) (ADJP (JJ active))) (, ,) (PP (VBG including) (NP (NP (NNP AML1/CBF) (NN beta)) (, ,) (NP (NNP C/EBP)) (, ,) (NP (NNP Ets)) (, ,) (NP (NNP c-Myb)) (, ,) (NP (NNP HOX)) (, ,) (CC and) (NP (NNP MZF-1))))) (. .)))
(TOP (S (S (NP (NP (JJ Few)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (VBP are) (VP (VBN expressed) (PP (ADVP (RB exclusively)) (IN in) (NP (JJ myeloid) (NNS cells)))))) (: ;) (S (ADVP (RB instead)) (NP (PRP it)) (VP (VBZ appears) (SBAR (IN that) (S (NP (PRP they)) (VP (ADVP (RB cooperatively)) (VBP regulate) (NP (NP (NN transcription)) (PP (IN of) (NP (JJ myeloid-specific) (NNS genes))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP discuss) (NP (NP (JJ recent) (NNS advances)) (PP (IN in) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN during) (NP (NN myelopoiesis))))))) (. .)))
(TOP (S (NP (JJ Transcription) (NN factor) (NN Egr-1) (NN activity)) (VP (VBZ down-regulates) (NP (NNP Fas) (CC and) (NNP CD23) (NN expression)) (PP (IN in) (NP (NNP B) (NNS cells)))) (. .)))
(TOP (S (NP (NP (NNP Activation)) (PP (IN of) (NP (NNP mature) (NNP B) (NNS cells))) (PP (IN via) (NP (NNP Ag) (NN receptor) (NN cross-linking)))) (VP (VBZ induces) (NP (NP (JJ transient) (NN expression)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN Egr-1))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (NP (DT the) (VBG activating) (NNS signals)) (VP (VBG leading) (PP (TO to) (NP (JJ Egr-1) (NN induction))))) (VP (VBP have) (VP (VBN been) (VP (VBN studied) (ADVP (RB extensively))))))) (, ,) (NP (NP (JJ little))) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (NNS genes)) (SBAR (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN placed) (ADVP (RB further)) (ADVP (JJ downstream)) (PP (IN within) (NP (DT this) (NN activation) (NN cascade))))))) (CC and) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (ADVP (RB transcriptionally)) (VBN regulated) (PP (IN by) (NP (NNP Egr-1)))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB identify) (NP (JJ such) (NN target) (NNS genes))))) (, ,) (NP (PRP we)) (VP (VBD established) (NP (JJ Egr-1-overexpressing) (NNS transfectants)) (PP (PP (IN from) (NP (NP (DT the) (JJ murine) (NN B) (NN cell) (NN line)) (ADJP (NNP K46)))) (CC and) (PP (IN from) (NP (JJ human) (NNP Ramos) (NNP B) (NNS cells))))) (. .)))
(TOP (S (NP (NP (DT All) (NNS clones)) (VP (VBN derived) (PP (IN from) (NP (NNP K46) (NNP B) (NNS cells))))) (VP (VBD showed) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NNP CD44))))) (. .)))
(TOP (S (ADVP (RBS Most) (RB interestingly)) (, ,) (NP (NP (NP (NN expression)) (PP (IN of) (NP (NNP CD95)))) (PP (PRN (-LRB- -LRB-) (NP (NN Fas/Apo-1)) (-RRB- -RRB-)) (CC and) (PP (IN of) (NP (NNP CD23))))) (VP (VBD was) (ADJP (JJ down-regulated) (PP (IN in) (NP (DT all) (CD K46) (NNS transfectants))))) (. .)))
(TOP (S (PP (IN As) (NP (DT a) (NN consequence))) (, ,) (NP (PRP they)) (VP (VBD became) (ADJP (JJ resistant) (PP (TO to) (NP (NP (NNS apoptosis)) (VP (VBN induced) (PP (IN by) (NP (NNP anti-CD95) (NNP Ab) (NN treatment)))))))) (. .)))
(TOP (S (ADVP (RB Similarly)) (, ,) (NP (DT the) (JJ Egr-1-expressing) (NNP Ramos) (NNS cells)) (VP (VBD showed) (NP (NP (JJ reduced) (NNS levels)) (PP (IN of) (NP (NNP CD95) (NN expression))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NN Egr-1)) (VP (VBZ seems) (S (VP (TO to) (VP (VB control) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ downstream) (NN target) (NNS genes)))) (PP (CONJP (RB not) (RB only)) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN activator))) (, ,) (CONJP (CC but) (RB also)) (PP (IN as) (NP (DT a) (NN repressor) (NN molecule)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NNP B) (NNS cells))) (, ,) (NP (NNP Egr-1)) (ADVP (RB therefore)) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (S (VP (VBG integrating) (NP (NP (DT the) (JJ short-lived) (NN signal)) (VP (VBN delivered) (PP (IN by) (S (VP (VBG triggering) (PP (IN of) (NP (DT the) (NNP Ag) (NN receptor))) (PP (IN into) (NP (NP (JJ phenotypic) (NNS changes)) (, ,) (PP (VBG including) (NP (NP (NN repression)) (PP (IN of) (NP (NNP CD95) (CC and) (NNP CD23) (NN transcription)))))))))))))))) (. .)))
(TOP (NP (NP (NP (JJ Genomic) (NN organization)) (, ,) (NP (NN sequence)) (, ,)) (CC and) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (JJ human) (NN eotaxin) (NN gene)))) (. .)))
(TOP (S (NP (NNP Eotaxin)) (VP (VBZ is) (NP (NP (DT an) (JJ eosinophil) (JJ specific) (NN beta-chemokine)) (VP (VBN assumed) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (JJ eosinophilic) (JJ inflammatory) (NNS diseases)) (PP (JJ such) (IN as) (NP (NP (JJ atopic) (NNS dermatitis)) (, ,) (NP (JJ allergic) (NN rhinitis)) (, ,) (NP (NN asthma)) (CC and) (NP (JJ parasitic) (NNS infections))))))))))))) (. .)))
(TOP (S (NP (PRP$ Its) (NN expression)) (VP (VBZ is) (ADJP (JJ stimulus-) (CC and) (JJ cell-specific))) (. .)))
(TOP (S (NP (NP (PRP We)) (ADVP (RB here))) (VP (VBP describe) (NP (NP (NP (DT the) (JJ genomic) (NN organisation)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 3) (NNS exons)) (PP (IN of) (NP (CD 132)))) (, ,) (NP (CD 112)) (CC and) (NP (CD 542) (NN bp))) (CC and) (NP (NP (NP (CD 2) (NNS introns)) (PP (IN of) (NP (CD 1211)))) (CC and) (NP (CD 378) (NN bp)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN sequence)) (PP (VBG including) (NP (NP (CD 3) (NN kb)) (PP (IN of) (NP (NN DNA))))) (PP (IN from) (NP (NP (DT the) (JJ immediate) (CD 5') (JJ upstream) (NN region)) (PP (IN of) (NP (DT the) (JJ human) (NN eotaxin) (NN gene)))))))) (. .)))
(TOP (PP (IN Among) (NP (NP (NP (DT the) (JJ regulatory) (NN promoter) (NNS elements)) (VP (VP (ADVP (RB potentially)) (VBG regulating) (NP (JJ eotaxin) (NN gene) (NN expression))) (CC and/or) (VP (VBG mediating) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ anti-inflammatory) (NNS drugs))) (SBAR (S (NP (PRP we)) (VP (VBD identified) (NP (NP (NN consensus) (NNS sequences)) (VP (VBN known) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (JJ nuclear) (NNS factors)) (PP (IN like) (NP (NP (NNP NF-IL6)) (, ,) (NP (NNP AP-1)) (, ,))))))))))))))) (NP (DT a) (NN NF-kappa-B)) (PP (IN like) (NP (NP (NN consensus) (NN sequence)) (CC and) (NP (NN gamma-interferon-)))))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ glucocorticoid) (NN response) (NNS elements)) (. .))))
(TOP (NP (NP (NNP Vitamin) (NNP D) (NN receptor)) (: :) (NP (NP (DT no) (NN evidence)) (PP (IN for) (NP (JJ allele-specific) (NNP mRNA) (NN stability))) (PP (IN in) (NP (NNS cells))) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADJP (JJ heterozygous) (PP (IN for) (NP (DT the) (NNP Taq) (NNP I) (NN restriction) (NN enzyme) (NN polymorphism)))))))) (. .)))
(TOP (S (NP (NP (JJ Allelic) (NNS variations)) (PP (IN of) (NP (DT the) (JJ vitamin) (NNP D) (NN receptor) (PRN (-LRB- -LRB-) (NNP VDR) (-RRB- -RRB-)) (NN gene)))) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NN prostate) (NN cancer)) (PP (IN in) (NP (NP (NNS men) (CC and) (NNS osteoporosis)) (PP (IN in) (NP (JJ postmenopausal) (NNS women)))))))))))))) (. .)))
(TOP (S (NP (NP (CD Three) (NNS RFLPs)) (PRN (-LRB- -LRB-) (NP (NNP TaqI)) (, ,) (NP (NNP ApaI)) (, ,) (NP (NNP BsmI)) (-RRB- -RRB-))) (VP (VBP define) (NP (NP (CD two) (JJ common) (NNS haplotypes)) (: :) (NP (NNP BAt) (CC and) (NNP baT)))) (. .)))
(TOP (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (NNS polymorphisms)))) (VP (VBP change) (NP (DT the) (VBN translated) (NN protein))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP (NP (NN sequence) (NNS variations)) (PP (IN in) (NP (NP (DT the) (CD 3') (NNP UTR)) (PP (IN of) (NP (NNP VDR)))))) (VP (VBP have) (VP (VBN been) (VP (VBN linked) (PP (TO to) (NP (DT the) (JJ different) (NNS haplotypes)))))))) (, ,) (NP (NNS investigators)) (VP (VBP have) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (DT the) (NN stability)) (PP (IN of) (NP (NNP VDR) (NNP mRNA)))) (VP (VBZ is) (VP (VBN influenced) (PP (IN by) (NP (JJ allelic) (NNS variations))))))))) (. .)))
(TOP (S (NP (JJ Indirect) (NN evidence)) (VP (VBD suggested) (SBAR (IN that) (FRAG (SBAR (IN allele) (S (NP (NNP T)) (VP (VBZ is) (ADJP (ADJP (RBR less) (JJ stable)) (PP (IN than) (NP (JJ allele) (NN t)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (DT a) (NN RT-PCR)) (PP (VBN based) (NP (NP (NN approach)) (SBAR (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN stability)) (PP (IN of) (NP (NP (NP (DT the) (JJ big) (NN T)) (CC and) (NP (NP (JJ small) (NN t) (NN allele)) (PP (IN in) (NP (JJ normal) (JJ heterozygous) (NNS lymphocytes))))) (CC and) (NP (NP (NP (DT the) (JJ heterozygous) (NN cell) (NNS lines) (NNP NB4)) (PRN (-LRB- -LRB-) (NP (JJ myeloid) (NN leukemia)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NNP PC-3)) (CC and) (NP (NNP DU) (CD 145))) (PRN (-LRB- -LRB-) (NP (NN prostate) (NNS cancers)) (-RRB- -RRB-)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT all) (CD three) (NNS cases))) (, ,) (NP (PRP we)) (VP (VBD did) (RB not) (VP (VB find) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (NN stability)))))) (. .)))
(TOP (S (ADVP (RB Interestingly)) (, ,) (NP (PRP we)) (VP (ADVP (RB consistently)) (VBD observed) (NP (NP (ADJP (NP (CD 30) (NN %)) (RBR less) (JJ RT-PCR)) (NN product)) (VP (VBN derived) (PP (IN from) (NP (NP (NP (DT the) (JJ small) (NN t)) (PP (IN allele) (NP (NNP mRNA))) (PP (IN in) (NP (JJ steady) (NN state)))) (, ,) (NP (NP (DT a) (NN finding)) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBZ speaks) (PP (IN against) (NP (NP (DT a) (JJR higher) (NN stability)) (PP (IN of) (NP (NP (DT the) (JJ small) (NN t)) (PP (IN allele) (NP (NNP mRNA)))))))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP indicate) (NP (NP (DT a) (NN variation)) (PP (IN in) (NP (NP (JJ transcriptional) (NN regulation)) (PP (RB rather) (IN than) (NP (NP (JJ mRNA) (NN stability)) (PP (IN between) (NP (DT the) (NNS alleles))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (NP (DT an) (JJ unknown) (NN gene) (CC or) (NNS genes)) (PP (IN in) (NP (NP (NN linkage)) (PP (IN with) (NP (DT the) (NNS polymorphisms)))))) (VP (VBZ is) (PRN (-LRB- -LRB-) (INTJ (VBP are)) (-RRB- -RRB-)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN risk)) (PP (IN of) (NP (NP (NN prostate) (NN cancer)) (CC and) (NP (NNP VDR) (NNS polymorphisms))))))))))))) (. .)))
(TOP (S (NP (NNP Rel/NF-kappa)) (VP (NNP B) (NP (NP (NN transcription) (NNS factors)) (CC and) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NN apoptosis)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN process)) (PP (IN of) (NP (NN apoptosis)))) (VP (VBZ is) (VP (VBN used) (S (VP (TO to) (VP (VB eliminate) (NP (JJ unwanted) (NNS cells)) (PP (IN from) (NP (NP (DT a) (JJ wide) (NN variety)) (PP (IN of) (NP (NNS organisms)))))))))) (. .)))
(TOP (S (NP (NP (JJ Various) (JJ extracellular) (NNS signals)) (, ,) (VP (ADVP (RB often)) (VBG converging) (PP (IN in) (NP (JJ common) (JJ intracellular) (NNS pathways)))) (, ,)) (VP (MD can) (VP (VB induce) (NP (NN apoptosis)) (PP (IN in) (NP (DT a) (JJ cell-type-specific) (NN fashion))))) (. .)))
(TOP (S (NP (NP (JJ Recent) (NN work)) (PP (IN from) (NP (JJ several) (NNS laboratories)))) (VP (VBZ has) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NNP Rel/NF-kappa) (NNP B) (NN transcription) (NNS factors)) (VP (VBP regulate) (NP (NN apoptosis)) (PP (IN in) (NP (JJ many) (NN cell) (NNS types)))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (JJS most) (NNS cells))) (, ,) (NP (NNP Rel/NF-kappa) (NNP B) (NN transcription) (NNS factors)) (VP (VBP appear) (S (VP (TO to) (VP (VB mediate) (NP (NP (NN survival) (NNS signals)) (SBAR (WHNP (WDT that)) (S (VP (VBP protect) (NP (NNS cells)) (PP (IN from) (NP (NN apoptosis)))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (PP (IN under) (NP (DT some) (NNS circumstances))) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (MD may) (ADVP (RB also)) (VP (VB promote) (NP (NN apoptosis))))) (. .)))
(TOP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (NP (NNP Rel/NF-kappa) (NNP B) (NNS proteins)) (PP (IN in) (NP (JJ viral) (NN oncogenesis)))) (CC and) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ viral) (NN transcription)))))) (. .)))
(TOP (S (NP (NNP Rel/NF-kappa) (NNP B)) (VP (VBZ is) (NP (NP (DT a) (JJ ubiquitous) (NN transcription) (NN factor)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ consists) (PP (IN of) (NP (JJ multiple) (NN polypeptide) (NNS subunits)))) (, ,) (CC and) (VP (VBZ is) (ADJP (JJ subject) (PP (TO to) (NP (NP (JJ complex) (JJ regulatory) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP involve) (NP (NP (JJ protein-protein) (NNS interactions)) (, ,) (NP (NN phosphorylation)) (, ,) (NP (NN ubiquitination)) (, ,) (NP (JJ proteolytic) (NN degradation)) (, ,) (CC and) (NP (JJ nucleocytoplasmic) (NN translocation))))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ sophisticated) (NN control)) (PP (IN of) (NP (NNP Rel/NF-kappa) (NNP B) (NN activity)))) (VP (VBZ is) (RB not) (ADJP (JJ surprising)) (SBAR (IN since) (S (NP (DT this) (NN transcription) (NN factor)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT a) (JJ wide) (NN array)) (PP (IN of) (NP (JJ cellular) (NNS responses))) (PP (TO to) (NP (JJ extracellular) (NNS cues))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (NN growth)) (, ,) (NP (NN development)) (, ,) (NP (NN apoptosis)) (, ,) (CC and) (NP (NN pathogen) (NN invasion)))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (PRP it))) (VP (VBZ is) (ADJP (RB not) (JJ unexpected)) (SBAR (IN that) (S (NP (DT this) (RB versatile) (JJ cellular) (JJ homeostatic) (NN switch)) (VP (MD would) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ viral) (NNS pathogens)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP have) (VP (VBN evolved) (NP (NP (NNS mechanisms)) (SBAR (S (VP (TO to) (VP (VB utilize) (NP (NP (JJ various) (NNS aspects)) (PP (IN of) (NP (NNP Rel/NF-kappa) (NNP B) (NN activity))))))))) (S (VP (TO to) (VP (VB facilitate) (NP (NP (PRP$ their) (NN replication)) (, ,) (NP (NN cell) (NN survival)) (CC and) (ADVP (RB possibly)) (NP (NP (NN evasion)) (PP (IN of) (NP (JJ immune) (NNS responses)))))))))))))))))))))) (. .)))
(TOP (S (NP (DT This) (NN review)) (VP (MD will) (VP (VB cover) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN utilized) (PP (IN by) (NP (JJ mammalian) (JJ oncogenic) (NNS viruses))) (S (VP (TO to) (VP (VB affect) (NP (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP Rel/NF-kappa) (NNP B) (NN transcription) (NNS factors)))) (CC and) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Rel/NF-kappa) (NNP B))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ viral) (NN gene) (NN expression) (CC and) (NN replication))))))))))))))))) (. .)))
(TOP (NP (NP (NP (NNS Mutations)) (PP (IN in) (NP (DT the) (NNP TSC2) (NN gene)))) (: :) (NP (NP (NN analysis)) (PP (IN of) (NP (NP (DT the) (JJ complete) (NN coding) (NN sequence)) (VP (VBG using) (NP (NP (DT the) (NN protein) (NN truncation) (NN test)) (PRN (-LRB- -LRB-) (NP (NNP PTT)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP (NP (NNS Mutations)) (PP (IN in) (NP (NP (DT the) (NNP TSC2) (NN gene)) (PP (IN on) (NP (NN chromosome) (CD 16p13.3)))))) (VP (VBP are) (ADJP (JJ responsible) (PP (IN for) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (PP (IN of) (NP (NP (JJ familial) (JJ tuberous) (NN sclerosis)) (PRN (-LRB- -LRB-) (NP (NNP TSC)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP (DT The) (NN gene)) (VP (VBZ has) (NP (NP (CD 41) (JJ small) (NNS exons)) (VP (VP (VBG spanning) (NP (NP (CD 45) (NN kb)) (PP (IN of) (NP (JJ genomic) (NN DNA))))) (CC and) (VP (VBG encoding) (NP (DT a) (CD 5.5) (NN kb) (NN mRNA)))))) (. .)))
(TOP (S (S (NP (NP (JJ Large) (NN germline) (NNS deletions)) (PP (IN of) (NP (NNP TSC2)))) (VP (VBP occur) (PP (IN in) (NP (NP (QP (CD &lt;) (CD 5)) (NN %)) (PP (IN of) (NP (NNS cases))))))) (, ,) (CC and) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ small) (JJ intragenic) (NNS mutations)))) (VP (VBP have) (VP (VBN been) (VP (VBN described))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD analysed) (NP (NNP mRNA)) (PP (IN from) (NP (NP (NP (CD 18) (JJ unrelated) (NNS cases)) (PP (IN of) (NP (NNP TSC)))) (PP (IN for) (NP (NP (NNP TSC2) (NNS mutations)) (VP (VBG using) (NP (NP (DT the) (NN protein) (NN truncation) (NN test)) (PRN (-LRB- -LRB-) (NP (NNP PTT)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP (CD Three) (NNS cases)) (VP (VBD were) (VP (VBN predicted) (SBAR (S (VP (TO to) (VP (VB be) (NP (JJ TSC2) (NNS mutations)) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NN linkage) (NN analysis)))))))) (CC or) (SBAR (IN because) (S (NP (NP (DT a) (NN hamartoma)) (PP (IN from) (NP (DT the) (NN patient)))) (VP (VBD showed) (NP (NP (NN loss)) (PP (IN of) (NP (NP (NN heterozygosity)) (PP (IN for) (NP (JJ 16p13.3) (NNS markers)))))))))))) (. .)))
(TOP (S (NP (NP (CD Three) (VBG overlapping) (NNP PCR) (NNS products)) (, ,) (VP (VBG covering) (NP (NP (DT the) (JJ complete) (NN coding) (NN sequence)) (PP (IN of) (NP (NNP mRNA))))) (, ,)) (VP (VBD were) (VP (VBN generated) (PP (IN from) (NP (NP (JJ lymphoblastoid) (NN cell) (NNS lines)) (, ,) (VP (VP (VBN translated) (PP (IN into) (NP (JJ 35S-methionine) (JJ labelled) (NN protein)))) (, ,) (CC and) (VP (VBN analysed) (PP (IN by) (NP (NNP SDS-PAGE))))))))) (. .)))
(TOP (S (S (NP (NP (NNP PCR) (NNS products)) (VP (VBG showing) (NP (NNP PTT) (NNS shifts)))) (VP (VBD were) (VP (ADVP (RB directly)) (VBN sequenced)))) (, ,) (CC and) (S (NP (NNS mutations)) (VP (VBN confirmed) (PP (IN by) (NP (NP (NN restriction) (NN enzyme) (NN digestion)) (SBAR (WHADVP (WRB where)) (S (ADJP (JJ possible)))))))) (. .)))
(TOP (S (NP (CD Six) (NNP PTT) (NNS shifts)) (VP (VBD were) (VP (VBN identified))) (. .)))
(TOP (S (S (NP (NP (CD Five)) (PP (IN of) (NP (DT these)))) (VP (VBD were) (VP (VBN caused) (PP (IN by) (NP (NP (NNS mutations)) (VP (VBN predicted) (S (VP (TO to) (VP (VB produce) (NP (DT a) (JJ truncated) (NN protein))))))))))) (: :) (S (S (PRN (-LRB- -LRB-) (FW i) (-RRB- -RRB-)) (S (NP (DT a) (JJ sporadic) (NN case)) (VP (VBD showed) (NP (DT a) (ADJP (CD 32) (NN bp)) (NN deletion)) (PP (IN in) (NP (NN exon) (CD 11))))) (, ,) (CC and) (S (NP (NP (DT a) (JJ mutant) (NN mRNA)) (PP (IN without) (NP (NN exon) (CD 11)))) (VP (VBD was) (VP (VBN produced))))) (: ;) (S (NP (DT the) (JJ normal) (NN exon) (CD 10)) (VP (VBD was) (ADVP (RB also)) (VP (VBN spliced) (PRT (RP out))))) (: ;) (S (PRN (-LRB- -LRB-) (FW ii) (-RRB- -RRB-)) (NP (DT a) (JJ sporadic) (NN case)) (VP (VBD had) (NP (NP (NP (DT a) (CD 1) (NN bp) (NN deletion)) (PP (IN in) (NP (NN exon) (CD 12)))) (PRN (-LRB- -LRB-) (NP (NNP 1634delT)) (-RRB- -RRB-))))) (: ;) (S (PRN (-LRB- -LRB-) (NP (NN iii)) (-RRB- -RRB-)) (NP (DT a) (JJ TSC2-linked) (NN mother) (CC and) (NN daughter) (NN pair)) (VP (VBD had) (NP (DT a) (NNP G) (JJ --&gt;) (NNP T) (NN transversion)) (PP (IN in) (NP (NP (NP (NN exon) (CD 23)) (PRN (-LRB- -LRB-) (NP (NNP G2715T)) (-RRB- -RRB-))) (VP (VBG introducing) (NP (NP (DT a) (JJ cryptic) (NN splice) (NN site)) (VP (VBG causing) (NP (NP (DT a) (ADJP (CD 29) (NN bp)) (NN truncation)) (PP (IN of) (NP (NNP mRNA)))) (PP (IN from) (NP (NN exon) (CD 23)))))))))) (: ;) (S (PRN (-LRB- -LRB-) (NP (NN iv)) (-RRB- -RRB-)) (NP (DT a) (JJ sporadic) (NN case)) (VP (VBD showed) (NP (DT a) (ADJP (CD 2) (NN bp)) (NN deletion)) (PP (IN in) (NP (NN exon) (CD 36))))) (: ;) (S (PRN (-LRB- -LRB-) (NP (NN v)) (-RRB- -RRB-)) (NP (DT a) (JJ sporadic) (NN case)) (VP (VBD showed) (NP (NP (DT a) (CD 1) (NN bp) (NN insertion)) (VP (VBG disrupting) (NP (NP (NP (DT the) (NN donor) (NN splice) (NN site)) (PP (IN of) (NP (NN exon) (CD 37)))) (PRN (-LRB- -LRB-) (NP (NNP 5007+2insA)) (-RRB- -RRB-))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT an) (JJ upstream) (JJ exonic) (JJ cryptic) (NN splice) (NN site))) (S (VP (TO to) (VP (VB cause) (NP (NP (DT a) (ADJP (CD 29) (NN bp)) (NN truncation)) (PP (IN of) (NP (NNP mRNA)))) (PP (IN from) (NP (NN exon) (CD 37))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (CD one) (NN case))) (, ,) (NP (DT the) (NNP PTT) (NN shift)) (VP (VBD was) (VP (VBN explained) (PP (IN by) (NP (JJ in-frame) (NN splicing))) (PP (IN out) (PP (IN of) (NP (NN exon) (CD 10)))) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (JJ normal) (NN exon) (CD 10) (JJ genomic) (NN sequence))))))) (. .)))
(TOP (S (NP (NP (NNP Alternative) (NN splicing)) (PP (IN of) (NP (NP (NN exon) (CD 10)) (PP (IN of) (NP (DT the) (NNP TSC2) (NN gene)))))) (VP (MD may) (VP (VB be) (NP (DT a) (JJ normal) (NN variant)))) (. .)))
(TOP (S (NP (CD Three) (JJ 3rd) (NN base) (NN substitution) (NNS polymorphisms)) (VP (VBD were) (ADVP (RB also)) (VP (VBN detected) (PP (IN during) (NP (NP (JJ direct) (NN sequencing)) (PP (IN of) (NP (NNP PCR) (NNS products))))))) (. .)))
(TOP (S (S (NP (VBN Confirmed) (NNS mutations)) (VP (VBD were) (VP (VBN identified) (PP (PP (IN in) (NP (NP (CD 28) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS families)) (VP (VBN studied)))))) (CC and) (PP (IN on) (NP (DT the) (NN assumption) (SBAR (IN that) (S (NP (NP (NN half)) (PP (IN of) (NP (DT the) (JJ sporadic) (NNS cases)))) (VP (MD should) (VP (VB have) (NP (CD TSC2) (NNS mutations)))))))))))) (, ,) (NP (NP (DT a) (JJ crude) (NN estimate)) (PP (IN of) (NP (DT the) (NN detection) (NN rate)))) (VP (MD would) (VP (VB be) (NP (CD 60) (NN %)))) (. .)))
(TOP (S (S (NP (DT This)) (VP (VBZ compares) (ADVP (RB favourably)) (PP (IN with) (NP (NP (JJ other) (VBG screening) (NNS methods)) (VP (VBN used) (PP (IN for) (NP (NP (NNP TSC2)) (, ,) (ADVP (RB notably)) (NP (NNP SSCP))))))))) (, ,) (CC and) (S (SBAR (IN since) (S (NP (NNP PTT)) (VP (VBZ involves) (NP (ADJP (RB much) (JJR less)) (NN work))))) (NP (PRP it)) (VP (MD may) (VP (VB be) (NP (NP (DT the) (NN method)) (PP (IN of) (NP (NN choice))))))) (. .)))
(TOP (NP (NP (NN Selection)) (PP (IN of) (NP (NP (JJ down-regulated) (NNS sequences)) (PP (IN along) (NP (NP (DT the) (JJ monocytic) (NN differentiation)) (PP (IN of) (NP (JJ leukemic) (NNP HL60) (NNS cells))))))) (. .)))
(TOP (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB dissect) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (JJ monocytic) (NN differentiation)))))))) (NP (PRP we)) (VP (VBP have) (VP (VBN developed) (NP (NP (DT a) (JJ subtractive) (NN hybridisation) (NN method)) (VP (VBN based) (PP (IN on) (NP (NP (DT a) (VBN simplified) (POS ')) (JJ representational) (NN difference) (NN analysis))))))) ('' ') (. .)))
(TOP (S (NP (PRP We)) (VP (VP (VBP have) (VP (VBN selected) (NP (CD 16) (NNS sequences)))) (CC and) (VP (VBD confirmed) (NP (PRP$ their) (NN down-regulation)) (PP (IN along) (NP (NP (DT the) (JJ TPA-induced) (JJ monocytic) (NN differentiation)) (PP (IN of) (NP (JJ HL60) (NNS cells))))))) (. .)))
(TOP (S (PP (IN Among) (NP (DT these) (NNS sequences))) (NP (PRP we)) (VP (VBP have) (VP (VBN identified) (NP (NP (DT the) (NN alpha-tubulin)) (, ,) (NP (DT the) (NNP TaxREB) (NN protein)) (CC and) (NP (NP (CD two) (JJ ribosomal) (NN protein) (NNS sequences)) (SBAR (WHNP (WDT which)) (S (VP (VBD had) (RB not) (VP (VBN been) (ADVP (RB previously)) (VP (VBN described) (SBAR (IN as) (S (VP (ADVP (RB differentially)) (VBN expressed))))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VP (VBP add) (PP (TO to) (NP (NP (PRP$ our) (NN knowledge)) (PP (IN about) (NP (NP (DT the) (NNS molecules)) (VP (VBN implicated) (PP (IN along) (NP (NP (DT the) (JJ monocytic) (NN differentiation)) (CC and) (NP (NP (NN growth) (NN arrest)) (PP (IN of) (NP (JJ leukemic) (NNS cells)))))))))))) (CC and) (VP (VB provide) (NP (NP (DT a) (JJ first) (NN step)) (PP (IN in) (NP (NP (DT the) (NN study)) (PP (IN of) (NP (PRP$ their) (JJ respective) (NNS roles)))))))) (. .)))
(TOP (NP (NP (NN Activation)) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN gene)) (PP (IN in) (NP (NP (CD 3q21) (CC and) (NN identification)) (PP (IN of) (NP (JJ intergenic) (NN fusion) (NNS transcripts))))) (PP (IN with) (NP (NP (JJ ecotropic) (JJ viral) (NN insertion) (NN site)) (NP (NP (NN I)) (PP (IN in) (NP (NN leukemia)))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN identified) (NP (NP (DT a) (NN novel) (NN gene)) (, ,) (NP (NNP GR6)) (, ,) (VP (VBN located) (PP (IN within) (NP (NP (DT the) (NN leukemia) (NN breakpoint) (NN region)) (PP (IN of) (NP (CD 3q21)))))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB normally)) (VP (VBN expressed) (PP (PP (IN in) (NP (JJ early) (JJ fetal) (NN development))) (CC but) (PP (RB not) (IN in) (NP (JJ adult) (JJ peripheral) (NN blood))))))))))) (. .)))
(TOP (S (NP (NNP GR6)) (VP (VBZ is) (VP (VBN activated) (PP (PP (IN in) (NP (DT the) (JJ UCSD-AML1) (NN cell) (NN line))) (CC and) (PP (IN in) (NP (NP (DT a) (JJ leukemic) (NN sample)) (, ,) (SBAR (WHNP (WHNP (DT both)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP carry) (NP (DT a) (NN t-LRB-3;3-RRB--LRB-q21;q26-RRB-)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NNP UCSD-AML1))) (, ,) (NP (PRP we)) (VP (VBP have) (ADVP (RB also)) (VP (VBN identified) (NP (NP (NN fusion) (NNS transcripts)) (PP (PP (IN between) (NP (NP (DT the) (JJ ecotropic) (JJ viral) (NN insertion) (NN site)) (SBAR (S (NP (NP (PRP I)) (PRN (-LRB- -LRB-) (NP (NNP EVI1)) (-RRB- -RRB-))) (VP (NN gene) (PP (IN in) (NP (CD 3q26) (CC and) (NNP GR6)))))))) (CC and) (PP (IN between) (NP (NP (NNP EVI1)) (CC and) (NP (NNP Ribophorin) (PRP I))))) (SBAR (WHNP (IN that)) (S (VP (NNS maps) (NP (NP (CD 30) (NN kb)) (ADVP (JJ telomeric) (PP (TO to) (NP (NNP GR6))))) (PP (IN in) (NP (CD 3q21))))))))) (. .)))
(TOP (S (NP (DT All) (NNS fusions)) (VP (VBP splice) (NP (NP (DT the) (CD 5') (NNS ends)) (PP (IN of) (NP (DT the) (CD 3q21) (NNS genes)))) (PP (IN into) (NP (NP (NP (NN exon) (CD 2)) (PP (IN of) (NP (DT the) (NNP EVI1) (NN gene)))) (, ,) (NP (NP (DT an) (NN event)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ similar) (PP (PP (TO to) (NP (NP (DT the) (JJ normal) (JJ intergenic) (NN splicing)) (PP (IN of) (NP (NN MDS1-EVI1))))) (CC and) (PP (TO to) (NP (NP (DT those)) (VP (ADVP (RB previously)) (VBN documented) (PP (IN in) (NP (NP (NNS leukemias)) (PP (IN with) (NP (NP (NNP t-LRB-3;21-RRB-) (CC and) (NNP t-LRB-3;12-RRB-)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (JJ acute) (JJ myelogenous) (NN leukemia) (NN 1-EVI1) (NNS fusions)) (CC and) (NP (NN ETV6-EVI1) (NNS fusions))) (, ,) (ADVP (RB respectively)) (, ,) (VP (VB occur)))))))))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNP Ribophorin) (NNP I-EVI1) (NN fusion)) (PP (IN in) (NP (JJ particular)))) (VP (MD may) (VP (VB be) (NP (NP (DT a) (JJ common) (NN occurrence)) (PP (IN in) (NP (NN t-LRB-3;3-RRB-)))))) (. .)))
(TOP (S (NP (NP (JJ Abnormal) (NN apoptosis) (CC and) (NN cell) (NN cycle) (NN progression)) (PP (IN in) (NP (NNS humans)))) (VP (VBN exposed) (PP (TO to) (NP (NP (NN methyl) (JJ tertiary-butyl) (NN ether)) (CC and) (NP (NP (NN benzene)) (VP (VBG contaminating) (NP (NN water))))))) (. .)))
(TOP (S (LST (LS 1) (. .)) (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD hypothesized) (SBAR (IN that) (S (PP (IN in) (NP (NP (NNS individuals)) (PP (IN with) (NP (JJ certain) (JJ genetic) (NN makeup))))) (, ,) (NP (NNP MTBE) (, ,) (NN benzene) (CC or) (PRP$ their) (NNS metabolites)) (VP (VP (VBP act) (PP (IN as) (NP (NNS adducts)))) (CC and) (VP (MD may) (VP (VB induce) (NP (JJ programmed) (NN cell) (NN death)))))))) (. .)))
(TOP (S (LST (LS 2) (. .)) (NP (PRP$ Our) (NN study)) (VP (VBD involved) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (CD 60) (ADJP (JJ male) (CC and) (JJ female)) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NNP MTBE) (CC and) (JJ benzene-contaminated) (NN water) (NNS concentrations))) (PP (IN up) (PP (TO to) (NP (NP (NP (CD 76) (NNP PPB)) (PP (IN for) (NP (NNP MTBE)))) (CC and) (NP (NP (CD 14) (NNP PPB)) (PP (IN for) (NP (NN benzene))))))) (, ,) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (QP (CD 5) (TO to) (CD 8)) (NNS years))))))))))))) (. .)))
(TOP (S (PP (IN For) (NP (NN comparison))) (, ,) (NP (PRP we)) (VP (VBD recruited) (NP (NP (DT a) (NN control) (NN group)) (VP (VBG consisting) (PP (IN of) (NP (NP (CD 32) (JJ healthy) (NNS males)) (CC and) (NP (NNS females)))))) (PP (PP (IN with) (NP (JJ similar) (NN age) (NN distribution))) (CC and) (PP (IN without) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NN exposure)) (SBAR (S (VP (TO to) (VP (VB MTBE) (CC or) (VB benzene))))))))))) (. .)))
(TOP (S (NP (NP (LS 3) (. .) (JJ Peripheral) (NN blood) (NNS lymphocytes)) (PRN (-LRB- -LRB-) (NP (NNP PBL)) (-RRB- -RRB-)) (PP (IN of) (NP (DT both) (NNS groups)))) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (NP (JJ apoptotic) (NNS cells)) (CC and) (NP (NN cell) (NN cycle) (NN progression))) (VP (VBG using) (NP (NN flow) (NN cytometry))))))))) (. .)))
(TOP (S (LST (LS 4) (. .)) (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ apoptotic) (NNS lymphocytes)) (PP (IN from) (NP (JJ exposed) (NNS individuals)))) (VP (VBD were) (VP (VBN compared) (PP (TO to) (NP (NP (JJ apoptotic) (NNS lymphocytes)) (PP (IN from) (NP (DT the) (NN control) (NN group))))))))) (, ,) (NP (NP (JJ statistically-significant) (NNS differences)) (PP (IN between) (NP (DT each) (JJ mean) (NN group)))) (VP (VBD were) (VP (VBN detected) (PRN (-LRB- -LRB-) (NP (NP (CD 26.4) (NN +/-) (CD 1.8)) (CC and) (NP (CD 12.1) (NN +/-) (CD 1.3))) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-)) (, ,) (S (VP (VBG indicating) (NP (NP (DT an) (VBN increased) (NN rate)) (PP (IN of) (NP (NN apoptosis))) (PP (IN in) (NP (NP (CD 80.5) (NN %)) (PP (IN of) (NP (JJ exposed) (NNS individuals))))) (PRN (-LRB- -LRB-) (NP (NP (FW P) (FW &lt;) (CD 0.0001)) (, ,) (NP (NNP Mann-Whitney) (NNP U-Test))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP (NP (NNP MTBE)) (CC and) (NP (JJ benzene-induced) (NN apoptosis))) (VP (VBZ is) (VP (VBN attributed) (PP (TO to) (NP (DT a) (JJ discrete) (NN block))) (PP (IN within) (NP (DT the) (NN cell) (NN cycle) (NN progression))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP (NN cell) (NN cycle) (NN analysis)) (VP (VBD showed) (NP (IN that)) (PP (IN in) (NP (NNP PBL))) (PP (IN from) (NP (JJ chemically-exposed) (NNS individuals)))))) (, ,) (NP (NP (QP (IN between) (CD 20-50)) (NN %)) (PP (IN of) (NP (NNS cells)))) (VP (VBD were) (VP (VBN accumulated) (PP (IN at) (NP (DT the) (NNP S-G2/M) (NNS boundaries))))) (. .)))
(TOP (S (NP (NP (CD 5) (. .) (CD One)) (PP (IN of) (NP (DT the) (VBG signaling) (NNS molecules))) (SBAR (WHNP (WDT which)) (S (VP (NNS mediates) (NP (VBD programmed) (NN cell) (NN death)))))) (VP (VBZ is) (NP (NP (JJ nuclear) (NN factor) (NNP Kappa-B)) (PRN (-LRB- -LRB-) (NP (NNP NF-kappa) (NNP B)) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP (NNP NF-kappa) (NNP B)) (VP (VBD was) (VP (VBN examined) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ many) (JJ molecular) (NNS mechanisms)) (PP (IN for) (S (VP (VBG mediating) (NP (NN cell) (NN death)) (PP (IN by) (NP (NNP MTBE) (CC and) (NN benzene)))))))))))) (. .)))
(TOP (S (ADVP (RB Indeed)) (, ,) (NP (NP (NN addition)) (PP (IN of) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (NNP NF-kappa) (NNP B) (NN activation) (NN pyrrolidine) (NN dithiocarbamate)) (PRN (-LRB- -LRB-) (NP (NNP PDTC)) (-RRB- -RRB-)))) (, ,) (PP (TO to) (NP (NP (DT the) (NNS lymphocytes)) (PP (IN of) (NP (DT the) (JJ chemically-exposed) (NN group)))))))) (VP (VBD was) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG inhibiting) (NP (JJ programmed) (NN cell) (NN death)) (PP (IN by) (NP (CD 40) (NN %)))))))) (. .)))
(TOP (S (NP (NP (DT This) (NN reversal)) (PP (IN of) (NP (NN apoptosis))) (PP (ADVP (RB almost)) (TO to) (NP (NP (DT the) (NN control) (NN level)) (PP (IN by) (NP (NP (NN inhibitor)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NN activation)))))))) (VP (MD may) (VP (VB indicate) (NP (NP (NN involvement)) (PP (IN of) (NP (DT this))) (VP (VBG signaling) (NP (NN molecule)) (PP (IN in) (NP (NP (NNP MTBE)) (CC and) (NP (NP (JJ benzene) (NN induction)) (PP (IN of) (NP (JJ programmed) (NN cell) (NN death)))))))))) (. .)))
(TOP (NP (NP (JJ Alcohol-induced) (NN regulation)) (PP (IN of) (NP (NP (JJ nuclear) (JJ regulatory) (NN factor-kappa) (NN beta)) (PP (IN in) (NP (JJ human) (NNS monocytes))))) (. .)))
(TOP (S (NP (JJ Acute) (NN ethanol) (NN exposure)) (VP (VBZ has) (NP (DT the) (NN capacity) (S (VP (TO to) (VP (VB modulate) (NP (JJ immune) (NNS functions)))))) (, ,) (ADVP (RB particularly)) (, ,) (S (VP (TO to) (VP (ADVP (RB down)) (VB regulate) (NP (NP (JJ monocyte) (NN production)) (PP (IN of) (NP (JJ inflammatory) (NNS cytokines)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ intracellular) (NNS mechanisms)) (PP (IN for) (NP (NP (DT these) (NNS effects)) (PP (IN of) (NP (NN ethanol)))))) (VP (VBP are) (ADVP (RB yet)) (S (VP (TO to) (VP (VB be) (VP (VBN understood)))))) (. .)))
(TOP (S (S (VP (VBG Considering) (SBAR (IN that) (S (NP (JJ nuclear) (JJ regulatory) (NN factor-kappa) (NN beta) (PRN (-LRB- -LRB-) (NNP NF-kappa) (NNP B) (-RRB- -RRB-)) (NNP /Rel)) (VP (VBZ is) (NP (NP (DT a) (JJ common) (JJ regulatory) (NN element)) (PP (IN of) (NP (NP (NP (DT the) (NN promoter) (NN region)) (PP (IN of) (NP (DT the) (JJ inflammatory) (NN cytokine) (NNS genes)))) (, ,) (NP (NN herein)))))))))) (, ,) (NP (PRP we)) (VP (VBD tested) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ acute) (NN ethanol)) (VP (VBZ affects) (NP (NP (NNP NF-kappa) (NNP B) (NN activation)) (PP (IN in) (NP (JJ human) (NNS monocytes))))))))) (. .)))
(TOP (S (NP (JJ Adherence-isolated) (NNS monocytes)) (VP (VBD showed) (NP (NP (JJ constitutive) (NN DNA) (VBG binding) (NN activity)) (PP (IN of) (NP (NNP NF-kappa) (NNP B))))) (. .)))
(TOP (S (NP (NP (DT A) (ADJP (RB clinically) (JJ relevant)) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN mM)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (JJ acute) (NN ethanol) (NN treatment)) (PP (IN in) (NP (NN vitro)))))) (VP (VP (VBD increased) (NP (NP (NNP NF-kappa) (NNP B) (VBG binding) (NN activity)) (PP (IN in) (NP (NNS monocytes)))) (PP (IN with) (NP (NP (DT a) (JJ preferential) (NN induction)) (PP (IN of) (NP (DT the) (JJ inhibitory) (, ,) (JJ p50/p50) (, ,) (JJ NF-kappa) (NNP B/Rel) (NN homodimer)))))) (, ,) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (NN induction)) (PP (IN of) (NP (DT the) (JJ p65/p50) (NN heterodimer))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NN lipopolysaccharide) (NN stimulation)) (ADVP (RB primarily)) (VP (VBD induced) (NP (NP (DT the) (JJ p65/p50) (NN heterodimer)) (SBAR (WHNP (WDT that)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NN gene) (NN activation))))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ such) (JJ unique) (NN activation)) (PP (IN of) (NP (DT the) (JJ inhibitory) (JJ p50/p50) (NN homodimer))) (PP (IN by) (NP (JJ acute) (NN ethanol) (NN treatment)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NN inhibition)) (CONJP (RB rather) (IN than)) (NP (NP (NN activation)) (PP (IN of) (NP (JJ NF-kappa) (JJ B-regulated) (JJ inflammatory) (NN cytokine) (NNS genes)))))))) (. .)))
(TOP (S (ADVP (RB Consequently)) (, ,) (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (ADJP (RB physiologically) (JJ relevant)) (NNS concentrations)) (PP (IN of) (NP (NN ethanol)))) (VP (MD may) (VP (VP (VB affect) (SBAR (S (NP (NP (NN production)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS cytokines)) (, ,) (PP (JJ such) (IN as) (NP (NN tumor)))))) (VP (VBZ necrosis) (NP (JJ factor-alpha) (, ,) (JJ interleukin-1) (NN beta)))))) (, ,) (CC and) (VP (ADJP (JJ interleukin-6)) (PP (IN by) (S (VP (VBG disrupting) (NP (NP (NNP NF-kappa) (NNP B)) (VP (VBG signaling) (PP (IN in) (NP (NNS monocytes)))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NNP BHRF1))) (S (VP (TO to) (VP (VB inhibit) (NP (NN apoptosis)))))) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN on) (NP (NN stimulus) (CC and) (NN cell) (NN type))))) (. .)))
(TOP (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (NP (NN resistance)) (SBAR (S (VP (TO to) (VP (VB host) (NP (NP (NN defense) (NNS mechanisms)) (PP (JJ such) (IN as) (NP (NP (NN tumor) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP TNF)) (-RRB- -RRB-)))))))))) (: -) (CC and) (NP (NP (JJ Fas-mediated) (NN apoptosis)) (PP (IN of) (NP (VBN transformed) (CC or) (JJ virus-infected) (NNS cells))))))) (VP (MD may) (VP (VB be) (NP (NP (DT a) (JJ critical) (NN component)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN disease)))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB find) (NP (NP (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP protect) (NP (NNS cells)) (PP (IN from) (NP (NN apoptosis)))))))))) (, ,) (NP (PRP we)) (VP (VP (VBD used) (NP (DT an) (NN expression) (VBG cloning) (NN strategy))) (CC and) (VP (VBN identified) (NP (NP (NNP BHRF1)) (, ,) (NP (NP (DT an) (NNP Epstein-Barr) (NN virus) (PRN (-LRB- -LRB-) (NNP EBV) (-RRB- -RRB-)) (JJ early-lytic-cycle) (NN protein)) (PP (IN with) (NP (JJ distant) (NN homology))) (PP (TO to) (NP (NN Bcl-2)))) (, ,)) (PP (IN as) (NP (DT an) (JJ anti-apoptosis) (NN protein))))) (. .)))
(TOP (S (NP (NP (NN Expression)) (PP (IN of) (NP (NNP BHRF1))) (PP (IN in) (NP (NNP MCF-Fas) (NNS cells)))) (VP (VBD conferred) (NP (NP (ADJP (RB nearly) (JJ complete)) (NN resistance)) (PP (IN against) (NP (DT both) (NP (JJ anti-Fas) (NN antibody)) (CC and) (NP (JJ TNF-mediated) (NN apoptosis)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NNP BHRF1)) (VP (VP (VBD protected) (NP (DT these) (NNS cells)) (PP (IN from) (NP (JJ monocyte-mediated) (NN killing)))) (CC but) (VP (VBD failed) (S (VP (TO to) (VP (VB protect) (NP (PRP them)) (PP (IN from) (NP (NP (VBG killing)) (VP (VBN mediated) (PP (IN by) (NP (JJ lymphokine-activated) (NN killer) (NNS cells))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NNP BHRF1))) (S (VP (TO to) (VP (VB protect) (NP (JJ MCF-Fas) (NNS cells)) (PP (IN from) (NP (NP (NN apoptosis)) (VP (VBN induced) (PP (IN by) (NP (JJ various) (NNS stimuli)))))))))) (VP (VBD was) (ADJP (JJ identical) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNP Bcl-2) (CC and) (NNP Bcl-xL))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP BHRF1)))))) (VP (VBD resembled) (NP (NP (IN that)) (PP (IN of) (NP (NNP Bcl-2) (CC and) (NNP Bcl-xL)))) (SBAR (IN as) (S (NP (PRP it)) (VP (VP (VBD inhibited) (NP (NP (ADJP (JJ TNF-) (CC and) (JJ anti-Fas-induced)) (NN activation)) (PP (IN of) (NP (NP (NP (CD two) (NNS enzymes)) (VP (VBG participating) (PP (IN in) (NP (DT the) (NN apoptosis) (NN pathway))))) (, ,) (NP (NP (JJ cytosolic) (NN phospholipase)) (NP (NN A2) (CC and) (NN caspase-3/CPP32))))))) (, ,) (CC but) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ NF-kappaB-like) (NN transcription) (NNS factors))))))))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ putative) (NN function)) (PP (IN of) (NP (NNP BHRF1))) (PP (IN in) (NP (JJ EBV-infected) (JJ epithelial) (NNS cells)))) (VP (MD may) (VP (VB be) (S (VP (TO to) (VP (VB protect) (NP (JJ virus-infected) (NNS cells)) (PP (IN from) (NP (NNP TNF-) (CC and/or) (JJ anti-Fas-induced) (NN cell) (NN death))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maximize) (NP (NN virus) (NN production))))))))))) (. .)))
(TOP (S (ADVP (RB Surprisingly)) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT neither) (NNP BHRF1) (CC nor) (NNP Bcl-2)) (PP (IN in) (NP (NP (DT a) (JJ B-cell) (NN line)) (, ,) (NP (NNP BJAB)) (, ,)))))) (VP (VBD protected) (NP (NP (DT the) (NNS cells)) (PP (IN from) (NP (JJ anti-Fas-mediated) (NN apoptosis)))) (SBAR (RB even) (IN though) (S (NP (PRP they)) (VP (VBD increased) (NP (NP (DT the) (NN survival)) (PP (IN of) (NP (JJ serum-starved) (NNS cells)))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (JJ protective) (NN role)) (PP (IN of) (NP (NNP BHRF1))) (PP (IN against) (NP (NN apoptosis)))) (VP (VBZ resembles) (NP (NP (IN that)) (PP (IN of) (NP (NN Bcl-2)))) (PP (IN in) (S (VP (VBG being) (NP (NP (NN cell) (NN type)) (ADJP (JJ specific) (CC and) (JJ dependent) (PP (IN on) (NP (DT the) (JJ apoptotic) (NN stimulus))))))))) (. .)))
(TOP (NP (NP (NN Expression)) (PP (IN of) (NP (NP (JJ bcl-6) (NN protein)) (PP (IN in) (NP (NP (JJ normal) (NN skin)) (CC and) (NP (NN epidermal) (NNS neoplasms)))))) (. .)))
(TOP (S (NP (JJ Bcl-6) (NN protein)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB recently) (VBN identified)) (JJ novel) (NN transcription) (NN factor)) (SBAR (WHNP (WP$ whose) (VBN deregulated) (NN expression)) (S (VP (VBZ is) (VP (VBN associated) (PP (IN with) (S (VP (NN diffuse) (NP (JJ large) (NN B) (NN cell) (NNS lymphomas))))))))))) (. .)))
(TOP (S (NP (PRP It)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN shown) (PP (IN by) (NP (PRP us))) (SBAR (IN that) (S (NP (DT the) (NN protein)) (VP (VBZ is) (VP (VBN located) (PP (IN in) (NP (NP (JJ germinal) (NN center) (NN B) (NNS cells)) (CC and) (NP (PRP$ their) (JJ neoplastic) (NNS counterparts)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (NP (NP (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ bcl-6) (NN protein))) (PP (IN on) (NP (JJ normal) (NNS epidermis)))) (, ,) (ADJP (JJ benign)) (, ,)) (CC and) (NP (JJ malignant) (NNS tumors))) (VP (VBG originating) (PP (IN from) (NP (JJ epidermal) (NNS cells))))) (, ,) (CC and) (NP (JJ squamous) (NN cell) (NN carcinoma) (PRN (-LRB- -LRB-) (NNP SCC) (-RRB- -RRB-)) (NN cell) (NNS lines))) (VP (VBP are) (VP (VBN investigated))) (. .)))
(TOP (S (PP (IN With) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN immunohistochemistry))))) (, ,) (NP (JJ bcl-6) (NN protein)) (VP (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB stain) (ADVP (RB intensely)) (PP (IN on) (NP (JJ normal) (JJ prickle) (NNS cells)))))))) (, ,) (CC but) (VP (NP (NN none)) (S (VP (TO to) (ADVP (RB only) (RB slightly)) (PP (IN on) (NP (JJ epidermal) (JJ basal) (NNS cells))))))) (. .)))
(TOP (S (NP (NNS Papillomas) (CC and) (NNS keratoacanthomas)) (VP (VBD copied) (NP (NP (PRP$ their) (JJ normal) (NNS counterparts)) (PP (IN in) (NP (NP (DT the) (NN mode)) (PP (IN of) (NP (NN expression))))))) (. .)))
(TOP (S (NP (NP (JJ Various) (NNS levels)) (PP (IN of) (NP (NN expression)))) (VP (VBD were) (VP (VBN found) (PP (IN on) (NP (JJ seborrheic) (NNS keratoses))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NN expression) (NN level)) (PP (IN on) (NP (JJ basal) (NN cell) (NNS epitheliomas)))) (VP (VBD was) (ADJP (JJ low))))))) (. .)))
(TOP (S (ADVP (RB Peculiarly)) (, ,) (NP (NP (JJ eccrine) (NNS poromas)) (CC and) (NP (JJ undifferentiated) (JJ spindle-shaped) (NN basal) (NN cell) (NNS epitheliomas))) (VP (VBD were) (ADJP (RB totally) (JJ unstained))) (. .)))
(TOP (S (NP (JJ Squamous) (NN cell) (NNS carcinomas)) (VP (VBD showed) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN expression) (NNS levels)))) (, ,) (SBAR (IN while) (S (NP (NP (CD two) (JJ undifferentiated) (JJ spindle-shaped) (NNS carcinomas)) (CC and) (NP (CD one) (JJ undifferentiated) (NNP SCC) (NN cell) (NN line))) (VP (VBD remained) (ADJP (JJ unstained)))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ bcl-6) (NN protein)))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (JJ morphological) (NN differentiation)) (PP (IN in) (NP (ADJP (JJ normal) (CC and) (JJ neoplastic)) (JJ epidermal) (NNS cells))))))))))) (. .)))
(TOP (S (NP (NP (NN Tissue) (JJ transglutaminase-dependent) (JJ posttranslational) (NN modification)) (PP (IN of) (NP (DT the) (NN retinoblastoma) (NN gene)))) (VP (NN product) (PP (IN in) (NP (JJ promonocytic) (NNS cells))) (S (VP (VBG undergoing) (NP (NN apoptosis))))) (. .)))
(TOP (S (NP (NP (DT The) (NN retinoblastoma) (NN gene) (NN product)) (PRN (-LRB- -LRB-) (NN pRB) (-RRB- -RRB-))) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG controlling) (NP (DT both) (NN cell) (NN release)) (PP (IN from) (NP (DT the) (NNP G1) (NN phase) (CC and) (NN apoptosis))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP show) (ADVP (RB here)) (SBAR (IN that) (S (PP (IN in) (NP (NP (DT the) (JJ early) (NNS phases)) (PP (IN of) (NP (NN apoptosis))))) (, ,) (NP (NNP pRB)) (VP (VBZ is) (VP (ADVP (RB posttranslationally)) (VBN modified) (PP (IN by) (NP (DT a) (NN tissue) (NN transglutaminase) (PRN (-LRB- -LRB-) (NNP tTG) (-RRB- -RRB-)) (JJ -catalyzed) (NN reaction)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN fact))) (, ,) (PP (IN by) (S (VP (VBG employing) (NP (NP (DT a) (JJ novel) (JJ haptenized) (NN lysis) (NN synthetic) (NN substrate)) (SBAR (WHNP (WDT which)) (S (VP (VBZ allows) (NP (NP (DT the) (NN isolation)) (PP (IN of) (NP (NP (JJ glutaminyl-tTG) (NNS substrates)) (PP (IN in) (NP (NN vivo))))))))))))) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (NNP pRB)) (PP (IN as) (NP (NP (DT a) (JJ potential) (NNP tTG) (NN substrate)) (PP (IN in) (NP (NNP U937) (NNS cells))) (VP (VBG undergoing) (NP (NN apoptosis)))))) (. .)))
(TOP (S (PP (IN In) (S (VP (VBG keeping) (PP (IN with) (NP (DT this) (NN finding)))))) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN apoptosis)) (PP (IN of) (NP (NNP U937) (NNS cells)))) (VP (VBZ is) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (JJ rapid) (NN disappearance)) (PP (IN of) (NP (DT the) (CD 105,000-))) (PP (TO to) (NP (JJ 110,000-molecular-weight) (NN pRB) (NNS forms))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NP (DT a) (NN smear)) (PP (IN of) (NP (JJ immunoreactive) (NNS products))) (PP (IN with) (NP (NP (DT a) (JJ molecular) (NN weight)) (PP (IN of) (NP (QP (JJR greater) (IN than) (CD 250,000))))))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN shift)) (PP (IN in) (NP (JJ pRB) (JJ molecular) (NN weight)))) (VP (VP (VBD was) (VP (VBN reproduced) (PP (IN by) (S (VP (VBG adding) (NP (JJ exogenous) (JJ purified) (NN tTG)) (PP (TO to) (NP (NP (NNS extracts)) (VP (VBN obtained) (PP (IN from) (NP (JJ viable) (NNP U937) (NNS cells))))))))))) (CC and) (VP (VBD was) (VP (VBN prevented) (PP (IN by) (NP (NP (NN dansylcadaverine)) (, ,) (NP (DT a) (JJ potent) (NN enzyme) (NN inhibitor))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (DT the) (NNP pRB) (JJ posttranslational) (NN modification))) (PP (IN during) (NP (NN apoptosis)))) (VP (VBD was) (VP (VBN investigated) (PP (PP (IN by) (S (VP (VBG determining) (NP (DT the) (JJ E2F-1) (NNS levels))))) (CC and) (PP (IN by) (S (VP (VBG isolating) (CC and) (VBG characterizing) (NP (JJ pRB-null) (NNS clones)) (PP (IN from) (NP (JJ U937) (NNS cells))))))))) (. .)))
(TOP (S (ADVP (RB Notably)) (, ,) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NN pRB))) (PP (IN in) (NP (DT these) (JJ U937-derived) (NNS clones)))) (VP (VBZ renders) (S (NP (DT these) (JJ p53-null) (NNS cells)) (ADJP (RB highly) (JJ resistant) (PP (TO to) (NP (NP (NNS apoptosis)) (VP (VBN induced) (PP (IN by) (NP (NP (NN serum) (NN withdrawal)) (, ,) (NP (NN calphostin) (NNP C)) (, ,) (CC and) (NP (NN ceramide)))))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP tTG)) (, ,) (S (VP (VBG acting) (PP (IN on) (NP (DT the) (NNP pRB) (NN protein))))) (, ,) (VP (MD might) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (DT the) (NN cell) (NN progression))) (PP (IN through) (NP (DT the) (NN death) (NN program)))))))) (. .)))
(TOP (NP (NN Evidence) (SBAR (DT that) (S (NP (NN calcineurin)) (VP (VBZ is) (ADJP (JJ rate-limiting) (PP (IN for) (NP (JJ primary) (JJ human) (NN lymphocyte) (NN activation))))))) (. .)))
(TOP (S (NP (NP (NNP Cyclosporine)) (PRN (-LRB- -LRB-) (NP (NNP CsA)) (-RRB- -RRB-))) (VP (VBZ is) (NP (DT both) (NP (DT a) (JJ clinical) (JJ immunosuppressive) (NN drug)) (CC and) (NP (NP (DT a) (NN probe)) (SBAR (S (VP (TO to) (VP (VB dissect) (NP (JJ intracellular) (VBG signaling) (NNS pathways))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN vitro))) (, ,) (NP (NNP CsA)) (VP (VBZ inhibits) (NP (JJ lymphocyte) (NN gene) (NN activation)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (DT the) (JJ phosphatase) (NN activity)) (PP (IN of) (NP (NN calcineurin))) (PRN (-LRB- -LRB-) (NP (NNP CN)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ clinical) (NN use))) (, ,) (NP (NNP CsA) (NN treatment)) (VP (VBZ inhibits) (NP (NP (CD 50-75) (NN %)) (PP (IN of) (NP (NNP CN) (NN activity)))) (PP (IN in) (S (VP (VBG circulating) (NP (NNS leukocytes)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD modeled) (NP (NP (DT this) (NN degree)) (PP (IN of) (NP (NP (NNP CN) (NN inhibition)) (PP (IN in) (NP (NP (JJ primary) (JJ human) (NNS leukocytes)) (PP (IN in) (NP (NN vitro)))))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ partial) (NNP CN) (NN inhibition))) (PP (IN on) (NP (NP (DT the) (JJ downstream) (VBG signaling) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP lead) (PP (TO to) (NP (NN gene) (NN activation)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ CsA-treated) (NNS leukocytes)) (VP (VBN stimulated) (PP (IN by) (NP (NN calcium) (NN ionophore)))))) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN in) (NP (NNP CN) (NN activity)))))) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (S (NP (NP (NP (DT a) (JJ similar) (NN degree)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN of) (NP (DT each) (NN event))))))) (VP (VBD tested) (: :) (NP (NP (NP (NP (NN dephosphorylation)) (PP (IN of) (NP (JJ nuclear) (NN factor))) (PP (IN of) (NP (VBN activated) (NNP T) (NN cell) (NNS proteins)))) (, ,) (NP (JJ nuclear) (NN DNA) (VBG binding)) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (DT a) (VBN transfected) (NN reporter) (NN gene) (VB construct)))) (, ,) (NP (NNP IFN-gamma)) (CC and) (NP (NNP IL-2) (NNP mRNA) (NN accumulation))) (, ,) (CC and) (NP (JJ IFN-gamma) (NN production)))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NNP CN) (NN inhibition)))) (VP (VBD was) (VP (VBN reflected) (PP (IN by) (NP (NP (DT a) (JJ similar) (NN degree)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NP (JJ lymphocyte) (NN proliferation)) (CC and) (NP (NN IFN-gamma) (NN production))) (PP (IN in) (NP (DT the) (JJ allogeneic) (JJ mixed) (NN lymphocyte) (NNS cultures))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP support) (NP (DT the) (NN conclusion) (SBAR (IN that) (S (NP (NNP CN) (NN activity)) (VP (VBZ is) (ADJP (JJ rate-limiting) (PP (IN for) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ primary) (JJ human) (NN T) (NNS lymphocytes))))))))))) (. .)))
(TOP (S (S (ADVP (RB Thus)) (, ,) (PRN (S (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NNP CN) (NN activity)))) (VP (VBD observed) (PP (IN in) (NP (JJ CsA-treated) (NNS patients)))))) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ similar) (NN degree)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN in) (NP (JJ lymphocyte) (NN gene) (NN activation)))))))))) (, ,) (CC and) (S (NP (NP (NNS accounts)) (PP (IN for) (NP (DT the) (NN immunosuppression)))) (VP (VBD observed))) (. .)))
(TOP (S (NP (NP (DT The) (NN DNA) (VBG binding) (NN domain)) (PP (IN of) (NP (DT the) (NNP A-MYB) (NN transcription) (NN factor)))) (VP (VP (VBZ is) (ADJP (JJ responsible) (PP (IN for) (NP (PRP$ its) (NNP B) (JJ cell-specific) (NN activity))))) (CC and) (VP (VBZ binds) (PP (TO to) (NP (NP (DT a) (NN B) (NN cell)) (NP (JJ 110-kDa) (JJ nuclear) (NN protein)))))) (. .)))
(TOP (S (NP (NP (NN Expression) (NNS studies)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ transgenic) (NNS animals))))) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (DT the) (NNP A-MYB) (NN transcription) (NN factor)) (VP (VBZ plays) (NP (ADJP (JJ central) (CC and) (JJ specific)) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NNP mature) (NNP B) (NN cell) (NN proliferation) (CC and/or) (NN differentiation)))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (VP (VBZ is) (VP (ADVP (RB highly)) (VBN expressed) (PP (IN in) (NP (NP (NNP Burkitt) (POS 's)) (NN lymphoma) (NNS cells))))) (CC and) (VP (MD may) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT this) (NN disease)))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VP (VBP have) (ADVP (RB therefore)) (VP (VBN investigated) (NP (NP (NP (DT the) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NNP A-MYB)))) (CC and) (NP (NP (PRP$ its) (NN regulation)) (PP (IN in) (NP (NP (JJ several) (JJ human) (JJ lymphoid) (NN cell) (NNS lines)) (VP (VBG using) (NP (NN co-transfection) (NNS assays))))))))) (CC and) (VP (VBP show) (SBAR (IN that) (S (NP (NNP A-MYB)) (VP (VBZ is) (ADJP (RB transcriptionally) (JJ active)) (PP (PP (IN in) (NP (NP (DT all)) (SBAR (S (NP (DT the) (NNP B) (NN cell) (NNS lines)) (VP (VBD studied)))))) (, ,) (CC but) (RB not) (PP (IN in) (NP (NNP T) (NNS cells))))))))) (. .)))
(TOP (SINV (PP (IN In) (NP (JJ particular) (DT the) (JJS best) (NN responder) (NN cell) (NN line))) (VP (VBD was)) (NP (NP (DT the) (NNP Burkitt) (POS 's)) (NN cell) (NN line) (NNP Namalwa)) (. .)))
(TOP (S (NP (NP (NP (DT The) (NN activity)) (PP (IN of) (NP (NN A-MYB))) (PP (IN in) (NP (NNP B)))) (CC and) (RB not) (NP (NNP T) (NNS cells))) (VP (VBD was) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (CC either) (S (S (NP (DT an) (NN artificial)) (VP (VB construct))) (CC or) (NP (DT the) (JJ c-MYC) (NN promoter)))) (VP (VBD was) (VP (VBN used) (PP (IN as) (NP (DT a) (NN reporter))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (JJ functional) (NNS domains)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (NNP DNA) (VBG binding)) (, ,) (NP (NN transactivation)) (, ,) (CC and) (NP (NP (JJ negative) (NN regulation)) (, ,) (VP (ADVP (RB previously)) (VBN characterized) (PP (IN in) (NP (DT a) (JJ fibroblast) (NN context)))) (, ,)))))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB have) (NP (JJ similar) (NN activity)) (PP (IN in) (NP (NN B) (NNS cells)))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN region)) (PP (IN of) (NP (NN A-MYB))) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (NNP B) (NN cell) (NN specific) (NN activity))))) (VP (VBD was) (VP (VBN defined) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (JJ N-terminal) (CD 218) (JJ amino) (NNS acids)) (VP (VBG containing) (NP (DT the) (NN DNA) (VBG binding) (NN domain))))))))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (NP (DT a) (JJ 110-kDa) (NN protein)) (VP (VBZ has) (VP (VBN been) (VP (VBN identified) (PP (IN in) (NP (NP (NP (DT the) (NN nuclei)) (PP (IN of) (NP (PDT all) (DT the) (NNP B)))) (, ,) (CC but) (RB not) (NP (NP (NNP T)) (, ,) (NP (NP (NN cell) (NNS lines)) (SBAR (WHNP (WDT that)) (S (ADVP (RB specifically)) (VP (VBZ binds) (PP (TO to) (NP (DT this) (NNP A-MYB) (NNP N-terminal) (NN domain))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (DT this) (JJ 110-kDa) (NN protein)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (ADJP (RB functionally) (JJ important)) (NNP B) (JJ cell-specific) (NN co-activator)) (PP (IN of) (NP (NNP A-MYB))))))))) (. .)))
(TOP (NP (NP (DT The) (JJ A-myb) (NN transcription) (NN factor)) (PP (IN in) (NP (JJ neoplastic) (CC and) (JJ normal) (NN B) (NNS cells))) (. .)))
(TOP (S (NP (NP (DT The) (JJ myb) (NN family)) (PP (IN of) (NP (NN transcription) (NNS factors)))) (VP (VBZ has) (VP (VBN been) (VP (ADVP (RB strongly)) (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NN cell) (NN growth)) (CC and) (NP (NP (NN differentiation)) (PP (IN in) (NP (DT the) (JJ haematopoietic) (NN system))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ v-myb) (NN oncogene)) (, ,) (VP (VBN carried) (PP (IN by) (NP (JJ avian) (JJ defective) (NNS retroviruses)))) (, ,)) (VP (VP (VBZ causes) (NP (NP (NNS leukaemias)) (PP (IN in) (NP (DT the) (NN chicken))))) (CC and) (VP (VBZ transforms) (NP (NP (JJ haematopoietic) (NNS cells)) (PP (IN in) (NP (NN vitro)))))) (. .)))
(TOP (S (NP (PRP$ Its) (JJ normal) (JJ cellular) (JJ equivalent) (NN c-myb)) (, ,) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VP (VB promote) (NP (DT the) (NN proliferation))) (CC and) (VP (VB block) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (NP (JJ haematopoietic) (NNS cells)) (PP (IN in) (NP (JJ several) (JJ experimental) (NNS models))))))))))))) (CC and) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (JJ fetal) (NN haematopoiesis)))))) (. .)))
(TOP (S (NP (NP (CD Two) (JJ other) (NNS members)) (PP (IN of) (NP (DT the) (NN family)))) (VP (VBP have) (VP (VBN been) (VP (VP (VBN cloned) (ADVP (ADVP (RBR more) (RB recently)) (, ,) (NNP A-myb) (CC and) (NNP B-myb))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP show) (NP (NP (NN sequence)) (ADJP (NN homology) (PP (IN with) (NP (NN c-myb)))) (PP (IN in) (NP (NP (JJ several) (NNS domains)) (, ,) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (NP (DT the) (NN DNA) (VBG binding) (NN domain)) (CONJP (RB as) (RB well) (IN as)) (NP (JJ other) (JJ regulatory) (NNS domains)))))))))))))) (. .)))
(TOP (S (NP (DT Both)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP (JJ transcription) (NNS factors)))))))) (. .)))
(TOP (S (S (NP (NN B-myb)) (VP (VBZ is) (ADVP (RB also)) (ADJP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NN proliferation) (CC and) (NN differentiation)))))))) (, ,) (CC but) (, ,) (S (PP (IN unlike) (NP (NN c-myb))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (JJ many) (NN cell) (NNS types)))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ third) (NN member)) (PP (IN of) (NP (NP (DT the) (NN family)) (, ,) (NP (NNP A-myb)) (, ,)))) (VP (VBZ shows) (NP (NP (DT the) (ADJP (RBS most) (JJ restricted)) (NN pattern)) (PP (IN of) (NP (NN expression)))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (ADJP (RB very) (JJ specific)) (NN role)) (PP (IN for) (NP (DT this) (NN transcription) (NN factor))))))) (. .)))
(TOP (S (NP (NN A-myb)) (VP (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (NP (DT a) (NN subpopulation)) (PP (IN of) (NP (NP (JJ normal) (NN B) (NNS lymphocytes)) (VP (VP (VBN activated) (PP (IN in) (NP (NN vivo)))) (CC and) (VP (VBN localised) (PP (IN in) (NP (NP (DT the) (JJ germinal) (NN center)) (PP (IN of) (NP (JJ peripheral) (JJ lymphoid) (NNS organs))))))))))))) (CC and) (VP (VBZ is) (RB not) (VP (VBN detected) (PP (IN at) (NP (NP (JJ significant) (NNS levels)) (PP (IN in) (NP (NP (DT all) (JJ other) (ADJP (JJ mature) (CC or) (JJ immature)) (JJ haematopoietic) (NNS populations)) (VP (VBD studied)))) (, ,) (PP (VBG including) (NP (NP (NN bone) (NN marrow) (NNS cells)) (, ,) (NP (NN T) (NNS lymphocytes)) (, ,) (NP (NNS granulocytes)) (, ,) (NP (NNS monocytes)) (, ,) (NP (CC either) (PP (IN at) (NP (NN rest)))) (CC or) (PP (IN after) (PP (IN in) (NP (NN vitro) (NN activation))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP A-myb)) (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN during) (NP (NP (DT a) (JJ narrow) (NN window)) (PP (IN of) (NP (JJ normal) (NN B) (NN cell) (NN differentiation))))))))) (. .)))
(TOP (S (NP (JJ A-myb) (NN expression)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (JJ neoplastic) (NN B) (NNS cells))) (, ,) (VP (VBG representing) (NP (NP (DT the) (JJ whole) (NN spectrum)) (PP (IN of) (NP (NN B) (NN cell) (NN differentiation)))))))))) (. .)))
(TOP (S (NP (NN A-myb)) (VP (VBZ is) (VP (ADVP (RB strongly)) (VBN expressed) (PP (PP (IN in) (NP (NP (NP (NP (NNP Burkitt) (POS 's)) (NNS lymphomas)) (PRN (-LRB- -LRB-) (NP (NNP BL)) (-RRB- -RRB-))) (CC and) (NP (NP (FW slg+) (FW B-acute) (FW lymphoblastic) (FW leukaemias)) (PRN (-LRB- -LRB-) (NP (NNP B-ALL)) (-RRB- -RRB-))))) (CC and) (RB not) (PP (IN in) (NP (NP (DT all) (JJ other) (NNS leukaemias/lymphomas)) (VP (VBN tested)))) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NP (NNP CLL)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN about) (CD 25)) (NN %)) (PP (IN of) (NP (NNS cases)))) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP (NP (PRP It))) (VP (VBZ is) (ADJP (JJ intriguing)) (SBAR (IN that) (S (NP (DT the) (JJ A-myb) (NN genome)) (VP (VBZ has) (VP (VBN been) (VP (VBN localised) (ADVP (RB relatively) (RB close) (PP (TO to) (NP (NP (DT the) (JJ c-myc) (NN gene)) (PP (IN on) (NP (NN chromosome) (CD 8)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT the) (JJ c-myc) (NN translocation)) (PP (IN in) (NP (NNP BL) (CC and) (NNP B-ALL)))) (VP (MD may) (VP (VB affect) (NP (JJ A-myb) (NN transcription)))))))))))))) (. .)))
(TOP (S (NP (NNS Studies)) (VP (VBP are) (PP (IN in) (NP (NN progress))) (S (VP (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ functional) (NN relationship)) (PP (IN between) (ADJP (JJ A-myb) (CC and) (JJ c-myc)))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NNP BL) (NNS cells))))))) (CC and) (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NNP A-myb)) (VP (VBZ is) (VP (VBN deregulated) (PP (IN in) (NP (DT these) (NNS cells)))))))))))) (. .)))
(TOP (S (NP (JJ Human) (NNS neutrophils)) (VP (VBP express) (NP (NP (JJ GH-N) (NN gene) (NNS transcripts)) (CC and) (NP (DT the) (JJ pituitary) (NN transcription) (NN factor) (NN Pit-1b)))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP (NNP GH)) (VP (VBZ stimulates) (NP (NP (DT the) (NN development) (CC and) (NN function)) (PP (IN of) (NP (NNS granulocytes))))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP GH))) (PP (IN in) (NP (JJ granulocyte) (NNS subsets))))) (. .)))
(TOP (S (PP (IN By) (NP (NN immunocytochemistry))) (, ,) (NP (NP (CD 25) (NN +/-) (CD 7) (NN %)) (PP (IN of) (NP (DT the) (JJ human) (NNS neutrophils)))) (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB express) (NP (JJ immunoreactive) (NNP GH))))) (, ,) (SBAR (IN whereas) (S (NP (NNS eosinophils)) (VP (VBD were) (ADJP (JJ negative))))))) (. .)))
(TOP (S (NP (VBN Reversed) (NN transcription) (PRN (-LRB- -LRB-) (NNP RT) (-RRB- -RRB-)) (NN -PCR) (NN analysis)) (VP (VBD demonstrated) (NP (NNP GH) (NNP mRNA)) (PP (IN in) (NP (NNS neutrophils)))) (. .)))
(TOP (S (NP (NN Restriction) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNS neutrophils)) (VP (VBP express) (NP (NP (DT the) (NNP GH-N) (NN gene)) (CC but) (RB not) (NP (DT the) (JJ GH-V) (NN gene))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (PP (IN by) (NP (JJ western) (NN blot) (NN analysis))) (SBAR (IN that) (S (NP (NNS neutrophils)) (VP (VBP express) (NP (NP (DT an) (ADJP (RB alternatively) (JJ spliced)) (NN variant)) (PP (IN of) (NP (NP (DT the) (JJ pituitary) (NN transcription) (NN factor) (NN Pit-1)) (, ,) (VP (VBN designated) (S (NP (NN Pit-1b))))))))))) (. .)))
(TOP (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (JJ myeloid-associated) (NNS genes)) (PP (IN in) (NP (JJ human) (JJ hematopoietic) (NN progenitor) (NNS cells))))) (. .)))
(TOP (S (NP (NP (DT The) (NN distribution)) (PP (IN of) (NP (NP (JJ myeloid) (JJ lineage-associated) (NN cytokine) (NNS receptors)) (CC and) (NP (JJ lysosomal) (NNS proteins))))) (VP (VBD was) (VP (VBN analyzed) (PP (IN in) (NP (NP (JJ human) (NNP CD34+) (NN cord) (NN blood) (NN cell)) (PRN (-LRB- -LRB-) (NP (NNP CB)) (-RRB- -RRB-)))) (SBAR (S (VP (VBZ subsets) (PP (IN at) (NP (NP (JJ different) (NNS stages)) (PP (IN of) (NP (NP (JJ myeloid) (NN commitment)) (PP (IN by) (NP (NP (JJ reverse-transcriptase) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (NP (NP (NP (DT The) (ADJP (RB highly) (JJ specific)) (JJ granulomonocyte-associated) (JJ lysosomal) (NNS proteins) (NN myeloperoxidase)) (PRN (-LRB- -LRB-) (NP (NNP MPO)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN lysozyme)) (PRN (-LRB- -LRB-) (NP (NNP LZ)) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (NN transcription) (NN factor) (NNP PU.1)) (, ,))) (VP (VBD were) (ADVP (RB already)) (ADJP (JJ detectable)) (PP (IN in) (NP (DT the) (ADJP (RBS most) (JJ immature)) (NN CD34+Thy-1+) (NN subset)))) (. .)))
(TOP (S (S (NP (NP (NNP Messenger) (NNP RNA) (PRN (-LRB- -LRB-) (NNP mRNA) (-RRB- -RRB-)) (NNS levels)) (PP (IN for) (NP (NP (DT the) (JJ granulocyte-colony) (JJ stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP G-CSF)) (-RRB- -RRB-)))) (NP (NP (NN receptor) (, ,) (NN granulocyte-macrophage) (PRN (-LRB- -LRB-) (NNP GM) (-RRB- -RRB-)) (JJ -CSF) (NN receptor) (NN alpha) (NN subunit) (CC and) (NN tumor) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP TNF)) (-RRB- -RRB-)))) (VP (NNS receptors) (NP (PRP I)) (PRN (-LRB- -LRB-) (INTJ (CD p55)) (-RRB- -RRB-)))) (CC and) (S (NP (NP (NNP II)) (PRN (-LRB- -LRB-) (NP (CD p75)) (-RRB- -RRB-))) (VP (VBD were) (ADVP (RB also)) (VP (VBN detected) (PP (IN in) (NP (DT this) (NN subset))) (PP (IN in) (NP (NP (NP (NN addition)) (PP (TO to) (ADJP (JJ c-kit) (CC and) (JJ flt-3)))) (, ,) (NP (NP (NNS receptors)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN expressed) (PP (IN on) (NP (NN progenitor) (NNS cells)))))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (NP (DT the) (JJ monocyte-macrophage) (NN colony) (VBG stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP M-CSF)) (-RRB- -RRB-)) (NN receptor)) (VP (VBD was) (ADJP (RB largely) (JJ absent) (PP (PP (IN at) (NP (DT this) (NN stage))) (CC and) (PP (IN in) (NP (DT the) (JJ CD34+Thy-1-CD45RA-) (NNS subsets)))))) (. .)))
(TOP (S (NP (DT The) (NNP M-CSF) (NN receptor)) (VP (VBD was) (ADJP (RB first) (JJ detectable)) (PP (IN in) (NP (DT the) (JJ myeloid-committed) (NN CD34+Thy-l-CD45RA+) (NN subset)))) (. .)))
(TOP (S (NP (NP (DT All) (JJ other) (NNS molecules)) (VP (VBN studied))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (VBN expressed) (PP (IN at) (NP (NP (DT this) (NN stage)) (PP (IN of) (NP (NN differentiation))))))))))) (. .)))
(TOP (S (NP (NP (JJ Different) (NNS cocktails)) (PP (IN of) (NP (DT the) (VBN identified) (NNS ligands)))) (VP (VBD were) (VP (VBN added) (S (VP (TO to) (VP (VBN sorted) (NP (JJ CD34+Thy-1+) (JJ single) (NNS cells))))))) (. .)))
(TOP (S (NP (NNP Low) (JJ proliferative) (NN capacity)) (VP (VBD was) (VP (VBN observed) (PP (IN after) (NP (NP (CD 1) (NN week)) (PP (IN in) (NP (NN culture))))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NP (NN stem) (NN cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP SCF)) (-RRB- -RRB-))) (FW +) (NP (FW Flt-3) (FW ligand) (PRN (-LRB- -LRB-) (NP (NNP FL)) (-RRB- -RRB-)) (NNP +) (NNP G-CSF)))))))) (. .)))
(TOP (S (S (NP (NP (NN Addition)) (PP (IN of) (NP (NNP GM-CSF))) (PP (TO to) (NP (DT this) (JJ basic) (NN cocktail)))) (VP (ADVP (RB consistently)) (VBD increased) (NP (NP (DT the) (JJ clonogenic) (NN capacity)) (PP (IN of) (NP (JJ single) (JJ CD34+Thy-1+) (NNS cells)))))) (, ,) (CC and) (S (NP (DT this) (NN effect)) (VP (VBD was) (VP (ADVP (RB further)) (VBN enhanced) (PRN (-LRB- -LRB-) (NP (NP (QP (IN up) (TO to) (CD 72.3) (CD +/-) (CD 4.3)) (NN %)) (PP (IN on) (NP (NN day) (CD 7)))) (-RRB- -RRB-)) (PP (IN by) (NP (NP (DT the) (NN inclusion)) (PP (IN of) (NP (NNP TNF-alpha)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ myeloid-associated) (NN growth) (NN factor) (NN receptor) (NNS transcripts))) (PP (IN in) (NP (NNP CD34+) (NNP CB) (NNS subsets)))) (VP (VBZ does) (RB not) (VP (JJ discriminate) (NP (NP (DT the) (JJ various) (NNS stages)) (PP (IN of) (NP (NN differentiation)))) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (DT the) (NNP M-CSF) (NN receptor))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP TNF-alpha)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (JJ costimulatory) (NN factor)) (PP (IN of) (NP (DT the) (ADJP (RB very) (JJ immature)) (NNP CD34+Thy-1+) (NNP CB) (NN subset)))))))) (. .)))
(TOP (NP (NP (NP (NP (NNS Glucocorticoids)) (CC and) (NP (DT the) (JJ immune) (NN function))) (PP (IN in) (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus) (NN infection)))) (: :) (NP (NP (DT a) (NN study)) (PP (IN in) (NP (ADJP (JJ hypercortisolemic) (CC and) (JJ cortisol-resistant)) (NNS patients)))) (. .)))
(TOP (S (NP (NP (JJ Immunological) (NNS studies)) (PP (IN in) (NP (JJ human) (NN immunodeficiency) (NN virus) (PRN (-LRB- -LRB-) (NNP HIV) (-RRB- -RRB-)) (JJ -positive) (NNS patients)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (NN disease) (NN progression)) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ defective) (NN production)) (PP (IN of) (NP (NP (NN type) (CD 1) (NNS cytokines)) (PRN (-LRB- -LRB-) (NP (NP (NN interleukin-2) (-LRB- -LRB-) (NN IL-2) (-RRB- -RRB-)) (CC and) (NP (NNP IL-12) (NNP -RSB-))) (, ,) (NP (NP (DT an) (VBN increased) (NN production)) (PP (IN of) (NP (NP (NN type) (CD 2) (NNS cytokines)) (PRN (-LRB- -LRB-) (NP (NP (NN IL-4)) (, ,) (NP (NNP IL-6)) (, ,) (CC and) (NP (NNP IL-10))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (DT an) (VBN increased) (NN production)) (PP (IN of) (NP (NNP IgE)))) (. .)))))))))))))
(TOP (S (NP (NNP HIV) (NN infection)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT the) (JJ hypothalamo-pituitary-adrenal) (NN axis) (NN function)) (CC and) (NP (VBN increased) (UCP (NN plasma) (CC and) (JJ urinary)) (NN cortisol) (NNS concentrations)))))))) (. .)))
(TOP (S (SBAR (IN As) (S (NP (NN cortisol)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ physiological) (NN regulation)) (PP (IN of) (NP (NNS cytokines))))))))) (, ,) (NP (DT a) (NN study)) (VP (VBD was) (VP (VBN conducted) (S (VP (TO to) (VP (VB examine) (NP (JJ cytokine) (NNS patterns)) (PP (IN in) (NP (NP (NP (CD two) (NNS groups)) (PP (IN of) (NP (JJ hypercortisolemic) (NNS patients)))) (, ,) (NP (NP (CD one)) (PP (IN with) (NP (NP (JJ normal) (NN sensitivity)) (PP (TO to) (NP (NNS glucocorticoids)))))) (CC and) (NP (NP (DT the) (JJ other)) (PP (IN with) (NP (JJ glucocorticoid) (NN resistance))))))))))) (. .)))
(TOP (S (NP (NP (CD Ten) (JJ HIV-infected) (NNS patients)) (PP (IN with) (NP (JJ normal) (NN receptor)))) (VP (NN affinity) (PP (TO to) (NP (NP (NP (NNS glucocorticoids)) (PRN (-LRB- -LRB-) (NP (NNP AIDS-C)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 10) (JJ HIV-infected) (NNS patients)) (PP (IN with) (NP (NP (JJ low) (NN receptor) (NN affinity)) (PP (TO to) (NP (NP (NNS glucocorticoids)) (PRN (-LRB- -LRB-) (NP (NNP AIDS-GR)) (-RRB- -RRB-))))))) (, ,) (CC and) (NP (CD 20) (JJ healthy) (NNS subjects)))) (SBAR (S (VP (VBD were) (VP (VBN studied)))))) (. .)))
(TOP (S (NP (NP (NN Receptor) (NNS characteristics)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NN mononuclear) (NNS cells)))) (VP (VBD were) (VP (VBN evaluated) (PP (IN by) (NP (NP (NN -LSB-3H-RSB-dexamethasone)) (VP (VBG binding)))))) (. .)))
(TOP (S (NP (NP (NNP Serum) (NN cortisol)) (CC and) (NP (JJ urinary) (JJ free) (NN cortisol))) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (NNP RIA))))) (. .)))
(TOP (S (NP (NP (NNP Serum) (NNP ACTH)) (CC and) (NP (NNP IgE))) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (NP (JJ immunoradiometric) (NN assay)) (, ,) (CC and) (NP (NP (NN IL-2)) (, ,) (NP (NN IL-4)) (, ,) (CC and) (NP (NN IL-10) (NNS cytokines)) (CC and) (NP (NNS interferon-gamma))))) (SBAR (S (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (JJ enzyme-linked) (JJ immunosorbent) (NN assay))))))))) (. .)))
(TOP (S (S (NP (NN AIDS-C) (NNS patients)) (VP (VBD showed) (NP (NP (JJ low) (NN IL-2)) (CC and) (NP (NP (JJ high) (NN IL-4)) (, ,) (NP (NN IL-10)) (, ,) (CC and) (NP (NNP IgE) (NNS concentratios)))))) (: ;) (S (ADVP (RB conversely)) (, ,) (NP (NN AIDS-GR) (NNS patients)) (VP (VBD showed) (NP (NP (JJ high) (NN IL-2)) (CC and) (NP (JJ low) (UCP (NN IL-4) (CC and) (JJ IgE)) (NNS concentrations))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (PP (IN in) (NP (NNP HIV) (NN infection))) (, ,) (VP (VP (VBD elevated) (NP (NN cortisol) (NNS levels))) (VP (VBP suppress) (NP (JJ cell-mediated) (NN immunity))) (CC and) (VP (VB stimulate) (NP (JJ humoral) (NN immunity))) (, ,) (SBAR (IN whereas) (S (NP (DT this) (NN response)) (VP (VBZ is) (RB not) (VP (VBN detected) (PP (IN in) (NP (JJ cortisol-resistant) (NNS patients)))))))) (. .)))
(TOP (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN cortisol)) (CC and) (NP (PRP$ its) (NNS receptors))) (VP (VBP are) (VP (ADVP (RB critically)) (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (JJ immune) (NN function)) (PP (IN in) (NP (NNP HIV) (NN infection)))))))))))) (. .)))
(TOP (S (NP (NNP Dominant) (JJ cytotoxic) (NNP T) (NN lymphocyte)) (VP (NN response) (PP (TO to) (NP (NP (DT the) (JJ immediate-early) (NN trans-activator) (NN protein)) (, ,) (NP (NNP BZLF1)) (, ,))) (PP (IN in) (NP (JJ persistent) (NN type) (NNP A) (CC or) (NNP B) (NNP Epstein-Barr) (NN virus) (NN infection)))) (. .)))
(TOP (S (NP (CD Five) (JJ healthy) (JJ human) (NN leukocyte) (NN antigen-B8) (PRN (-LRB- -LRB-) (NN HLA-B8) (-RRB- -RRB-)) (JJ -positive) (NN virus) (NNS carriers)) (VP (VBD were) (VP (VBN studied) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNP CD8+) (JJ cytotoxic) (NNP T) (NN lymphocyte) (PRN (-LRB- -LRB-) (NNP CTL) (-RRB- -RRB-)) (NN response)) (PP (TO to) (NP (NP (NP (DT an) (JJ HLA-B8-restricted) (NN peptide)) (, ,) (NP (NNP RAKFKQLLQ)) (, ,)) (VP (VBN located) (PP (IN in) (NP (NP (DT the) (NNP Epstein-Barr) (NN virus) (PRN (-LRB- -LRB-) (NNP EBV) (-RRB- -RRB-)) (JJ immediate-early) (NN trans-activator) (NN protein)) (, ,) (NP (NNP BZLF1))))))))))))) (. .)))
(TOP (S (PP (IN Of) (NP (DT the) (CD 5) (NN virus) (NNS carriers))) (, ,) (NP (CD 4)) (VP (VBD were) (VP (VBN infected) (PP (IN with) (NP (NN type) (NNP A) (CC and) (CD 1))) (PP (IN with) (NP (NN type) (NNP B) (NNP EBV))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NP (JJ limiting-dilution) (NN analysis)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NN mononuclear) (NNS cells)))))) (, ,) (NP (DT a) (JJ high) (JJ RAKFKQLLQ-specific) (NNP CTL) (NN precursor) (NN frequency)) (VP (VBD was) (VP (VBN demonstrated) (PP (IN after) (NP (NP (JJ specific) (NN peptide)) (CC or) (NP (NP (JJ autologous) (JJ lymphoblastoid) (NN cell) (NN line) (NN stimulation)) (PP (IN in) (NP (DT both) (NN type) (NN A) (CC and) (NN type) (NNP B) (NNP EBV) (NNS carriers)))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ RAKFKQLLQ-specific) (NNP CTL) (NN precursor) (NNS frequencies)) (PP (IN in) (NP (QP (DT all) (CD 5)) (NNS persons)))) (VP (VBD were) (ADJP (ADJP (ADVP (IN at) (JJS least)) (RB as) (JJ dominant)) (SBAR (IN as) (S (NP (DT those)) (VP (VBN observed) (PP (IN with) (NP (CD two) (JJ other) (JJ EBV-associated) (, ,) (JJ HLA-B8-restricted) (NN latent) (NNS epitopes) (, ,) (NNP FLRGRAYGL) (CC and) (NNP QAKWRLQTL)))))))) (. .)))
(TOP (S (NP (DT These) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (JJ healthy) (NN virus) (NNS carriers)) (VP (VBP maintain) (NP (NP (DT a) (JJ high) (NN frequency)) (PP (IN of) (NP (JJ BZLF1-specific) (NN memory) (NN T) (NNS cells))) (, ,) (SBAR (S (ADVP (RB potentially)) (VP (TO to) (VP (VB control) (NP (NN virus) (NN spread)) (PP (IN from) (NP (ADJP (RB lytically) (JJ infected)) (NNS cells)))))))))))) (. .)))
(TOP (NP (NP (JJ Molecular) (NN characterization)) (CC and) (NP (NP (NN pattern)) (PP (IN of) (NP (NP (NN tissue) (NN expression)) (PP (IN of) (NP (NP (DT the) (NN gene)) (PP (IN for) (NP (NP (NN neutrophil) (JJ gelatinase-associated) (NN lipocalin)) (PP (IN from) (NP (NNS humans)))))))))) (. .)))
(TOP (S (NP (NP (NNP Neutrophil) (JJ gelatinase-associated) (NN lipocalin)) (PRN (-LRB- -LRB-) (NP (NNP NGAL)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ 25-kDa) (NN lipocalin)) (VP (ADVP (RB first)) (VBN identified) (PP (IN as) (NP (NP (DT a) (NN protein)) (VP (VBN stored) (PP (IN in) (NP (NP (JJ specific) (NNS granules)) (PP (IN of) (NP (DT the) (JJ human) (NN neutrophil))))))))))) (. .)))
(TOP (S (NP (DT The) (NN protein)) (VP (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (NN bind) (NP (NP (JJ small) (JJ lipophilic) (NNS substances)) (PP (JJ such) (IN as) (NP (NP (JJ bacterial) (VBN derived) (NNS formylpeptides) (CC and) (NNS lipopolysaccharides)) (PRN (-LRB- -LRB-) (NP (NNP LPS)) (-RRB- -RRB-)))))))))) (CC and) (VP (MD might) (VP (VB function) (PP (IN as) (NP (NP (DT a) (NN modulator)) (PP (IN of) (NP (NN inflammation)))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB characterize) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NNP NGAL)))) (ADVP (RBR further))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN cloned) (CC and) (VBN sequenced) (NP (NP (DT a) (JJ 5869-bp) (NN region)) (PP (IN of) (NP (DT the) (NNP NGAL) (NN gene))) (PP (VBG including) (NP (NP (NP (CD 1695) (NN bp)) (PP (IN of) (NP (DT the) (CD 5') (JJ nontranscribed) (NN region)))) (CC and) (NP (NP (DT a) (JJ 3696-bp) (NN coding) (NN region)) (VP (VBG encompassing) (NP (NP (CD seven) (NNS exons)) (CC and) (NP (CD six) (NNS introns)))))))))) (. .)))
(TOP (S (NP (DT The) (JJ transcriptional) (NN start) (NNS sites)) (VP (VBD were) (VP (VBN identified) (PP (IN by) (NP (DT an) (NNP RNase) (NN protection) (NN assay))))) (. .)))
(TOP (S (NP (DT The) (NNP NGAL) (NN gene)) (VP (VBZ is) (ADVP (RB highly) (RB homologous)) (PP (TO to) (NP (NP (DT the) (NN mouse) (NN gene)) (ADJP (JJ 24p3))))) (. .)))
(TOP (S (NP (NNP NGAL)) (VP (VBD was) (VP (VBN expressed) (PP (PP (IN in) (NP (NN bone) (NN marrow))) (CC and) (PP (IN in) (NP (NP (NNS tissues)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ prone) (PP (TO to) (NP (NP (NN exposure)) (PP (TO to) (NP (NNS microorganisms)))))))))))))) (. .)))
(TOP (S (NP (JJ Potential) (JJ cis-acting) (NNS elements)) (VP (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NN promoter) (NN region)) (PP (IN of) (NP (DT the) (NNP NGAL) (NN gene))))) (PP (IN by) (NP (NN computer) (NN analysis))))) (CC and) (VP (VBP include) (NP (NP (NP (VBG binding) (NNS sites)) (PP (IN for) (NP (NNP CTF/CBP)))) (, ,) (NP (DT the) (JJ hematopoietic) (NN transcription) (NNS factors) (NNP GATA-1) (CC and) (NNP PU.1)) (, ,) (CC and) (NP (DT the) (JJ LPS-inducible) (NN factor) (NNP NF-kappa) (NNP B))))) (. .)))
(TOP (S (NP (NP (JJ Monocytic) (NN differentiation)) (PP (IN of) (NP (JJ HL-60) (JJ promyelocytic) (NN leukemia) (NNS cells)))) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Bcl-xL)))))) (. .)))
(TOP (S (NP (NP (NNP Treatment)) (PP (IN of) (NP (NP (JJ human) (JJ promyelocytic) (NN leukemia) (NN HL-60) (NNS cells)) (PP (IN with) (NP (JJ phorbol) (NNS esters)))))) (ADVP (RB ultimately)) (VP (VBZ induces) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (DT these) (NNS cells))) (PP (IN along) (NP (DT the) (NN monocyte/macrophage) (NN lineage)))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ retinoic) (NN acid)) (CC or) (NP (NNP DMSO))))) (VP (VBZ induces) (NP (JJ granulocytic/neutrophillic) (NN differentiation)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (NP (NP (DT the) (JJ disparate) (NNS fates)) (PP (IN of) (NP (NP (NN HL-60) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT the) (JJ phorbol) (NN ester) (JJ 12,13-phorbol) (JJ dibutyric) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP PDBu)) (-RRB- -RRB-))) (CC or) (NP (NNP DMSO))))))))) (. .)))
(TOP (S (PP (IN After) (NP (NNP DMSO) (NN treatment))) (, ,) (NP (NN HL-60) (NNS cells)) (ADVP (RB eventually)) (VP (VBD died) (PP (IN via) (NP (NN apoptosis))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN viability)) (PP (IN of) (NP (JJ PDBu-treated) (NNS cells)))) (VP (VBD was) (RB not) (VP (VBN affected) (PP (IN during) (NP (DT the) (JJ same) (NN interval)))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNS levels)) (PP (IN of) (NP (DT the) (NN apoptosis) (NN effector) (NNS proteins) (NNP Bak) (CC and) (NNP Bad)))) (VP (VBD were) (VP (VBN enhanced) (, ,) (SBAR (IN whereas) (S (NP (EX there)) (VP (VBD was) (NP (NP (DT a) (JJ slight) (NN down-regulation)) (PP (IN of) (NP (DT the) (NN apoptosis) (NN suppressor) (NN protein) (NN Bcl-2)))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (DT the) (NNS cells)) (PP (IN with) (NP (NNP PDBu) (CC and) (NNP DMSO)))))))))))) (. .)))
(TOP (S (NP (NP (NNP Treatment)) (PP (IN with) (NP (NNP DMSO)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (DT the) (NN apoptosis) (NN effector) (NNP Bax))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NNP PDBu)))) (VP (VBD did) (RB not) (VP (ADVP (RB significantly)) (VB alter) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (DT this) (NN protein))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NN HL-60) (NNS cells)) (PP (IN with) (NP (NNP PDBu)))))) (VP (VBD induced) (NP (NP (DT the) (JJ rapid) (NN expression)) (PP (IN of) (NP (DT the) (NN apoptosis) (NN suppressor) (NN protein) (NNP Bcl-xL)))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT this) (NN protein)))) (VP (VBD remained) (ADJP (JJ unaltered)) (PP (IN in) (NP (JJ DMSO-treated) (NNS cells))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN generality)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBD was) (VP (VBN confirmed) (PP (IN by) (NP (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Bcl-xL))) (PP (IN in) (NP (JJ human) (JJ myeloid) (NN U-937) (NNS cells)))) (, ,) (NP (NP (JJ human) (JJ peripheral) (NN blood) (NNS monocytes)) (VP (VBN exposed) (S (VP (TO to) (VP (VB phorbol) (NP (NN ester))))))) (, ,) (CC and) (NP (NN mouse) (JJ thioglycollate-activated) (CC and) (JJ resident) (JJ peritoneal) (NNS macrophages)))))) (. .)))
(TOP (S (NP (JJ PDBu-treated) (NN HL-60) (NNS cells)) (VP (VP (VBD remained) (ADJP (JJ viable)) (PP (IN for) (NP (CD 7) (NNS days)))) (CC and) (VP (ADVP (RB thereafter)) (VBD began) (S (VP (TO to) (VP (VB die) (PP (IN via) (NP (NN apoptosis))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ concomitant) (NN down-regulation)) (PP (IN of) (NP (NNP Bcl-xL)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP (JJ Bcl-xL) (NN expression)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN differentiation) (CC and) (NN survival)) (PP (IN of) (NP (NP (JJ hematopoietic) (NNS cells)) (PP (IN along) (NP (DT the) (NN monocyte/macrophage) (NN lineage)))))))))))) (. .)))
(TOP (NP (NP (NP (DT The) (JJ spatial) (NN distribution)) (PP (IN of) (NP (JJ human) (NN immunoglobulin) (NNS genes))) (PP (IN within) (NP (DT the) (NN nucleus)))) (: :) (NP (NP (NN evidence)) (PP (IN for) (NP (NP (NN gene) (NN topography)) (ADJP (JJ independent) (PP (IN of) (NP (NP (NN cell) (NN type)) (CC and) (NP (JJ transcriptional) (NN activity)))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ three-dimensional) (NN positioning)) (PP (IN of) (NP (NN immunoglobulin) (PRN (-LRB- -LRB-) (NN Ig) (-RRB- -RRB-)) (NNS genes))) (PP (IN within) (NP (NP (DT the) (NN nucleus)) (PP (IN of) (NP (JJ human) (NNS cells)))))) (VP (VBD was) (VP (VBN investigated) (S (VP (VBG using) (PP (IN in) (NP (NP (NN situ) (NN hybridization)) (CC and) (NP (JJ confocal) (NN microscopy)))))))) (. .)))
(TOP (S (S (NP (NP (DT The) (NN visualization)) (PP (IN of) (NP (ADJP (JJ heavy) (CC and) (JJ light)) (NN chain) (NNS genes))) (PP (IN in) (NP (JJ B-lymphoid) (NNS cells)))) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (CD three) (NNP Ig) (NNS genes)) (VP (VP (VBP are) (ADVP (RB differentially))) (CC and) (VP (ADVP (RB nonrandomly)) (VBN distributed) (PP (IN in) (NP (JJ different) (JJ nuclear) (NNS subvolumes))))))))) (: :) (S (NP (DT the) (NN kappa) (NNS genes)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (ADVP (RB preferentially)) (VBN confined) (PP (TO to) (NP (DT an) (JJ outer) (JJ nuclear) (NN volume))))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NN gamma) (CC and) (NN lambda) (NNS genes)) (VP (ADVP (RB consistently)) (VBD occupied) (NP (NP (NP (RBR more) (JJ central) (NNS positions)) (PP (IN within) (NP (DT the) (NN nucleus)))) (, ,) (NP (NP (DT the) (NN lambda) (NNS genes)) (VP (VBG being) (NP (RBR more) (JJ interior)) (SBAR (WHADVP (WRB when)) (S (PP (VBN compared) (PP (IN with) (NP (DT the) (NN gamma) (NNS genes))))))))))))))) (. .)))
(TOP (S (NP (DT The) (NNS data)) (VP (ADVP (RB further)) (VBP show) (SBAR (IN that) (S (NP (DT these) (JJ overall) (JJ topographical) (NNS distributions)) (VP (VP (VBP are) (ADJP (JJ independent) (PP (IN of) (NP (NN gene) (JJ transcriptional) (NN activity))))) (CC and) (VP (VBP are) (VP (VBN conserved) (PP (IN in) (NP (JJ different) (NN cell) (NNS types))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (NP (JJ subtle) (NN gene) (NNS movements)) (PP (IN within) (NP (DT those) (VBN defined) (JJ topographical) (NNS regions)))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN excluded) (PP (IN by) (NP (DT this) (NN study)))))))) (, ,) (NP (DT the) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN tissue) (NN specificity)) (PP (IN of) (NP (NN gene) (NN expression)))) (VP (VBZ is) (RB not) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ drastic) (NNS changes)) (PP (IN in) (NP (NN gene) (JJ nuclear) (NN topography))))) (, ,) (PP (RB rather) (S (VP (VBG suggesting) (SBAR (DT that) (S (NP (NP (NN gene) (NN organization)) (PP (IN within) (NP (DT the) (NN nucleus)))) (VP (MD may) (VP (VB be) (ADJP (RB primarily) (JJ dependent) (PP (IN on) (NP (NP (JJ structural) (NNS constraints)) (VP (VBN imposed) (PP (IN on) (NP (DT the) (JJ respective) (NNS chromosomes))))))))))))))))))) (. .)))
(TOP (S (NP (NNP Epstein-Barr) (NN virus) (NNP EBNA3C)) (VP (VP (VBZ represses) (NP (NP (NNP Cp)) (, ,) (NP (NP (DT the) (JJ major) (NN promoter)) (PP (IN for) (NP (NNP EBNA) (NN expression)))))) (, ,) (CC but) (VP (VBZ has) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN promoter)) (PP (IN of) (NP (DT the) (NN cell) (NN gene) (NNP CD21)))))))) (. .)))
(TOP (S (NP (NNP EBNA3C)) (VP (VBZ is) (NP (NP (DT a) (JJ potent) (NN repressor)) (PP (IN of) (NP (NN transcription)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN bound) (PP (TO to) (NP (NNP DNA))) (PP (IN as) (NP (NP (DT a) (NN fusion)) (PP (IN with) (NP (NP (DT the) (NN DNA) (VBG binding) (NN domain)) (PRN (-LRB- -LRB-) (NP (NNP DBD)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP GALA))))))))))) (. .)))
(TOP (S (NP (NP (DT A) (NN survey)) (PP (IN of) (NP (NNS promoters)))) (VP (VBZ has) (VP (VBN revealed) (SBAR (IN that) (S (NP (DT the) (JJ wild-type) (, ,) (JJ unfused) (NNP EBNA3C)) (VP (MD can) (ADVP (RB specifically)) (VP (VB repress) (NP (NN expression)) (PP (IN from) (NP (NP (NN reporter) (NNS plasmids)) (VP (VBG containing) (NP (DT the) (NNP Epstein-Barr) (NN virus) (NNP Cp) (JJ latency-associated) (NN promoter))))))))))) (. .)))
(TOP (S (NP (NP (NN Repression)) (PP (IN of) (NP (NN Cp) (NN activity)))) (VP (VBD required) (NP (JJ amino) (NNS acids)) (NP (NP (CD 207)) (PP (TO to) (NP (CD 368))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encompasses) (NP (NP (DT a) (NN region)) (VP (VBG resembling) (NP (NP (DT a) (JJ basic) (NNP DBD)) (ADJP (JJ adjacent) (PP (TO to) (NP (NP (DT a) (JJ leucine) (NN zipper) (NN DNA) (VBG binding) (NN motif)) (CC and) (NP (NP (DT a) (NN site)) (SBAR (WHNP (WDT which)) (S (VP (VBZ binds) (PP (TO to) (NP (DT the) (JJ cellular) (NN factor) (NN CBF1/RBP-Jkappa)))))))))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (JJ amino) (NNS acids) (QP (CD 207) (TO to) (CD 368))) (VP (VBP are) (ADJP (JJ dispensable)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN protein)) (VP (VBZ is) (VP (VBN bound) (PP (TO to) (NP (NP (NNP DNA)) (PP (IN as) (NP (NP (DT a) (NN fusion)) (PP (IN with) (NP (DT the) (NNP GAL4) (NNP DBD))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG implicating) (S (NP (NP (DT this) (NN region)) (PP (IN in) (NP (NNP DNA)))) (ADJP (VBG binding)))))))))) (. .)))
(TOP (S (NP (NP (NN Mutation)) (PP (IN of) (NP (NP (DT the) (NN CBF1/RBP-Jkappa) (VBG binding) (NN site)) (PP (IN in) (NP (NNP EBNA3C)))))) (VP (VBD abrogated) (NP (NN repression)) (, ,) (S (VP (ADVP (RB strongly)) (VBG suggesting) (SBAR (DT that) (S (NP (NN CBF1/RBP-Jkappa)) (VP (VBZ is) (ADJP (JJ necessary)) (PP (IN for) (S (VP (VBG targeting) (NP (DT the) (JJ viral) (NN protein)) (PP (TO to) (NP (NNP Cp)))))))))))) (. .)))
(TOP (S (S (ADJP (JJ Consistent) (PP (IN with) (NP (DT this) (NN result))))) (, ,) (NP (NP (NN mutation)) (PP (IN of) (NP (NP (DT the) (NNP EBNA2) (NN response) (NN element)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CBF1/RBP-Jkappa) (VBG binding) (NN site)) (-RRB- -RRB-)) (PP (IN in) (NP (NNP Cp)))))) (ADVP (RB also)) (VP (VBD prevented) (NP (JJ significant) (NN repression))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ amino) (NNS acids)) (NP (QP (CD 346) (TO to) (CD 543))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (ADVP (RB previously)) (VP (VBN defined) (PP (IN as) (ADJP (JJ important) (PP (IN for) (NP (NP (DT the) (JJ repressor) (NN activity)) (PP (IN of) (NP (DT the) (NNP GAL4-EBNA3C) (NN fusion) (NNS proteins))))))))))) (, ,)) (ADVP (RB also)) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (ADJP (JJ necessary)) (PP (IN for) (NP (NP (DT the) (NN repression)) (PP (IN of) (NP (NNP Cp))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP (NP (NN repression)) (PP (IN by) (NP (DT these) (NNS fusions)))) (VP (VBD was) (RB not) (VP (VBN observed) (PP (IN in) (NP (DT all) (NN cell) (NNS types))))))) (, ,) (NP (PRP it)) (VP (VBZ seems) (ADJP (JJ likely) (SBAR (IN that) (S (NP (NNP EBNA3C)) (ADVP (RB either)) (VP (VBZ depends) (PP (IN on) (NP (NP (DT a) (NN corepressor)) (SBAR (WHNP (WDT which)) (S (VP (VP (MD may) (VP (VB interact) (PP (IN with) (NP (JJ amino) (NNS acids))) (NP (NP (CD 346)) (PP (TO to) (NP (CD 543)))))) (CC or) (VP (VBZ is) (VP (VBN modified) (PP (IN in) (NP (DT a) (JJ cell-specific) (NN manner))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB repress))))))))))))))))) (. .)))
(TOP (S (S (NP (DT These) (NNS data)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (S (NP (NNP EBNA3C)) (VP (VBG contributing) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NNP EBNA) (NN expression))) (PP (IN in) (NP (ADJP (RB latently) (JJ infected)) (NN B) (NNS cells))) (PP (IN through) (NP (NP (NN CBF1/RBP-Jkappa)) (CC and) (NP (DT another) (NN factor)))))))))))) (, ,) (CC but) (S (NP (DT this) (NN need)) (RB not) (VP (ADVP (RB directly)) (VB involve) (NP (NNP EBNA2)))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NNP EBNA3C)) (VP (MD can) (VP (VB upregulate) (NP (NNP CD21)) (PP (IN in) (NP (DT some) (NN B) (NNS cells)))))))))))) (, ,) (NP (PRP we)) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (DT any) (NN effect)) (PP (IN of) (NP (NNP EBNA3C))) (PP (IN on) (NP (NP (NN reporter) (NNS plasmids)) (SBAR (WHNP (WDT which)) (S (VP (VBP contain) (NP (DT the) (NNP CD21) (NN promoter))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Late) (NN gene) (NN expression)) (PP (IN from) (NP (DT the) (NNP Epstein-Barr) (NN virus) (NNP BcLF1) (CC and) (NNP BFRF3) (NNS promoters)))) (VP (VBZ does) (RB not) (VP (VB require) (NP (NN DNA) (NN replication)) (PP (IN in) (NP (NN cis))))) (. .)))
(TOP (S (NP (JJ Late) (NN gene) (NN expression)) (VP (VP (VBZ follows)) (CC and) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN upon) (NP (NP (JJ lytic) (NN replication)) (PP (IN of) (NP (DT the) (JJ viral) (NN genome)))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (JJ experimental) (NN evidence)) (VP (VBZ is) (VP (VBG lacking))))) (, ,) (NP (JJ lytic) (JJ viral) (NN DNA) (NN replication)) (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB remove) (NP (NP (NNS modifications)) (CC or) (NP (VBG binding) (NNS factors))) (PP (IN from) (NP (NP (DT the) (NN genome)) (SBAR (WHNP (WDT which)) (S (VP (VBP serve) (S (VP (TO to) (VP (VB repress) (NP (JJ late) (NN gene) (NN expression)) (PP (IN during) (NP (NP (NN latency)) (CC or) (NP (DT the) (JJ early) (JJ lytic) (NN cycle))))))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN developed) (NP (NP (DT a) (NN reporter) (NN assay)) (SBAR (S (VP (TO to) (VP (VB begin) (S (VP (VBG characterizing) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (JJ late) (NN gene) (NN expression)) (PP (IN in) (NP (NP (NNP Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP EBV)) (-RRB- -RRB-))))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN model) (NN system))) (, ,) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (JJ late) (JJ promoter-reporter) (NNS fusions)))) (VP (VBP are) (VP (VBN measured) (PP (VBG following) (NP (NP (JJ transient) (NN transfection)) (PP (IN into) (NP (NP (NN tissue) (NN culture) (NNS cells)) (VP (VBG expressing) (NP (NNP EBV)) (PP (IN during) (NP (NP (JJ different) (NNS stages)) (PP (IN of) (NP (DT the) (JJ lytic) (NN cycle)))))))))))) (. .)))
(TOP (S (NP (DT This) (NN system)) (VP (ADVP (RB faithfully)) (VBZ recapitulates) (NP (JJ late) (NN expression) (NNS patterns)) (PP (IN from) (NP (DT the) (JJ endogenous) (NN virus))) (, ,) (S (VP (VBG implicating) (NP (JJ specific) (JJ cis-active) (NNS sequences)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (JJ late) (NN gene) (NN expression)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT these) (NNS promoters)) (VP (VBP respond) (ADVP (RB only) (RB indirectly)) (PP (TO to) (NP (NP (DT the) (JJ viral) (JJ immediate-early) (NN transactivator)) (, ,) (NP (NNP ZEBRA))))) (. .)))
(TOP (S (NP (DT This) (JJ indirect) (NN response)) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ other) (ADJP (JJ viral) (CC or) (RB virally) (VBN induced)) (NNS activities)) (ADJP (JJ downstream) (PP (IN of) (NP (NNP ZEBRA))) (PP (IN in) (NP (DT the) (JJ lytic) (NN cascade)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN system))) (, ,) (NP (JJ late) (NN gene) (NN expression)) (VP (VBZ is) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (DT the) (JJ viral) (NN DNA) (NN polymerase)) (PP (JJ such) (IN as) (NP (JJ phosphonoacetic) (NN acid)))))))) (, ,) (SBAR (IN although) (S (NP (DT the) (NNS reporters)) (VP (VP (VBP lack) (NP (NP (DT a) (JJ eukaryotic) (NN origin)) (PP (IN of) (NP (NN replication))))) (CC and) (VP (VBP are) (RB not) (VP (VBN replicated) (PP (IN under) (NP (DT the) (JJ assay) (NNS conditions))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (NN replication)) (PP (IN of) (NP (DT the) (JJ transcriptional) (NN template)))) (VP (VBZ is) (RB not) (NP (NP (NP (DT a) (NN prerequisite)) (PP (IN for) (NP (NN expression))) (PP (IN with) (NP (JJ late) (NNS kinetics)))) (, ,) (NP (NP (DT a) (NN finding)) (ADJP (JJ inconsistent) (PP (IN with) (NP (NP (DT the) (JJ current) (NNS models)) (SBAR (WHNP (WDT which)) (S (VP (VBP posit) (NP (NP (DT a) (JJ cis-active) (NN relationship)) (PP (IN between) (NP (NP (JJ lytic) (NNP EBV) (NNP DNA) (NN replication)) (CC and) (NP (JJ late) (NN gene) (NN expression)))))))))))))) (. .)))
(TOP (S (ADVP (RB Rather)) (, ,) (NP (NP (NN analysis)) (PP (IN of) (NP (DT this) (NN system)))) (VP (VBZ has) (VP (VP (VBN revealed) (NP (NP (DT a) (NNS trans) (NN relationship)) (PP (IN between) (NP (NP (JJ late) (NN gene) (NN expression)) (CC and) (NP (JJ viral) (NN DNA) (NN replication)))))) (CC and) (VP (VBZ highlights) (NP (NP (DT the) (ADJP (JJ indirect) (CC and) (JJ complex)) (NN link)) (PP (IN between) (NP (DT these) (CD two) (NNS events))))))) (. .)))
(TOP (NP (NP (NN Purification) (CC and) (NN characterization)) (PP (IN of) (NP (DT the) (JJ human) (NNP SR) (JJ 31747A-binding) (NN protein))) (. .)))
(TOP (S (NP (DT A) (JJ nuclear) (NN membrane) (NN protein)) (VP (VBN related) (PP (TO to) (NP (NN yeast) (NN sterol) (NN isomerase)))) (. .)))
(TOP (S (NP (NP (NNP SR) (NNP 31747A)) (, ,) (VP (VBN defined) (PP (IN as) (NP (DT a) (NN sigma) (NN ligand)))) (, ,)) (VP (VBZ is) (NP (NP (DT a) (JJ novel) (JJ immunosuppressive) (NN agent)) (SBAR (WHNP (IN that)) (S (VP (NNS blocks) (NP (NP (NN proliferation)) (PP (IN of) (NP (NN human) (CC and) (NN mouse) (NNS lymphocytes))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (DT a) (JJ radiolabeled) (NN chemical) (NN probe)))) (, ,) (NP (NP (PRP we)) (ADVP (RB here))) (VP (VP (VBD purified) (NP (NP (DT a) (NN target)) (PP (IN of) (NP (NNP SR) (NNP 31747A))))) (CC and) (VP (VBD called) (S (NP (PRP it)) (NP (NP (NNP SR) (NNP 31747A-binding) (NN protein)) (PRN (-LRB- -LRB-) (NP (NNP SR-BP)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP (NNP Purified) (NNP SR-BP)) (VP (VP (VBD retained) (NP (PRP$ its) (JJ binding) (NNS properties))) (CC and) (VP (VBN migrated) (PP (IN on) (NP (JJ SDS-polyacrylamide) (NN gel))) (PP (IN as) (NP (DT a) (NNP Mr) (CD 28,000) (NN protein))))) (. .)))
(TOP (S (S (VP (VBG Cloning) (PP (IN of) (NP (DT the) (NAC (NNP cDNA) (VBG encoding)) (JJ human) (NNP SR-BP))))) (VP (VBZ shows) (NP (NP (DT an) (JJ open) (NN reading) (NN frame)) (PP (IN for) (NP (NP (DT a) (JJ 223-amino) (NN acid) (NN protein)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADVP (RB homologous)) (PP (TO to) (NP (DT the) (ADJP (RB recently) (VBN cloned)) (NN sigma) (CD 1) (NN receptor)))))))))) (. .)))
(TOP (S (ADVP (RB Interestingly)) (, ,) (NP (DT the) (JJ deduced) (JJ amino) (NN acid) (NN sequence)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP (VBN related) (PP (TO to) (NP (NP (VB fungal) (NNP C8-C7) (JJ sterol) (NN isomerase)) (, ,) (VP (VBN encoded) (PP (IN by) (NP (DT the) (NNP ERG2) (NN gene)))))))))))) (. .)))
(TOP (S (NP (DT The) (NNP ERG2) (NN gene) (NN product)) (VP (VBZ has) (VP (VBN been) (VP (VBN identified) (ADVP (RB recently)) (PP (IN as) (NP (NP (DT the) (JJ molecular) (NN target)) (PP (IN of) (NP (NNP SR) (NNP 31747A))) (SBAR (WHNP (WDT that)) (S (VP (VBZ mediates) (NP (NP (JJ antiproliferative) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NN drug)) (PP (IN in) (NP (NN yeast)))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Northern) (NN blot) (NN analysis)) (PP (IN of) (NP (NNP SR-BP) (NN gene) (NN expression)))) (VP (VBD revealed) (NP (NP (DT a) (JJ single) (NN transcript)) (PP (IN of) (NP (CD 2) (NNS kilobases))) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (ADVP (RB widely)) (VBN expressed) (PP (IN among) (NP (NNS organs))))))) (, ,) (PP (IN with) (NP (NP (NP (DT the) (JJS highest) (NN abundance)) (PP (IN in) (NP (NN liver)))) (CC and) (NP (NP (DT the) (JJS lowest) (NN abundance)) (PP (IN in) (NP (NN brain)))))))) (. .)))
(TOP (S (NP (NP (JJ Subcellular) (NN localization) (NN analysis)) (PP (IN in) (NP (JJ various) (NNS cells)))) (, ,) (S (VP (VBG using) (NP (NP (DT a) (JJ specific) (JJ monoclonal) (NN antibody)) (VP (VBN raised) (PP (IN against) (NP (NNP SR-BP))))))) (, ,) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT this) (NN protein)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (DT the) (JJ nuclear) (NN envelope)))))))) (. .)))
(TOP (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBG studying) (NP (NP (NP (DT the) (VBG binding)) (PP (IN of) (NP (NNP SR) (NNP 31747A))) (PP (IN on) (NP (NP (NNS membranes)) (PP (IN from) (NP (NN yeast)))))) (VP (VBG expressing) (NP (NNP SR-BP))))))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (NP (DT a) (JJ pharmacological) (NN profile)) (PP (IN of) (NP (NN sigma) (CD 1) (NNS receptors)))))) (: ;) (S (NP (VBG binding)) (VP (VBD was) (VP (VBN displaced) (PP (IN by) (NP (NP (NP (NNP -LRB-+-RRB--pentazocine)) (, ,) (NP (NN haloperidol)) (, ,)) (CC and) (NP (NNP -LRB-+-RRB--SKF) (CD 10,047)))) (, ,) (PP (IN with) (S (NP (NNP -LRB-+-RRB--SKF) (CD 10,047)) (VP (VBG being) (NP (NP (DT a) (ADJP (RBR more) (JJ potent)) (NN competitor)) (PP (IN than) (NP (NNP -LRB---RRB--SKF) (CD 10,047)))))))))) (. .)))
(TOP (S (NP (JJ Scatchard) (NN plot) (NN analysis)) (VP (VBD revealed) (S (NP (NP (JJ Kd) (NNS values)) (PP (IN of) (NP (NP (CD 7.1) (NN nM)) (CC and) (NP (CD 0.15) (NNP nM)))) (PP (IN for) (NP (NP (NNP -LRB-+-RRB--pentazocine)) (CC and) (NP (NNP SR) (NNP 31747A)))) (, ,) (ADVP (RB respectively)) (, ,)) (VP (VBG indicating) (NP (NP (DT an) (NN affinity)) (PP (IN of) (NP (NNP SR-BP))) (ADJP (ADJP (ADJP (CD 50-fold) (JJR higher)) (PP (IN for) (NP (NNP SR) (NNP 31747A)))) (PP (IN than) (PP (IN for) (NP (NN pentazocine))))))))) (. .)))
(TOP (S (ADVP (RB Additionally)) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (DT that) (S (NP (NP (NN pentazocine)) (, ,) (NP (NP (DT a) (JJ competitive) (NN inhibitor)) (PP (IN of) (NP (NNP SR) (NNP 31747A))) (VP (VBG binding))) (, ,)) (ADVP (RB also)) (VP (VBZ prevents) (NP (NP (DT the) (JJ immunosuppressive) (NN effect)) (PP (IN of) (NP (NNP SR) (NNP 31747A)))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS findings)) (ADVP (RB strongly)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP SR-BP)) (VP (VBZ represents) (NP (NP (DT the) (JJ molecular) (NN target)) (PP (IN for) (NP (NNP SR) (NNP 31747A))) (PP (IN in) (NP (NP (JJ mammalian) (NNS tissues)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB be) (ADJP (JJ critical) (PP (IN for) (NP (NNP T) (NN cell) (NN proliferation))))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN tax) (NN protein)) (PP (IN of) (NP (JJ human) (NNP T-cell) (NN leukemia) (NN virus) (NN type) (CD 1)))) (VP (VBZ mediates) (NP (NP (DT the) (NN transactivation)) (PP (IN of) (NP (DT the) (JJ c-sis/platelet-derived) (NN growth) (NN factor-B) (NN promoter)))) (PP (IN through) (NP (NP (NNS interactions)) (PP (IN with) (NP (NP (DT the) (NN zinc) (NN finger) (NN transcription) (NNS factors)) (NP (NNP Sp1) (CC and) (NNP NGFI-A/Egr-1))))))) (. .)))
(TOP (S (NP (NP (JJ Transcriptional) (NN up-regulation)) (PP (IN of) (NP (DT the) (JJ c-sis/platelet-derived) (NN growth) (NN factor-B) (PRN (-LRB- -LRB-) (NN PDGF-B) (-RRB- -RRB-)) (NN proto-oncogene))) (PP (IN by) (NP (NP (DT the) (NNP Tax) (NN protein)) (PP (IN of) (NP (JJ human) (NNP T-cell) (NN leukemia) (NN virus) (NN type) (CD 1)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN as) (NP (NP (CD one) (JJ possible) (NN mechanism)) (PP (IN of) (NP (JJ cellular) (NN transformation))) (PP (IN by) (NP (JJ human) (NNP T-cell) (NN leukemia) (NN virus) (NN type) (CD 1)))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ previous) (NN work))) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (NP (NP (DT an) (JJ essential) (NN site)) (PP (IN in) (NP (DT the) (JJ c-sis/PDGF-B) (NN promoter)))) (, ,) (NP (NP (JJ Tax-responsive) (NN element) (CD 1)) (PRN (-LRB- -LRB-) (NP (CD TRE1)) (-RRB- -RRB-))) (, ,) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NN transactivation)) (PP (IN by) (NP (NNP Tax)))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD identified) (NP (NNP Sp1) (, ,) (NNP Sp3) (, ,) (CC and) (NNP NGFI-A/Egr-1)) (PP (IN as) (NP (NP (DT the) (JJ primary) (JJ nuclear) (NN transcription) (NNS factors)) (VP (VBG binding) (PP (TO to) (NP (NP (CD TRE1)) (SBAR (WHNP (WDT which)) (S (VP (VBP mediate) (NP (NN Tax) (NN responsiveness))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN work))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NN mechanism)) (PRN (-LRB- -LRB-) (NP (PRP s)) (-RRB- -RRB-)) (SBAR (WHADVP (WRB whereby)) (S (NP (NNP Tax)) (VP (VBZ transactivates) (NP (DT the) (JJ c-sis/PDGF-B) (NN proto-oncogene)))))))) (. .)))
(TOP (SINV (PP (IN In) (NP (NN vitro) (NN transcription) (NNS assays))) (VP (VBD showed)) (SBAR (IN that) (S (NP (NNP Tax)) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (VP (ADVP (RB significantly)) (VB increase) (NP (NP (DT the) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NP (DT a) (NN template)) (VP (VBG containing) (NP (NP (DT the) (CD -257)) (PP (TO to) (NP (NP (CD +74) (NN region)) (PP (IN of) (NP (DT the) (JJ c-sis/PDGF-B) (NN promoter))))))))))))))))) (. .)))
(TOP (S (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Tax)) (VP (VBD increased) (NP (NP (DT the) (NN DNA) (VBG binding) (NN activity)) (PP (IN of) (NP (DT both) (NNP Sp1) (CC and) (NNP NGFI-A/Egr-1)))) (S (VP (VBG using) (NP (DT a) (JJ TRE1) (NN probe)))))))) (. .)))
(TOP (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NN Tax) (NNS mutants)))) (VP (VBD showed) (SBAR (IN that) (S (NP (CD two) (NNS mutants) (, ,) (NNP IEXC29S) (CC and) (NNP IEXL320G) (, ,)) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (VP (ADVP (RB significantly)) (VB transactivate) (NP (DT the) (JJ c-sis/PDGF-B) (NN promoter)))))))))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (NP (NN co-immunoprecipitation) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNP Tax)) (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB stably) (NP (NN bind)) (PP (TO to) (NP (DT both) (NNP Sp1) (CC and) (NNP NGFI-A/Egr-1))))))))))) (. .)))
(TOP (S (ADVP (RB Interestingly)) (, ,) (NP (NN co-immunoprecipitation) (NN analysis)) (ADVP (RB also)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNP Tax) (JJ mutant) (NNP IEXC29S)) (VP (VBZ is) (ADJP (JJ unable) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NNP NGFI-A/Egr-1))))))) (, ,) (SBAR (IN whereas) (S (NP (NNP Tax) (JJ mutant) (NNP IEXL320G)) (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NNP NGFI-A/Egr-1)))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Stable) (NN transfection)) (PP (IN of) (NP (NP (JJ U937) (NNS cells)) (PP (IN with) (NP (NP (NN sense)) (CC or) (NP (NN antisense) (NNP RXR-alpha) (NNP cDNA))))))) (VP (VBZ suggests) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NNP RXR-alpha))) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (JJ monoblastic) (NN differentiation)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ retinoic) (NN acid)) (CC and) (NP (NN vitamin) (NNP D))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (NP (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP RA)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN known) (PP (IN for) (NP (JJ many) (NNS years))) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (JJ modulating) (NN agent)) (SBAR (WHNP (WDT that)) (S (VP (VBZ plays) (NP (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG generating) (NP (DT both) (NNS granulocytes) (CC and) (NNS monocytes)))))))))))))))))) (, ,) (NP (NP (DT the) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (DT this) (NN role)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN defined) (PP (IN in) (NP (DT the) (JJ monoblast) (NN lineage)))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (DT the) (NN part)) (VP (VBN played) (PP (IN by) (NP (NP (DT the) (JJ retinoid) (NNP X) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS RXRs)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (JJ steroid/thyroid) (NN hormone) (JJ nuclear) (NN receptor) (NN family))))))) (, ,))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN explored)))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (ADVP (RB therefore)) (, ,) (NP (DT the) (JJ human) (JJ monoblastic) (NN leukemia) (NN cell) (NN line) (NNP U937)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (IN as) (NP (DT a) (NN model) (NN system))) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS RXRs)) (, ,) (NP (NNP RXR-alpha)) (, ,))))) (PP (IN in) (NP (JJ monoblast) (NN differentiation)))))))))) (. .)))
(TOP (S (S (NP (NNP RXR-alpha) (NNP mRNA)) (VP (VBD was) (ADJP (JJ present)) (PP (IN in) (NP (JJ untreated) (NNP U937) (NNS cells))))) (, ,) (CC and) (S (NP (NNS levels)) (VP (VBD increased) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NP (NN differentiation)) (PP (IN with) (NP (JJ phorbol) (NN ester))))))))) (. .)))
(TOP (S (NP (DT The) (JJ same)) (VP (VBD was) (VP (VBN found) (PP (IN for) (NP (NNP RXR-beta) (NNP mRNA))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NP (NP (NNS plasmids)) (VP (VBG containing) (NP (NN sense)))) (CC or) (NP (NP (JJ antisense) (JJ RXR-alpha) (NNS sequences)) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT an) (JJ inducible) (NN promoter))))))))) (, ,) (NP (PRP we)) (VP (VBD generated) (NP (NP (ADJP (RB stably) (VBN transfected)) (NN cell) (NNS lines)) (SBAR (WHNP (WDT which)) (S (VP (VBD expressed) (SBAR (S (NP (CC either)) (VP (VBD increased) (CC or) (VBD decreased) (NP (NP (NNS levels)) (PP (IN of) (NP (NNP RXR-alpha)))) (, ,) (ADVP (RB respectively)))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN sense) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NP (NNP U) (NN alpha) (NNP S)) (CC and) (NP (PRP$ its) (JJ clonal) (JJ derivative) (NN alpha) (NNP G2S))) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (VBN increased) (NN sensitivity)) (PP (TO to) (NP (NNP RA)))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (JJ antisense) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NP (NNP U) (NN alpha) (NNP A)) (CC and) (NP (PRP$ its) (JJ clonal) (JJ derivative) (NN alpha) (NNP B5A))) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (VBN decreased) (NN sensitivity)) (PP (TO to) (NP (NNP RA)))) (, ,) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (PP (IN by) (NP (NN growth) (NN inhibition))) (CC and) (PP (IN by) (NP (NP (NN regulation)) (PP (IN of) (NP (DT an) (JJ RA-responsive) (NN reporter) (NN gene))))))))))))) (. .)))
(TOP (S (S (NP (DT Both) (NNP U) (NN alpha) (NN A) (CC and) (NN alpha) (NNP B5A)) (ADVP (RB also)) (VP (VBD failed) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (DT another) (VBG modulating) (NN agent)) (, ,) (ADJP (ADJP (CD 1) (JJ alpha,25-dihydroxycholecalciferol)) (PRN (-LRB- -LRB-) (NP (NNP DHCC)) (-RRB- -RRB-)))))))))) (, ,) (CC but) (S (NP (NP (RB only) (NNP U) (NN alpha) (NNP S)) (CC and) (RB not) (NP (NN alpha) (NNP G2S))) (VP (VBD showed) (NP (NP (DT an) (JJ enhanced) (NN response)) (PP (TO to) (NP (NNP DHCC)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NNP RA) (CC and) (NNP DHCC)))) (ADVP (RB together)) (VP (VBD inhibited) (NP (NP (NN growth)) (PP (IN of) (NP (DT both) (NN sense) (CC and) (JJ antisense) (NN cell) (NNS lines))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN alpha) (NNP G2S)) (VP (VBD exhibited) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NNP CD11b) (CC and) (NNP CD54)))) (, ,) (SBAR (IN while) (S (NP (NN alpha) (NN B5A) (NNS cells)) (VP (VBD showed) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NNP CD102))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNP RXR-alpha)) (VP (VBZ has) (NP (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (NN expression)) (PP (IN of) (NP (NN cell) (NN adhesion) (NNS molecules)))) (PP (IN in) (NP (NNP U937) (NNS cells))))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NNP RXR-alpha)) (VP (VBZ has) (NP (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG mediating) (NP (NP (NN growth) (NN inhibition)) (CC and) (NP (NN cell) (NN adhesion))) (PP (IN during) (NP (JJ myelomonocytic) (NN differentiation))))))))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ different) (NNS species)) (PP (IN of) (NP (NP (NNS heterodimers)) (VP (VBG involving) (NP (NNP RXR-alpha)))))) (VP (MD may) (VP (VB control) (NP (NP (DT the) (NN acquisition)) (PP (IN of) (NP (NP (JJ different) (NNS features)) (PP (IN of) (NP (JJ mature) (NN monocyte/macrophage) (NN function)))))))))))) (. .)))
(TOP (NP (NP (NP (JJ B-lymphoblastoid) (NN cell) (NNS lines)) (PP (IN from) (NP (JJ multiple) (NN sclerosis) (NNS patients)))) (CC and) (NP (NP (DT a) (JJ healthy) (NN control)) (VP (VBG producing) (NP (DT a) (JJ putative) (JJ new) (JJ human) (NN retrovirus) (CC and) (NNP Epstein-Barr) (NN virus)))) (. .)))
(TOP (S (PP (IN On) (NP (JJ several) (NNS occasions))) (NP (PRP we)) (VP (VBP have) (VP (VBN observed) (NP (NP (JJ retrovirus-like) (NNS particles)) (PRN (-LRB- -LRB-) (NP (NNS RVLPs)) (-RRB- -RRB-)) (PP (IN by) (NP (NP (NN transmission) (NN electron) (NN microscopy)) (PRN (-LRB- -LRB-) (NP (NNP EM)) (-RRB- -RRB-)) (PP (IN of) (NP (VBN cultured) (NNP T) (NNS cells))))) (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP MS)))))))) (. .)))
(TOP (S (ADVP (RB Later)) (NP (PRP we)) (VP (VBD established) (NP (NP (ADJP (RB spontaneously) (VBN formed)) (JJ B-lymphoblastoid) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NNPS LCLs)) (-RRB- -RRB-))) (PP (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (DT an) (JJ MS-like) (NN disease))))) (CC and) (PP (IN from) (NP (NP (DT another) (NN patient)) (PP (IN with) (NP (NNP MS))) (SBAR (WHNP (WP who)) (S (VP (VBD had) (NP (DT a) (VBN reactivated) (NNP Epstein-Barr) (NN virus) (PRN (-LRB- -LRB-) (NNP EBV) (-RRB- -RRB-)) (NN infection))))))))) (. .)))
(TOP (S (NP (DT Both) (NNS LCLs)) (VP (VBD were) (VP (VBN found) (PP (IN by) (NP (NNP EM))) (S (VP (TO to) (VP (VB produce) (NP (NNP RVLP) (CC and) (NNP EBV) (NNS particles))))))) (. .)))
(TOP (S (NP (VB Reverse) (NN transcriptase) (PRN (-LRB- -LRB-) (NNP RT) (-RRB- -RRB-)) (NNS assays)) (VP (VBD were) (ADJP (JJ positive)) (PP (IN in) (NP (NP (JJ purified) (JJ viral) (NN material)) (PP (IN from) (NP (DT both) (NNS LCLs)))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB substantiate) (NP (DT these) (NNS findings))))) (NP (PRP we)) (VP (VP (VBD initiated) (NP (DT an) (VBN intensified) (NN culturing) (NN procedure))) (CC and) (VP (VBD were) (ADJP (JJ able) (S (VP (TO to) (VP (VB establish) (NP (NNS LCLs)) (PP (IN from) (NP (CD 5))) (PP (IN out) (PP (IN of) (NP (CD 21) (JJ consecutive) (NNP MS) (NNS patients) (CC and) (CD 1)))) (PP (IN out) (PP (IN of) (NP (CD 13) (JJ consecutive) (JJ healthy) (NNS controls)))))))))) (. .)))
(TOP (S (NP (DT All) (NNS LCLs)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB produce) (NP (DT both) (NNP RVLP) (CC and) (NNP EBV) (NNS particles)) (PP (IN by) (NP (NNP EM)))))))) (. .)))
(TOP (S (S (SBAR (IN Whether) (S (NP (NP (NP (DT the) (JJ putative) (JJ new) (NN retrovirus)) (PRN (-LRB- -LRB-) (NP (NNS es)) (-RRB- -RRB-))) (CC and) (NP (NNP EBV))) (VP (VBP have) (NP (NP (DT any) (JJ causal) (NN relationship)) (PP (TO to) (NP (NNP MS))))))) (VP (VBZ is) (ADVP (RB still)) (RB not) (VP (VBN known)))) (, ,) (CC but) (S (NP (DT the) (NNS findings)) (VP (VBP support) (NP (DT this) (NN possibility)))) (. .)))
(TOP (NP (NP (NN Involvement)) (PP (IN of) (NP (NP (JJ different) (NN transduction) (NNS pathways)) (PP (IN in) (NP (NNP NF-kappa) (NNP B) (NN activation))) (PP (IN by) (NP (JJ several) (NNS inducers))))) (. .)))
(TOP (S (NP (NN Double-stimulation)) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB demonstrate) (SBAR (IN that) (, ,) (S (PP (IN in) (NP (NP (DT a) (NNP T) (JJ lymphocytic) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NNP CEM)) (-RRB- -RRB-)))) (, ,) (NP (FW phorbol) (FW myristate) (FW acetate) (PRN (-LRB- -LRB-) (NNP PMA) (-RRB- -RRB-))) (VP (ADVP (RB rapidly)) (VBN induced) (NP (NNP NF-kappa) (NNP B)) (PP (IN through) (NP (NP (DT a) (VBG signaling) (NN pathway)) (SBAR (WHNP (WDT which)) (S (VP (VP (VBD did) (RB not) (VP (VB involve) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNP ROS)) (-RRB- -RRB-))))) (CC and) (VP (VBD was) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (NN activation)) (VP (VBN triggered) (PP (IN by) (NP (NP (DT either) (NN H2O2) (CC or) (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-)))))))))))))))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP (DT these) (JJ latter) (NNS compounds)) (VP (VBD were) (VP (VBN known) (S (VP (TO to) (VP (VB activate) (NP (NNP NF-kappa) (NNP B) (NN translocation)) (PP (IN in) (NP (DT a) (JJ redox-sensitive) (NN way)))))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NNP NF-kappa) (NNP B) (NN activation)) (PP (IN by) (NP (NNP PMA)))) (VP (VBD was) (ADJP (ADJP (JJ resistant) (PP (TO to) (NP (NP (JJ antioxidant) (NNP N-acetyl-L-cysteine)) (PRN (-LRB- -LRB-) (NP (NNP NAC)) (-RRB- -RRB-))))) (CC and) (ADJP (JJ sensitive) (S (VP (TO to) (VP (VB kinase) (NP (NNS inhibitors) (NNP staurosporine) (CC and) (NNP H7))))))) (SBAR (IN while) (S (NP (NP (NN activation)) (PP (IN by) (NP (NNP H2O2) (CC or) (NNP TNF-alpha)))) (VP (VBD were) (RB not))))))))) (. .)))
(TOP (NP (NP (NNP Association)) (PP (IN of) (NP (NP (JJ glucocorticoid) (NN insensitivity)) (PP (IN with) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (JJ glucocorticoid) (NN receptor) (NN beta))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ many) (JJ chronic) (JJ inflammatory) (NNS disorders))) (, ,) (NP (NN glucocorticoid) (PRN (-LRB- -LRB-) (NNP GC) (-RRB- -RRB-)) (NN insensitivity)) (VP (VBZ is) (NP (NP (DT a) (JJ challenging) (JJ clinical) (NN problem)) (VP (VBN associated) (PP (IN with) (NP (JJ life-threatening) (NN disease) (NN progression)))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ molecular) (NN basis)) (PP (IN of) (NP (NNP GC) (NN insensitivity)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ is) (ADJP (JJ unknown))) (. .)))
(TOP (S (NP (NP (NNP Alternative) (NN splicing)) (PP (IN of) (NP (DT the) (NNP GC) (NN receptor) (PRN (-LRB- -LRB-) (NN R) (-RRB- -RRB-)) (NN pre-messenger) (NNP RNA)))) (VP (VP (VBZ generates) (NP (DT a) (JJ second) (NNP GCR))) (, ,) (VP (VBD termed) (NP (NP (NNP GCR-beta)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ does) (RB not) (VP (NN bind) (NP (VBZ GCs)))) (CC but) (VP (VBZ antagonizes) (NP (NP (DT the) (VBG transactivating) (NN activity)) (PP (IN of) (NP (NP (DT the) (JJ classic) (NNP GCR)) (, ,) (VP (VBD termed) (S (NP (NNP GCR-alpha)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (JJ GC-insensitive) (NN asthma)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN number)) (PP (IN of) (NP (NP (JJ GCR-beta-immunoreactive) (NNS cells)) (PP (IN in) (NP (JJ peripheral) (NN blood)))))) (PP (IN than) (NP (NP (JJ GC-sensitive) (NNS asthmatics)) (CC or) (NP (JJ normal) (NNS controls))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NNS patients)) (PP (IN with) (NP (JJ GC-insensitive) (NN asthma)))) (VP (VBP have) (NP (NP (JJ cytokine-induced) (NNS abnormalities)) (PP (IN in) (NP (NP (DT the) (NN DNA) (VBG binding) (NN capability)) (PP (IN of) (NP (DT the) (NNP GCR)))))))))) (. .)))
(TOP (S (NP (DT These) (NNS abnormalities)) (VP (MD can) (VP (VB be) (VP (VBN reproduced) (PP (IN by) (NP (NP (NN transfection)) (PP (IN of) (NP (NP (NN cell) (NNS lines)) (PP (IN with) (NP (NP (DT the) (JJ GCR-beta) (NN gene)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJ significant) (NN reduction)) (PP (IN of) (NP (PRP$ their) (JJ GCR-alpha) (NN DNA) (VBG binding) (NN capacity))))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (JJ GCR-beta)))) (VP (VP (NNS is) (VP (VBP cytokine) (ADJP (JJ inducible)))) (CC and) (VP (MD may) (VP (VB account) (PP (IN for) (NP (NP (NNP GC) (NN insensitivity)) (PP (IN in) (NP (DT this) (JJ common) (JJ inflammatory) (NN condition))))))))))) (. .)))
(TOP (S (NP (NP (NNP Inhibition)) (PP (IN of) (NP (NP (NNP T) (NN cell) (CC and) (NN promotion)) (PP (IN of) (NP (JJ natural) (NN killer) (NN cell) (NN development))) (PP (IN by) (NP (DT the) (JJ dominant) (JJ negative) (NN helix) (NN loop) (NN helix) (NN factor)))))) (VP (NN Id3)) (. .)))
(TOP (S (NP (NNP Bipotential) (NNP T/natural) (NN killer) (PRN (-LRB- -LRB-) (NNP NK) (-RRB- -RRB-)) (NN progenitor) (NNS cells)) (VP (VBP are) (ADJP (JJ present) (PP (IN in) (NP (DT the) (JJ human) (NN thymus))))) (. .)))
(TOP (S (PP (IN Despite) (NP (PRP$ their) (JJ bipotential) (NN capacity))) (, ,) (NP (DT these) (NNS progenitors)) (VP (VBP develop) (ADVP (RB predominantly)) (PP (TO to) (NP (NP (NNP T) (NNS cells)) (PP (IN in) (NP (DT the) (NN thymus)))))) (. .)))
(TOP (S (NP (NP (DT The) (NNS mechanisms)) (VP (VBG controlling) (NP (DT this) (JJ developmental) (NN choice)))) (VP (VBP are) (ADJP (JJ unknown))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP present) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (DT a) (NN member)) (PRN (-LRB- -LRB-) (NP (PRP s)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (NN family)) (PP (IN of) (NP (JJ basic) (NN helix) (NN loop) (NN helix) (PRN (-LRB- -LRB-) (NNP bHLH) (-RRB- -RRB-)) (NN transcription) (NNS factors)))))) (VP (VBZ determines) (NP (NP (NN lineage) (NN specification)) (PP (IN of) (NP (NNP NK/T) (NN cell) (NNS progenitors))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ natural) (JJ dominant) (JJ negative) (NNP HLH) (NN factor) (NNP Id3)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (NNS blocks) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ known) (NNP bHLH) (NNS factors))))))))) (, ,)) (VP (VBD was) (VP (VBN expressed) (PP (IN in) (NP (NP (CD CD34+) (NN progenitor) (NNS cells)) (PP (IN by) (NP (JJ retrovirus-mediated) (NN gene) (NN transfer))))))) (. .)))
(TOP (NP (NP (JJ Constitutive) (NN expression)) (PP (IN of) (NP (NP (NNP Id3) (ADJP (RB completely) (NNS blocks)) (NN development)) (PP (IN of) (NP (NNP CD34+) (NNS cells))) (PP (IN into) (NP (NP (NNP T) (NNS cells)) (PP (IN in) (NP (NP (DT a) (JJ fetal) (JJ thymic) (NN organ) (NN culture)) (PRN (-LRB- -LRB-) (NP (NNP FTOC)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN development)) (PP (IN into) (NP (NP (NNP NK) (NNS cells)) (PP (IN in) (NP (DT an) (NNP FTOC)))))) (VP (VBZ is) (VP (VBN enhanced))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT a) (JJ bHLH) (NN transcription) (NN factor)))) (VP (VBZ is) (ADJP (JJ necessary)) (PP (IN for) (NP (NP (NNP T) (NN lineage) (NN differentiation)) (PP (IN of) (NP (JJ bipotential) (NNS precursors))))) (, ,) (PP (IN in) (NP (NP (DT the) (NN absence)) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (NP (DT a) (NN default) (NN pathway)) (VP (VBG leading) (PP (TO to) (NP (NNP NK) (NN cell) (NN development))))) (VP (VBZ is) (VP (VBN chosen)))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS results)) (VP (VB identify) (NP (NP (DT a) (JJ molecular) (NN switch)) (PP (IN for) (NP (NN lineage) (NN specification))) (PP (IN in) (NP (NP (JJ early) (JJ lymphoid) (NNS precursors)) (PP (IN of) (NP (NNS humans))))))) (. .)))
(TOP (NP (NP (NN Suppression)) (PP (IN of) (NP (NNP MHC) (NN class) (NNP II) (NN expression))) (PP (IN by) (NP (JJ human) (NN class) (NNP II) (NN trans-activator) (NNS constructs))) (VP (VBG lacking) (NP (DT the) (JJ N-terminal) (NN domain))) (. .)))
(TOP (S (NP (NP (DT The) (NN class) (NNP II) (NNP trans-activator)) (PRN (-LRB- -LRB-) (NP (NNP CIITA)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (ADJP (JJ bi-) (CC or) (JJ multi-functional)) (NN domain) (NN protein)) (SBAR (WHNP (WDT which)) (S (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP MHC) (NN class) (NNP II) (NNS genes)))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT that) (NN removal)) (PP (IN of) (NP (DT the) (JJ N-terminal) (CD 151) (JJ amino) (NNS acids)))) (, ,) (S (VP (VP (VBG encompassing) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (JJ acidic) (NN domain))))) (CC but) (VP (VBG leaving) (NP (JJ intact) (DT the) (JJ proline/serine/threonine-rich) (NN domain))))) (, ,) (NP (NP (NNS results)) (PP (IN in) (NP (NP (DT a) (JJ mutant) (NN protein)) (PP (IN with) (NP (NP (JJ potent) (JJ suppressive) (NNS properties)) (PP (IN for) (NP (NNP MHC) (NN class) (NNP II) (NN expression))))))))) (. .)))
(TOP (S (NP (NP (NN HeLa) (NNS cells)) (VP (ADVP (RB stably) (CC or) (RB transiently)) (VBN transfected) (PP (IN with) (NP (JJ mutant) (NNP CIITA) (NNS constructs))))) (VP (VBD showed) (NP (NP (ADJP (QP (IN up) (TO to) (CD 99)) (NN %)) (NN suppression)) (PP (IN of) (NP (NNP MHC) (NN class) (NNP II) (NN antigen) (NN induction))) (PP (IN by) (NP (NP (NNP IFN-gamma)) (CC and) (NP (NP (JJ marked) (NN suppression)) (PP (IN of) (NP (NNP HLA-DRA) (NNP mRNA) (NN expression)))))))) (. .)))
(TOP (S (NP (NP (JJ Transient) (NN transfection)) (PP (IN of) (NP (DT a) (NN B) (NN lymphoma) (NN line)))) (VP (VBD resulted) (PP (IN in) (NP (NP (ADJP (QP (IN up) (TO to) (CD 89)) (NN %)) (NN reduction)) (PP (IN of) (NP (JJ constitutive) (NNP MHC) (NN class) (NNP II) (NN expression))) (PP (IN within) (NP (NP (CD 5) (NNS days) (CC and) (NN suppression)) (PP (IN of) (NP (NNP HLA-DRA) (NNP mRNA) (NN synthesis)))))))) (. .)))
(TOP (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (NN proliferation)) (CC and) (NP (NP (NN apoptosis)) (PP (IN of) (NP (NN human) (CC and) (NN rat) (NN T) (NNS lymphocytes)))))) (PP (IN by) (NP (NP (NN curcumin)) (, ,) (NP (DT a) (VB curry) (NN pigment)))) (. .)))
(TOP (S (NP (NP (NNP Curcumin)) (PRN (-LRB- -LRB-) (NP (NN diferuoylmethane)) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (JJ yellow) (NN pigment)) (PP (IN in) (NP (NP (DT the) (NN rhizome)) (PP (IN of) (NP (JJ tumeric)))))) (PRN (-LRB- -LRB-) (NP (NNP Curcuma) (NN longa)) (-RRB- -RRB-)) (, ,) (NP (NP (DT an) (NN ingredient)) (PP (IN of) (NP (VB curry) (NN spice)))) (, ,)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB exhibit) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ pharmacological) (NNS effects)) (PP (VBG including) (NP (ADJP (JJ antitumor) (, ,) (JJ antiinflammatory) (, ,) (CC and) (JJ antiinfectious)) (NNS activities))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (NP (PRP$ its) (JJ precise) (NN mode)) (PP (IN of) (NP (NN action)))) (VP (VBZ remains) (ADJP (JJ elusive))))) (, ,) (NP (NN curcumin)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB suppress) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (DT the) (JJ AP-1) (NN transcription) (NN factor)) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN stimulated) (S (VP (TO to) (VP (VB proliferate)))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD observed) (SBAR (DT that) (S (NP (NP (NN curcumin)) (PRN (-LRB- -LRB-) (NP (CD 50) (NNP microM)) (-RRB- -RRB-))) (VP (VBD inhibited) (NP (NP (NN proliferation)) (PP (IN of) (NP (NP (NN rat) (NNS thymocytes)) (VP (VBN stimulated) (PP (IN with) (NP (NP (NP (NN concanavalin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN Con) (NN A)) (-RRB- -RRB-))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ human) (NNP Jurkat) (NN lymphoblastoid) (NNS cells)) (PP (IN in) (NP (DT the) (JJ logarithmic) (NN growth) (NN phase)))))))))))))))) (. .)))
(TOP (S (NP (DT The) (NN pigment)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NN apoptosis)) (PP (PP (IN in) (NP (JJ dexamethasone-treated) (NN rat) (NNS thymocytes))) (CC and) (PP (IN in) (NP (JJ UV-irradiated) (NN Jurkat) (NNS cells)))) (SBAR (IN as) (S (VP (VBN judged) (PP (IN by) (NP (NP (NNP DNA) (NN ladder) (NN formation)) (, ,) (NP (JJ cellular) (JJ morphological) (NNS changes)) (, ,) (CC and) (NP (NN flow) (NN cytometry) (NN analysis))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN inhibition)) (PP (IN of) (NP (NN apoptosis))) (PP (IN by) (NP (NN curcumin))) (PP (IN in) (NP (NN rat) (NNS thymocytes)))) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ partial) (NN suppression)) (PP (IN of) (NP (JJ AP-1) (NN activity))))))) (. .)))
(TOP (S (NP (NP (JJ Complete) (NN suppression)) (PP (IN of) (NP (JJ AP-1) (NN activity)))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NN Con) (JJ A-treated))) (, ,) (S (VP (VBG proliferating) (NP (NNS thymocytes)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN capacity)) (PP (IN of) (NP (NN curcumin))) (S (VP (TO to) (VP (VB inhibit) (NP (DT both) (NP (NN cell) (NN growth) (CC and) (NN death)) (ADVP (RB strongly))))))) (VP (VBZ implies) (SBAR (SBAR (IN that) (S (NP (DT these) (CD two) (JJ biological) (NNS processes)) (VP (VBP share) (NP (DT a) (JJ common) (NN pathway)) (PP (IN at) (NP (DT some) (NN point)))))) (CC and) (SBAR (DT that) (S (NP (NN curcumin)) (VP (VBZ affects) (NP (NP (DT a) (JJ common) (NN step)) (, ,) (VP (ADVP (RB presumably)) (VBG involving) (NP (NP (DT a) (NN modulation)) (PP (IN of) (NP (DT the) (JJ AP-1) (NN transcription) (NN factor))))))))))) (. .)))
(TOP (S (NP (NP (JJ Nuclear) (NN localization)) (PP (IN of) (NP (NNP RelB)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (JJ effective) (JJ antigen-presenting) (NN cell) (NN function))))) (. .)))
(TOP (S (NP (NP (JJ Dendritic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP DC)) (-RRB- -RRB-))) (VP (VBP are) (NP (NP (JJ potent) (NNS APCs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP enter) (NP (VBG resting) (NNS tissues)) (PP (IN as) (NP (NNS precursors)))) (CC and) (, ,) (VP (PP (IN after) (NP (NN Ag) (NN exposure))) (, ,) (VB differentiate) (CC and) (VB migrate) (PP (TO to) (S (VP (VBG draining) (NP (NN lymph) (NNS nodes))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN phenotype)) (PP (IN of) (NP (NNP RelB) (NN knockout) (NNS mice)))) (VP (VBZ implicates) (NP (NP (DT this) (NN member)) (PP (IN of) (NP (DT the) (NNP NF) (FW kappa) (NNP B/Rel) (NN family)))) (PP (IN in) (NP (NNP DC) (NN differentiation)))) (. .)))
(TOP (S (S (VP (TO To) (VP (ADVP (RBR further)) (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP RelB))) (PP (IN in) (NP (NP (NNP DC) (NN differentiation)) (, ,) (NP (NNP mRNA)) (, ,) (NP (JJ intracellular) (NN protein) (NN expression)) (, ,) (CC and) (NP (NP (NNP DNA) (JJ binding) (NN activity)) (PP (IN of) (NP (NNP RelB)))))))))) (VP (VBD were) (VP (VP (VBN examined) (PP (IN in) (ADJP (NN immature)))) (CC and) (VP (VBN differentiated) (NP (NP (JJ human) (NNP DC)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ other) (NNP PB) (NN mononuclear) (NN cell) (NNS populations)))))) (. .)))
(TOP (S (NP (NN RelB) (NN protein) (CC and) (NNP mRNA)) (VP (VBD were) (VP (VBN detected) (ADVP (RB constitutively)) (PP (PP (IN in) (NP (NNS lymphocytes))) (CC and) (PP (IN in) (NP (NP (VBN activated) (NNS monocytes)) (, ,) (NP (VBN differentiated) (NNP DC)) (, ,) (CC and) (NP (JJ monocyte-derived) (NNP DC))))))) (. .)))
(TOP (S (NP (JJ Immunohistochemical) (NN staining)) (VP (VP (VBD demonstrated) (NP (NNP RelB)) (PP (IN within) (NP (NP (DT the) (JJ differentiated) (NN lymph) (NN node)) (VP (VBG interdigitating) (NP (NP (NNP DC)) (CC and) (NP (JJ follicular) (NNP DC))))))) (, ,) (CC but) (RB not) (VP (JJ undifferentiated) (NP (NNP DC)) (PP (IN in) (NP (JJ normal) (NN skin))))) (. .)))
(TOP (S (NP (JJ Active) (JJ nuclear) (NN RelB)) (VP (VBD was) (VP (VBN detected) (PP (IN by) (NP (NN supershift) (NN assay))) (PP (PP (ADVP (RB only)) (IN in) (NP (NP (JJ differentiated) (NN DC)) (VP (VBN derived) (PP (IN from) (NP (DT either) (NNP PB) (NNS precursors) (CC or) (NNS monocytes)))))) (CC and) (PP (IN in) (NP (VBN activated) (NN B) (NNS cells)))))) (. .)))
(TOP (S (NP (DT These) (NNP RelB+) (NNP APC)) (VP (VBD were) (NP (NP (JJ potent) (NNS stimulators)) (PP (IN of) (NP (DT the) (NNP MLR))))) (. .)))
(TOP (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ RelB) (NN expression)) (VP (VBZ is) (VP (VBN regulated) (ADVP (DT both) (RB transcriptionally) (CC and) (RB post-translationally)) (PP (IN in) (NP (JJ myeloid) (NNS cells)))))))) (. .)))
(TOP (S (PP (IN Within) (NP (DT the) (NN nucleus))) (, ,) (NP (NNP RelB)) (VP (MD may) (ADVP (RB specifically)) (VP (VB transactivate) (NP (NP (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ critical) (PP (IN for) (NP (NNP APC) (NN function)))))))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor-kappa) (NNP B)) (CC and) (NP (PRP$ its) (NN inhibitor)))) (SBAR (S (NP (PRP I)) (VP (VBP kappa) (S (ADJP (JJ B-alpha/MAD-3))) (PP (IN in) (NP (NNS monocytes))) (PP (PP (IN by) (NP (NNP Mycobacterium) (NN tuberculosis))) (CC and) (PP (IN during) (NP (JJ human) (NN tuberculosis))))))) (. .)))
(TOP (S (NP (NP (NNP Blood) (NNS monocytes)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ active) (NNS tuberculosis)))))) (VP (VBP are) (VP (VBN activated) (PP (IN in) (NP (NN vivo))) (, ,) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (VBN stimulated) (NN release)) (PP (IN of) (NP (NP (NP (JJ proinflammatory) (NNS cytokines)) (, ,) (PP (JJ such) (IN as) (NP (NNP TNF-alpha))) (, ,)) (CC and) (NP (NP (DT the) (JJ spontaneous) (NN expression)) (PP (IN of) (NP (NN IL-2R))))))))))))))) (. .)))
(TOP (S (ADVP (RB Further)) (, ,) (NP (NP (NNS monocytes)) (PP (IN from) (NP (NNS patients)))) (VP (VBP demonstrate) (NP (NP (DT an) (JJ augmented) (NN susceptibility)) (PP (TO to) (NP (DT a) (JJ productive) (NN infection))) (PP (IN with) (NP (NP (NNP HIV-1)) (PP (IN in) (NP (NN vitro))))))) (. .)))
(TOP (S (NP (NP (NN Mycobacterium) (NNS tuberculosis)) (CC and) (NP (PRP$ its) (NNS components))) (VP (VBP are) (NP (JJ strong) (NNS signals) (S (VP (TO to) (VP (VB activate) (NP (NNS monocytes)) (PP (TO to) (NP (NP (NN production)) (PP (IN of) (NP (NNS cytokines)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NN activation)) (PP (IN of) (NP (NNS monocytes)))))) (PP (PP (IN during) (NP (JJ active) (NN tuberculosis))) (CC and) (PP (IN by) (NP (NNP M.) (NNS tuberculosis))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (NP (DT a) (JJ constitutive) (NN degradation)) (PP (IN of) (NP (PRP I)))) (VP (VBP kappa) (ADJP (JJ B-alpha))))) (, ,) (NP (NP (DT the) (JJ major) (JJ cytoplasmic) (NN inhibitor)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP NF-kappa) (NNP B)) (-RRB- -RRB-)))) (, ,) (PP (IN in) (NP (NP (ADJP (RB freshly) (VBN isolated)) (NNP PBMC) (CC and) (NNS monocytes)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NN tuberculosis))))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (PRP I)) (VP (VBP kappa) (NP (JJ B-alpha) (NNS levels)) (PP (IN in) (NP (NNP PBMC) (CC and) (NNS monocytes))) (PP (IN from) (NP (JJ healthy) (NNS subjects))))) (CC or) (S (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ nontuberculous) (JJ pulmonary) (NNS conditions))))) (VP (VBD were) (ADJP (JJ intact)))) (. .)))
(TOP (S (ADVP (RB Further)) (, ,) (PP (IN by) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))) (, ,) (NP (NNP NF-kappa) (NNP B)) (VP (VBD was) (VP (VBN activated) (PP (IN in) (NP (NNS monocytes))) (PP (IN from) (NP (JJ tuberculous) (NNS patients))))) (. .)))
(TOP (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (PRP I)))) (VP (VBP kappa) (SBAR (S (NP (NP (JJ B-alpha) (NN gene)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ responsive) (PP (TO to) (NP (NP (NN activation)) (PP (IN by) (NP (NNP NF-kappa) (NNP B))))))))) (, ,)) (VP (VBD was) (ADJP (JJ up-regulated)) (PP (PP (IN in) (NP (NP (NNP PBMC) (CC and) (NNS monocytes)) (PP (IN from) (NP (NNS patients))))) (, ,) (CC but) (RB not) (PP (IN in) (NP (NP (JJ mononuclear) (NNS cells)) (PP (IN from) (NP (NP (JJ healthy) (NNS subjects)) (CC or) (NP (NP (DT those)) (PP (IN with) (NP (JJ nontuberculous) (NN lung) (NNS diseases))))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ other) (JJ adherence-associated) (JJ early) (NNS genes))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP IL-8)) (CC and) (NP (NNP IL-1) (NN beta)))) (, ,)) (VP (VBD was) (RB not) (ADJP (JJ up-regulated)) (PP (IN in) (NP (NP (NNP PBMC)) (PP (IN of) (NP (JJ tuberculous) (NNS patients)))))) (. .)))
(TOP (S (S (S (ADVP (RB Further)) (, ,) (NP (NP (NNP M.) (NNS tuberculosis)) (CC and) (NP (PRP$ its) (NN tuberculin) (, ,) (JJ purified) (NN protein) (NN derivative))) (, ,) (VP (VBD induced) (SBAR (S (NP (NP (DT the) (NN degradation)) (PP (IN of) (NP (PRP I)))) (VP (VBP kappa) (NP (NNP B-alpha))))))) (CC and) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (PRP I)))) (VP (VBP kappa) (NP (NNP B-alpha) (NNP mRNA))))) (, ,) (CC and) (S (NP (JJ purified) (NN protein) (NN derivative)) (VP (VBD induced) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B))) (PP (IN in) (NP (NNS monocytes)))))) (. .)))
(TOP (NP (NP (NN Relationship)) (PP (IN between) (NP (NP (JJ glucocorticoid) (NN receptor)) (CC and) (NP (NP (NN response)) (PP (TO to) (NP (JJ glucocorticoid) (NN therapy))) (PP (IN in) (NP (JJ ulcerative) (NNS colitis)))))) (. .)))
(TOP (NP (NP (NN PURPOSE)) (: :) (S (S (VP (TO To) (VP (VB clarify) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (DT the) (JJ glucocorticoid) (NN receptor)) (CC and) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (JJ glucocorticoid) (NN therapy))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ulcerative) (NNS colitis)))))))))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (NP (DT the) (NN number)) (CC and) (NP (JJ apparent) (NN dissociation))) (ADJP (JJ constant) (PP (IN of) (NP (NP (JJ glucocorticoid) (NN receptor)) (PP (IN in) (NP (NP (JJ peripheral) (NN blood) (NN mononuclear) (NNS leukocytes)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ulcerative) (NNS colitis))))))))))))) (. .)))
(TOP (NP (NP (NNP MATERIALS) (CC AND) (NNPS METHODS)) (: :) (S (NP (NP (NP (CD Eleven) (NNS patients)) (PP (IN with) (NP (JJ ulcerative) (NNS colitis))) (PRN (-LRB- -LRB-) (NP (NP (CD 5)) (SBAR (WHNP (WP who)) (S (VP (VBD responded) (PP (TO to) (NP (NP (NP (JJ intravenous) (NNS glucocorticoids)) (CC and) (NP (CD 6))) (SBAR (WHNP (WP who)) (S (VP (VBD did) (RB not)))))))))) (-RRB- -RRB-))) (CC and) (NP (VB ten) (NN control) (NNS subjects))) (VP (VBD were) (VP (VBN studied)))) (. .)))
(TOP (S (NP (NP (DT The) (NN number)) (CC and) (NP (NP (JJ apparent) (NN dissociation)) (ADJP (JJ constant) (PP (IN of) (NP (JJ glucocorticoid) (NN receptor)))))) (VP (VBD were) (VP (VBN measured) (S (VP (VBG using) (NP (DT a) (JJ whole-cell) (JJ binding) (NN assay)))))) (. .)))
(TOP (S (NP (NNS Results)) (VP (VBD were) (VP (VBN expressed) (PP (IN as) (NP (NP (DT a) (NN median)) (PRN (-LRB- -LRB-) (NP (JJ interquartile) (NN range)) (-RRB- -RRB-)))))) (. .)))
(TOP (NP (NP (NNS RESULTS)) (: :) (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ glucocorticoid) (NNS receptors))) (PP (IN from) (NP (NP (DT the) (CD six) (NNS nonresponders)) (, ,) (NP (CD five) (NNS responders)) (, ,) (CC and) (NP (VB ten) (JJ healthy) (NNS controls))))) (VP (VBD were) (NP (NP (CD 4922) (PRN (-LRB- -LRB-) (NN range) (, ,) (CD 4484-5643) (-RRB- -RRB-))) (, ,) (NP (NP (CD 3413)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 3183-4450))) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD 3610) (PRN (-LRB- -LRB-) (NN range) (, ,) (CD 2594-3979) (-RRB- -RRB-)) (VBG binding) (NN sites/cell)) (, ,) (ADVP (RB respectively))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ apparent) (NN dissociation)) (ADJP (JJ constant) (PP (IN of) (NP (NP (DT the) (JJ glucocorticoid) (NNS receptors)) (PP (IN from) (NP (NP (DT the) (NNS nonresponders)) (, ,) (NP (NNS responders)) (, ,) (CC and) (NP (JJ healthy) (NNS controls)))))))) (VP (VBD were) (NP (NP (CD 7.03) (PRN (-LRB- -LRB-) (NN range) (, ,) (CD 5.66-10) (-RRB- -RRB-))) (, ,) (NP (NP (CD 4.27)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (, ,) (NP (CD 4-5.13))) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD 6.18) (PRN (-LRB- -LRB-) (NN range) (, ,) (CD 5.86-6.74) (-RRB- -RRB-)) (NN nM)) (, ,) (ADVP (RB respectively)))) (. .)))
(TOP (S (NP (NNS Nonresponders)) (VP (VBD had) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (PP (ADVP (DT both)) (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ binding) (NNS sites))))) (CC and) (PP (IN in) (NP (NP (DT the) (JJ apparent) (NN dissociation)) (ADJP (JJ constant)))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS responders)) (PRN (-LRB- -LRB-) (S (S (NP (NNP P)) (VP (SYM =) (NP (CD 0.045)))) (: ;) (S (NP (NNP P)) (VP (SYM =) (NP (CD 0.029))))) (-RRB- -RRB-)))))) (. .)))
(TOP (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (DT The) (VBN increased) (NN number)) (CC and) (NP (NP (JJ apparent) (NN dissociation)) (ADJP (JJ constant) (PP (IN of) (NP (NN glucocorticoid) (NN receptor)))))) (VP (VBP are) (VP (ADVP (RB closely)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (JJ glucocorticoid) (NN therapy)))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN measurement)) (PP (IN of) (NP (NP (NP (DT the) (NN number)) (CC and) (NP (JJ apparent) (NN dissociation))) (ADJP (JJ constant) (PP (IN of) (NP (JJ glucocorticoid) (NN receptor))))))) (VP (MD may) (VP (VB be) (ADJP (JJ useful)) (PP (IN in) (S (VP (VBG predicting) (NP (NP (NN response)) (PP (TO to) (NP (NNS glucocorticoids))))))))) (. .)))
(TOP (NP (S (VP (VBG Switching) (NP (NNS gears)) (PP (IN during) (NP (JJ T-cell) (NN maturation))))) (: :) (NP (NP (NNS RANTES)) (CC and) (NP (JJ late) (NN transcription))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (RB much)) (VP (VBZ is) (VP (VBN understood) (PP (IN about) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN expressed) (ADVP (RB early)) (PRN (-LRB- -LRB-) (PP (IN within) (NP (CD 24) (NN h))) (-RRB- -RRB-)) (PP (IN after) (NP (NNP T-cell) (NN activation)))))))))))) (, ,) (NP (NP (JJ little))) (VP (VBZ is) (VP (VBN known) (PP (IN about) (SBAR (S (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NNS genes)))))) (VP (VBD expressed) (NP (POS ') (JJ late)))))) ('' ') (PRN (-LRB- -LRB-) (NP (QP (CD three) (CC or) (JJR more)) (NNS days)) (-RRB- -RRB-)) (ADJP (NN post-stimulation)))) (. .)))
(TOP (S (NP (NP (DT A) (JJR better) (NN understanding)) (PP (IN of) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN at) (NP (NP (DT this) (JJ important) (NN stage)) (PP (IN of) (NP (JJ T-cell) (NN maturation)))))))) (VP (MD may) (VP (VB yield) (NP (NP (JJ new) (NNS insights)) (PP (IN into) (NP (NP (JJ T-cell) (NN development)) (CC and) (NP (JJ new) (JJ immunotherapeutic) (NNS targets))))))) (. .)))
(TOP (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (JJ huGATA-3) (NN transcription) (NN factor)) (CC and) (NP (NP (CD three) (NNP GATA) (JJ regulatory) (NNS elements)) (PP (IN of) (NP (NNP HIV-1) (JJ long) (NN terminal) (NN repeat)))))) (, ,) (PP (IN by) (NP (NN surface) (NN plasmon) (NN resonance))))) (. .)))
(TOP (S (NP (NP (JJ Relative) (NNS affinities)) (PP (IN of) (NP (JJ transcriptional) (JJ regulatory) (NNS elements))) (PP (IN for) (NP (PRP$ their) (JJ respective) (NN factor)))) (VP (VBP have) (VP (VBN been) (ADVP (RB essentially)) (VP (VBN studied) (PP (IN by) (NP (NN bandshift) (NN analysis)))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (JJ real-time) (NN study)) (PP (IN of) (NP (NNP factor/DNA) (NNS interactions))) (VP (VBG using) (NP (NP (DT a) (NN surface) (NN plasmon) (NN resonance) (NN approach)) (CC and) (NP (NP (JJ further) (NN characterization)) (PP (IN of) (NP (NP (VBN recovered) (NNS proteins)) (VP (VBN involved) (PP (IN in) (NP (DT this) (NN interaction))))))))))) (. .)))
(TOP (S (PP (IN For) (NP (DT this) (NN purpose))) (, ,) (NP (NP (NP (JJ human) (NN GATA-3)) (, ,) (NP (CC either) (ADJP (ADJP (JJ recombinant)) (CC or) (PP (IN in) (NP (JJ nuclear) (NNS extracts))))) (, ,)) (CC and) (NP (NP (CD three) (JJ natural) (NNP GATA) (NNS elements)) (PP (IN of) (NP (NP (DT the) (NNP HIV-1) (JJ long) (NN terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NNS sites) (CD 1) (, ,) (CD 2) (, ,) (CC and) (CD 3)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VP (VBN chosen)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ only) (NN site) (CD 2)) (VP (VBZ is) (NP (DT a) (JJ noncanonical) (NNP GATA) (NN site))))))) (. .)))
(TOP (S (NP (NP (NP (JJ Direct) (NN analysis)) (PP (IN of) (NP (NNS sensorgrams)))) (, ,) (PP (IN with) (NP (JJ recombinant) (NN huGATA-3))) (, ,)) (VP (VBD allowed) (NP (NP (DT the) (NN comparison)) (PP (IN of) (NP (NP (NN association)) (CC and) (NP (NP (NN dissociation) (NNS profiles)) (PP (IN of) (NP (NP (DT the) (CD three) (NN DNA) (NNS regions)) (CC and) (NP (PRP$ their) (NN ranking)))))))) (PP (VBG according) (PP (TO to) (NP (PRP$ their) (JJ relative) (NNS affinities))))) (. .)))
(TOP (S (NP (DT This) (NN result)) (, ,) (S (VP (VBN confirmed) (PP (IN by) (NP (NP (NNS competitions)) (PP (IN with) (NP (DT each) (NNP GATA) (NN site))))))) (, ,) (VP (VBD demonstrated) (NP (NP (DT the) (JJR higher) (JJ relative) (NN affinity)) (PRN (-LRB- -LRB-) (ADJP (ADVP (IN at) (JJS least)) (JJ sevenfold)) (-RRB- -RRB-)) (PP (IN of) (NP (NN site) (CD 3))))) (. .)))
(TOP (S (NP (NP (NNS Interactions)) (PP (IN between) (NP (DT the) (ADJP (JJ canonical) (CC and) (JJ unique)) (NNP GATA) (NN site) (CD 3) (CC and) (JJ nuclear) (NNS extracts)))) (VP (VBD were) (ADVP (RB also)) (VP (VP (VBN studied) (PP (IN in) (NP (JJ real) (NN time)))) (CC and) (VP (VBD provided) (NP (NP (NN information)) (PP (IN on) (NP (NP (PRP$ its) (NX (NX (NN association)) (CC and) (NX (NN dissociation) (NNS rates)))) (PP (IN for) (NP (JJ native) (NN huGATA-3))))))))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (NP (VBD recovered) (NN protein)) (VP (VBD was) (VP (VBN identified) (PP (IN as) (NP (NP (JJ genuine) (NN huGATA-3)) (PP (IN by) (NP (NP (NNP SDS-PAGE)) (, ,) (NP (NNP Western) (VBG blotting)) (, ,) (CC and) (NP (NN bandshift) (NNS assays)))))))) (. .)))
(TOP (NP (NN Copyright) (CD 1997) (NNP Academic) (NNP Press) (. .)))
(TOP (S (NP (DT The) (NNP Epstein-Barr) (NN virus) (NN oncogene) (NN product) (NN latent) (NN membrane) (NN protein) (CD 1)) (VP (VBZ engages) (NP (DT the) (NN tumor) (NN necrosis) (NN factor) (JJ receptor-associated) (NN death) (NN domain) (NN protein)) (S (VP (TO to) (VP (VP (VB mediate) (NP (NN B) (NN lymphocyte) (NN growth) (NN transformation))) (CC and) (VP (VBP activate) (NP (NNP NF-kappaB))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNP Epstein-Barr) (NN virus) (NN latent) (NN membrane) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (CD LMP1)) (-RRB- -RRB-))) (VP (VBZ is) (ADJP (JJ essential)) (PP (IN for) (NP (NP (DT the) (NN transformation)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN into) (NP (JJ lymphoblastoid) (NN cell) (NNS lines)))))) (. .)))
(TOP (S (NP (JJ Previous) (NNS data)) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (DT a) (NN model) (SBAR (IN that) (S (NP (NNP LMP1)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB constitutively) (VBN activated)) (NN receptor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ transduces) (NP (NP (NNS signals)) (PP (IN for) (NP (NP (NN transformation)) (PP (IN through) (NP (PRP$ its) (JJ carboxyl-terminal) (JJ cytoplasmic) (NN tail))))))))))))))))) (. .)))
(TOP (S (NP (NP (CD One) (NN transformation) (NN effector) (NN site)) (PRN (-LRB- -LRB-) (NP (CD TES1)) (-RRB- -RRB-)) (, ,) (VP (VBN located) (PP (IN within) (NP (NP (DT the) (FW membrane) (FW proximal) (CD 45) (NNS residues)) (PP (IN of) (NP (DT the) (JJ cytoplasmic) (NN tail)))))) (, ,)) (VP (ADVP (RB constitutively)) (VBZ engages) (SBAR (S (NP (NN tumor) (NNS necrosis)) (VP (VBP factor) (NP (JJ receptor-associated) (NNS factors)))))) (. .)))
(TOP (S (S (NP (NP (NNS Signals)) (PP (IN from) (NP (NNP TES1)))) (VP (VBP are) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB drive) (NP (NP (JJ initial) (NN proliferation)) (PP (IN of) (NP (JJ infected) (VBG resting) (NN B) (NNS lymphocytes)))))))))) (, ,) (CC but) (S (NP (RBS most) (JJ lymphoblastoid) (NNS cells)) (VP (VBN infected) (PP (IN with) (NP (NP (DT a) (NN virus)) (SBAR (WHNP (WDT that)) (S (VP (VBZ does) (RB not) (VP (VB express) (SBAR (S (NP (NP (DT the) (CD 155) (NNS residues)) (PP (IN beyond) (NP (NNP TES1)))) (VP (VBP fail) (S (VP (TO to) (VP (VB grow) (PP (IN as) (NP (JJ long-term) (NN cell) (NNS lines))))))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB now)) (VP (VBP find) (SBAR (IN that) (S (S (VP (VBG mutating) (NP (CD two) (NNS tyrosines)) (PP (TO to) (NP (NP (DT an) (NN isoleucine)) (PP (IN at) (NP (NP (DT the) (NN carboxyl) (NN end)) (PP (IN of) (NP (DT the) (JJ cytoplasmic) (NN tail))))))))) (VP (NNS cripples) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP EBV))) (S (VP (TO to) (VP (VB cause) (NP (JJ lymphoblastoid) (NN cell)) (NP (NN outgrowth)))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG marking) (NP (NP (DT a) (JJ second) (NN transformation) (NN effector) (NN site)) (, ,) (NP (NNP TES2))))))))) (. .)))
(TOP (S (NP (DT A) (NN yeast) (JJ two-hybrid) (NN screen)) (VP (VBD identified) (NP (NP (CD TES2) (VBG interacting) (NNS proteins)) (, ,) (PP (VBG including) (NP (NP (DT the) (NN tumor) (NN necrosis) (NN factor) (JJ receptor-associated) (NN death) (NN domain) (NN protein)) (PRN (-LRB- -LRB-) (NP (NNP TRADD)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP (NNP TRADD)) (VP (VBD was) (NP (NP (DT the) (JJ only) (NN protein)) (SBAR (WHNP (WDT that)) (S (VP (VBD interacted) (PP (PP (IN with) (NP (JJ wild-type) (NNP TES2))) (CC and) (RB not) (PP (IN with) (NP (JJ isoleucine-mutated) (NNP TES2))))))))) (. .)))
(TOP (S (NP (NNS TRADD)) (VP (VBN associated) (PP (PP (IN with) (NP (JJ wild-type) (NNP LMP1))) (CC but) (RB not) (PP (IN with) (NP (NP (NP (JJ isoleucine-mutated) (NNP LMP1)) (PP (IN in) (NP (JJ mammalian) (NNS cells)))) (, ,) (CC and) (NP (NP (NNP TRADD)) (VP (ADVP (RB constitutively)) (VBN associated) (PP (IN with) (NP (NNP LMP1))) (PP (IN in) (NP (JJ EBV-transformed) (NNS cells))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN transfection) (NNS assays))) (, ,) (NP (NNP TRADD) (CC and) (NNP TES2)) (VP (ADVP (RB synergistically)) (VBD mediated) (NP (JJ high-level) (NNP NF-kappaB) (NN activation))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP LMP1)) (VP (VBZ appropriates) (NP (NNP TRADD)) (S (VP (TO to) (VP (VB enable) (SBAR (S (NP (JJ efficient) (JJ long-term) (JJ lymphoblastoid) (NN cell)) (VP (NN outgrowth))))))))))) (. .)))
(TOP (S (NP (JJ High-level) (NNP NF-kappaB) (NN activation)) (ADVP (RB also)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (JJ critical) (NN component)) (PP (IN of) (NP (JJ long-term) (NN outgrowth)))))))) (. .)))
(TOP (NP (NP (NP (NN Modulation)) (PP (IN of) (NP (NP (JJ mRNA) (NN expression)) (PP (IN of) (NP (DT a) (JJ novel) (JJ human) (JJ myeloid-selective) (NN CCAAT/enhancer) (VBG binding) (NN protein) (NN gene)))))) (PRN (-LRB- -LRB-) (NP (NNP C/EBP) (NN epsilon)) (-RRB- -RRB-)) (. .)))
(TOP (S (NP (NNP Human) (NNP C/EBP) (NN epsilon)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB newly) (VBN cloned)) (NN gene) (VBG coding)) (PP (IN for) (NP (NP (DT a) (NNP CCAAT/enhancer) (JJ binding) (NN protein)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ myeloid) (NN differentiation)))))))))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNS levels)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA)))) (VP (VBD were) (VP (ADVP (RB markedly)) (VBN increased) (PP (IN in) (NP (NP (CD NB4) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ promyelocytic) (NN leukemia) (NN line)) (-RRB- -RRB-)))) (, ,) (SBAR (IN because) (S (NP (PRP they)) (VP (VBD were) (VP (VBN induced) (PP (IN by) (NP (NP (JJ 9-cis) (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (JJ 9-cis) (NNP RA)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VB differentiate) (PP (IN towards) (NP (NNS granulocytes))))))))))))))) (. .)))
(TOP (S (S (NP (NP (NNP Accumulation)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA)))) (VP (VBD occurred) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (NP (CD 1) (NN hour)))) (PP (IN after) (NP (NP (NN exposure)) (PP (IN of) (NP (CD NB4) (NNS cells))) (PP (TO to) (NP (NP (JJ 9-cis) (NNP RA)) (PRN (-LRB- -LRB-) (NP (CD 5)) (VP (LS x) (NP (NNP 10-LRB--7-RRB-) (NNP mol/L))) (-RRB- -RRB-)))))))) (: ;) (CC and) (S (PP (IN at) (NP (CD 48) (NNS hours))) (, ,) (NP (NNS levels)) (VP (VBD were) (VP (VBN increased) (PP (IN by) (ADJP (JJ 5.1-fold)))))) (. .)))
(TOP (S (S (NP (JJ Dose-response) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNP 10-LRB--7-RRB-)) (PP (TO to) (NP (NNP 10-LRB--6-RRB-) (NNP mol/L)))) (VP (VBZ 9-cis) (SBAR (S (NP (NP (NNP RA)) (PRN (-LRB- -LRB-) (NP (CD 12) (NNS hours)) (-RRB- -RRB-))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ peak) (NNS levels)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA))))))))))))) (: ;) (CC but) (S (NP (RB even) (NNP 10-LRB--10-RRB-) (NNP mol/L)) (VP (VBZ 9-cis) (NP (NP (NNP RA) (VBN increased) (NNS levels)) (PP (IN of) (NP (DT these) (NNS transcripts)))))) (. .)))
(TOP (S (S (NP (NP (CD NB4) (NNS cells)) (ADJP (JJ pulse-exposed) (PRN (-LRB- -LRB-) (NP (CD 30) (NNS minutes)) (-RRB- -RRB-)) (PP (TO to) (NP (NP (JJ all-trans) (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP ATRA)) (-RRB- -RRB-)) (, ,) (VP (VBN washed)) (, ,) (CC and) (ADJP (VBN cultured) (PRN (-LRB- -LRB-) (NP (CD 3) (NNS days)) (-RRB- -RRB-)) (PP (IN with) (NP (DT either) (NP (NP (NN dimethylsulfoxide)) (PRN (-LRB- -LRB-) (NP (NNP DMSO)) (-RRB- -RRB-))) (CC or) (NP (NP (NN hexamethylene) (NN bisacetamide)) (PRN (-LRB- -LRB-) (NP (NNP HMBA)) (-RRB- -RRB-)))))))))) (VP (VBD had) (NP (NP (NP (DT a) (JJ prominent) (NN increase)) (PP (IN in) (NP (NP (NNS levels)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA)))))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ granulocytic) (NN differentiation))))))) (, ,) (CC but) (S (NP (NP (NN exposure)) (PP (TO to) (NP (NP (DT either) (NNP DMSO) (CC or) (NNP HMBA)) (ADVP (RB alone))))) (VP (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN base) (NNS levels)) (PP (IN of) (NP (NNP C/EBP) (NN epsilon)))))) (CC and) (VP (VBD did) (RB not) (VP (VB induce) (NP (NN differentiation)))))) (. .)))
(TOP (NP (NP (NN Macrophage-differentiation)) (PP (IN of) (NP (NP (CD NB4) (JJ reduced) (NNS levels)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA))))) (. .)))
(TOP (S (NP (NP (JJ Nuclear) (JJ run-off) (NNS assays)) (CC and) (NP (NN half-life) (NNS studies))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN accumulation)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA))) (PP (IN by) (NP (CD 9-cis) (NNP RA)))) (VP (VBD was) (ADJP (JJ due) (PP (TO to) (NP (JJ enhanced) (NN transcription)))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (DT this) (NNP C/EBP) (NNP epsilon) (NNP mRNA) (NN accumulation)) (VP (VBD did) (RB not) (VP (VB require) (NP (NP (NN synthesis)) (PP (IN of) (NP (JJ new) (NN protein) (NNS factors)))) (SBAR (IN because) (S (NP (JJ 9-cis) (NNP RA)) (VP (VBD induced) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA)) (S (VP (NN accumulation) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ new) (NN protein) (NN synthesis)))))))))))) (. .)))
(TOP (S (NP (NNP ATRA)) (ADVP (RB also)) (VP (VBD induced) (NP (NP (NN expression)) (PP (IN of) (NP (NNP C/EBP) (NN epsilon) (NN protein)))) (PP (IN in) (NP (CD NB4) (NNS cells))) (, ,) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NNP Western) (VBG blotting))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon))) (PP (IN in) (NP (CD 9-cis) (JJ RA-mediated) (JJ granulocytic) (NN differentiation))))))) (, ,) (NP (NP (DT the) (JJ DMSO-induced) (NN differentiation)) (PP (IN of) (NP (NP (NN HL-60) (NNS cells)) (PP (IN down) (NP (DT the) (JJ granulocytic) (NN pathway)))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ initial) (NN reduction)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA) (NNS levels))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN summary))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN discovered) (SBAR (DT that) (S (NP (NP (NN expression)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA)))) (VP (VBZ is) (VP (ADVP (RB markedly)) (VBN enhanced) (SBAR (IN as) (S (NP (DT the) (NNP NB4) (NNS promyelocytes)) (VP (VBP are) (VP (VBN induced) (PP (IN by) (NP (NNS retinoids))) (S (VP (TO to) (VP (VB differentiate) (PP (IN towards) (NP (NNS granulocytes)))))))))))))))) (. .)))
(TOP (S (NP (NP (DT This) (NN induction)) (PP (IN of) (NP (NNP C/EBP) (NNP epsilon) (NNP mRNA) (NN expression)))) (VP (VP (VBZ is) (VP (ADVP (RB transcriptionally)) (VBN mediated))) (CC and) (VP (VBZ occurs) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NN synthesis)) (PP (IN of) (NP (JJ additional) (NN protein) (NNS factors))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP suspect) (SBAR (IN that) (S (NP (DT the) (NNP C/EBP) (NN epsilon) (NN promoter/enhancer)) (VP (VBZ contains) (NP (NP (DT a) (JJ retinoic) (JJ acid-response) (NN element)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (ADVP (RB directly)) (VBN stimulated) (PP (IN by) (NP (NNS retinoids)))))))))))) (. .)))
(TOP (NP (NP (NN Expression)) (PP (IN of) (NP (NP (JJ c-fos) (NNS correlates)) (PP (IN with) (NP (NP (JJ IFN-alpha) (NN responsiveness)) (PP (IN in) (NP (NNP Philadelphia) (NN chromosome) (JJ positive) (JJ chronic) (JJ myelogenous) (NN leukemia))))))) (. .)))
(TOP (S (NP (DT This) (NN study)) (VP (VBZ evaluates) (NP (NP (PRN (-LRB- -LRB-) (FW i) (-RRB- -RRB-)) (JJ constitutive) (NNS levels)) (PP (IN of) (NP (NP (NP (NN oncogene) (CC and) (NN p53) (NNS transcripts)) (PP (IN in) (NP (JJ chronic) (NN phase) (NNP CML) (NNS patients)))) (CC and) (NP (PRN (-LRB- -LRB-) (FW ii) (-RRB- -RRB-)) (NP (PRP$ their) (NNS modulations)) (JJ subsequent))))) (PP (TO to) (PP (IN in) (NP (NP (NN vivo) (NN therapy)) (PP (IN with) (NP (JJ rIFN-alpha) (NN 2c))))))) (. .)))
(TOP (S (NP (NP (NP (JJ Peripheral) (NN blood) (NN mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NN pbmc) (-RRB- -RRB-))) (CC and) (NP (NP (NN bone) (NN marrow) (NNS cells)) (PP (IN of) (NP (CD 26) (NNS patients))))) (VP (VBD were) (VP (VBN examined) (PP (IN for) (NP (NP (NNS c-fos)) (, ,) (NP (JJ c-myc)) (, ,) (NP (NN p53)) (CC and) (NP (DT the) (JJ hybrid) (NN bcr/abl) (NN mRNA) (NNS levels)))))) (. .)))
(TOP (S (NP (NNS Results)) (VP (VBD indicated) (SBAR (IN that) (S (S (NP (WHADVP (-LRB- -LRB-) (FW i) (-RRB- -RRB-)) (NN constitutive) (VBZ c-fos) (NN transcript) (NNS levels)) (VP (VP (VBP are) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB subsequently)) (VBG responding) (PP (TO to) (NP (JJ IFN-alpha) (NN therapy)))))) (PRN (-LRB- -LRB-) (FRAG (FW p) (NP (FW &lt;) (CD 0.01))) (-RRB- -RRB-))) (CC and) (VP (ADVP (RB positively)) (JJ correlated) (PP (IN with) (NP (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NNS lymphocytes)))) (PRN (-LRB- -LRB-) (S (NP (SYM r)) (VP (SYM =) (NP (CD 0.6895)))) (, ,) (NP (FW p) (FW &lt;) (CD 0.01)) (-RRB- -RRB-))))) (CC and) (VP (ADVP (RB negatively)) (PP (IN with) (NP (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NP (JJ immature) (NNS cells)) (PRN (-LRB- -LRB-) (S (NP (SYM r)) (VP (SYM =) (NP (CD -0.568)))) (, ,) (NP (FW p) (FW &lt;) (CD 0.01)) (-RRB- -RRB-)) (VP (VBN contained) (PP (IN in) (NP (NP (DT the) (JJ pbmc) (NNS preparations)) (VP (VBN tested)))))))) (, ,) (NP (PRN (-LRB- -LRB-) (NN ii) (-RRB- -RRB-)) (NP (NP (JJ constitutive) (NNP mRNA) (NNS levels)) (PP (IN of) (NP (DT the) (JJ hybrid) (NN bcr/abl))))) (, ,))) (SBAR (S (NP (NN c-myc) (CC and) (NN p53)) (VP (VP (VBP are) (VP (ADVP (RB positively)) (VBN correlated) (PP (IN with) (NP (DT each) (JJ other))))) (, ,) (CC but) (VP (VBD failed) (S (VP (TO to) (VP (VB relate) (PP (TO to) (NP (NN disease) (NNS parameters))))))))))))) (, ,) (CC and) (S (PRN (-LRB- -LRB-) (NP (NN iii)) (-RRB- -RRB-)) (ADJP (ADJP (JJ acute) (CC and) (JJ chronic)) (PP (IN in) (NP (NP (NN vivo) (NN exposure)) (PP (TO to) (NP (NNP IFN-alpha)))))) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (NN upregulation)) (PP (IN of) (NP (NNS c-fos)))) (CC and) (NP (NP (NN downregulation)) (PP (IN of) (NP (NP (JJ c-myc) (NNP mRNA) (NNS levels)) (PP (IN in) (NP (NN responder) (NNS patients)))))))))))))) (. .)))
(TOP (NP (NP (JJ Paternal) (NN expression)) (PP (IN of) (NP (CD WT1))) (PP (IN in) (NP (JJ human) (NNS fibroblasts) (CC and) (NNS lymphocytes))) (. .)))
(TOP (S (NP (NP (NP (DT The) (NNP Wilms) (POS ')) (NN tumor) (NN suppressor) (NN gene)) (PRN (-LRB- -LRB-) (NP (CD WT1)) (-RRB- -RRB-))) (VP (VBD was) (ADVP (RB previously)) (VP (VBN identified) (PP (IN as) (S (VP (VBG being) (VP (VBN imprinted))))) (, ,) (PP (IN with) (NP (NP (JJ frequent) (JJ maternal) (NN expression)) (PP (IN in) (NP (NP (JJ human) (NN placentae)) (CC and) (NP (JJ fetal) (NNS brains)))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (JJ allele-specific) (NN expression)) (PP (IN of) (NP (NNP WT1))) (PP (IN in) (NP (JJ cultured) (JJ human) (NNS fibroblasts)))) (PP (IN from) (NP (CD 15) (NNS individuals)))) (. .)))
(TOP (S (S (NP (QP (CD Seven) (IN of) (CD 15)) (NN fibroblast) (NNS lines)) (VP (VBD were) (ADJP (JJ heterozygous) (PP (IN for) (NP (JJ polymorphic) (NNS alleles)))))) (, ,) (CC and) (S (NP (DT the) (NN expression) (NNS patterns)) (VP (VBD were) (NP (ADJP (ADJP (JJ variable)) (, ,) (ADJP (FW i.e.) (, ,) (JJ equal) (, ,) (ADJP (JJ unequal) (CC or) (JJ monoallelic)))) (JJ paternal) (NN expression)) (PP (IN in) (NP (NP (CD three)) (, ,) (NP (CD two)) (CC and) (NP (CD two) (NNS cases)))) (, ,) (ADVP (RB respectively)))) (. .)))
(TOP (S (NP (NP (JJ Exclusive) (JJ paternal) (NN expression)) (PP (IN of) (NP (NNP WT1)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN shown) (PP (IN in) (NP (JJ non-cultured) (JJ peripheral) (NNS lymphocytes))) (PP (IN from) (NP (DT the) (JJ latter) (CD two) (NNS individuals))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ allele-specific) (NN expression) (NNS profiles)) (PP (IN of) (NP (NP (JJ other) (JJ imprinted) (NNS genes)) (, ,) (NP (NNP IGF2)) (CC and) (NP (NNP H19)))) (, ,) (PP (IN on) (NP (JJ human) (NN chromosome) (CD 11)))) (VP (VBD were) (ADJP (ADJP (JJ constant)) (CC and) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (JJ other) (NNS tissues)))))))) (. .)))
(TOP (S (NP (NP (PRP$ Our) (JJ unexpected) (NNS observations)) (PP (IN of) (NP (NP (ADJP (JJ paternal) (CC or) (JJ biallelic)) (NN expression)) (PP (IN of) (NP (NNP WT1))) (PP (IN in) (NP (NNS fibroblasts) (CC and) (NNS lymphocytes))))) (, ,) (ADVP (RB together) (PP (IN with) (NP (NP (DT the) (JJ previous) (NNS findings)) (PP (IN of) (NP (NP (JJ maternal) (CC or) (JJ biallelic) (NN expression)) (PP (IN in) (NP (NN placentae) (CC and) (NNS brains)))))))) (, ,)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ allele-specific) (JJ regulatory) (NN system)) (PP (IN of) (NP (NNP WT1)))) (VP (VP (VBZ is) (ADJP (JJ unique))) (CC and) (VP (MD may) (VP (VB be) (VP (VBN controlled) (PP (IN by) (NP (DT a) (JJ putative) (ADJP (NN tissue-) (CC and) (JJ individual-specific)) (NN modifier)))))))))) (. .)))
(TOP (S (NP (NP (JJ Aberrant) (NN splicing)) (PP (IN of) (NP (DT the) (NNP TSG101) (CC and) (NNP FHIT) (NNS genes)))) (VP (VBZ occurs) (ADVP (RB frequently)) (PP (PP (IN in) (NP (JJ multiple) (NNS malignancies))) (CC and) (PP (IN in) (NP (NP (JJ normal) (NNS tissues)) (CC and) (NP (NP (NNS mimics) (NNS alterations)) (VP (ADVP (RB previously)) (VBN described) (PP (IN in) (NP (NNS tumours))))))))) (. .)))
(TOP (S (NP (NP (JJ Intragenic) (NNS deletions)) (PP (IN of) (NP (NP (NNP TSG101)) (, ,) (NP (NP (DT the) (JJ human) (NN homolog)) (PP (IN of) (NP (NP (DT a) (NN mouse) (NN gene)) (PRN (-LRB- -LRB-) (NP (CD tsg101)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBZ acts) (S (VP (TO to) (VP (VB suppress) (NP (JJ malignant) (NN cell) (NN growth))))))))))) (, ,)))) (VP (VBD were) (VP (VBN reported) (PP (IN in) (NP (JJ human) (NN breast) (NNS tumours))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD screened) (NP (NNP TSG101)) (PP (IN for) (NP (NP (NP (JJ somatic) (NNS mutations)) (PP (IN in) (NP (NNP DNA) (CC and) (NNP RNA) (NNS samples)))) (VP (VBD isolated) (PP (IN from) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ common) (JJ human) (NNS malignancies)) (, ,) (NP (JJ EBV-immortalised) (NNS B-cells)) (, ,) (CC and) (NP (JJ normal) (NN lung) (NN parenchyma)))))))))) (. .)))
(TOP (S (NP (NP (NNP Intragenic) (NNP TSG101) (NNS deletions)) (PP (IN in) (NP (NNP RNA) (NNS transcripts)))) (VP (VBD were) (ADVP (RB frequently)) (VP (VBN found) (PP (IN in) (NP (NP (DT all) (NNS types)) (PP (IN of) (NP (NNS samples))))))) (. .)))
(TOP (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NNP DNA)))) (VP (VBD failed) (S (VP (TO to) (VP (VB show) (NP (NP (JJ genomic) (NNS rearrangements)) (ADJP (JJ corresponding) (PP (TO to) (NP (NP (NNS transcripts)) (VP (VBG containing) (NP (NP (NNS deletions)) (PP (IN in) (NP (DT the) (JJ same) (NNS samples))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNS breakpoints)) (PP (IN of) (NP (JJS most) (NN transcript) (NNS deletions)))) (VP (VBP coincide) (PP (IN with) (NP (ADJP (JJ genuine) (CC or) (JJ cryptic)) (NN splice) (NN site) (NNS sequences))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (PRP they)) (VP (VBP result) (PP (IN from) (NP (ADJP (JJ alternative) (CC or) (JJ aberrant)) (NN splicing))))))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ similar) (NN spectrum)) (PP (IN of) (NP (NN transcript) (NNS deletions)))) (VP (VBZ has) (ADVP (RB previously)) (VP (VBN been) (VP (VBN described) (PP (IN in) (NP (DT the) (JJ putative) (NN tumour) (NN suppressor) (NN gene) (NNP FHIT)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VP (VBD analysed) (NP (NNP FHIT)) (PP (IN in) (NP (NP (DT the) (JJ same) (NN series)) (PP (IN of) (NP (NNP RNA) (NNS samples)))))) (CC and) (VP (VBD detected) (NP (VBN truncated) (NNP FHIT) (NNS transcripts)) (ADVP (RB frequently)) (PP (IN in) (NP (DT both) (NN tumour) (CC and) (JJ normal) (NNS tissues))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS transcripts)) (PP (IN from) (NP (NP (NNP TSG101)) (, ,) (NP (NNP FHIT)) (CC and) (NP (CD seven) (JJ other) (NNS genes))))) (VP (VBD were) (VP (VBN analysed) (PP (IN in) (NP (NNP RNA))) (S (VP (VBD isolated) (PP (IN from) (NP (JJ normal) (JJ peripheral) (NN blood) (NNS lymphocytes))))))) (. .)))
(TOP (S (S (NP (JJ Large) (NNP TSG101) (CC and) (NNP FHIT) (JJ intragenic) (NN transcript) (NNS deletions)) (VP (VBD were) (VP (VBN detected)))) (CC and) (S (NP (DT these)) (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (JJ predominant) (NN transcript)) (PP (IN in) ('' ') (NP (NP (VBN aged) (POS ')) (NNS lymphocytes))))))))) (. .)))
(TOP (S (NP (JJ Similar) (NNS alterations)) (VP (VBD were) (RB not) (VP (VBN detected) (PP (IN in) (NP (NP (NNS transcripts)) (PP (IN of) (NP (NP (DT the) (JJ other) (NNS genes)) (SBAR (WHNP (WDT which)) (S (VP (VBD were) (VP (VBN analysed))))))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS findings)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (VBN truncated) (NNP TSG101) (CC and) (NNP FHIT) (NNS transcripts)) (VP (VBP are) (VP (ADVP (RB commonly)) (VBN detected) (PP (IN in) (NP (DT both) (ADJP (JJ normal) (CC and) (JJ malignant)) (NNS tissues))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT a) (JJ significant) (NN fraction)) (PP (IN of) (NP (DT these)))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (JJ aberrant) (NN splicing))))))))))))) (. .)))
(TOP (S (SBAR (IN While) (S (NP (PRP we)) (VP (MD can) (RB not) (VP (VB exclude) (SBAR (IN that) (S (NP (NP (NNS alterations)) (PP (IN in) (NP (NNP TSG101) (CC and) (NNP FHIT)))) (VP (VBP occur) (PP (IN during) (NP (NN cancer) (NN development)))))))))) (, ,) (NP (PRP$ our) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN in) (NP (DT this) (NN context))) (NP (DT the) (ADJP (RB commonly) (JJ observed)) (NN transcript) (NNS abnormalities)) (VP (VBP are) (ADJP (JJ misleading)))))) (. .)))
(TOP (S (NP (VBN Impaired) (NN cortisol)) (VP (VBG binding) (PP (TO to) (NP (NP (JJ glucocorticoid) (NNS receptors)) (PP (IN in) (NP (JJ hypertensive) (NNS patients)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD compared) (NP (NP (JJ glucocorticoid) (NN receptor) (VBG binding) (NNS characteristics)) (CC and) (NP (NP (JJ glucocorticoid) (NN responsiveness)) (PP (IN of) (NP (NP (JJ human) (NN mononuclear) (NNS leukocytes)) (PRN (-LRB- -LRB-) (NP (NNP HML)) (-RRB- -RRB-)))))) (PP (IN from) (NP (NP (JJ hypertensive) (NNS patients)) (CC and) (NP (VBN matched) (JJ normotensive) (NNS volunteers))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD considered) (NP (NP (NNS associations)) (PP (IN of) (NP (DT these) (NNS variables)))) (PP (IN with) (NP (NP (NN plasma) (NN renin) (NN activity)) (, ,) (NP (NN aldosterone)) (, ,) (NP (NN cortisol)) (, ,) (NP (NN corticotropin)) (, ,) (CC and) (NP (JJ electrolyte) (NNS concentrations))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD calculated) (NP (NP (NP (VBG binding) (NN affinity)) (PRN (-LRB- -LRB-) (NP (NNP Kd)) (: ;) (NP (NNP nmol/L)) (-RRB- -RRB-))) (CC and) (NP (NP (NN capacity)) (PRN (-LRB- -LRB-) (NP (NNP Bmax)) (: ;) (NP (NNP sites/cell)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN dexamethasone) (CC and) (NN cortisol)) (PP (IN from) (NP (NP (ADJP (RB homologous) (CC and) (JJ heterologous)) (NN competition) (NNS curves)) (PP (IN for) (NP (NP (NP (JJ specific) (JJ -LSB-3H-RSB-dexamethasone) (JJ binding) (NNS sites)) (PP (IN on) (NP (NNP HML)))) (VP (VBD isolated) (PP (IN from) (NP (NP (DT the) (NN blood)) (PP (IN of) (NP (NP (JJ normotensive) (NNS volunteers)) (CC and) (NP (NP (NNS subjects)) (PP (IN with) (NP (JJ essential) (NN hypertension)))))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Glucocorticoid) (NN responsiveness)) (PP (IN of) (NP (NNP HML)))) (VP (VBD was) (VP (VBN evaluated) (PP (IN as) (NP (NP (CD IC50) (NNS values)) (PRN (-LRB- -LRB-) (NP (NNP nmol/L)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN dexamethasone) (CC and) (NN cortisol)) (PP (IN for) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN lysozyme) (NN release))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD measured) (NP (NN plasma) (NNS hormones)) (PP (IN by) (NP (NN radioimmunoassay)))) (. .)))
(TOP (S (NP (NP (NN Kd) (NNS values)) (PRN (-LRB- -LRB-) (NP (JJ mean+/-SE)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NN cortisol)) (PP (IN in) (NP (NNP HML))) (PP (IN of) (NP (JJ hypertensive) (NNS patients)))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (PP (IN than) (PP (IN in) (NP (NP (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NP (CD 24.6+/-2.4)) (PP (IN versus) (NP (CD 17.5+/-1.7) (NNP nmol/L)))) (, ,) (S (NP (NNP P)) (VP (VBD &lt;) (NP (CD .04)))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP (NP (NP (JJ Binding) (NN capacity)) (PRN (-LRB- -LRB-) (NP (NP (CD 4978+/-391)) (PP (IN versus) (NP (CD 4131+/-321) (NN sites/cell)))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (JJ Kd) (NNS values)) (PP (IN for) (NP (NN dexamethasone)))) (PRN (-LRB- -LRB-) (NP (NP (CD 6.7+/-0.5)) (PP (IN versus) (NP (CD 5.7+/-0.3) (NNP nmol/L)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP IC50) (NNS values)) (PP (IN for) (NP (NP (NP (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.4+/-0.3)) (PP (IN versus) (NP (CD 3.1+/-0.2) (NNP nmol/L)))) (-RRB- -RRB-))) (CC and) (NP (JJ cortisol))) (PRN (-LRB- -LRB-) (NP (NP (CD 12.2+/-1.6)) (PP (IN versus) (NP (CD 9.5+/-0.3) (NNP nmol/L)))) (-RRB- -RRB-)))))) (VP (VBD were) (RB not) (ADJP (RB significantly) (JJ different))) (. .)))
(TOP (S (NP (NP (NNPS Patients)) (PP (IN with) (NP (NN renin) (NNS values))) (NP (NP (QP (JJR less) (IN than) (CD 0.13)) (NN ng) (NN angiotensin) (NNP I/L)) (PP (IN per) (NP (JJ second))))) (VP (VBD were) (ADJP (ADJP (ADVP (RB markedly) (RBR less)) (JJ sensitive) (S (VP (TO to) (VP (VB cortisol))))) (PP (IN than) (NP (NP (DT those)) (PP (IN with) (NP (JJR higher) (NNS values))))))) (. .)))
(TOP (S (NP (NP (NP (DT Both) (NNP Kd)) (PRN (-LRB- -LRB-) (NP (NP (CD 30.3+/-2.5)) (PP (IN versus) (NP (CD 19.2+/-2.4) (NNP nmol/L)))) (-RRB- -RRB-))) (CC and) (NP (NP (CD IC50) (NNS values)) (PRN (-LRB- -LRB-) (NP (NP (CD 15.5+/-1.8)) (PP (IN versus) (NP (CD 8.9+/-1.2) (NNP nmol/L)))) (-RRB- -RRB-)) (PP (IN for) (NP (NN cortisol))))) (VP (VBD were) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJR lower) (NN renin) (NNS values)) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD &lt;) (NP (CD .03)))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP (NP (JJ Other) (NNS variables)) (, ,) (PP (VBG including) (NP (NP (NN plasma) (NN hormone)) (CC and) (NP (NP (NN electrolyte) (NNS values)) (CC and) (NP (NP (VBG binding) (NNS characteristics)) (PP (IN for) (NP (NN dexamethasone))))))) (, ,)) (VP (VBD were) (RB not) (ADJP (JJ different))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN cortisol)) (VP (VBG binding) (PP (TO to) (NP (JJ glucocorticoid) (NN receptor))))) (VP (VBZ is) (ADJP (RB slightly) (VBN impaired)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ essential) (NN hypertension))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN vivo))) (, ,) (NP (DT this)) (VP (MD could) (VP (VB lead) (PP (TO to) (NP (NP (JJ inappropriate) (VBG binding)) (PP (IN of) (NP (NN cortisol))) (PP (TO to) (NP (JJ mineralocorticoid) (NNS receptors))))))) (. .)))
(TOP (S (ADVP (RB Hence)) (, ,) (NP (NP (VBD decreased) (NN sensitivity)) (PP (TO to) (NP (NN cortisol)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NN renin) (NN suppression))))) (. .)))
(TOP (S (NP (DT This) (NN hypothesis)) (VP (VBZ is) (VP (VBN supported) (PP (IN by) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NN hypertension)) (CC and) (NP (NP (JJ low) (NN renin) (NN activity)) (, ,) (SBAR (WHNP (WDT which)) (S (NP (NNS others)) (VP (VBP have) (VP (VBN described) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ primary) (JJ glucocorticoid) (NN resistance))))) (PP (JJ due) (TO to) (NP (NP (NNS mutations)) (PP (IN of) (NP (DT the) (JJ glucocorticoid) (NN receptor)))))))))))))))) (. .)))
(TOP (S (NP (NP (NN Repression)) (PP (IN of) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1))) (PP (IN through) (NP (NP (DT the) (JJ novel) (NN cooperation)) (PP (IN of) (NP (NP (JJ human) (NNS factors) (NNP YY1)) (CC and) (NP (NNP LSF) (NNP -LSB-) (JJ published) (NN erratum))))))) (VP (VBZ appears) (PP (IN in) (NP (NNP J) (NNP Virol))) (NP (NP (CD 1998) (NNP Feb)) (: ;) (NP (NP (CD 72)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (: :) (NP (CD 1709) (NN -RSB-))))))
(TOP (S (NP (NP (DT A) (NN subpopulation)) (PP (IN of) (NP (NP (ADJP (RB stably) (JJ infected)) (NNP CD4+) (NNS cells)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG producing) (NP (NN virus)) (PP (IN upon) (NP (NN stimulation)))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN identified) (PP (IN in) (NP (NP (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP HIV)) (-RRB- -RRB-)) (NP (NP (JJ -positive) (NNS individuals)) (PRN (-LRB- -LRB-) (NP (NNP T.-W.Chun)) (, ,) (NP (NNP D.Finzi)) (, ,) (NP (NNP J.Margolick)) (, ,) (NP (NNP K.Chadwick)) (, ,) (NP (NNP D.Schwartz)) (, ,) (CC and) (NP (NP (NNP R.F.Siliciano)) (, ,) (NP (NNP Nat.Med.1))) (: :) (NP (NP (CD 1284-1290)) (, ,) (NP (CD 1995)))))))))) (-RRB- -RRB-) (. .)))
(TOP (S (NP (NP (JJ Few) (NN host) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (ADVP (RB directly)))))) (VP (VP (VBP limit) (NP (NNP HIV-1) (NN transcription))) (CC and) (VP (MD could) (VP (VB support) (SBAR (S (NP (NP (DT this) (NN state)) (PP (IN of) (NP (JJ nonproductive) (NNP HIV-1) (NN infection)))) (VP (VBP have) (VP (VBN been) (VP (VBN described))))))))) (. .)))
(TOP (S (NP (NP (CD YY1)) (, ,) (NP (DT a) (ADJP (RB widely) (VBN distributed)) (JJ human) (NN transcription) (NN factor)) (, ,)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NNP HIV-1) (JJ long) (NN terminal) (NN repeat) (PRN (-LRB- -LRB-) (NNP LTR) (-RRB- -RRB-)) (NN transcription) (CC and) (NN virus) (NN production))))))) (. .)))
(TOP (S (S (NP (NP (NNP LSF)) (PRN (-LRB- -LRB-) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP (NNP LBP-1) (, ,) (NNP UBP) (, ,) (CC and) (NN CP-2)))) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB repress) (NP (NNP LTR) (NN transcription)) (PP (IN in) (NP (NN vitro)))))))))) (, ,) (CC but) (S (NP (NP (JJ transient) (NN expression)) (PP (IN of) (NP (NNP LSF)))) (VP (VBZ has) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NNP LTR) (NN activity)) (PP (IN in) (NP (NN vivo)))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP report) (SBAR (IN that) (S (NP (DT both) (NNP YY1) (CC and) (NNP LSF)) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (DT a) (NN complex)) (SBAR (WHNP (WDT that)) (S (VP (VBZ recognizes) (NP (NP (DT the) (NN initiation) (NN region)) (PP (IN of) (NP (DT the) (NNP HIV-1) (NNP LTR))))))))))))))) (. .)))
(TOP (S (ADVP (RB Further)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN found) (SBAR (IN that) (S (NP (DT these) (NNS factors)) (VP (VBP cooperate) (PP (IN in) (NP (NP (DT the) (NN repression)) (PP (IN of) (NP (NP (NNP LTR) (NN expression)) (CC and) (NP (JJ viral) (NN replication))))))))))) (. .)))
(TOP (S (NP (DT This) (JJ cooperative) (NN function)) (VP (MD may) (VP (VB account) (PP (IN for) (S (NP (NP (DT the) (JJ divergent) (NNS effects)) (PP (IN of) (NP (NNP LSF)))) (ADVP (RB previously)) (VP (VBD observed) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN cooperation)) (PP (IN of) (NP (CD two) (JJ general) (JJ cellular) (NN transcription) (NNS factors)))) (VP (MD may) (VP (VB allow) (PP (IN for) (NP (NP (DT the) (JJ selective) (NN downregulation)) (PP (IN of) (NP (NNP HIV) (NN transcription))))))) (. .)))
(TOP (S (PP (IN Through) (NP (NP (DT this) (NN mechanism)) (PP (IN of) (NP (NN gene) (NN regulation))))) (, ,) (NP (NNP YY1) (CC and) (NNP LSF)) (VP (MD could) (VP (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN establishment) (CC and) (NN maintenance)) (PP (IN of) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (NNS cells))))))) (ADVP (RB stably))) (CC but) (VP (ADVP (RB nonproductively)) (VBN infected) (PP (IN with) (NP (NNP HIV-1)))))) (. .)))
(TOP (S (NP (NP (JJ Ras-related) (JJ GTP-binding) (NNS proteins)) (CC and) (NP (JJ leukocyte) (NN signal))) (VP (NN transduction)) (. .)))
(TOP (S (NP (NP (JJ Many) (NNS aspects)) (PP (IN of) (NP (NN leukocyte) (NN function)))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP (NP (DT both) (NP (ADJP (JJ heterotrimeric) (CC and) (JJ Ras-related)) (JJ GTP-binding) (NNS proteins)) (, ,) (CC but) (NP (EX there))) (VP (VBZ is) (NP (NP (JJ little) (JJ definite) (NN information)) (PP (IN about) (NP (NP (PRP$ their) (NNS roles)) (PP (IN in) (NP (NP (DT the) (JJ specialized) (NNS processes)) (VP (VBN utilized) (PP (IN by) (NP (NP (NNS leukocytes)) (PP (IN for) (NP (NN cell) (NN killing)))))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Recent) (NN progress)) (PP (IN in) (S (VP (VBG understanding) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (JJ phagocyte) (NNP NADPH) (NN oxidase))) (PP (IN by) (NP (DT the) (NNP Rac) (JJ GTP-binding) (NNS proteins)))))))) (VP (VBZ provides) (NP (NP (DT a) (NN basis)) (PP (IN for) (S (VP (VBG defining) (NP (NP (DT the) (JJ operational) (NNS characteristics)) (PP (IN of) (NP (CD one) (JJ such) (JJ phagocyte) (NN system))))))))) (. .)))
(TOP (S (NP (NP (PRP It))) (VP (VBZ is) (ADJP (JJ clear)) (PP (IN from) (NP (NP (JJ various) (NNS studies)) (SBAR (WHNP (IN that)) (S (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (NNP NADPH) (NN oxidase)))) (VP (MD can) (VP (VB be) (VP (VBN modulated) (PP (IN through) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT the) (NNP GTP-GDP) (NN state)) (PP (IN of) (NP (NNP Rac))))))))))))))) (. .)))
(TOP (S (S (NP (NNPS Proteins)) (VP (VBP exist) (PP (IN in) (NP (NP (NNS leukocytes)) (ADJP (JJ able) (S (VP (TO to) (VP (VB modify) (NP (JJ GTP-binding) (NN protein) (NN function)) (PP (IN in) (NP (DT this) (NN manner))))))))))) (, ,) (CC and) (S (NP (PRP$ their) (NN activity)) (VP (MD may) (VP (VB be) (VP (VBN regulated) (PP (IN by) (NP (NP (NNS signals)) (VP (VBN generated) (PP (IN on) (NP (JJ phagocyte) (NN stimulation)))))))))) (. .)))
(TOP (S (NP (NP (NNPS Proteins)) (PP (IN of) (NP (DT the) (NNP Ras) (NN superfamily)))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (ADJP (VBN involved) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ normal) (JJ phagocyte) (NNS functions)))))) (UCP (PP (IN through) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB modulate) (NP (NP (NP (DT the) (NN assembly)) (PP (IN of) (NP (NN actin) (NNS filaments)))) (, ,) (NP (JJ direct) (NN vesicle) (NN trafficking)) (CC and) (NP (NN fusion)))))))) (, ,) (CC and) (ADVP (RB so) (RB forth)))))))) (. .)))
(TOP (S (NP (NNP OCA-B)) (VP (VP (VBZ is) (NP (NP (DT a) (JJ functional) (NN analog)) (PP (IN of) (NP (NNP VP16))))) (CC but) (VP (VBZ targets) (NP (NP (DT a) (JJ separate) (NN surface)) (PP (IN of) (NP (DT the) (NNP Oct-1) (NNP POU) (NN domain) (NNP -LSB-) (VBD published) (JJ erratum))))) (VP (NNS appears) (PP (IN in) (NP (NP (NNP Mol) (NNP Cell) (NNP Biol) (CD 1998) (NNP Apr)) (: ;) (NP (NP (CD 18)) (PRN (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-))) (: :) (NP (NP (CD 2430)) (NN -RSB-))))))))
(TOP (S (NP (NNP OCA-B)) (VP (VBZ is) (NP (NP (DT a) (JJ B-cell-specific) (NN coregulator)) (PP (IN of) (NP (DT the) (ADJP (RB broadly) (VBN expressed)) (NNP POU) (NN domain) (NN transcription) (NN factor) (NN Oct-1))))) (. .)))
(TOP (S (NP (NP (NN OCA-B) (NNS associates)) (PP (IN with) (NP (NP (DT the) (NNP Oct-1) (NNP POU) (NN domain)) (, ,) (NP (NP (DT a) (JJ bipartite) (JJ DNA-binding) (NN structure)) (VP (VBG containing) (NP (DT a) (JJ POU-specific) (PRN (-LRB- -LRB-) (NNP POU-LSB-S-RSB-) (-RRB- -RRB-)) (NN domain))))))) (VP (VBN joined) (PP (IN by) (NP (DT a) (JJ flexible) (NN linker))) (PP (TO to) (NP (NP (DT a) (NNP POU) (NN homeodomain)) (PRN (-LRB- -LRB-) (NP (NNP POU-LSB-H-RSB-)) (-RRB- -RRB-))))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP OCA-B)) (VP (VBZ alters) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP Oct-1)))) (PP (IN in) (NP (CD two) (NNS ways))))))) (. .)))
(TOP (S (S (NP (PRP It)) (VP (VBZ provides) (NP (NP (DT a) (JJ transcriptional) (NN activation) (NN domain)) (SBAR (WHNP (WDT which)) (S (, ,) (PP (IN unlike) (NP (NNP Oct-1))) (, ,) (VP (VBZ activates) (NP (DT an) (JJ mRNA-type) (NN promoter)) (ADVP (RB effectively)))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBZ stabilizes) (ADVP (JJ Oct-1)) (PP (IN on) (NP (DT the) (JJ Oct-1-responsive) (NN octamer) (NN sequence) (NNP ATGCAAAT))))) (. .)))
(TOP (S (NP (NP (DT These) (NNS properties)) (PP (IN of) (NP (NNP OCA-B)))) (VP (VBP parallel) (NP (NP (DT those)) (VP (VBN displayed) (PP (IN by) (NP (DT the) (NNS herpes) (NN simplex) (NN virus) (NNP Oct-1) (NNP coregulator) (NNP VP16)))))) (. .)))
(TOP (S (NP (NNP OCA-B)) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ interacts) (PP (IN with) (NP (NP (DT a) (JJ different) (NN surface)) (PP (IN of) (NP (DT the) (JJ DNA-bound) (NNP Oct-1) (NNP POU) (NN domain))))) (, ,) (S (VP (VBG interacting) (PP (IN with) (NP (NP (DT both) (DT the) (NNP POU-LRB-S-RRB-) (CC and) (NNP POU-LRB-H-RRB-) (NNS domains)) (CC and) (NP (NP (DT the) (NN center)) (PP (IN of) (NP (DT the) (NNP ATGCAAAT) (NN octamer) (NN sequence))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNP OCA-B) (CC and) (NNP VP16) (NNS interactions)) (PP (IN with) (NP (DT the) (NNP Oct-1) (NNP POU) (NN domain)))) (VP (VBP are) (ADJP (RB sufficiently) (JJ different) (S (VP (TO to) (VP (VB permit) (S (NP (NNP OCA-B) (CC and) (NNP VP16)) (VP (TO to) (VP (NN bind) (NP (DT the) (NNP Oct-1) (NNP POU) (NN domain)) (ADVP (RB simultaneously)))))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP emphasize) (NP (NP (DT the) (JJ structural) (NN versatility)) (PP (IN of) (NP (DT the) (NNP Oct-1) (NNP POU) (NN domain))) (PP (IN in) (NP (NP (PRP$ its) (NN interaction)) (PP (IN with) (NP (NNS coregulators))))))) (. .)))
(TOP (S (NP (NP (NN Extinction)) (PP (IN of) (NP (JJ immunoglobulin) (NN gene) (NN expression))) (PP (IN in) (NP (NP (NN B) (NNS cells)) (PP (IN upon) (NP (NN fusion))) (PP (IN with) (NP (NNP HeLa) (NNS cells)))))) (VP (VP (VBZ is) (VP (VBN preceded) (PP (IN by) (NP (NP (JJ rapid) (JJ nuclear) (NN depletion)) (PP (IN of) (NP (JJ essential) (NN transcription) (NNS factors))))))) (CC and) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ widespread) (NN inactivation)) (PP (IN of) (NP (NNS genes))) (VP (VBN expressed) (PP (IN in) (NP (DT a) (NNP B) (JJ cell-specific) (NN manner))))))))) (. .)))
(TOP (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN immunoglobulin) (PRN (-LRB- -LRB-) (NN Ig) (-RRB- -RRB-)) (VBG expressing) (NN B) (NNS cells)) (VP (VBP are) (VP (VBN fused) (PP (IN with) (NP (JJ non-B) (NNS cells))))))) (, ,) (NP (NN Ig) (NN expression)) (VP (VBZ is) (VP (ADVP (RB rapidly)) (VBN suppressed) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN transcription)))))))) (, ,) (S (NP (DT a) (NN phenomenon)) (VP (VBD termed) (NP (NN extinction)))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (DT that) (S (NP (NP (NN fusion)) (PP (IN of) (NP (JJ HeLa) (NNS cells))) (PP (IN with) (NP (DT either) (ADJP (JJ diploid) (CC or) (JJ tetraploid)) (NN B) (NNS cells) (PRN (-LRB- -LRB-) (NNP Daudi) (-RRB- -RRB-))))) (VP (NNS results) (PP (IN in) (NP (NP (JJ widespread) (NN extinction)) (PP (IN of) (NP (NP (JJ several) (JJ other) (NNP B) (JJ cell-encoded) (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN expressed) (PP (IN in) (NP (DT a) (NNP B) (JJ cell-specific) (NN manner))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (NNP B) (JJ cell-expressed) (NNS genes))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (ADJP (JJ dependent) (PP (IN on) (NP (JJ cell-specific) (NNS controls)))))))) (VP (VBZ is) (ADJP (JJ unaffected))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ molecular) (NN mechanism)) (PRN (-LRB- -LRB-) (NP (PRP s)) (-RRB- -RRB-)) (PP (VBG underlying) (NP (NNP Ig) (NN gene) (NN extinction)))) (VP (MD can) (VP (VB be) (VP (VBN explained) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (IN by) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ essential) (PP (IN for) (NP (NNP Ig) (NN gene) (NN transcription))))))))))))))))) (. .)))
(TOP (S (NP (DT These) (NN transcription) (NNS factors)) (VP (VP (VBP are) (ADVP (RB either)) (RB not) (VP (VBN produced) (S (ADJP (JJ due) (PP (TO to) (NP (NP (NN block)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (PRP$ their) (JJ respective) (NNS genes)) (PRN (-LRB- -LRB-) (NP (NNP Oct-2)) (, ,) (NP (NNP OBF-1)) (, ,) (NP (NNP PU.1)) (-RRB- -RRB-)))))))))))) (, ,) (CC or) (VP (VBP are) (VP (VBN rendered) (S (ADJP (JJ inactive))) (ADVP (RB posttranslationally)))) (PRN (-LRB- -LRB-) (NP (NP (NNP NF-kappa) (NNP B)) (, ,) (NP (NNP E47))) (-RRB- -RRB-))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG isolating) (NP (NNP Daudi) (LS x) (NNP HeLa) (NNS heterokaryons)) (PP (NP (DT a) (JJ few) (NNS hours)) (IN after) (NP (NN fusion)))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN studied) (NP (NP (DT the) (JJ initial) (NN fate)) (PP (IN of) (NP (NP (CD two) (NNP B) (JJ cell-specific) (NN transcription) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (NP (NN Ig) (NN gene)) (NP (NN transcription)) (, ,) (NP (NNP Oct-2)) (CC and) (NP (NNP NF-kappa) (NNP B)))))))))) (. .)))
(TOP (S (NP (DT This) (NN report)) (VP (VBZ provides) (NP (NP (DT the) (JJ first) (NN demonstration)) (SBAR (WHNP (IN that)) (S (PP (IN upon) (NP (NN fusion))) (PP (IN with) (NP (NNP HeLa) (NNS cells))) (, ,) (NP (NP (DT the) (JJ nuclear) (NNS contents)) (PP (IN of) (NP (NNP B) (JJ cell-expressed) (NN transcription) (NNS factors)))) (VP (VBP are) (VP (VBN depleted) (PP (IN within) (NP (DT a) (JJ few) (NNS hours))) (PP (IN with) (NP (NP (NNS kinetics)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (ADJP (IN as) (JJ fast) (CC or) (RBR faster)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Ig) (NN gene) (NN extinction))))))))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (DT the) (VBG extinguishing) (NN mechanism)) (VP (VBZ is) (ADJP (JJ effective)) (ADVP (RB very) (RB early)) (PP (IN after) (NP (NN fusion)))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP suggest) (SBAR (DT that) (S (NP (NP (NN extinction)) (PP (IN of) (NP (NN Ig) (NNS genes)))) (VP (VBZ is) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJ global) (NN mechanism)) (SBAR (WHNP (WDT that)) (S (VP (VBZ suppresses) (NP (NP (DT the) (NN differentiation) (NN program)) (ADJP (JJ foreign) (PP (TO to) (NP (DT the) (NNP HeLa) (NN phenotype))))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Nuclear) (NN accumulation)) (PP (IN of) (NP (NNP NFAT4))) (VP (VBN opposed) (PP (IN by) (NP (DT the) (NNP JNK))))) (VP (NN signal) (NP (NN transduction) (NN pathway))) (. .)))
(TOP (S (NP (NP (DT The) (JJ nuclear) (NN factor)) (PP (IN of) (NP (NP (VBN activated) (NNP T) (NNS cells) (PRN (-LRB- -LRB-) (NNP NFAT) (-RRB- -RRB-)) (NN group)) (PP (IN of) (NP (NN transcription) (NNS factors)))))) (VP (VBZ is) (VP (VBN retained) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (JJ quiescent) (NNS cells))))))) (. .)))
(TOP (S (NP (NN NFAT) (NN activation)) (VP (VBZ is) (VP (VBN mediated) (PP (IN in) (NP (NN part))) (PP (IN by) (S (VP (VBN induced) (NP (JJ nuclear) (NN import))))))) (. .)))
(TOP (S (NP (DT This) (NN process)) (VP (VBZ requires) (NP (NP (JJ calcium-dependent) (NN dephosphorylation)) (PP (IN of) (NP (NNP NFAT))) (VP (VBN caused) (PP (IN by) (NP (DT the) (NN phosphatase) (NN calcineurin)))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ c-Jun) (JJ amino-terminal) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NNP JNK)) (-RRB- -RRB-))) (VP (VBZ phosphorylates) (NP (NNP NFAT4)) (PP (IN on) (NP (CD two) (NNS sites)))) (. .)))
(TOP (S (NP (NP (JJ Mutational) (NN removal)) (PP (IN of) (NP (DT the) (NNP JNK) (NN phosphorylation) (NNS sites)))) (VP (VBD caused) (NP (NP (JJ constitutive) (JJ nuclear) (NN localization)) (PP (IN of) (NP (NNP NFAT4))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNP JNK) (NN activation)) (PP (IN in) (NP (JJ calcineurin-stimulated) (NNS cells)))) (VP (VBD caused) (NP (NP (JJ nuclear) (NN exclusion)) (PP (IN of) (NP (NNP NFAT4))))) (. .)))
(TOP (S (NP (DT These) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ nuclear) (NN accumulation)) (PP (IN of) (NP (NNP NFAT4))) (VP (VBN promoted) (PP (IN by) (NP (NN calcineurin))))) (VP (VBZ is) (VP (VBN opposed) (PP (IN by) (NP (DT the) (NNP JNK) (NN signal) (NN transduction) (NN pathway)))))))) (. .)))
(TOP (NP (NNPS Pathogenesis) (. .)))
(TOP (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ many) (NNS hypotheses)) (VP (VBG concerning) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN endometriosis)))))) (, ,) (SBAR (IN though) (S (NP (DT no) (JJ single) (NN theory)) (VP (MD can) (VP (VB explain) (NP (DT all) (NNS cases))))))) (. .)))
(TOP (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ likely) (SBAR (IN that) (S (NP (JJ several) (NNS mechanisms)) (VP (VBP are) (VP (VBN involved))))))) (. .)))
(TOP (S (NP (JJ Early) (NNS studies)) (VP (VBD concentrated) (PP (IN on) (NP (NP (DT the) (NN histogenesis)) (PP (IN of) (NP (DT the) (JJ endometriotic) (NN lesion)))))) (. .)))
(TOP (S (NP (JJ Recent) (NN evidence)) (VP (VBZ has) (VP (VBN implicated) (NP (NP (NNS components)) (PP (IN of) (NP (DT the) (JJ immune) (NN system)))) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN endometriosis))))))) (. .)))
(TOP (S (NP (DT This) (NN review)) (VP (VP (VBZ considers) (NP (NP (DT the) (NN evidence)) (PP (IN for) (NP (NP (JJ different) (NNS theories)) (PP (IN of) (NP (NP (DT the) (NN histogenesis)) (PP (IN of) (NP (NN endometriosis))))))))) (CC and) (VP (VBZ discusses) (NP (NP (JJ possible) (JJ immune) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (DT the) (NN disease))))))))))))) (. .)))
(TOP (VP (NN -LSB-) (NP (NP (DT The) (NN value)) (PP (IN of) (NP (NP (DT the) (JJ clinical) (NN test)) (PP (IN of) (NP (NP (JJ glucocorticoid) (NNS receptors)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NNS leukocytes))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ pulmonary) (NN heart) (NN disease)))))))))) (NN -RSB-)))
(TOP (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB inquire) (PP (IN into) (NP (NP (DT the) (JJ functional) (NN state)) (PP (IN of) (NP (JJ adrenal) (NN cortex))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pulmonary) (NN heart) (NN disease))))))))) (, ,) (S (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP GCR)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ pulmonary) (NN heart) (NN disease)))))))))) (VP (VBD was) (VP (VBN determined) (PP (IN with) (NP (JJ radioligand-binding) (NN assay)))))) (CC and) (S (NP (DT the) (JJ corresponding) (NN plasma) (NN cortisol) (NNS levels)) (VP (VBD were) (VP (VBN assessed) (PP (IN with) (NP (JJ radioimmune) (NNS assays)))))) (. .)))
(TOP (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (S (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNP GCR))) (PP (IN in) (NP (DT the) (NNS patients)))) (VP (VBD was) (ADJP (ADJP (RB significantly) (VBN reduced)) (PRN (-LRB- -LRB-) (ADVP (FW P) (FW &lt;) (CD 0.01)) (-RRB- -RRB-))))) (CC and) (S (NP (PRP it)) (VP (VBD was) (VP (VBN increased) (SBAR (WHADVP (WRB when)) (S (NP (PRP$ their) (NN health) (NN state)) (VP (VBD was) (VP (VBN improved))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (VBD was) (ADVP (RB still)) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (NP (DT that)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD &lt;) (NP (CD 0.01)))) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NNP GCR))) (PP (IN in) (NP (DT the) (NNS patients)))) (VP (VBD was) (VP (ADVP (RB greatly)) (VBN increased) (SBAR (WHADVP (WRB when)) (S (NP (DT these) (NNS patients)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NP (NN oxygen)) (PRN (-LRB- -LRB-) (NP (FW P) (FW &lt;) (CD 0.01)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP (NP (DT No) (NN difference)) (PP (IN in) (NP (NN plasma) (NN cortisol)))) (VP (VBD was) (VP (VBN found) (PP (IN between) (NP (NP (DT the) (NNS patients)) (CC and) (NP (NP (DT the) (JJ healthy) (NNS subjects)) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD &gt;) (NP (CD 0.05)))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NP (DT the) (NN function)) (PP (IN of) (NP (JJ adrenal) (NN cortex)))) (VP (MD may) (VP (VB be) (VP (VBN improved) (PP (IN by) (NP (NP (DT the) (NN compensation) (NN mechanism)) (PP (IN of) (NP (DT the) (NNS patients))))))))) (, ,) (CC but) (S (NP (DT the) (JJR lower) (NNP GCR) (NN number)) (VP (VBD was) (NP (NP (DT the) (NN result)) (PP (IN of) (S (VP (VBG lacking) (PP (IN of) (NP (NP (NN oxygen)) (PP (IN in) (NP (DT the) (NNS patients)))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NNP GCR)))) (VP (MD may) (VP (VB be) (VP (VBN improved) (PP (IN by) (NP (NP (NN inhalation)) (PP (IN of) (NP (NN oxygen)))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (NP (NN oxygen) (NN therapy)) (VP (VBZ is) (ADJP (JJ helpful)) (PP (IN in) (S (VP (VP (VBG raising) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ glucocorticoid) (NNS receptors))))) (CC and) (VP (VBG controlling) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (NN disease))))))))) (. .)))
(TOP (NP (NP (JJ Molecular) (NN cloning)) (CC and) (NP (NP (JJ functional) (NN characterization)) (PP (IN of) (NP (FW murine) (FW cDNA) (VBG encoding) (NN transcription) (NN factor) (NNP NFATc)))) (. .)))
(TOP (NP (NP (NP (JJ Transcription) (NNS factors)) (PP (IN of) (NP (NP (DT the) (NNP NFAT) (PRN (-LRB- -LRB-) (JJ nuclear) (NN factor))) (PP (IN of) (NP (VBN activated) (NNP T) (NNS cells)))))) (-RRB- -RRB-) (S (NP (NN family)) (VP (NN play) (NP (NP (JJ important) (NNS roles)) (PP (IN in) (NP (JJ immune) (CC and) (JJ inflammatory) (NNS responses)))) (PP (IN by) (S (VP (VBG regulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBG encoding) (NP (NP (NNS cytokines)) (CC and) (NP (JJ immunoregulatory) (NNS proteins)))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP describe) (NP (NP (NN cloning) (CC and) (NN characterization)) (PP (IN of) (NP (NP (JJ full-length) (NNP cDNA) (VBG encoding) (JJ murine) (PRN (-LRB- -LRB-) (NN m) (-RRB- -RRB-)) (NN NFATc)) (SBAR (WHNP (WDT which)) (S (VP (VBZ predicts) (SBAR (IN that) (S (NP (DT the) (NN protein)) (VP (VBZ has) (NP (NP (PDT all) (DT the) (JJ conserved) (JJ structural) (NNS motifs)) (PP (IN of) (NP (NNP NFAT) (NN family) (NNS members))) (, ,) (PP (VBG including) (NP (NP (DT the) (NN rel) (NN homology) (NN domain)) (, ,) (NP (DT the) (NNP NFAT) (NN homology) (NN domain)) (CC and) (NP (DT the) (JJ nuclear) (NN translocation) (NNS signals))))))))))))))) (. .)))
(TOP (S (NP (NNP mNFATc)) (VP (VBD complexed) (PP (IN with) (NP (NNP AP-1))) (S (VP (VP (VBD bound) (ADVP (RB specifically)) (PP (TO to) (NP (DT the) (JJ murine) (NNP IL-2) (NNP NFAT) (NN recognition) (NN sequence)))) (CC and) (VP (VBN activated) (NP (NN transcription)) (PP (IN from) (NP (DT the) (JJ co-transfected) (NN IL-2) (NN promoter))) (PP (IN in) (NP (NN COS-7) (NNS cells))))))) (. .)))
(TOP (S (NP (JJ Northern) (NN blot) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (NNP cDNA) (NN probe)) (VP (VBN hybridized) (PP (IN with) (NP (NP (DT a) (CD 4.5) (NN kb) (NN transcript)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (RB highly) (JJ inducible)) (PP (IN in) (NP (JJ murine) (NNP T) (NNS cells)))))))))))) (. .)))
(TOP (S (PP (PP (IN By) (NP (NNP Northern))) (CC and) (PP (IN in) (NP (NN situ) (NN hybridization)))) (, ,) (NP (JJ mNFATc) (NN transcript)) (VP (VBD was) (VP (VBN detected) (PP (IN from) (NP (NP (DT the) (JJ early) (NN stage)) (PP (IN of) (NP (NN development))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (NN mouse) (NN embryo))) (, ,) (NP (JJ mNFATc) (NN transcript)) (VP (VBD was) (VP (ADVP (RB strongly)) (VBN expressed) (UCP (PP (IN in) (NP (NP (NN thymus)) (, ,) (NP (NN lung)) (CC and) (NP (JJ submandibular) (NN gland)))) (CC and) (PP (ADVP (RB weakly)) (IN in) (NP (NP (JJ skeletal) (NN muscle)) (CC and) (NP (NP (NN heart)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNP mNFATc)) (VP (MD may) (VP (VB have) (NP (NP (DT a) (NN role)) (PP (DT both) (PP (IN in) (NP (NN embryogenesis))) (CC and) (PP (IN in) (NP (NNP mature) (NNP T) (NNS cells)))))))))))))))) (. .)))
(TOP (S (NP (NP (NNP Differanisole) (NNP A)) (, ,) (NP (DT a) (JJ novel) (NN antitumor) (JJ antibiotic)) (, ,)) (VP (VBZ enhances) (NP (NP (NN growth) (NN inhibition) (CC and) (NN differentiation)) (PP (IN of) (NP (NP (JJ human) (JJ myeloid) (NN leukemia) (NNS cells)) (VP (VBN induced) (PP (IN by) (NP (JJ 9-cis) (JJ retinoic) (NN acid)))))))) (. .)))
(TOP (NP (NP (NNP Differanisole) (NNP A) (, ,) (JJ 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic) (NN acid)) (, ,) (NP (NP (VBN inhibited) (NN growth)) (PP (IN of) (NP (JJ human) (JJ myeloid) (NN leukemia) (NNS cells)))) (. .)))
(TOP (S (NP (DT The) (NN compound)) (VP (VBD induced) (NP (NP (NP (CD G1) (NN arrest)) (CC and) (NP (JJ granulocytic) (NN differentiation))) (PP (IN of) (NP (NN HL-60) (NNS cells)))) (, ,) (SBAR (IN although) (S (NP (DT the) (JJ differentiation-inducing) (NN effect)) (VP (VBD was) (ADJP (JJ modest)))))) (. .)))
(TOP (S (NP (NP (NNP Differanisole) (NNP A)) (CC and) (NP (NP (JJ 9-cis) (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP 9cisRA)) (-RRB- -RRB-)))) (VP (VP (ADVP (RB synergistically)) (VBD inhibited) (NP (DT the) (NN growth))) (CC and) (VP (VBN induced) (NP (NP (ADJP (JJ functional) (CC and) (JJ morphologic)) (NN differentiation)) (PP (IN of) (NP (NNP HL-60) (CC and) (NNP NB4) (NNS cells))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (VBN combined) (NN treatment)) (PP (IN with) (NP (NP (NN differanisole) (ADJP (NN A) (CC and) (JJ all-trans)) (JJ retinoic) (NN acid)) (CC or) (NP (JJ 1alpha,25-dihydroxyvitamin) (NN D3))))) (VP (VBD was) (ADJP (RBR less) (JJ effective)))))) (. .)))
(TOP (S (NP (JJ Similar) (NNS results)) (VP (VBD were) (VP (VBN obtained) (PP (IN in) (NP (NP (JJ primary) (NN culture)) (PP (IN of) (NP (NN leukemia) (NNS cells))))) (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ acute) (JJ promyelocytic) (NN leukemia))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ synergistic) (NN effect)) (PP (IN on) (NP (NP (NN growth) (NN inhibition)) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NN differentiation))))))) (VP (VBN required) (NP (NP (JJ simultaneous) (NN treatment)) (PP (IN with) (NP (NP (NN differanisole) (NNP A)) (CC and) (NP (NNP 9cisRA)))))) (. .)))
(TOP (S (NP (NP (NP (NNP Differanisole) (NNP A)) (CC and) (NP (DT an) (JJ RXR-specific) (NN ligand))) (PRN (-LRB- -LRB-) (NN Ro47-5944) (-RRB- -RRB-))) (VP (ADVP (RB cooperatively)) (VBD inhibited) (NP (DT the) (NN cell) (NN growth)) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (VBN combined) (NN effect)) (PP (IN of) (NP (NP (NN differanisole) (NN A)) (CC and) (NP (DT an) (JJ RAR-specific) (NN ligand) (NNP Am80))))) (VP (VBD was) (NP (RB just) (JJ additive)))))) (. .)))
(TOP (S (NP (NP (NNP Differanisole) (NNP A)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP 9cisRA)))) (VP (MD may) (VP (VB have) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NN therapy)) (PP (IN of) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (NNS patients)))))))) (. .)))
(TOP (NP (NP (NP (JJ Molecular) (NNS mechanisms)) (PP (IN of) (NP (JJ anoxia/reoxygenation-induced) (NN neutrophil) (NN adherence)))) (PP (TO to) (NP (VB cultured) (JJ endothelial) (NNS cells))) (. .)))
(TOP (S (NP (NP (DT The) (NNS objectives)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD were) (PP (TO to) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (S (VP (VB determine) (NP (NP (DT the) (NN time) (NN course)) (PP (IN of) (NP (NP (NN neutrophil) (NN adhesion)) (PP (TO to) (NP (NP (NNS monolayers)) (PP (IN of) (NP (NP (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP HUVECs)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (NP (CD 60) (NNS minutes)) (PP (IN of) (NP (NN anoxia)))) (VP (VBN followed) (PP (IN by) (NP (NP (NP (QP (CD 30) (TO to) (CD 600)) (NNS minutes)) (PP (IN of) (NP (NN reoxygenation)))) (CC and) (S (VP (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (VB define) (NP (NP (DT the) (NNS mechanisms)) (ADJP (JJ responsible) (PP (IN for) (NP (DT both) (NP (NP (DT the) (JJ early) (PRN (-LRB- -LRB-) (NNS minutes) (-RRB- -RRB-)) (CC and) (JJ late) (PRN (-LRB- -LRB-) (NNS hours) (-RRB- -RRB-)) (NN hyperadhesivity)) (PP (IN of) (NP (JJ postanoxic) (NNS HUVECs))) (PP (TO to) (NP (JJ human) (NNS neutrophils))))))))))))))))))))))))))))) (. .)))
(TOP (S (NP (DT The) (NNS results)) (ADVP (RB clearly)) (VP (VBP demonstrate) (SBAR (DT that) (S (NP (NP (NN anoxia/reoxygenation)) (PRN (-LRB- -LRB-) (NP (NNP A/R)) (-RRB- -RRB-))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (JJ biphasic) (NN increase)) (PP (IN in) (NP (NN neutrophil) (NN adhesion))) (PP (TO to) (NP (NNP HUVECs))))) (, ,) (PP (IN with) (S (NP (JJ peak) (NNS responses)) (VP (VBG occurring) (PP (IN at) (NP (NP (NP (CD 30) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (NN phase) (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 240) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (NN phase) (CD 2)) (-RRB- -RRB-))))) (PP (IN after) (NP (NN reoxygenation)))))))))) (. .)))
(TOP (S (NP (NNP Oxypurinol) (CC and) (NN catalase)) (VP (VBD inhibited) (NP (JJ phase-1) (NN adhesion)) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (JJ xanthine) (NN oxidase)) (CC and) (NP (NNP H2O2)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN comparison))) (, ,) (NP (NP (NN platelet) (VBG activating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP PAF)) (-RRB- -RRB-))) (VP (VBD contributed) (PP (TO to) (NP (NP (DT both) (NNS phases)) (PP (IN of) (NP (NN neutrophil) (NN adhesion)))))) (. .)))
(TOP (S (NP (NP (NP (JJ Anti-intercellular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN ICAM-1)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ anti-P-selectin) (NNS antibodies)) (PRN (-LRB- -LRB-) (NP (JJ monoclonal) (NNS antibodies) (NNP -LSB-) (NNP mAbs) (NNP -RSB-)) (-RRB- -RRB-)))) (VP (VBD attenuated) (NP (NP (JJ phase-1) (NN neutrophil) (NN adhesion)) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (NNS roles)) (PP (IN for) (NP (NP (ADJP (RB constitutively) (VBN expressed)) (NN ICAM-1)) (CC and) (NP (NP (JJ enhanced) (NN surface) (NN expression)) (PP (IN of) (NP (JJ preformed) (NN P-selectin))))))))))) (. .)))
(TOP (S (NP (NN Phase-2) (NN neutrophil) (NN adhesion)) (VP (VBD was) (VP (VBN attenuated) (PP (IN by) (NP (DT an) (JJ anti-E-selectin) (NN mAb))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (JJ dominant) (NN role)) (PP (IN of) (NP (DT this) (NN adhesion) (NN molecule))) (PP (IN in) (NP (DT the) (JJ late) (NN phase) (NN response)))))))) (. .)))
(TOP (FRAG (PP (NP (NP (NP (NNP Pretreatment)) (PP (IN with) (NP (NNP actinomycin) (NNP D)))) (CC and) (NP (NN cycloheximide))) (CC or) (PP (IN with) (NP (NP (VBG competing) (NNS ds-oligonucleotides)) (VP (VBG containing) (NP (NP (DT the) (JJ nuclear) (NN factor-kappa) (NN B)) (CC or) (NP (NN activator) (JJ protein-1) (JJ cognate) (NN DNA) (NNS sequences))))))) (VP (ADVP (RB significantly)) (VBD attenuated) (NP (JJ phase-2) (NN response)) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (FW de) (FW novo) (FW macromolecule) (NN synthesis))))))) (. .)))
(TOP (S (NP (NP (NN Surface) (NN expression)) (PP (IN of) (NP (NNP ICAM-1) (, ,) (NNP P-selectin) (, ,) (CC and) (NNP E-selectin))) (PP (IN on) (NP (NNP HUVECs)))) (VP (VBD correlated) (PP (IN with) (NP (DT the) (ADJP (JJ phase-1) (CC and) (JJ -2)) (NN neutrophil) (NN adhesion) (NNS responses)))) (. .)))
(TOP (S (ADVP (RB Collectively)) (, ,) (NP (DT these) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP A/R)) (VP (VBZ elicits) (NP (NP (DT a) (JJ two-phase) (JJ neutrophil-endothelial) (NN cell) (NN adhesion) (NN response)) (SBAR (WHNP (WDT that)) (S (VP (VBZ involves) (NP (NP (JJ transcription-independent) (CC and) (JJ transcription-dependent) (NN surface) (NN expression)) (PP (IN of) (NP (JJ different) (JJ endothelial) (NN cell) (NN adhesion) (NNS molecules)))))))))))) (. .)))
(TOP (S (NP (NP (NN B) (NNS lymphocytes)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ lymphocytic) (NN leukemia)))))) (VP (VBP contain) (NP (NP (NN signal) (NN transducer) (CC and) (NN activator)) (PP (IN of) (NP (NP (NP (NN transcription) (PRN (-LRB- -LRB-) (NNP STAT) (-RRB- -RRB-)) (CD 1)) (CC and) (NP (CD STAT3))) (VP (ADVP (RB constitutively)) (VBN phosphorylated) (PP (IN on) (NP (JJ serine) (NNS residues)))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB explore) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (JJ chronic) (JJ lymphocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NNP CLL)) (-RRB- -RRB-)))))))) (, ,) (NP (PRP we)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NP (QP (CD one) (CC or) (JJR more)) (NN signal) (NN transducer)) (CC and) (NP (NP (NN activator)) (PP (IN of) (NP (NN transcription) (PRN (-LRB- -LRB-) (NNP STAT) (-RRB- -RRB-)) (NNS factors))))))) (VP (VBD was) (ADJP (JJ abnormal)) (PP (IN in) (NP (NP (NNS cells)) (PP (IN from) (NP (NNP CLL) (NNS patients))))))))) (. .)))
(TOP (S (NP (DT No) (JJ constitutive) (NN tyrosine) (NN phosphorylation)) (VP (VBD was) (VP (VBN detected) (PP (IN on) (NP (DT any) (NNP STAT))) (PP (IN in) (NP (NNP CLL) (NNS cells))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NP (JJ serine) (NNS residues)) (PP (IN of) (NP (NNP STAT1) (CC and) (NNP STAT3))) (PP (IN in) (NP (NNP CLL) (NNS cells))))))))) (, ,) (NP (PRP we)) (VP (VBD raised) (NP (NP (NP (NP (NNS antibodies)) (SBAR (WHNP (WDT that)) (S (VP (ADVP (RB specifically)) (VBP recognize) (SBAR (S (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NNP STAT1)))) (VP (VBD phosphorylated) (PP (IN on) (NP (NN ser-727)))))))))) (CC and) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NNP STAT3))))) (VP (VBD phosphorylated) (PP (IN on) (NP (NN ser-727)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (S (PP (IN in) (NP (NP (CD 100) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP CLL))))))) (PRN (-LRB- -LRB-) (INTJ (SYM n)) (VP (SYM =) (NP (CD 32))) (-RRB- -RRB-))) (, ,) (NP (NNP STAT1) (CC and) (NNP STAT3)) (VP (VBD were) (VP (ADVP (RB constitutively)) (VBN phosphorylated) (PP (IN on) (NP (NN serine)))))))) (. .)))
(TOP (S (NP (DT This)) (VP (VBD was) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (JJ normal) (JJ peripheral) (NN blood) (NN B) (NNS lymphocytes)) (CC or) (NP (NP (NN CD5+-RRB-) (NN B) (NNS cells)) (VP (VBN isolated) (PP (IN from) (NP (NP (NNS tonsils)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT this) (NN phosphorylation)) (VP (VBD was) (ADJP (JJ absent)))))))))))))) (. .)))
(TOP (S (S (NP (NP (JJ Serine) (NN phosphorylation)) (PP (IN of) (NP (NNP STAT1) (CC and) (NNP STAT3)))) (VP (VBD was) (VP (VBN seen) (ADVP (RB occasionally)) (PP (IN in) (NP (JJ other) (NNS leukemias)))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBD was) (NP (DT a) (JJ universal) (NN finding)) (PP (ADVP (RB only)) (IN in) (NP (NNP CLL))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ serine) (NN phosphorylation)) (PP (IN of) (NP (DT these) (NNS STATs)))) (VP (VBD was) (NP (DT a) (JJ continuous) (NN process)) (, ,) (SBAR (IN as) (S (NP (NP (NN incubation)) (PP (IN of) (NP (NNP CLL) (NNS cells))) (PP (IN with) (NP (DT the) (FW kinase) (FW inhibitor) (NNP H7)))) (VP (VBD led) (PP (TO to) (NP (NP (DT the) (NN dephosphorylation)) (PP (IN of) (NP (DT these) (JJ serine) (NNS residues))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNP STAT) (NN serine) (NN kinase)) (PP (IN in) (NP (NNP CLL) (NNS cells)))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN identified)))) (, ,) (CC and) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP (NP (ADJP (DT neither) (JJ mitogen-activated)) (NN protein) (NN kinase)) (CC nor) (NP (NN pp70-LRB-s6k-RRB-)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NP (DT the) (JJ constitutive) (JJ serine) (NN phosphorylation)) (PP (IN of) (NP (NNP STAT1) (CC and) (NNP STAT3)))) (VP (VBZ is) (ADJP (JJ present) (PP (IN in) (NP (NP (DT all) (NNP CLL) (NNS samples)) (VP (VBD tested) (PP (TO to) (NP (NN date))))))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (JJ physiologic) (NN significance)) (PP (IN of) (NP (DT this) (NN modification)))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN determined))))))))) (. .)))
(TOP (S (NP (NNP C/EBP)) (VP (VBZ activates) (NP (DT the) (JJ human) (NN corticotropin-releasing) (NN hormone) (NN gene) (NN promoter))) (. .)))
(TOP (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBD was) (S (VP (TO to) (VP (VB identify) (SBAR (IN whether) (S (NP (NP (NN transcription) (NNS factors)) (, ,) (VP (VBN associated) (PP (IN with) (NP (JJ cytokine) (NN signalling)))) (, ,)) (VP (JJ affected) (NP (NP (NN promoter) (NN activity)) (PP (IN of) (NP (DT the) (NN corticotropin) (VBG releasing) (NN hormone) (PRN (-LRB- -LRB-) (NNP CRH) (-RRB- -RRB-)) (NN gene))))))))))) (. .)))
(TOP (S (NP (NP (NNS Fragments)) (PP (IN of) (NP (NP (DT a) (CD 3.6) (NN kb) (NN sequence)) (PP (IN of) (NP (DT the) (JJ human) (NNP CRH) (NN gene) (NN promoter)))))) (VP (VBD were) (VP (VP (VBN amplified) (PP (IN by) (NP (NNP PCR)))) (CC and) (VP (VBD ligated) (ADVP (RB upstream) (PP (IN of) (NP (DT a) (NNP CAT) (NN reporter))))))) (. .)))
(TOP (S (NP (DT These) (NNS constructs)) (VP (VBD were) (VP (VBN transfected) (PP (IN into) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN cell) (NNS lines))) (, ,) (ADVP (CC either) (RB alone) (CC or) (RB together)) (, ,) (PP (IN with) (NP (NN transcription) (NN factor) (NN expression) (NNS vectors))))))) (. .)))
(TOP (S (NP (NP (JJ Basal) (NN activity)) (PP (IN of) (NP (DT a) (CD 3070) (NN bp) (NNP CRH) (NN promoter) (NN fragment)))) (VP (VBD was) (VP (ADVP (RB only)) (VBN seen) (PP (IN in) (NP (ADJP (JJ neuronal) (CC and) (JJ lymphoblastoid)) (NN cell) (NNS lines))))) (. .)))
(TOP (S (NP (NN Promoter) (NN activity)) (VP (VBD was) (VP (VBN increased) (PP (PP (IN by) (NP (NP (DT the) (NN transcription) (NNS factors)) (NP (NP (NNP C/EBPbeta)) (PRN (-LRB- -LRB-) (NP (NNP NF-IL6)) (-RRB- -RRB-))))) (CC and) (ADVP (RBR more) (RB strongly)) (, ,) (PP (IN by) (NP (NP (NNP C/EBPdelta)) (PRN (-LRB- -LRB-) (NP (NN NF-IL6beta)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP (NP (VBN Increased) (NNP CRH) (NN promoter) (NN activity)) (VP (VBG following) (NP (JJ phorbol) (NN ester) (NN treatment)))) (VP (VBD was) (VP (VBN inhibited) (PP (IN by) (NP (DT a) (JJ dominant) (JJ negative) (NN NF-IL6) (JJ mutant))) (, ,) (S (VP (VBG showing) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN phorbol) (NN ester)))) (VP (VBD were) (VP (ADVP (RB principally)) (VBN mediated) (PP (IN by) (NP (NNP C/EBP))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN inverse) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP CRH))))) (PP (IN in) (NP (NP (DT the) (NN hypothalamus) (CC and) (NNS spleens)) (PP (IN of) (NP (JJ arthritic) (NNS rats)))))) (VP (VBD were) (VP (VBN paralleled) (PP (IN by) (NP (NP (JJ similar) (NN inverse) (NNS changes)) (PP (IN in) (NP (NP (JJ NF-IL6beta) (NN expression)) (PP (IN in) (NP (DT these) (NNS organs))))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT some) (NN transcription) (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (JJ cytokine) (NN signalling))))) (VP (MD can) (ADVP (RB also)) (VP (VB activate) (NP (DT the) (NNP CRH) (NN promoter))))))) (. .)))
(TOP (NP (NP (DT A) (JJ novel) (NN form)) (PP (IN of) (NP (NP (DT the) (JJ myeloid-specific) (NN zinc) (NN finger) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN MZF-2)) (-RRB- -RRB-)))) (. .)))
(TOP (NP (NP (NN BACKGROUND)) (: :) (S (NP (JJ Myeloid) (NN cell) (NN development)) (VP (VBZ is) (VP (VBN controlled) (PP (IN by) (NP (JJ tissue-specific) (NN transcription) (NNS factors)))))) (. .)))
(TOP (S (NP (NP (JJ Human) (JJ myeloid) (NN zinc) (NN finger) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN MZF-1)) (-RRB- -RRB-))) (VP (VP (VBZ is) (NP (NP (DT a) (JJ putative) (NN transcription) (NN factor)) (VP (VBG containing) (NP (CD 13) (NN zinc) (NNS fingers))))) (, ,) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ regulates) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ neutrophilic) (NNS granulocytes))))))))))) (. .)))
(TOP (FRAG (NP (NNS RESULTS)) (: :) (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN isolated) (NP (NP (DT the) (ADJP (JJ murine) (CC and) (JJ human)) (NNS cDNAs)) (SBAR (WHNP (WDT which)) (S (VP (VBP encode) (NP (NP (DT a) (JJ novel) (NN form)) (PP (IN of) (NP (NP (NNP MZF) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN MZF-2)) (-RRB- -RRB-)))))))))))) (. .)))
(TOP (S (NP (UCP (JJ Murine) (CC and) (JJ human)) (NN MZF-2) (NNS proteins)) (VP (VP (VBD consisted) (PP (IN of) (NP (NP (QP (CD 814) (CC and) (CD 775)) (JJ amino) (NNS acids)) (, ,) (ADVP (RB respectively))))) (, ,) (CC and) (VP (VBP have) (NP (NP (NN identity)) (PP (IN of) (NP (CD 75.3) (NN %))) (PP (IN between) (NP (PRP them)))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ C-terminal) (NN half)) (PP (IN of) (NP (JJ human) (NN MZF-2)))) (, ,) (S (VP (VBG carrying) (NP (DT the) (NN zinc) (NN finger) (NNS domains)))) (, ,) (VP (VBD was) (ADJP (RB completely) (JJ identical) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (JJ human) (NN MZF-1)))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ N-terminal) (NN half)) (PP (IN of) (NP (NN MZF-2)))) (VP (VP (VBD was) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (JJ corresponding) (NN region)) (PP (IN of) (NP (JJ human) (NN MZF-1))))))) (, ,) (CC and) (VP (VBD was) (VP (VBN coded) (PP (IN by) (NP (JJ distinct) (NNS exons))))))))) (. .)))
(TOP (S (NP (NNP MZF-2) (NNP mRNA)) (VP (VBD was) (VP (VBN expressed) (PP (IN in) (NP (JJ myeloid) (NNS cells))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT the) (NNS cells)) (VP (VP (VBN committed) (PP (TO to) (NP (DT the) (JJ neutrophilic) (NN lineage)))) (, ,) (CC and) (VP (JJ down-regulated) (PP (IN by) (NP (NNP G-CSF))))))))) (. .)))
(TOP (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (NP (NN MZF-1)) (CC and) (NP (NN MZF-2) (NNS mRNAs))) (VP (VBP seem) (S (VP (TO to) (VP (VB be) (VP (VBN produced) (PP (IN by) (NP (NP (DT the) (JJ alternative) (NN use)) (PP (IN of) (NP (CD two) (JJ different) (NN transcription) (NN initiation) (NNS sites))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ distinct) (JJ N-terminal) (NN half)) (PP (IN of) (NP (NN MZF-2)))) (VP (VBZ carries) (NP (NP (CD two) (JJ characteristic) (NNS domains)) (, ,) (NP (NP (DT a) (JJ leucine-rich) (NN domain)) (VP (VBN called) (S (NP (NNP LeR))))) (CC and) (NP (NP (DT an) (JJ acidic) (NN domain)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ suggests) (NP (NP (DT a) (JJ unique) (NN function)) (PP (IN of) (NP (NP (NN MZF-2)) (PP (IN in) (NP (NN neutrophil) (NN development)))))))))))) (. .)))
(TOP (S (NP (ADJP (JJ c-Rel) (CC and) (JJ p65)) (NNS subunits)) (VP (NN bind) (PP (TO to) (NP (NP (NP (DT an) (JJ upstream) (NN NF-kappaB) (NN site)) (PP (IN in) (NP (JJ human) (JJ granulocyte) (JJ macrophage-colony) (JJ stimulating) (NN factor) (NN promoter)))) (VP (VBN involved) (PP (IN in) (NP (NP (JJ phorbol) (NN ester) (NN response)) (PP (IN in) (NP (CD 5637) (NNS cells))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (ADVP (RBR further)) (VB clarify) (NP (NP (DT the) (JJ complex) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (NP (DT the) (JJ human) (NNP GM-CSF) (NN gene)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (ADVP (RB extensively)) (VBN investigated) (PP (IN in) (NP (VBN activated) (NNP T) (NNS cells))))))))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN studied) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT an) (JJ upstream) (NN NF-kappaB))) (PP (IN like) (NP (NP (NN site)) (PP (IN in) (NP (NP (DT the) (CD 5637) (JJ non-lymphoid) (NN cell) (NN line)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ derives) (PP (IN from) (NP (DT a) (NN bladder) (NN carcinoma)))) (CC and) (VP (ADVP (RB constitutively)) (VBZ produces) (NP (NNP GM-CSF))))))))))))) (. .)))
(TOP (S (NP (NP (DT This) (NN sequence)) (, ,) (VP (VBD named) (S (NP (DT the) (NNP A) (NN element)))) (, ,)) (VP (VP (VBZ has) (NP (NP (DT an) (JJ active) (NN role)) (PP (IN on) (NP (NNP GM-CSF) (NN transcription))))) (CC and) (VP (VBZ is) (ADJP (JJ responsive) (PP (TO to) (NP (DT the) (NN tumor) (NN promoter) (NNP PMA))) (PP (IN in) (NP (JJ transient) (NN transfection) (NNS experiments)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP describe) (ADVP (RB here)) (NP (NP (DT a) (JJ heterodimeric) (JJ binding) (NN complex)) (PP (IN of) (NP (NP (JJ NF-kappaB) (NNS subunits)) (PRN (-LRB- -LRB-) (NP (NN c-Rel) (CC and) (NN p65)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ identical) (PP (TO to) (NP (NP (DT the) (NN one)) (VP (VBD obtained) (S (VP (VBG using) (NP (DT the) (JJ HIV-LTR-kappaB) (NN site)))) (SBAR (IN as) (S (NP (NP (NN recognition) (NN sequence)) (CC and) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (CD one)) (PRN (-LRB- -LRB-) (ADJP (JJ c-Rel) (CC and) (JJ p50)) (-RRB- -RRB-)))))) (VP (VBD observed) (PP (IN with) (NP (NP (JJ nuclear) (NNS extracts)) (PP (IN from) (NP (NNP Mo) (NNP T-lymphoid) (NNP HTLV-II) (JJ infected) (NNS cells))))))))))))))))))) (. .)))
(TOP (S (NP (NNP Cyclosporin) (NNP A)) (VP (VBZ inhibits) (NP (NP (JJ monocyte) (NN tissue) (NN factor) (NN activation)) (PP (IN in) (NP (JJ cardiac) (NN transplant) (NNS recipients))))) (. .)))
(TOP (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (NNP Fibrin) (NN deposition)) (CC and) (NP (NN thrombosis))) (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (DT both) (NP (JJ allograft) (NN rejection)) (CC and) (NP (NN vasculopathy)))) (PP (IN after) (NP (JJ cardiac) (NN transplantation))))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP (NNS monocytes)) (VP (VBP play) (NP (NP (DT a) (JJ pivotal) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (JJ intravascular) (NN coagulation) (NN activation)))))) (PP (IN through) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB synthesize) (NP (NP (NN tissue) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP TF)) (-RRB- -RRB-))))))))))) (, ,) (NP (PRP we)) (VP (VBD asked) (PRN (-LRB- -LRB-) (INTJ (CD 1)) (-RRB- -RRB-)) (SBAR (IN whether) (S (NP (JJ monocyte) (NNP TF) (NN activation)) (VP (VBZ occurs) (PP (IN in) (NP (NP (JJ cardiac) (NN transplant) (NNS recipients)) (CC and) (PRN (-LRB- -LRB-) (INTJ (CD 2)) (-RRB- -RRB-)))) (SBAR (IN whether) (S (NP (JJ monocyte) (NNP TF) (NN expression)) (VP (VBZ is) (VP (VBN affected) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN cyclosporin) (NNP A)) (PRN (-LRB- -LRB-) (NP (NNP CsA)) (-RRB- -RRB-)))))))))))))) (. .)))
(TOP (NP (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (NP (PRP We)) (VP (VBD measured) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NNP TF) (NN activity)) (PP (IN in) (NP (NP (JJ peripheral) (NN blood) (NN mononuclear) (NNS cells)) (CC and) (NP (ADJP (RB highly) (VBN purified)) (NNS monocytes/macrophages)))))) (PP (IN from) (NP (NP (CD 10) (JJ consecutive) (JJ cardiac) (NN transplant) (NNS recipients)) (CC and) (NP (CD 10) (JJ healthy) (NN control) (NNS subjects))))))) (. .)))
(TOP (S (NP (NP (NN TF) (NN activity)) (VP (VBN generated) (PP (IN by) (NP (DT both) (ADJP (JJ unstimulated) (CC and) (JJ endotoxin-stimulated)) (NNS cells))))) (VP (VBD was) (ADJP (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NN transplant) (NNS recipients)))) (PP (IN than) (PP (IN in) (NP (NP (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (S (NP (NNP P)) (VP (VBD &lt;) (NP (CD .05)))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (S (NP (NP (VBN Increased) (JJ monocyte) (NNP TF) (NN expression)) (PP (IN in) (NP (NN transplant) (NNS recipients)))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (VP (ADVP (RB adversely)) (VBN affected) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP CsA)))))))))))) (: :) (S (NP (NNP TF) (NN induction)) (VP (VBD was) (ADVP (RB markedly)) (VP (VBN reduced) (PP (IN by) (NP (NP (NNP CsA) (NN serum) (NNS concentrations)) (VP (VBG reaching) (NP (JJ peak) (NNP CsA) (NN drug) (NNS levels)))))))) (. .)))
(TOP (S (NP (NP (NNP Inhibition)) (PP (IN of) (NP (NP (NNP TF) (NN induction)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ high) (NNP CsA) (NN blood) (NNS concentrations)))))))) (VP (VBD was) (ADVP (RB also)) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN stimulation)) (PP (IN of) (NP (NNS cells)))) (VP (VBD was) (VP (VBN performed) (PP (IN with) (ADJP (JJ interferon-gamma) (CC or) (JJ interleukin-1beta))))))))) (. .)))
(TOP (S (SBAR (IN As) (S (VP (VBN shown) (PP (IN by) (NP (NP (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction)) (CC and) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)))) (, ,) (ADVP (RB respectively))))) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP CsA)))) (VP (VBZ leads) (S (VP (TO to) (VP (VBN decreased) (NP (NP (NNP TF) (NNP mRNA) (NN expression)) (CC and) (NP (NP (JJ reduced) (NN activation)) (PP (IN of) (NP (NP (DT the) (JJ NF-kappaB) (NN transcription) (NN factor)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (DT the) (NNP TF) (NN promotor)) (PP (IN in) (NP (JJ human) (NNS monocytes)))))))))))))))))))))) (. .)))
(TOP (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (NNP TF) (NN activation)) (, ,) (VP (VBG occurring) (PP (IN in) (NP (NP (JJ mononuclear) (NNS cells)) (PP (IN of) (NP (JJ cardiac) (NN transplant) (NNS recipients)))))) (, ,)) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP CsA))))))))))) (. .)))
(TOP (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (JJ monocyte) (NNP TF) (NN induction)) (PP (IN by) (NP (NNP CsA)))))) (VP (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (PRP$ its) (JJ successful) (NN use)) (PP (IN in) (NP (JJ cardiac) (NN transplant) (NN medicine))))))) (CC and) (VP (MD might) (VP (VB be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG managing) (NP (NP (JJ further) (NNS settings)) (PP (IN of) (NP (NP (JJ vascular) (NN pathology)) (VP (ADVP (RB also)) (VBN known) (S (VP (TO to) (VP (VB involve) (NP (NP (NNP TF) (NN expression)) (CC and) (NP (JJ NF-kappaB) (NN activation))))))))))))))))) (. .)))
(TOP (NP (NP (JJ Agonistic) (NN activity)) (PP (IN of) (NP (NP (DT a) (JJ CD40-specific) (JJ single-chain) (NN Fv)) (VP (VBN constructed) (PP (IN from) (NP (NP (DT the) (JJ variable) (NNS regions)) (PP (IN of) (NP (NNP mAb) (NNP G28-5)))))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ single-chain) (NNP Fv)) (PRN (-LRB- -LRB-) (NP (NNP sFv)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN expressed) (PP (IN from) (NP (NP (DT the) (JJ variable) (NNS regions)) (PP (IN of) (NP (DT the) (JJ CD40-specific) (NNP mAb) (NNP G28-5))))))) (. .)))
(TOP (S (NP (DT The) (NN molecule)) (VP (VP (VBD bound) (NP (NNP CD40)) (PP (IN with) (NP (NP (DT a) (JJ high) (NN affinity)) (PRN (-LRB- -LRB-) (NP (CD 2.2) (NN nM)) (-RRB- -RRB-))))) (CC and) (VP (VBD was) (NP (NP (DT a) (NN monomer)) (PP (IN in) (NP (NN solution)))))) (. .)))
(TOP (S (ADVP (RB Surprisingly)) (, ,) (NP (NNP G28-5) (NNP sFv)) (VP (VBD was) (NP (NP (DT a) (JJ potent) (NNP CD40) (NN agonist)) (SBAR (WHNP (WDT that)) (S (VP (VP (ADVP (RB rapidly)) (VBD crosslinked) (NP (NNP CD40)) (PP (IN on) (NP (DT the) (NN cell) (NN surface)))) (CC but) (VP (VBD did) (RB not) (VP (VB crosslink) (NP (NP (NN CD40-Ig)) (PP (IN in) (NP (NN solution))))))))))) (. .)))
(TOP (S (NP (NNP G28-5) (NNP sFv)) (VP (VP (VBD was) (NP (NP (DT a) (ADJP (RBR more) (JJ potent)) (NN agonist)) (PP (IN than) (NP (NNP G28-5) (NNP IgG))))) (CC and) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (VP (VB stimulate) (NP (JJ CD40) (NNS responses)) (PP (IN by) (NP (NNP B) (NNS cells) (CC and) (NNS monocytes))))))))) (. .)))
(TOP (S (NP (NNP G28-5) (NNP IgG)) (VP (ADVP (RB partially)) (VBD blocked) (, ,) (SBAR (IN whereas) (S (NP (NNP G28-5) (NNP sFv)) (VP (VBD augmented) (NP (CD CD40) (NNS responses)) (PP (IN during) (NP (NN stimulation))) (PP (IN with) (NP (NP (JJ natural) (NN ligand)) (PRN (-LRB- -LRB-) (NP (JJ gp39-CD8) (NN fusion) (NN protein)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ functional) (NN activity)) (PP (IN of) (NP (NP (NNS ligands)) (VP (VBN built) (PP (IN from) (NP (NP (DT the) (JJ binding) (NN site)) (PP (IN of) (NP (NNP G28-5))))))))) (VP (VBZ is) (ADJP (RB highly) (JJ dependent) (PP (IN upon) (NP (NP (DT the) (NX (NX (NN size)) (CC and) (NX (JJ physical) (NNS properties)))) (PP (IN of) (NP (DT the) (NN molecule))) (PP (DT both) (PP (IN in) (NP (NN solution))) (CC and) (PP (IN on) (NP (DT the) (NN cell) (NNS surfaces))))))))))) (. .)))
(TOP (NP (NP (JJ Competent) (NN transcription) (NN initiation)) (PP (IN by) (NP (NNP RNA) (NN polymerase) (NNP II))) (PP (IN in) (NP (NP (JJ cell-free) (NNS extracts)) (PP (IN from) (NP (NN xeroderma) (NN pigmentosum) (NNS groups) (NNP B) (CC and) (NNP D))) (PP (IN in) (NP (DT an) (VBN optimized) (NNP RNA) (NN transcription) (NN assay))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ human) (JJ autosomal) (JJ recessive) (NN disease)) (, ,) (NP (NP (NN xeroderma) (NN pigmentosum)) (PRN (-LRB- -LRB-) (NP (NNP XP)) (-RRB- -RRB-))) (, ,)) (VP (MD can) (VP (VB result) (PP (IN from) (NP (NP (NNS mutations)) (PP (IN in) (NP (NP (DT any) (CD one)) (PP (IN of) (NP (CD seven) (NNS genes))) (, ,) (VP (VBN designated) (S (NP (NNP XPA))) (PP (IN through) (NP (NNP XPG)))))))))) (. .)))
(TOP (S (PP (IN Of) (NP (DT these))) (, ,) (NP (DT the) (NNP XPB) (CC and) (NNP XPD) (NNS genes)) (VP (VBP encode) (NP (NP (NNS proteins)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS subunits)) (PP (IN of) (NP (NP (DT a) (JJ general) (NN transcription) (NN factor)) (, ,) (NP (NNP TFIIH)) (, ,))) (VP (VBN involved) (PP (IN in) (NP (DT both) (NP (NP (JJ nucleotide) (NN excision) (NN repair)) (PRN (-LRB- -LRB-) (NP (NNP NER)) (-RRB- -RRB-))) (CC and) (NP (NP (NN initiation)) (PP (IN of) (NP (NNP mRNA) (NN transcription))) (PP (IN by) (NP (NNP RNA) (NN polymerase) (NNP II))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NNS humans))) (, ,) (NP (NP (NN mutation)) (PP (IN of) (NP (DT the) (NNP XPB) (CC or) (NNP XPD) (NN gene)))) (VP (VBZ impairs) (NP (NNP NER)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NN hyper-sensitivity))) (PP (TO to) (NP (NP (NN sunlight)) (CC and) (NP (ADJP (RB greatly) (VBN increased)) (NN skin) (NN tumor) (NN formation))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (DT no) (NN transcription) (NN deficiency)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (DT either) (NNP XP-B) (CC or) (NNP XP-D)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN employed) (NP (DT an) (JJ optimized) (JJ cell-free) (NNP RNA) (NN transcription) (NN assay)) (S (VP (TO to) (VP (VB analyze) (NP (NP (NN transcription) (NN activity)) (PP (IN of) (NP (NNP XP-B) (CC and) (NNP XP-D))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (DT the) (NN growth) (NN rate)) (VP (VBD was) (ADJP (JJ normal))))) (, ,) (NP (DT the) (NNP XP-B) (CC and) (NNP XP-D) (NNS cells)) (VP (VBD contained) (NP (NP (JJ reduced) (NNS amounts)) (PP (IN of) (NP (NNP TFIIH))))) (. .)))
(TOP (S (NP (NP (NNS Extracts)) (VP (VBN prepared) (PP (IN from) (NP (NNP XP-B) (CC and) (NNP XP-D) (JJ lymphoblastoid) (NNS cells))))) (VP (VBD exhibited) (NP (JJ similar) (NN transcription) (NN activity)) (PP (IN from) (NP (DT the) (JJ adenovirus) (JJ major) (JJ late) (NN promoter))) (SBAR (WHADVP (WRB when)) (S (PP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (NP (NNS extracts)) (PP (IN from) (NP (JJ normal) (NNS cells))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (NNP XP-B) (CC and) (NNP XP-D) (JJ lymphoblastoid) (NNS cells)) (VP (VBP do) (RB not) (VP (VB have) (VP (VBN impaired) (NP (NNP RNA) (NN transcription) (NN activity)))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VP (VBP consider) (NP (NP (DT the) (JJ possible) (NNS consequences)) (PP (IN of) (NP (NP (DT the) (VBN reduced) (JJ cellular) (NN content)) (PP (IN of) (NP (NNP TFIIH))))) (PP (IN for) (NP (NP (DT the) (JJ clinical) (NNS symptoms)) (PP (IN in) (NP (NP (NNP XP-B)) (CC or) (NP (NNP XP-D) (NNS patients)))))))) (, ,) (CC and) (VP (VB discuss) (NP (NP (DT a) (POS ') (JJ conditional) (NN phenotype)) ('' ') (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB involve) (NP (NP (DT an) (NN impairment)) (PP (IN of) (NP (JJ cellular) (NN function)))) (PP (ADVP (RB only)) (IN under) (NP (JJ certain) (NN growth) (NNS conditions)))))))))) (. .)))
(TOP (S (NP (NNP Cyclosporin) (NNP A)) (VP (VBZ inhibits) (NP (NP (JJ early) (NNP mRNA) (NN expression)) (PP (IN of) (NP (NP (CD G0/G1) (NN switch) (NN gene) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN G0S2)) (-RRB- -RRB-)) (PP (IN in) (NP (VBN cultured) (JJ human) (NN blood) (NN mononuclear) (NNS cells))))))) (. .)))
(TOP (S (NP (NP (NNP Cyclosporin) (NNP A)) (PRN (-LRB- -LRB-) (NP (NNP CsA)) (-RRB- -RRB-))) (VP (MD may) (VP (VB achieve) (NP (PRP$ its) (JJ immunosuppressive) (NNS effects)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (DT the) (ADJP (JJ calcium-) (CC and) (JJ calmodulin-dependent)) (NN phosphatase) (NN calcineurin)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (NN activation)) (PP (IN of) (NP (NP (NP (NN target) (NNS genes)) (PP (IN by) (NP (NP (NNS members)) (PP (IN of) (NP (NP (DT the) (NNP NFAT) (PRN (-LRB- -LRB-) (JJ nuclear) (NN factor))) (PP (IN of) (NP (VBN activated) (NNP T) (NNS cells)))))))) (-RRB- -RRB-) (NP (NN transcription) (NN factor) (NN family)))))))))))))))) (. .)))
(TOP (SINV (PP (IN Among) (NP (DT these) (NN target) (NNS genes))) (VP (VBZ is)) (NP (NP (DT the) (NN gene)) (VP (VBG encoding) (NP (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (CD IL2)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN cytokine)) (VP (VBG facilitating) (NP (NN progression)) (PP (IN through) (NP (NP (DT the) (NNP G1) (NN phase)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (NNP IL2)) (VP (VBZ does) (RB not) (VP (VB reverse) (NP (NNP CsA) (NN inhibition)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (QP (IN at) (JJS least) (CD one)) (JJ other) (JJ NFAT-sensitive) (NN gene)) (VP (MD may) (VP (VB be) (VP (VBN involved)))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ human) (NNP G0/G1) (NN switch) (NN gene)) (, ,) (NP (NNP G0S2)) (, ,)) (VP (VP (VBZ has) (NP (NP (JJ potential) (JJ NFAT-binding) (NNS sites)) (PP (IN in) (NP (DT the) (CD 5') (NN flank))))) (CC and) (VP (VBZ encodes) (NP (NP (DT a) (JJ small) (JJ basic) (JJ potential) (NN phosphoprotein)) (PP (IN of) (NP (JJ unknown) (NN function)))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (DT a) (JJ sensitive) (, ,) (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction) (PRN (-LRB- -LRB-) (NN RT-PCR) (-RRB- -RRB-)) (NN assay)))) (, ,) (NP (NNP G0S2) (NNP mRNA) (NNS levels)) (VP (VBD were) (VP (VBN assayed) (PP (IN in) (NP (JJ cultured) (NN blood) (NN mononuclear) (NNS cells))))) (. .)))
(TOP (S (ADVP (RB Freshly)) (NP (VBN isolated) (NNS cells)) (VP (VBP contain) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (NNP G0S2) (NNP mRNA)) (SBAR (WHNP (WDT which)) (S (VP (ADVP (RB rapidly)) (VBP decline)))))))) (. .)))
(TOP (S (NP (DT This) (`` ``) (JJ spontaneous) (NN stimulation)) (VP (VP (VBZ is) (ADVP (RB also)) (VP (VBN noted) (PP (IN with) (NP (DT some) (JJ other) (JJ G0S) (NNS genes))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (DT some) (NN aspect)) (PP (IN of) (NP (DT the) (NN isolation) (NN procedure))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN been) (VP (VBN preincubated) (PP (TO to) (NP (VB lower) (NNP mRNA) (NNS levels)))))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ transient) (NN increase)) (PP (IN in) (NP (NNP G0S2) (NNP mRNA)))) (, ,) (S (VP (VBG peaking) (PP (PP (IN between) (NP (CD 1-2) (NN h))) (, ,) (PP (IN in) (NP (NP (NN response)) (PP (PP (TO to) (NP (NP (NNP Concanavalin-A)) (PRN (-LRB- -LRB-) (NP (NNP ConA)) (-RRB- -RRB-)))) (, ,) (CC or) (PP (TO to) (NP (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (FW phorbol) (FW ester)) (PRN (-LRB- -LRB-) (NP (NNP TPA)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (DT the) (NN calcium) (NN ionophore)) (, ,) (NP (NN ionomycin)))))))))))) (. .)))
(TOP (S (NP (DT Both) (DT these) (NNS responses)) (VP (VBP are) (VP (VBN inhibited) (PP (IN by) (NP (NNP CsA))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (JJ G0S2) (NN expression)) (VP (VBZ is) (VP (VBN required) (S (VP (TO to) (VP (VB commit) (NP (NNS cells)) (S (VP (TO to) (VP (VB enter) (NP (NP (DT the) (NNP G1) (NN phase)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle)))))))))))))) (, ,) (CC and) (SBAR (IN that) (, ,) (S (SBAR (IN while) (S (RB not) (VP (VBG excluding) (NP (JJ other) (JJ possible) (NNS targets))))) (, ,) (NP (NP (JJ early) (NN inhibition)) (PP (IN of) (NP (JJ G0S2) (NN expression))) (PP (IN by) (NP (NNP CsA)))) (VP (MD may) (VP (VB be) (ADJP (JJ important) (PP (IN in) (S (VP (VBG achieving) (NP (NN immunosuppression)))))))))))) (. .)))
(TOP (S (NP (CD G0S2)) (VP (MD may) (VP (VB be) (PP (IN of) (NP (NN value))) (PP (IN as) (NP (NP (DT a) (NN reporter) (NN gene)) (PP (IN for) (S (VP (VBG analyzing) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NP (NN action)) (PP (IN of) (NP (NNP CsA)))) (CC and) (NP (NP (PRP$ its) (NN influence)) (PP (IN on) (NP (NP (DT the) (ADJP (JJ positive) (CC and) (JJ negative)) (NN selection)) (PP (IN of) (NP (NNS lymphocytes)))))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (NN self)) (CC and) (NP (JJ not-self) (NNS antigens)))))))))))))) (. .)))
(TOP (S (NP (NN Estrogen) (NN receptor)) (VP (VBZ diminishes) (NP (NP (JJ DNA-binding) (NNS activities)) (PP (IN of) (NP (NP (NN chicken) (NN GATA-1)) (CC and) (NP (JJ CACCC-binding) (NNS proteins)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP ER)) (-RRB- -RRB-))) (VP (JJ repressed) (NP (NP (JJ erythroid) (NN differentiation)) (CC and) (NP (JJ erythroid-specific) (NN gene) (NN expression)))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP ER) (NN alpha))) (PRN (-LRB- -LRB-) (VP (VBD referred) (PP (TO to)) (PP (IN throughout) (PP (IN as) (NP (NNP ER))))) (-RRB- -RRB-)) (PP (IN on) (NP (NP (JJ DNA-binding) (NNS activities)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (VP (VBN involved) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ erythroid-specific) (NNS genes))))))))))))) (, ,) (CC and) (, ,) (PP (IN in) (NP (JJ particular))) (, ,) (NP (DT the) (NN histone) (NN H5) (NN gene)))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)))) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN rabbit) (NN reticulocyte) (NN lysate))))) (, ,) (NP (JJ human) (NNP ER)) (VP (VBD reduced) (NP (NP (DT the) (JJ binding) (NNS activities)) (PP (IN of) (NP (NN chicken) (NN immature) (VBD erythrocyte) (JJ nuclear) (VBN extracted) (NNS proteins)))) (PP (TO to) (NP (NP (NNP GATA) (CC and) (NNP CACCC) (NNS sites)) (PP (IN in) (NP (DT the) (NNP H5) (NN promoter) (CC and) (NN enhancer))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (JJ binding) (NNS activities)) (PP (IN of) (NP (NNP NF1) (CC and) (NNP Sp1)))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NNP ER))))) (. .)))
(TOP (S (S (VP (VBG Binding) (PP (IN of) (NP (NNP ER))) (PP (TO to) (NP (DT an) (NN estrogen) (NN response) (NN element))))) (VP (VBD was) (VP (VBN enhanced) (PP (IN by) (NP (NP (NN addition)) (PP (IN of) (NP (NN rabbit) (NN reticulocyte) (NN lysate))))))) (. .)))
(TOP (S (NP (DT This) (NN lysate)) (VP (VBD was) (ADVP (RB also)) (ADJP (JJ necessary)) (SBAR (IN for) (S (NP (NNP ER)) (VP (TO to) (VP (VB diminish) (NP (NP (DT the) (JJ DNA-binding) (NN activity)) (PP (IN of) (NP (NN GATA-1))))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ additional) (NN factor)) (PRN (-LRB- -LRB-) (NP (PRP s)) (-RRB- -RRB-))) (VP (VBP are) (ADJP (JJ necessary)) (PP (IN for) (NP (JJ full) (NNP ER) (NN function))))))) (. .)))
(TOP (S (NP (DT Both) (ADJP (JJ GATA-1) (CC and) (JJ CACCC-binding)) (NNS proteins)) (VP (VBP are) (ADJP (JJ critical) (PP (IN for) (NP (NP (DT the) (ADJP (RB developmentally) (JJ regulated)) (NN expression)) (PP (IN of) (NP (JJ erythroid-specific) (NNS genes))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (DT that) (S (NP (NP (NN interference)) (PP (IN in) (NP (NP (JJ DNA-binding) (NNS activities)) (PP (IN of) (NP (NN GATA-1) (CC and) (JJ CACCC-binding) (NNS proteins)))))) (VP (VBZ is) (NP (NP (DT the) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (DT the) (NNP ER)) (VP (VBZ inhibits) (NP (NP (NN regulation)) (PP (IN of) (NP (DT these) (NNS genes)))))))))))) (. .)))
(TOP (NP (NP (NNP HLA) (VBG binding) (NNS characteristics)) (CC and) (NP (NP (NN generation)) (PP (IN of) (NP (JJ cytotoxic) (NNS lymphocytes))) (PP (IN against) (NP (NP (NNS peptides)) (VP (VBN derived) (PP (IN from) (NP (JJ oncogenic) (NNS proteins))))))) (. .)))
(TOP (NP (NP (NNP AIMS) (CC AND) (NNP BACKGROUND)) (: :) (S (NP (NP (ADJP (RB Structurally) (VBN altered)) (NNS proteins)) (PRN (-LRB- -LRB-) (VP (VBN derived) (PP (IN from) (NP (NP (JJ chromosomal) (NNS translocations)) (CC or) (NP (NN gene) (NNS mutations))))) (-RRB- -RRB-))) (VP (VP (MD can) (VP (VB be) (VP (VBN considered) (S (NP (NN tumor) (NN specific) (NNS antigens)))))) (CC and) (VP (VBP represent) (NP (NP (DT an) (JJ attractive) (NN target)) (PP (IN for) (NP (DT a) (JJ T-cell) (JJ mediated) (NN response))))))) (. .)))
(TOP (S (NP (NN T) (NNS lymphocytes)) (VP (VBP recognize) (NP (NP (NNS antigens)) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NP (NNS peptides)) (VP (VBN bound) (PP (TO to) (NP (NNS HLA-molecules)))))))))) (. .)))
(TOP (NP (NP (NNP MATERIALS) (CC AND) (NNPS METHODS)) (: :) (S (S (NP (NP (NNS Peptides)) (VP (VBN derived) (PP (IN from) (NP (JJ oncogenic) (NNS proteins))))) (VP (VBD were) (VP (VBN screened) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP HLA) (VBG binding) (NNS motifs)))))))) (: ;) (S (NP (JJ actual) (JJ binding)) (VP (VBD were) (VP (VBN evaluated) (PP (IN by) (NP (NP (NNP HLA) (NN stabilization) (NNS experiments)) (VP (VBG using) (NP (NP (NNS transfectants)) (CC and) (NP (JJ specific) (JJ anti-HLA) (NNS antibodies)))))))))) (. .)))
(TOP (S (NP (JJ Specific) (NNS lymphocytes)) (VP (VBD were) (VP (VP (VBN induced) (PP (IN by) (PP (IN in) (NP (NN vitro) (NN peptide) (NN sensitization))))) (CC and) (VP (VBN screened) (PP (IN by) (NP (NP (JJ thymidine) (NN uptake)) (CC or) (NP (JJ cellular) (JJ cytotoxic) (NNS assays))))))) (. .)))
(TOP (NP (NP (NNS RESULTS)) (: :) (S (NP (PRP We)) (VP (VBD identified) (NP (NP (NP (NNS peptides)) (VP (VBN derived) (PP (PP (IN from) (NP (JJ EWS/FLI-1) (NN fusion) (NN protein))) (CC and) (PP (IN from) (NP (VBN mutated) (NNP K-RAS) (NN protein)))))) (PRN (-LRB- -LRB-) (NP (S (VP (VBG encompassing) (ADVP (RB respectively)) (NP (DT the) (NN fusion) (NN point)))) (CC and) (NP (NP (DT the) (NN mutation)) (PP (IN at) (NP (NN position) (CD 12))))) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD showed) (NP (NP (VBG binding) (NN motif)) (PP (IN for) (NP (NP (NNP HLA-Cw*0702) (CC and) (NNP HLA-A3)) (ADVP (RB respectively))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ actual) (VBG binding)) (PP (IN of) (NP (DT these) (NNS peptides)))) (VP (VBD was) (VP (VBN analysed) (PP (IN in) (NP (DT a) (NN stabilization) (NN assay))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD detected) (S (VP (VBG binding) (PP (PP (IN for) (NP (DT the) (NNP EWS/FLI-1) (NN peptide))) (CC and) (PP (IN for) (NP (NP (CD 5) (NNP RAS) (NNS peptides)) (PRN (-LRB- -LRB-) (S (NP (NP (CD 1) (JJ wild) (NN type)) (CC and) (NP (CD 4))) (VP (VBN mutated))) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NP (NN temperature)) (, ,) (NP (NP (JJ beta) (JJ 2-microglobulin)) (PRN (-LRB- -LRB-) (NP (JJ beta) (NN 2-m)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ fetal) (NN calf) (NN serum)) (PRN (-LRB- -LRB-) (NP (NNP FCS)) (-RRB- -RRB-)) (PP (IN on) (NP (DT the) (JJ binding))))) (CC and) (NP (NP (DT the) (NN stability)) (PP (IN of) (NP (DT the) (NNP HLA/peptide) (NN complex))))))) (VP (VBD was) (VP (VBN studied))) (. .)))
(TOP (S (NP (NP (DT A) (JJ low) (NN temperature)) (PRN (-LRB- -LRB-) (NP (CD 26) (NNS degrees) (NNP C)) (-RRB- -RRB-))) (VP (VBD increased) (NP (NP (DT the) (VBG binding) (DT both)) (PP (IN in) (NP (NNP HLA-A3) (CC and) (NNP HLA-Cw*0702)))) (, ,) (SBAR (IN while) (S (NP (NNP FCS)) (VP (VBD reduced) (NP (PRP it)))))) (. .)))
(TOP (S (NP (JJ beta) (NN 2-m)) (VP (VP (VBD increased) (NP (NP (DT the) (VBG binding)) (PP (TO to) (NP (DT the) (JJ HLA-A3) (NN molecule))))) (CC but) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (VBG binding)) (PP (TO to) (NP (DT the) (NN HLA-Cw*0702))))))) (. .)))
(TOP (S (S (NP (NP (DT The) (NN stability)) (PP (IN of) (S (VP (ADVP (RB already)) (VBN formed) (ADJP (VBN complexed)))))) (VP (VBD was) (ADJP (RB somewhat) (JJ different) (PP (IN in) (NP (DT the) (NN HLA-A3) (CC and) (NN HLA-Cw*0702) (NN system)))))) (: :) (S (S (NP (DT both)) (VP (VBD were) (ADJP (ADJP (RBR more) (JJ stable))) (PP (IN at) (NP (CD 26) (NNS degrees) (NNP C))) (PP (IN than) (PP (IN at) (NP (CD 37) (NNS degrees) (NNP C)))))) (CC but) (S (SBAR (IN while) (S (NP (DT the) (JJ beta) (NN 2-m) (CC and) (NNP FCS)) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (NN stability)) (PP (IN of) (NP (DT the) (JJ HLA-A3/peptide) (NN complex)))))))) (, ,) (NP (PRP they)) (VP (VBD seemed) (S (VP (TO to) (VP (VB cause) (NP (NP (NP (JJ opposite) (NNS effects)) (PP (IN in) (NP (DT the) (NN HLA-Cw*0702) (NN system)))) (PRN (-LRB- -LRB-) (S (S (NP (JJ beta) (NN 2-m)) (VP (VBD stabilized))) (CC and) (S (NP (NNP FCS)) (VP (VBD destabilized) (NP (DT the) (NN complex))))) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBD were) (ADJP (JJ able) (S (VP (TO to) (VP (VB generate) (NP (NP (DT a) (JJ specific) (NNP CD8+) (NNP CTL) (NN line)) (PP (IN against) (NP (DT a) (NNP K-RAS) (VBN mutated) (NN peptide))))))))) (. .)))
(TOP (NP (NP (NNS CONCLUSIONS)) (: :) (S (SBAR (IN Although) (S (NP (NP (NP (VBG binding) (NNS motifs)) (CC and) (NP (JJ actual) (NNP HLA))) (VP (VBG binding))) (VP (MD can) (VP (VB be) (VP (VBN detected) (PP (IN in) (NP (JJ several) (NNS cases)))))))) (, ,) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (DT a) (JJ cellular) (NN response)))) (VP (VBZ is) (ADJP (JJ infrequent)) (, ,) (S (VP (VBG confirming) (SBAR (IN that) (S (NP (NP (NNP HLA)) (VP (VBG binding))) (VP (VBZ is) (ADJP (ADJP (JJ necessary)) (CC but) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB obtain) (NP (NP (DT an)) (PP (IN in) (NP (NN vitro) (NN response)))))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Further) (NN optimization)) (PP (IN of) (NP (NP (NN culture) (NNS conditions)) (, ,) (NP (NP (NN type)) (PP (IN of) (NP (NP (NP (NNP Antigen) (NNP Presenting) (NNP Cells)) (PRN (-LRB- -LRB-) (NP (NNP APC)) (-RRB- -RRB-))) (, ,) (NP (NNS peptides)) (, ,)))) (NP (NP (NN use)) (PP (IN of) (NP (NP (NNS stabilizers)) (PP (IN like) (NP (JJ beta) (NN 2-m))))))))) (VP (VBP are) (ADVP (RB still)) (VP (VBN needed))) (. .)))
(TOP (NP (NP (NNP Control)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NN activity))) (PP (IN by) (NP (DT the) (ADJP (PRP I)) (VBP kappa) (NN B) (NN beta) (NN inhibitor))) (. .)))
(TOP (S (NP (DT The) (NN transcription) (NN factor) (NNP NF-kappa) (NNP B)) (VP (VBZ is) (VP (VBN maintained) (PP (IN in) (NP (NP (DT an) (JJ inactive) (JJ cytoplasmic) (NN state)) (PP (IN by) (NP (PRP I))))) (NP (VBP kappa) (NN B) (NNS inhibitors)))) (. .)))
(TOP (S (S (PP (IN In) (NP (JJ mammalian) (NNS cells))) (, ,) (NP (PRP I)) (VP (VBP kappa) (NP (NN B) (NN alpha)))) (CC and) (S (NP (PRP I)) (VP (VBP kappa) (SBAR (S (NP (NN B) (NN beta) (NNS proteins)) (VP (VBP have) (VP (VP (VBN been) (VP (VBN purified))) (CC and) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (NNS inhibitors)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))) (PP (IN through) (NP (NP (PRP$ their) (NN association)) (PP (IN with) (NP (DT the) (ADJP (JJ p65) (CC or) (JJ c-Rel)) (NNS subunits))))))))))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN isolated) (NP (DT a) (JJ third) (NN NF-kappa) (NN B) (NN inhibitor))))) (, ,) (NP (PRP I)) (VP (VBP kappa) (NP (NP (NN B) (NN epsilon)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)))) (. .)))
(TOP (S (S (PP (IN Upon) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (DT a) (JJ large) (NN variety)) (PP (IN of) (NP (NNS inducers))))))) (, ,) (NP (PRP I)) (VP (VBP kappa) (NP (NN B) (NN alpha)))) (, ,) (NP (PRP I)) (VP (VBP kappa) (NP (NN B) (SBAR (S (NP (NN beta)) (VP (VBP are) (ADJP (RB proteolytically) (JJ degraded)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NNP NF-kappa) (NNP B) (NN translocation))) (PP (IN into) (NP (DT the) (NN nucleus)))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (SBAR (IN that) (S (S (PP (IN in) (NP (NNP E29.1) (NNP T) (NN cell) (NN hybridoma))) (NP (PRP I)) (VP (VBP kappa) (NP (NN B) (NN alpha)))) (CC and) (S (NP (PRP I)) (VP (VBP kappa) (SBAR (S (NP (NN B) (NN beta)) (VP (VBP are) (VP (ADVP (RB equally)) (VBN associated) (PP (IN with) (NP (CD p65))))))))))) (CC and) (SBAR (IN that) (S (NP (PRP I)) (VP (VBP kappa) (NP (NN B) (SBAR (S (NP (NN beta)) (VP (VBZ is) (ADJP (JJ degraded)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP TNF) (NN alpha))))) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (SBAR (WHNP (WP what)) (S (VP (VBZ has) (VP (VBN been) (ADVP (RB originally)) (VP (VBN published)))))))))))))))))) (. .)))
(TOP (S (NP (PRP$ Our) (NNS data)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (, ,) (S (PP (IN unlike) (S (NP (PRP I)) (VP (VBP kappa) (NP (NN B) (NN alpha))))) (, ,) (NP (PRP I)) (VP (VBP kappa) (SBAR (S (NP (NN B) (NN beta)) (VP (VBZ is) (UCP (ADJP (RB constitutively) (VBN phosphorylated)) (CC and) (VP (VBN resynthesized) (PP (IN as) (NP (DT a) (VBN hypophosphorylated) (NN form)))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN absence)) (PP (IN of) (NP (NP (NP (JJ slow) (VBG migrating) (NNS forms)) (PP (IN of) (NP (PRP I)))) (NP (VBP kappa) (NN B) (NN beta) (VBG following) (NN stimulation))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT the) (NN phosphorylation)) (VP (VBZ does) (RB not) (ADVP (RB necessarily)) (VP (VB constitute) (NP (NP (DT the) (JJ signal-induced) (NN event)) (SBAR (WHNP (WDT which)) (S (VP (VBZ targets) (NP (DT the) (NN molecule)) (PP (IN for) (NP (NN proteolysis)))))))))))) (. .)))
(TOP (NP (NP (NP (NNP LPS) (NN tolerance)) (PP (IN in) (NP (NNS monocytes/macrophages)))) (: :) (S (NP (QP (CD three) (CD 3')) (NNS cytosins)) (VP (VBP are) (VP (VBN required) (PP (IN in) (NP (NP (DT the) (NN DNA) (VBG binding) (NN motif)) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (JJ upregulated) (NNP NF-kappa) (NNP B) (JJ p50) (NNS homodimers)))))))))) (. .)))
(TOP (S (S (SBAR (WHADVP (WRB When)) (S (NP (NNS monocytes)) (VP (VBP are) (VP (VBN stimulated) (PP (IN with) (NP (NP (NNP LPS)) (PRN (-LRB- -LRB-) (NP (NN lipopolysaccharide)) (-RRB- -RRB-)))) (ADVP (RB repeatedly)))))) (ADVP (RB then)) (NP (NP (DT the) (ADJP (RB initially) (JJ high)) (NN expression)) (PP (IN of) (NP (DT the) (NNP TNF) (PRN (-LRB- -LRB-) (NN tumor) (NN necrosis) (NN factor) (-RRB- -RRB-)) (NN gene)))) (VP (VBZ is) (ADJP (RB only) (RB very) (JJ low)))) (, ,) (FW i.e.) (S (NP (DT the) (NNS cells)) (VP (VBP are) (ADJP (JJ tolerant) (PP (TO to) (NP (NNP LPS)))))) (. .)))
(TOP (S (S (NP (JJ Tolerant) (NNS cells)) (ADVP (RB still)) (VP (VBP express) (NP (DT the) (NNP CD14) (NN receptor)))) (CC and) (S (NP (PRP they)) (VP (MD can) (ADVP (RB still)) (VP (VB be) (VP (VBN activated) (S (VP (TO to) (VP (VB mobilize) (NP (NNP NF-kappa) (NNP B)) (PP (IN into) (NP (NN nucleus)))))))))) (. .)))
(TOP (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (JJ binding) (NNS proteins)) (VP (VBG employing) (NP (NP (DT the) (CD -605) (NN motif)) (PP (IN of) (NP (NP (DT the) (JJ human) (NNP TNF) (NN promoter)) (PRN (-LRB- -LRB-) (NP (NNP GGGGCTGTCCC)) (-RRB- -RRB-))))))))) (VP (VBD revealed) (SBAR (IN that) (S (PP (IN in) (NP (NP (JJ tolerant) (NNS cells)) (PP (IN of) (NP (DT the) (JJ human) (JJ monocytic) (NN cell) (NN line))))) (NP (NNP Mono) (NNP Mac) (CD 6)) (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN predominance)) (PP (IN of) (NP (NP (CD p50p50)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB now)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT a) (JJ mutant) (NN motif)) (SBAR (WHNP (IN that)) (S (VP (NNS exchanges) (NP (DT the) (NN terminal) (CD 3') (NNP C)) (PP (IN for) (NP (DT a) (NNP G))))))) (VP (VBZ fails) (S (VP (TO to) (VP (NN bind) (NP (NP (DT the) (JJ p50) (NN homodimer)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN upregulated) (PP (IN in) (NP (NNP LPS) (NN toler) (NN ant) (JJ human) (NNP Mono) (NNP Mac) (CD 6) (NNS cells))))))))))))))) (. .)))
(TOP (S (NP (DT The) (JJ same)) (VP (VBZ is) (ADJP (JJ true)) (PP (IN for) (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN taken) (PP (IN from) (NP (DT the) (JJ murine) (NNP P388D1) (NN macrophage) (NN cell) (NN line))) (SBAR (WHADVP (WRB when)) (S (VP (VBN tested) (PP (IN with) (NP (NP (DT the) (CD -516) (NN motif)) (PP (IN of) (NP (NP (DT the) (JJ murine) (NNP TNF) (NN promoter)) (PRN (-LRB- -LRB-) (NP (NNP GGGGGCTTTCCC)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (DT the) (JJ wild) (NN type) (NN motif)) (VP (VBZ gives) (NP (NP (JJ efficient) (VBG binding)) (PP (IN of) (NP (CD p50p50))) (SBAR (WHNP (WDT that)) (S (ADVP (RB again)) (VP (VBZ is) (VP (VBN upregulated) (PP (IN in) (NP (JJ tolerant) (NNS cells))) (SBAR (IN whereas) (S (NP (NP (DT a) (JJ mutant)) (PP (IN with) (NP (DT a) (CD 3') (NNP G)))) (VP (NNS shows) (ADVP (RB hardly)) (NP (NP (DT any) (VBG binding)) (PP (IN of) (NP (CD p50p50))))))))))))) (. .)))
(TOP (S (ADVP (RB Conversely)) (, ,) (NP (NP (DT the) (JJ murine) (NN kappa) (NN light) (NN chain) (NN enhancer) (NN motif)) (PRN (-LRB- -LRB-) (NP (NNP GGGGACTTTCCG)) (-RRB- -RRB-))) (VP (VBZ does) (RB not) (VP (ADVP (RB efficiently)) (NN bind) (NP (DT the) (JJ nuclear) (NN p50p50)) (PP (IN from) (NP (JJ tolerant) (JJ murine) (NN P388) (NNS macrophages))))) (. .)))
(TOP (S (NP (VBG Binding)) (VP (VBZ is) (, ,) (ADVP (RB however)) (, ,) (VP (ADVP (RB readily)) (VBN detected) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (CD 3') (NNP G)) (VP (VBZ is) (VP (VBN replaced) (PP (IN by) (NP (DT a) (NNP C))))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (JJ upregulated) (JJ p50) (NNS homodimers))) (PP (IN in) (NP (NNP LPS) (JJ tolerant) (NNS cells)))) (VP (VBZ is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (JJ subtle) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN sequence)) (PP (IN of) (NP (DT the) (NN DNA) (VBG binding) (NN motif)))))))))))) (. .)))
(TOP (S (NP (DT The) (JJ winged-helix) (NN transcription) (NN factor) (NNP Trident)) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (S (VP (ADVP (RB actively)) (VBG dividing) (NP (NNS lymphocytes))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB recently)) (VP (VP (VBD identified) (NP (DT the) (JJ winged-helix) (NN transcription) (NN factor) (NNP Trident))) (CC and) (VP (VBD described) (NP (NP (PRP$ its) (NN expression) (NN pattern)) (PP (IN in) (NP (VBN synchronized) (NNS fibroblasts)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (ADVP (RB now)) (VP (VBN studied) (NP (NNP Trident) (NN expression)) (PP (IN in) (NP (NN cell) (NNS lines))) (, ,) (UCP (S (VP (VBG differentiating) (NP (NNS thymocytes)))) (CC and) (PP (IN in) (NP (NP (NNS lymphocytes)) (VP (VBN derived) (PP (IN from) (NP (JJ peripheral) (NN blood))))))))) (. .)))
(TOP (S (PP (IN During) (NP (NNP T) (NN cell) (NN differentiation))) (, ,) (NP (NN expression)) (VP (VBD peaked) (PP (IN in) (NP (DT the) (ADJP (RB actively) (VBG dividing)) (JJ immature) (JJ single) (JJ positive) (NNS cells)))) (. .)))
(TOP (S (PP (IN In) (NP (JJ peripheral) (NN blood) (NNS lymphocytes))) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (NNP Trident) (NNP mRNA)))) (VP (VP (VBD was) (ADJP (JJ absent))) (, ,) (CC but) (VP (MD could) (VP (VB be) (VP (VBN induced) (PP (IN upon) (NP (NN stimulation))) (PP (IN with) (NP (NP (NNS mitogens)) (PP (IN in) (NP (NN vitro))))))))) (. .)))
(TOP (S (NP (DT These) (NNS observations)) (VP (VBP imply) (NP (NP (DT a) (NN function)) (PP (IN for) (NP (NNP Trident))) (PP (IN in) (S (VP (VBG dividing) (NP (NNS lymphocytes))))))) (. .)))
(TOP (NP (NP (JJ Temporal) (NN control)) (PP (IN of) (NP (NNP IgH) (NN gene) (NN expression))) (PP (IN in) (S (VP (VBG developing) (NP (NNP B) (NNS cells)) (PP (IN by) (NP (DT the) (CD 3') (NN locus) (NN control) (NN region)))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ suggested) (NNS roles)) (PP (IN of) (NP (NP (DT the) (JJ downstream) (CD 3') (NNS regions)) (VP (VBG acting) (PP (IN as) (NP (NP (DT a) (NNP Locus) (NNP Control) (NNP Region)) (PRN (-LRB- -LRB-) (NP (NNP LCR)) (-RRB- -RRB-)))))))) (, ,) (VP (VBP have) (VP (VBN allowed) (NP (NP (NNS comparisons)) (SBAR (S (VP (TO to) (VP (VB be) (VP (VBN made) (PP (IN between) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (NNP IgH) (NN locus))) (PP (IN with) (NP (NP (JJ other) (NN model) (NNS systems)) (SBAR (WHNP (WP$ whose) (NN gene) (NN expression)) (S (VP (VBZ is) (VP (VBN governed) (PP (IN by) (NP (NNP LCR) (NN activity))))))))))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VP (VBP summarize) (NP (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT the) (NNP IgH) (NNP 3'LCR)))) (CC and) (NP (NP (PRP$ its) (JJ putative) (JJ functional) (NN role)) (PP (IN in) (NP (NNP IgH) (NN gene) (NN expression)))))) (CC and) (VP (VB compare) (NP (PRP it)) (PP (IN with) (NP (NP (DT the) (NNP 5'LCR) (JJ regulatory) (NN region)) (PP (IN of) (NP (DT the) (JJ human) (JJ beta-globin) (NN locus))))))) (. .)))
(TOP (NP (NP (NP (NN Expression)) (PP (IN of) (NP (NN transcription) (NN factor) (NNS genes))) (PP (IN after) (NP (NN influenza)))) (NP (DT A) (NN virus) (NN infection)) (. .)))
(TOP (S (NP (NP (NN Infection)) (PP (IN of) (NP (NP (JJ human) (NNS monocytes)) (PP (IN with) (NP (NN influenza) (DT A) (NN virus)))))) (VP (VBZ induces) (NP (NP (DT a) (JJ broad) (NN range)) (PP (IN of) (NP (NP (NP (JJ proinflammatory) (NNS cytokines)) (CC and) (NP (NN mononuclear) (NN cell))) (VP (VBG attracting) (NP (NNS chemokines)))))) (SBAR (IN before) (S (NP (DT the) (JJ infected) (NNS cells)) (VP (VBP undergo) (NP (NN apoptosis)))))) (. .)))
(TOP (S (NP (NP (DT The) (VBG underlying) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (DT the) (JJ corresponding) (NNS genes)) (VP (VBP are) (VP (ADVP (RB transcriptionally)) (VBN initiated) (PP (IN after) (NP (NN virus) (NN infection)))))))) (VP (VBP are) (ADVP (RB still)) (VP (ADVP (RB poorly)) (VBN understood))) (. .)))
(TOP (S (NP (NP (NNP Activation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))) (VP (VP (VBZ seems) (S (VP (TO to) (VP (VB play) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ many) (JJ proinflammatory) (NN cytokine) (NNS genes)))))))))) (, ,) (CC but) (VP (MD can) (RB not) (VP (VB be) (NP (DT the) (JJ only) (NN mechanism)) (, ,) (SBAR (IN since) (S (NP (JJ several) (JJ cytokine) (NNS genes)) (VP (VBP lack) (NP (NP (JJ respective) (JJ binding) (NNS sites)) (PP (IN in) (NP (PRP$ their) (NN promoter) (NNS regions)))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (ADVP (RB additionally)) (VP (VBD investigated) (NP (NP (JJ other) (NN transcription) (NNS factors)) (PP (IN of) (NP (NP (JJ possible) (NN importance)) (PP (JJ such) (IN as) (NP (NP (NNP CREB)) (, ,) (NP (NNP CTF)) (, ,) (NP (NNP OTF-1)) (, ,) (CC and) (NP (NNP OTF-2)))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB explore) (NP (JJ long-term) (JJ regulatory) (NNS mechanisms))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (PP (IN on) (NP (DT the) (NN gene) (NN expression) (NN level))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (ADJP (JJ important) (S (VP (TO to) (VP (VB substitute) (PP (IN for) (NP (VBN metabolized) (NN transcription) (NN factor) (NNS proteins))))))) (PP (IN after) (NP (PRP$ their) (NN activation))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD identified) (NP (NP (DT a) (JJ cell-type-specific) (NN differential) (NN response)) (: :) (S (NP (NP (NNP CREB) (, ,) (NNP CTF) (, ,) (NNP OTF-1) (, ,) (NNP OFT-2)) (, ,) (CC and) (NP (NNP NF-kappa) (NNP B) (NNS genes))) (VP (VBD were) (VP (ADVP (RB strongly)) (VBN induced) (PP (NP (QP (CD 1) (TO to) (CD 4)) (NNS hours)) (IN after) (NP (NP (NN influenza)) (NP (NP (DT A) (NN virus) (NN infection)) (PP (IN in) (NP (NP (DT the) (JJ monocytic) (NN cell) (NN line)) (NP (NNP Mono) (NNP Mac) (CD 6))))))) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (ADJP (RB freshly) (JJ prepared)) (JJ human) (NNS monocytes))) (NP (DT no) (JJ significant) (NNS changes)) (VP (VBD were) (VP (VBN detected)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ infected) (NNS monocytes)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP die) (PP (IN by) (NP (NP (NN apoptosis)) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNP CREB)) (, ,) (NP (NNP CTF)))))))))))) (, ,) (CC and) (NP (NNP OTF-2)) (VP (VBD was) (ADVP (RB rather)) (VP (VBN suppressed) (PP (NP (CD 8) (NNS hours)) (IN after) (NP (NN infection))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT the) (JJ long-term) (NN regulation)) (PP (IN of) (NP (NN transcription) (NN factor) (NN gene) (NN expression))) (PP (IN in) (NP (JJ non-proliferating) (NNS cells)))) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (PP (IN of) (NP (JJ minor) (NN importance))) (PP (IN after) (NP (NP (NN influenza) (NN infection)) (PP (IN since) (PP (IN in) (NP (JJ apoptosisprone) (NNS cells)))))) (SBAR (S (NP (NP (DT an) (JJ immediate) (NN availability)) (PP (IN of) (NP (NN transcription) (NN factor) (NNS proteins)))) (VP (VBZ is) (VP (VBN required))))))))) (. .)))
(TOP (NP (NP (NN Induction)) (PP (IN of) (NP (JJ interleukin-12) (JJ p40) (NN transcript))) (PP (IN by) (NP (JJ CD40) (NN ligation))) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (JJ nuclear) (NN factor-kappaB))))) (. .)))
(TOP (S (NP (NN Interleukin-12)) (VP (VBZ is) (VP (VP (VBN produced) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NN infection))) (PP (PP (IN with) (NP (NNS bacteria) (CC or) (NNS parasites))) (CC or) (PP (TO to) (NP (NP (JJ bacterial) (NNS constituents)) (PP (JJ such) (IN as) (NP (NNP LPS))) (PP (IN in) (NP (NP (NNS monocytes/macrophages)) (CC and) (NP (JJ dendritic) (NNS cells)))))))))) (, ,) (CC and) (VP (ADVP (RB also)) (VBN generated) (PP (IN by) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (VBN activated) (NNP T) (NNS cells)) (CC and) (NP (JJ antigen-presenting) (NNS cells)))) (PP (IN via) (NP (NP (NN CD40-CD40) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NNP CD40L)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (ADVP (RB So) (RB far)) (, ,) (NP (NP (JJ transcriptional) (NNS analyses)) (PP (IN of) (NP (CD p40)))) (VP (VBP have) (VP (VBN been) (VP (VBN carried) (PP (IN out) (S (VP (ADVP (RB only)) (VBG using) (NP (NP (JJ bacterial) (NNS constituents)) (PP (JJ such) (IN as) (NP (NNP LPS)))) (PP (IN as) (NP (NNS stimuli))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN characterized) (NP (NP (DT the) (JJ transcriptional) (NN induction)) (PP (IN of) (NP (CD p40)))) (PP (IN by) (NP (NP (NP (CD CD40) (NN ligation)) (PP (IN in) (NP (NP (DT a) (JJ human) (NN B) (NN lymphoblastoid) (NN cell) (NN line)) (, ,) (NP (NNP Daudi)) (, ,)))) (CC and) (NP (NP (DT a) (JJ human) (JJ acute) (JJ monocytic) (NN leukemia) (NN cell) (NN line)) (, ,) (NP (NNP THP-1))))))) (. .)))
(TOP (S (NP (NP (DT These) (NNS cells)) (, ,) (VP (VBN stimulated) (PP (PP (IN by) (NP (NP (DT an) (JJ agonistic) (JJ monoclonal) (NN antibody)) (PP (IN against) (NP (NNP CD40))))) (CC or) (PP (IN by) (NP (NN transfection)))) (PP (IN with) (NP (DT a) (NNP CD40L) (NN expression) (NN vector)))) (, ,)) (VP (VP (VBD secreted) (NP (CD p40))) (CC and) (VP (VBD showed) (NP (JJ enhanced) (JJ p40) (NN mRNA) (NN expression)))) (. .)))
(TOP (S (NP (NP (NN Sequence) (NN analysis)) (PP (IN of) (NP (DT the) (JJ p40) (NN promoter) (NN region)))) (VP (VBD identified) (NP (NP (CD two) (JJ potential) (JJ nuclear) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP NF)) (-RRB- -RRB-)) (NP (NP (JJ -kappaB) (VBG binding) (NNS sites)) (VP (VBN conserved) (PP (IN between) (NP (NN mouse) (CC and) (NN human))))))) (. .)))
(TOP (S (NP (JJ Electrophoretic) (NN mobility) (NN shift) (RB assay)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (JJ potential) (NN NF-kappaB) (VBG binding) (NN sequence)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN located) (PP (IN around) (NP (NP (CD 120) (NN bp)) (ADVP (RB upstream)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN initiation) (NN site)) (PP (IN in) (NP (JJ murine) (CC and) (JJ human) (JJ p40) (NNS genes)))))))))))) (VP (VBD formed) (NP (NP (DT an) (JJ NF-kappaB) (NN complex)) (PP (IN with) (NP (NP (JJ nuclear) (VBP extract)) (PP (IN from) (NP (NP (NNP Daudi) (NNS cells)) (VP (VBN stimulated) (PP (IN by) (NP (NNP CD40) (NN ligation))))))))))))) (. .)))
(TOP (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN transfection)) (PP (IN of) (NP (NP (NNP Daudi) (NNS cells)) (PP (IN with) (NP (DT the) (VBN polymerized) (NN NF-kappaB) (VBG binding) (NN sequence)))))) (VP (VBD ligated) (PP (TO to) (NP (NP (DT a) (JJ thymidine) (NN kinase/chloramphenicol) (NN acetyltransferase) (PRN (-LRB- -LRB-) (NNP CAT) (-RRB- -RRB-)) (NN reporter) (NN plasmid)) (VP (ADVP (RB greatly)) (VBN induced) (NP (NNP CAT) (NN activity))))))) (, ,) (CC but) (S (NP (NP (NN transfection)) (PP (IN with) (NP (DT the) (NN polymerized) (VBD mutated) (JJ NF-kappaB) (JJ binding) (NN sequence)))) (VP (VBD did) (RB not))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ NF-kappaB) (JJ binding) (NN site)) (VP (VBN located) (PP (IN around) (NP (NP (CD 120) (NN bp)) (ADVP (RB upstream)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN initiation) (NN site)) (PP (IN in) (NP (JJ murine) (CC and) (JJ human) (JJ p40) (NN promoter) (NNS regions))))))))) (VP (MD could) (VP (VB be) (ADJP (JJ important) (PP (IN for) (NP (NP (DT the) (JJ p40) (NN induction)) (PP (IN by) (NP (JJ CD40) (NN ligation)))))) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (NNP NF-kappaB)))))))))) (. .)))
(TOP (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ nuclear) (NN factor) (NN kappa) (NNP B)))) (VP (VBD subunit) (NP (CD p65) (NNP mRNA)) (S (VP (NN accumulation) (PP (IN in) (NP (NP (JJ lipopolysaccharide-stimulated) (JJ human) (JJ monocytic) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NN sodium) (NN salicylate))))))))) (. .)))
(TOP (S (NP (NNP Lipopolysaccharide)) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN trigger) (NNS substances)) (PP (IN for) (NP (NP (NNS monocytes) (CC and) (NNS macrophages)) (VP (VBG causing) (NP (NP (NN secretion)) (UCP (PP (IN of) (NP (NP (JJ inflammatory) (NNS mediators)) (PP (JJ such) (IN as) (NP (NN tumor) (NN necrosis) (NN factor))))) (CC and) (ADJP (JJ interleukin-1))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN nature)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (NP (NN regulation)) (PP (IN of) (NP (DT these) (JJ cytokine) (NNS genes))))))))) (VP (VBZ is) (ADVP (RB still)) (ADJP (JJ unknown))) (. .)))
(TOP (S (NP (NP (JJ Nuclear) (NN factor) (NN kappa) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP NF-kappa) (NNP B)) (: ;) (NP (NP (NN heterodimer)) (PP (IN of) (NP (CD p50) (CC and) (CD p65)))) (-RRB- -RRB-)) (NNS proteins)) (VP (VBP have) (VP (VBN been) (VP (VBN suggested) (S (VP (TO to) (VP (VB play) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NN gene) (NN transcription)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators)))))) (SBAR (WHADVP (WRB when)) (S (NP (NNS monocytes)) (VP (VBP are) (VP (VBN stimulated) (PP (IN with) (NP (NN lipopolysaccharide))))))))))))) (. .)))
(TOP (S (S (NP (NP (JJ Nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PP (JJ such) (IN as) (NP (NNS salicylates)))) (VP (VBP have) (VP (VBN been) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NNS symptoms)) (PP (IN of) (NP (NN inflammation)))))))))) (, ,) (CC and) (S (NP (NP (DT a) (JJ new) (NN mechanism)) (PP (IN of) (NP (NN drug) (NN action)))) (VP (VBD was) (VP (VBN suggested) (ADVP (RB recently))))) (. .)))
(TOP (S (NP (NNS Salicylates)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (JJ lipopolysaccharide-induced) (NN gene) (NN transcription))))) (PP (IN via) (NP (NP (NN inhibition)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NN activation))))) (PP (IN by) (S (VP (VBG preventing) (NP (NP (NP (DT the) (NN degradation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B) (NN inhibitor)))) (`` ``) (S (NP (PRP I)) (VP (VBP kappa) (NP (NNP B)))))))) (, ,) (S (VP (VBG blocking) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NNP NF-kappa) (NNP B))) (PP (IN into) (NP (DT the) (JJ nuclear) (NN compartment))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN nature)) (PP (IN of) (NP (NP (DT the) (NN subunit)) (VP (VBN involved) (PP (IN in) (NP (DT this) (NN mechanism))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN defined)))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNS salicylates)) (VP (VBP affect) (NP (JJ cytokine) (NN gene) (NN transcription))))))))) (, ,) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (ADJP (JJ active) (CC and) (JJ inactive)) (NNP NF-kappa) (NNP B) (CC and) (NNP NF-kappa) (NNP B) (NNP mRNA) (, ,))) (PP (IN in) (NP (NNP Porphyromonas) (NNS gingivalis))) (VP (VBD lipopolysaccharide-stimulated) (NP (JJ human) (JJ monocytic) (NNS cells)))) (VP (VBD was) (VP (VBN assessed))) (. .)))
(TOP (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NN sodium) (NN salicylate)))) (VP (VBD suppressed) (NP (NNP NF-kappa) (NNP B) (FW p65) (FW mRNA) (NN accumulation)) (, ,) (SBAR (S (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN suppression)) (PP (IN of) (NP (NP (JJ total) (NNP NF-kappa) (NNP B)) (, ,) (NP (NP (CD p50)) (PP (IN on) (NP (NN tissue) (NN oligonucleotide)))))))))) (VP (VBD had) (NP (NP (DT no) (NNS effects)) (PP (IN on) (NP (JJ lipopolysaccharide-induced) (NNP NF-kappa) (NNP B) (NN activation)))))))) (. .)))
(TOP (S (NP (DT The) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT the) (JJ p65) (NN subunit)) (PP (IN of) (NP (NNP NF-kappa) (NNP B)))) (VP (VBZ is) (VP (VP (VBN inhibited) (PP (IN by) (NP (NN salicylate) (NN treatment)))) (CC and) (VP (VB highlight) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN salicylate))) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (NN gene) (NN expression)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators)))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Glucocorticoid) (NNS receptors)) (PP (PP (IN in) (NP (NP (NN cord) (NN blood) (NNS lymphocytes)) (PP (IN of) (NP (JJ healthy) (NNS neonates))))) (CC and) (PP (IN of) (NP (NNS preterms))))) (VP (VBG suffering) (PP (IN from) (NP (JJ respiratory) (NN distress) (NN syndrome)))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD measured) (NP (NP (DT the) (NN number)) (PP (PP (IN of) (NP (NP (NP (JJ glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP GR)) (-RRB- -RRB-)) (PP (IN in) (NP (NN cord) (NN blood) (NNS lymphocytes)))) (CC and) (NP (NP (DT the) (JJ binding) (NN affinity)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-)) (PP (IN in) (NP (CD 15) (NN term)))))) (CC and) (PP (IN in) (NP (CD 20) (NN preterm) (NNS babies)))))) (. .)))
(TOP (S (NP (NP (CD Thirteen) (NNS preterms)) (PP (IN of) (NP (DT the) (JJ latter) (NN group)))) (VP (VBD received) (NP (JJ prenatal) (JJ steroid) (NN treatment))) (. .)))
(TOP (S (NP (CD Seven) (NNS preterms)) (VP (VBD developed) (NP (NP (JJ neonatal) (JJ respiratory) (NN distress) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NNP NRDS)) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NNP GR)) (CC and) (NP (DT the) (NN Kd))))) (VP (VBD were) (ADJP (JJ similar)) (PP (IN in) (NP (NP (DT the) (NN term) (CC and) (NN preterm)) (PRN (-LRB- -LRB-) (PP (IN with) (CC and) (IN without) (NP (NNP NRDS))) (-RRB- -RRB-)) (NP (NNS babies))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ maximum) (JJ -LRB-3H-RRB--thymidine) (NN incorporation)) (PP (IN into) (NP (NP (NN DNA)) (PP (IN of) (NP (NN cord) (NN blood)))))) (VP (NNS lymphocytes) (PP (PP (IN from) (NP (DT all) (NNS preterms))) (, ,) (PP (IN with) (CC or) (IN without) (S (NP (NNP NRDS)) (VP (VBD was) (VP (VBN suppressed) (SBAR (WHADVP (WRB when)) (S (PP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN from) (NP (NP (NN term) (NNS babies)) (CC or) (NP (NNS adults))))))))))))))) (. .)))
(TOP (S (NP (DT This)) (VP (MD could) (ADVP (RB partly)) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP (DT the) (JJ antenatal) (JJ steroid) (NN treatment)))))) (. .)))
(TOP (S (NP (NP (NN Sensitivity)) (PRN (-LRB- -LRB-) (NP (CD ID50)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (NNS lymphocytes)) (PP (IN for) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN dexamethasone)))))))) (VP (VBD was) (NP (NP (DT the) (JJ same)) (PP (IN in) (NP (DT all) (NNS groups))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT this) (NN study)) (PP (IN on) (NP (NP (DT the) (NN number) (CC and) (NN function)) (PP (IN of) (NP (NNP GR))) (PP (IN in) (NP (NNS lymphocytes))))))) (, ,) (NP (PRP we)) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (VP (VB find) (NP (NP (DT a) (NN relation)) (PP (IN between) (NP (NP (DT the) (NN functionality)) (PP (IN of) (NP (NP (DT the) (NNP GR)) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP NRDS)))))))))))))) (. .)))
(TOP (NP (NP (NNS Oxidants)) (, ,) (NP (NN transcription) (NNS factors)) (, ,) (CC and) (NP (JJ intestinal) (NN inflammation)) (. .)))
(TOP (S (NP (NP (PRP It))) (VP (VBZ is) (ADVP (RB now)) (VP (ADVP (RB well)) (VBN appreciated) (SBAR (IN that) (S (NP (JJ chronic) (NN gut) (NN inflammation)) (VP (VBZ is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ enhanced) (NN production)) (PP (IN of) (NP (NP (JJ reactive) (NNS metabolites)) (PP (IN of) (NP (NN oxygen) (CC and) (NN nitrogen))))))))))))) (. .)))
(TOP (S (NP (NP (DT Some)) (PP (IN of) (NP (DT these) (NNS oxidants)))) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB modulate) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (DT the) (ADJP (JJ immune) (CC and) (JJ inflammatory)) (NNS responses))))))))))))))))) (. .)))
(TOP (S (PP (IN For) (NP (NN example))) (, ,) (NP (JJ certain) (NNS oxidants)) (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB activate) (NP (NP (DT the) (JJ nuclear) (NN transcription) (NN factor) (NNP kappa) (NNP B)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ regulates) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ different) (NN adhesion) (NNS molecules)) (, ,) (NP (NNS cytokines)) (, ,) (CC and) (NP (NNS enzymes)))))))))))))))) (. .)))
(TOP (S (NP (NNS Oxidants)) (VP (VBP are) (ADVP (RB also)) (VP (VBN known) (S (VP (TO to) (VP (VB activate) (NP (DT another) (NN transcription) (NN factor))))) (, ,) (S (VP (NN activator) (ADJP (JJ protein-1)))))) (. .)))
(TOP (S (NP (DT This) (NN transcription) (NN factor)) (VP (VP (VBZ is) (VP (VBN composed) (PP (IN of) (NP (NP (NNS products)) (PP (IN from) (NP (DT the) (NX (NX (NNS fos)) (CC and) (NX (NN jun) (JJ proto-oncogene) (NN family))))))))) (CC and) (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB be) (ADJP (JJ important) (PP (IN in) (S (VP (VBG regulating) (NP (NN cell) (NN growth) (CC and) (NN proliferation)))))))))))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (S (NP (NNS oxidants)) (VP (VBP are) (VP (VBN believed) (S (VP (TO to) (VP (VB promote) (NP (JJ intestinal) (JJ epithelial) (NN cell) (NN apoptosis)))))))) (, ,) (CC and) (S (NP (DT the) (JJ B-cell) (JJ lymphoma/leukemia-2) (NN gene) (NN product)) (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB inhibit) (NP (DT this) (NN phenomenon)) (PP (IN in) (NP (DT an) (JJ antioxidant-dependent) (NN manner))))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ nontoxic) (NNS concentrations)) (PP (IN of) (NP (NP (JJ reactive) (NNS metabolites)) (PP (IN of) (NP (NN oxygen) (CC and) (NN nitrogen)))))) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN involved) (PP (PP (IN in) (NP (DT the) (JJ inflammatory) (NN response))) (CC and) (PP (IN in) (S (VP (VBG modulating) (NP (NN apoptosis))))))))))))))))) (. .)))
(TOP (NP (NP (JJ Glucocorticoid) (NNS receptors)) (, ,) (NP (NN fibromyalgia)) (CC and) (NP (JJ low) (NN back) (NN pain)) (. .)))
(TOP (S (ADVP (RB Recently)) (, ,) (NP (NP (NN fibromyalgia)) (PRN (-LRB- -LRB-) (NP (NNP FMS)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (NN disorder)) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ altered) (NN functioning)) (PP (IN of) (NP (DT the) (NN stress) (NN response) (NN system)))))))))))) (. .)))
(TOP (S (NP (NNP FMS) (NNS patients)) (VP (VBP display) (NP (DT a) (JJ hyperreactive) (JJ pituitary) (JJ adrenocorticotropic) (NN hormone) (PRN (-LRB- -LRB-) (NNP ACTH) (-RRB- -RRB-)) (NN release)) (PP (IN in) (NP (NP (NN response)) (PP (PP (TO to) (NP (NP (JJ corticotropin-releasing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NNP CRH)) (-RRB- -RRB-)))) (CC and) (PP (TO to) (NP (JJ insulin-induced) (NN hypoglycemia))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD suggested) (SBAR (DT that) (S (NP (NP (JJ negative) (NN feedback)) (PP (IN of) (NP (NN cortisol)))) (VP (MD could) (VP (VB be) (VP (VBN deranged))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (NP (PRP we)) (VP (VP (VBD investigated) (NP (NP (DT the) (NNS properties) (CC and) (NN function)) (PP (IN of) (NP (NP (DT the) (JJ glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP GR)) (-RRB- -RRB-)) (PP (IN in) (NP (NNP FMS) (NNS patients))))))) (CC and) (VP (VBD compared) (NP (NP (DT the) (NNS results)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (JJ healthy) (NNS persons)) (CC and) (NP (NNS patients)))) (PP (IN with) (NP (NP (JJ chronic) (JJ low) (NN back) (NN pain)) (PRN (-LRB- -LRB-) (NP (NNP LBP) (DT a) (JJ localized) (NN pain) (NN condition)) (-RRB- -RRB-))))))))) (. .)))
(TOP (NP (NP (NP (NP (CD Forty) (JJ primary) (NNP FMS) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP F)) (: :) (S (NP (NNP M)) (VP (SYM =) (NP (NP (CD 36)) (: :) (NP (CD 4))))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (CD 28) (NNP LBP) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP (CD 25) (: :) (CD 3))) (-RRB- -RRB-))) (CC and) (NP (QP (CD 14) (-LRB- -LRB-) (CD 12) (: :) (LS 2)))) (-RRB- -RRB-)) (SBAR (S (NP (ADJP (JJ healthy) (, ,) (JJ sedentary)) (NN control) (NNS persons)) (VP (VBD were) (VP (VBN recruited) (PP (IN for) (NP (DT the) (NN study))))))) (. .)))
(TOP (S (NP (NP (JJ Urinary) (JJ free) (NN cortisol) (NN excretion)) (PP (IN in) (NP (NNP FMS) (CC and) (NNP LBP) (NNS patients)))) (VP (VBD was) (ADJP (JJR lower)) (PP (VBN compared) (PP (TO to) (NP (NNS controls))))) (. .)))
(TOP (S (NP (RB Only) (NNP FMS) (NNS patients)) (VP (VBD displayed) (NP (NP (JJR lower) (NNP CBG)) (CC and) (NP (JJ basal) (NN serum) (NN cortisol) (NNS concentrations))) (SBAR (WHADVP (WRB when)) (S (PP (VBN compared) (PP (TO to) (NP (NNS controls))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (NN plasma) (JJ free) (NN cortisol) (NNS concentrations)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT the) (CD three) (NNS groups))))) (. .)))
(TOP (S (S (NP (EX There)) (VP (VBD was) (NP (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNP GR))) (PP (IN per) (NP (NN cell))) (PP (IN among) (NP (NP (DT the) (CD three) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NNP FMS)) (: :) (NP (NP (NP (CD 6498) (NN +/-) (CD 252)) (, ,) (NP (NNP LBP))) (: :) (NP (NP (NP (CD 6625) (NN +/-) (CD 284)) (, ,) (NP (NNS controls))) (: :) (NP (NP (CD 6576)) (PP (NN +/-) (NP (CD 304))))))) (-RRB- -RRB-))))))) (, ,) (CC but) (NP (NP (NP (DT the) (NN dissociation) (JJ constant)) (PRN (-LRB- -LRB-) (NN Kd) (-RRB- -RRB-)) (PP (IN of) (NP (DT the) (NNP FMS)))) (PRN (-LRB- -LRB-) (NP (CD 14.5) (NN +/-) (CD 0.9) (NN nmol/l)) (-RRB- -RRB-)))))) (CC and) (S (NP (NNP LBP) (PRN (-LRB- -LRB-) (ADJP (ADJP (CD 14.7) (NN +/-)) (ADJP (CD 1.3) (NN nmol/l))) (-RRB- -RRB-)) (NNS subjects)) (VP (VBD was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NNS controls)))) (PRN (-LRB- -LRB-) (NP (CD 10.9) (NN +/-) (CD 0.8) (NN nmol/l)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (FW p) (FW &lt;) (CD .05)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ maximal) (NN stimulation)) (PP (IN of) (NP (DT the) (NNS lymphocytes)))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (DT the) (JJ maximal) (NN thymidine) (NN incorporation)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN cortisol))))) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NNP FMS) (NN group)))))))) (VP (VBD was) (ADJP (ADJP (ADJP (NP (QP (RB approximately) (CD 1.5)) (NNS times)) (JJR higher)) (PRN (-LRB- -LRB-) (FW p) (ADJP (FW &lt;) (CD .05)) (-RRB- -RRB-))) (PP (IN than) (PP (IN in) (NP (DT the) (NN control) (CC or) (NNP LBP) (NN group)))))) (. .)))
(TOP (S (NP (NP (DT The) (NNP ED50)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (NN cortisol) (NN concentration)) (VP (VBG giving) (NP (CD 50) (NN %)) (NP (NP (NN inhibition)) (PP (IN of) (NP (DT the) (JJ thymidine) (NN incorporation)))))) (-RRB- -RRB-))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD was) (ADJP (JJ identical)) (PP (IN in) (NP (DT all) (CD three) (NNS groups)))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP FMS) (NNS patients)) (VP (VBP have) (NP (NP (DT a) (JJ mild) (NN hypocortisolemia)) (, ,) (NP (NP (VBN increased) (NN cortisol) (NN feedback) (NN resistance)) (PP (IN in) (NP (NN combination))) (PP (ADVP (RB probably)) (IN with) (NP (NP (DT a) (VBN reduced) (NNP CRH) (NN synthesis)) (CC or) (NP (NP (NN release)) (PP (IN in) (NP (DT the) (NN hypothalamus)))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (DT the) (NNP GR) (CC and) (JJ mineralocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP MR)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (NNP CRH) (NN regulation)) (PP (IN in) (NP (DT the) (NNP FMS) (NNS patients)))))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN solved)))))) (. .)))
(TOP (NP (NP (NN Transcription) (NNS factors)) (VP (VBN required) (PP (IN for) (NP (JJ lymphoid) (NN lineage) (NN commitment)))) (. .)))
(TOP (S (NP (NP (JJ Intimate) (NNS interactions)) (PP (IN between) (NP (NP (JJ multipotential) (JJ hemopoietic) (NN stem) (NNS cells)) (CC and) (NP (PRP$ their) (NN microenvironment))))) (VP (NN work) (PP (IN towards) (S (VP (VBG redefining) (NP (NP (DT the) (NN identity)) (CC and) (NP (NP (DT the) (JJ differentiative) (NN fate)) (PP (IN of) (NP (DT these) (JJ primitive) (NNS cells))))))))) (. .)))
(TOP (S (NP (NP (JJ Molecular) (NNS cues)) (VP (VBN delivered) (PP (IN by) (NP (DT the) (NN microenvironment))))) (ADVP (RB frequently)) (VP (VBP act) (PP (IN in) (NP (DT an) (JJ instructive) (NN fashion))) (PP (IN by) (S (VP (VBG initiating) (NP (NP (JJ intracellular) (VBG signaling) (NNS pathways)) (SBAR (WHNP (WDT that)) (S (ADVP (RB ultimately)) (VP (VBP target) (NP (NP (DT a) (JJ select) (NN group)) (PP (IN of) (NP (NN transcription) (NNS factors)))))))))))) (. .)))
(TOP (S (NP (DT These) (JJ transcriptional) (NNS regulators)) (PP (IN in) (NP (NN turn))) (VP (VBP trigger) (NP (NP (DT a) (NN cascade)) (PP (IN of) (NP (NP (JJ genetic) (NNS changes)) (SBAR (WHNP (WDT that)) (S (ADVP (RB ultimately)) (VP (VBP determine) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NP (DT the) (NNS cells)) (PP (IN during) (NP (NN differentiation))))))))))))) (. .)))
(TOP (S (NP (NP (NNP Gene) (NN inactivation) (NNS studies)) (PP (IN on) (NP (DT the) (NNP PU.1) (, ,) (NNP Ikaros) (CC and) (NNP GATA-3) (NNS genes)))) (VP (VBP have) (VP (VBN revealed) (SBAR (IN that) (S (NP (PRP$ their) (JJ encoded) (NNS factors)) (VP (VBP are) (ADJP (JJ essential)) (PP (IN for) (NP (NP (DT the) (JJS earliest) (NN commitment) (NN step)) (PP (IN into) (NP (DT the) (NNP B) (CC and) (NNP T) (JJ lymphoid) (NNS lineages)))))))))) (. .)))
(TOP (S (NP (NP (JJ Cytokine) (NN rescue)) (PP (IN from) (NP (NP (JJ glucocorticoid) (VBN induced) (NN apoptosis)) (PP (IN in) (NP (NNP T) (NNS cells)))))) (VP (VBZ is) (VP (VBN mediated) (PP (IN through) (NP (NP (NN inhibition)) (PP (IN of) (NP (NNP IkappaBalpha))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (SBAR (SBAR (DT that) (S (NP (NP (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (NNP DEX)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ synthetic) (NN glucocorticoid)) (, ,)) (VP (VBZ causes) (NP (NN apoptosis)) (PP (IN in) (NP (NNP mature) (NNP Th) (NN cell) (NNS lines)))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (DT this) (NN induction)) (PP (IN of) (NP (NN cell) (NN death)))) (VP (VBZ is) (VP (VBN prevented) (PP (IN by) (NP (JJ specific) (NNS cytokines))) (, ,) (ADVP (RB namely)) (, ,) (PP (PP (IN by) (NP (NP (NN IL-2)) (PP (IN in) (NP (JJ Th1) (NNS cells))))) (CC and) (PP (IN by) (NP (NP (NN IL-4)) (PP (IN in) (NP (JJ Th2) (NNS cells)))))))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB now)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT this) (NN differential) (NN rescue)) (PP (IN by) (NP (NP (JJ specific) (NNS cytokines)) (PP (IN in) (NP (JJ Th) (NNS cells)))))) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NNP IkappaBalpha))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP (NNP DEX) (CC and) (NNS cytokines))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT both) (NN cell) (NNS types))) (NP (NP (DT the) (JJ cellular) (NNS levels)) (PP (IN of) (NP (NP (NNP IkappaBalpha) (NNP mRNA)) (CC and) (NP (NN protein))))) (VP (VBD were) (VP (VBN evaluated) (PP (IN by) (NP (NNP DEX) (NN treatment))))) (. .)))
(TOP (S (ADVP (RB Interestingly)) (, ,) (NP (DT the) (NNP DEX-mediated) (NNP IkappaBalpha) (NN induction)) (VP (VBD was) (VP (ADVP (RB completely)) (VBN inhibited) (PP (IN by) (NP (NP (NN IL-2)) (, ,) (CC but) (RB not) (NP (NN IL-4)) (, ,))) (PP (IN in) (NP (JJ Th1) (NNS cells))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ reverse) (NN profile)) (VP (VBD was) (VP (VBN seen) (PP (IN in) (NP (JJ Th2) (NNS cells))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT both) (NN cell) (NNS types))) (, ,) (NP (NP (DT the) (NN cytokine)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP IkappaBalpha))) (PP (IN by) (NP (NNP DEX)))))))) (, ,) (ADVP (RB also)) (VP (VBZ rescues) (NP (DT these) (NNS cells)) (PP (IN from) (NP (JJ DEX-induced) (NN apoptosis))) (, ,) (SBAR (IN although) (S (NP (DT the) (NN rescue) (NN cytokine)) (VP (VBZ is) (ADJP (JJ different) (PP (IN in) (NP (ADJP (JJ Th1) (CC and) (JJ Th2)) (NNS cells)))))))) (. .)))
(TOP (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP imply) (SBAR (IN that) (S (NP (NNP T) (NNS cells)) (VP (VBP need) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT a) (JJ certain) (NN level)) (PP (IN of) (NP (JJ NF-kappaB) (JJ transcriptional) (NN activity)))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB survive))))))))))))) (: ;) (S (NP (NP (NN up-) (CC or) (NN down-regulation)) (PP (IN of) (NP (JJ nuclear) (NNP NF) (NNP kappaB))) (PP (IN through) (NP (NP (NN modulation)) (PP (IN of) (NP (NNP IkappaBalpha) (NN expression))) (PP (IN by) (NP (NNS cytokines) (CC or) (NNP DEX)))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NP (NN cell) (NN survival)) (CC or) (NP (NN cell) (NN death))) (, ,) (ADVP (RB respectively))))))) (. .)))
(TOP (NP (NP (NNS Genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP regulate) (NP (NN interleukin-4) (NN expression)) (PP (IN in) (NP (NNP T) (NNS cells)))))) (. .)))
(TOP (S (NP (NN Interleukin-4)) (VP (VBZ is) (NP (NP (DT an) (JJ immunomodulatory) (NN cytokine)) (SBAR (WHNP (WDT which)) (S (VP (VBZ plays) (NP (DT a) (JJ central) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (ADJP (JJ allergic) (CC and) (JJ atopic)) (JJ immune) (NNS responses)))))))))) (. .)))
(TOP (S (NP (JJ Significant) (NN progress)) (VP (VBZ has) (VP (VBN been) (VP (VBN made) (PP (IN in) (S (VP (VBG gaining) (NP (NP (DT a) (VBN detailed) (NN understanding)) (PP (IN of) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NN interleukin-4) (NN gene)))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ recent) (NN identification) (CC and) (NN characterization)) (PP (IN of) (NP (JJ several) (JJ key) (NN transcription) (NNS factors)))) (VP (VBZ has) (VP (VBN helped) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NNP T) (NN helper) (NN cell) (NN cytokine) (NN gene) (NN expression))))))))) (. .)))
(TOP (S (NP (JJ Xenogeneic) (JJ human) (NN serum)) (VP (VBZ promotes) (NP (NP (JJ leukocyte) (NN adhesion)) (SBAR (S (VP (TO to) (VP (VB porcine) (NP (NN endothelium)) (PP (IN under) (NP (NN flow) (NNS conditions))) (, ,) (PP (ADVP (RB possibly)) (IN through) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NNP NF-kappa) (NNP B))))))))))) (. .)))
(TOP (S (NP (NP (JJ Endothelial) (NN cell) (NN activation)) (CC and) (NP (NN leukocyte) (NN infiltration))) (VP (VBP are) (NP (NP (DT a) (JJ consistent) (NN feature)) (PP (IN of) (NP (JJ discordant) (NN xenograft) (NN rejection))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBD evaluated) (SBAR (IN whether) (S (NP (NP (JJ xenogeneic) (NN serum)) (, ,) (VP (PP (IN as) (NP (NP (DT a) (NN source)) (PP (IN of) (NP (JJ xenoreactive) (JJ natural) (NNS antibodies))))) (CC and) (VP (VB complement))) (, ,)) (VP (VBN induced) (NP (JJ endothelial) (NN cell) (NN activation)) (PP (IN with) (NP (NP (JJ consequent) (JJ leukocyte) (NN adhesion)) (PP (IN under) (NP (NN flow) (NNS conditions))))))))) (. .)))
(TOP (S (NP (NP (JJ Porcine) (JJ aortic) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP PAEC)) (-RRB- -RRB-))) (VP (VBD were) (VP (VP (VBN incubated) (PP (IN for) (NP (NP (NP (CD 1) (NN hr)) (NP (CD 30) (NN min))) (CC or) (NP (NP (CD 5) (NN hr)) (PP (IN with) (NP (NP (NP (NP (CD 10) (NN %)) (ADJP (RB homologous) (JJ porcine)) (NN serum)) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-))) (CC or) (NP (ADJP (CD 10) (NN %)) (JJ xenogeneic) (JJ human) (NN serum)))))))) (CC and) (VP (ADVP (RB then)) (VBN perfused) (PP (IN with) (NP (JJ total) (JJ human) (NNS leukocytes))) (PP (IN in) (NP (NP (DT a) (JJ parallel) (NN plate) (NN flow) (NN chamber)) (PP (IN under) (NP (NP (NN laminar) (NN flow)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (CD dynes/cm2)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP (JJ Adherent) (NNS cells)) (VP (VBD were) (VP (VBN counted) (PP (IN by) (NP (JJ digital) (NN image) (NN analysis))))) (. .)))
(TOP (S (NP (NP (JJ Xenogeneic) (JJ human) (NN serum)) (VP (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P) (VBD &lt;) (CD 0.01)) (-RRB- -RRB-)))) (VP (VBD increased) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ adherent) (NNS leukocytes)))) (PP (IN as) (PP (VBN compared) (PP (IN with) (NP (JJ porcine) (NN serum)))))) (. .)))
(TOP (S (NP (DT A) (JJ similar) (JJ adhesive) (NN response)) (VP (VBD was) (VP (VBN elicited) (PP (IN by) (NP (NP (NNP TNF) (NN alpha)) (PRN (-LRB- -LRB-) (NP (CD 100) (NNP U/ml)) (-RRB- -RRB-)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NNS inducers)) (PP (IN of) (NP (JJ endothelial) (NN cell) (NN adhesive) (NNS properties))) (, ,) (VP (ADVP (RB here)) (VBN used) (PP (IN as) (NP (JJ positive) (NN control))))))))))) (. .)))
(TOP (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (NP (JJ possible) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (JJ endothelial) (NN cell) (NN activation)) (PP (IN by) (NP (JJ xenogeneic) (NN serum)))))))))) (, ,) (NP (PRP we)) (VP (VBD focussed) (PP (IN on) (NP (NP (NN transcription) (NN factor) (NNP NF-kappa) (NNP B)) (, ,) (NP (NP (DT a) (JJ central) (NN regulator)) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (JJ different) (NNS genes)) (, ,) (PP (VBG including) (NP (JJ adhesive) (NNS molecules) (CC and) (NNS chemoattractants))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (JJ confocal) (NN fluorescence) (NN microscopy))) (, ,) (NP (PRP we)) (VP (VBD observed) (SBAR (S (NP (NP (DT a) (JJ positive) (NN staining)) (PP (IN for) (NP (NP (NNP NF-kappa) (NNP B)) (PRN (-LRB- -LRB-) (NP (FW p65) (FW subunit)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (NN nuclei)) (PP (IN of) (NP (NNP PAEC)))))) (VP (VBN exposed) (PP (IN for) (NP (NP (CD 1) (NN hr)) (NP (CD 30) (NN min)))) (PP (TO to) (NP (NP (JJ human) (NN serum)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD indicated) (NP (NP (NNP NF-kappa) (NNP B) (NN activation)) (PP (IN in) (NP (DT this) (NN setting))))))))))))) (. .)))
(TOP (SINV (S (PP (IN At) (NP (NN variance))) (, ,) (PP (IN in) (NP (NNP PAEC))) (VP (VBD incubated) (PP (IN with) (NP (DT the) (ADJP (RB homologous) (JJ serum)) (, ,) (JJ NF-kappa) (NN B))))) (VP (VBD was)) (VP (ADVP (RB strictly)) (VBN localized) (PP (IN in) (NP (DT the) (NN cell) (NN cytoplasm)))) (. .)))
(TOP (S (NP (NP (NNP Treatment)) (PP (IN of) (NP (NNP PAEC)))) (VP (VBN exposed) (PP (TO to) (NP (NP (NP (JJ xenogeneic) (NN serum)) (PP (IN with) (NP (NP (NP (DT the) (NNP NF-kappa) (NNP B) (NNS inhibitors) (NN pyrrolidinedithiocarbamate)) (PRN (-LRB- -LRB-) (NP (NP (NNP PDTC)) (, ,) (NP (CD 25) (NNP microM))) (-RRB- -RRB-))) (CC and) (NP (JJ tosyl-phechloromethylketone) (PRN (-LRB- -LRB-) (NP (NNP TPCK)) (, ,) (NP (CD 25) (NNP microM)) (-RRB- -RRB-))))) (ADVP (RB significantly))) (PRN (-LRB- -LRB-) (NP (NNP P) (VBD &lt;) (CD 0.01)) (-RRB- -RRB-)) (VP (VBN reduced) (NP (NN leukocyte) (NN adhesion)) (PP (IN in) (NP (NP (NN respect)) (PP (TO to) (NP (NNP PAEC))) (VP (VBN treated) (PP (IN with) (NP (NP (JJ human) (NN serum)) (ADVP (RB alone))))))))))) (. .)))
(TOP (S (NP (NNS Findings) (SBAR (IN that) (S (NP (JJ xenogeneic) (NN serum)) (VP (VBZ promotes) (NP (NN leukocyte-endothelium) (NN interaction)) (ADVP (RB possibly)) (PP (IN through) (NP (NNP NF-kappa) (NNP B) (NN activation))))))) (VP (MD might) (VP (VB be) (ADJP (JJ relevant) (PP (IN for) (S (VP (VBG designing) (NP (NP (JJ future) (JJ therapeutic) (NNS strategies)) (VP (VBN aimed) (PP (IN at) (S (VP (VBG prolonging) (NP (NN xenograft) (NN survival))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Delta-opioid) (NNS receptors)) (VP (VBN expressed) (PP (IN by) (NP (NNP Jurkat) (NNP T) (NNS cells))))) (VP (VBP enhance) (NP (NN IL-2) (NN secretion)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (NN AP-1) (NNS complexes)) (CC and) (NP (NP (NN activity)) (PP (IN of) (NP (DT the) (JJ NF-AT/AP-1-binding) (NN promoter) (NN element))))))))) (. .)))
(TOP (S (NP (JJ Recent) (JJ molecular) (NN evidence)) (VP (NNS points) (PP (TO to) (NP (NP (ADJP (JJ transient) (CC and/or) (JJ stage-specific)) (NN expression)) (PP (IN of) (NP (NP (ADJP (JJ delta-) (CC and) (JJ kappa-opioid)) (NNS receptors)) (PP (IN by) (NP (UCP (JJ thymic) (CC and) (JJ peripheral)) (NNP T) (NNS lymphocytes)))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP (NP (JJ medical) (NNS treatments)) (CC or) (NP (NN stress))) (ADVP (RB commonly)) (VP (VB increase) (NP (JJ opioid) (NNS levels))))) (, ,) (NP (NP (PRP it))) (VP (VBZ is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB understand) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNS opioids)) (VP (VBP affect) (NP (NNP T) (NN lymphocyte) (NNS functions)))))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD created) (CC and) (VBD studied) (NP (NP (DT a) (NNP T) (NN cell) (NN line)) (VP (VBG expressing) (NP (NP (DT the) (VBN cloned) (JJ delta-opioid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (CD DOR1)) (-RRB- -RRB-)))))) (. .)))
(TOP (NP (NP (NP (CD DOR1) (NN ligation)) (PP (IN by) (NP (DT a) (JJ specific) (NNP DOR1) (NN agonist)))) (, ,) (NP (NN deltorphin)) (, ,) (NP (JJ augmented) (NN IL-2) (NN secretion)) (PP (IN by) (S (VP (VBG synergizing) (PP (IN with) (NP (NP (NNS signals)) (PP (IN from) (NP (NNP TCR-CD3) (CC and) (NNP CD28)))))))) (. .)))
(TOP (S (NP (NN Reporter) (NN gene) (NNS constructs)) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB map) (NP (NP (DT this) (NN effect)) (PP (IN of) (NP (NN deltorphin)))) (PP (TO to) (NP (NP (DT the) (NN AP-1-)) (CC and) (NP (NP (JJ NF-AT/AP-1-binding) (NNS sites)) (PP (IN of) (NP (DT the) (NN IL-2) (NN promoter))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (NNP DOR1)) (VP (VBG signaling) (NP (VBN increased) (NN -LSB-Ca2+-RSB-i))))) (, ,) (NP (NN deltorphin)) (VP (VBD enhanced) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN of) (NP (DT the) (JJ NF-AT/AP-1-binding) (NN site)))) (PP (IN via) (NP (NP (DT a) (NN mechanism)) (ADJP (ADJP (JJ independent) (PP (IN of) (NP (NN calcineurin)))) (CC and) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ elevated) (NN -LSB-Ca2+-RSB-i)))))))))) (. .)))
(TOP (S (NP (NNP Deltorphin)) (ADVP (RB also)) (VP (VBD increased) (NP (NP (NN accumulation)) (PP (IN of) (NP (JJ AP-1) (NN transcription) (NN factor) (NNS complexes)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNP DOR1)) (VP (VBZ augments) (NP (NN IL-2) (NN secretion)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (JJ AP-1) (NN component)) (PP (IN of) (NP (DT the) (NNP NF-AT/AP-1) (NN transcription) (NN factor))))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VP (VBP advance) (NP (NP (DT the) (JJ molecular) (NN understanding)) (PP (IN of) (NP (NP (JJ opioid) (NNS effects)) (PP (IN on) (NP (NNS lymphocytes))))))) (, ,) (CC and) (VP (PP (IN in) (NP (NN addition))) (, ,) (VB demonstrate) (NP (NP (NN regulation)) (PP (IN of) (NP (NP (NN IL-2) (NN synthesis)) (CC and) (NP (NN secretion)))) (PP (IN by) (NP (NP (DT the) (NN novel) (NN mechanism)) (PP (IN of) (NP (JJ receptor-mediated) (JJ AP-1) (NN induction)))))))) (. .)))
(TOP (NP (NP (JJ Pharmacological) (NN control)) (PP (IN of) (NP (NP (NN antigen) (NN responsiveness)) (PP (IN in) (NP (ADJP (RB genetically) (VBN modified)) (NNP T) (NNS lymphocytes))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ chimeric) (NNP TCR) (NN gene)) (, ,) (VP (VBG comprising) (NP (NP (DT an) (JJ anti-hapten) (JJ single-chain) (NNP Ab) (JJ variable) (NN fragment)) (VP (VBD fused) (PP (TO to) (NP (NP (DT the) (NN transmembrane) (CC and) (JJ cytoplasmic) (NNS regions)) (PP (IN of) (NP (DT the) (JJ human) (NNP TCR) (NN zeta-chain)))))))) (, ,)) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (DT the) (JJ tetracycline-regulatable) (NN system)) (VP (MD could) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB regulate) (NP (NN gene) (NN expression)) (PP (IN in) (NP (NNP T) (NNS cells)))))))))))))))) (. .)))
(TOP (S (NP (NNP Jurkat) (NNP T) (NNS cells)) (VP (VBD were) (VP (ADVP (RB stably)) (VBN transfected) (PP (IN with) (NP (NP (NP (DT a) (JJ single) (NN vector)) (VP (VBG encoding) (NP (NP (DT the) (JJ tetracycline) (NN trans-activator) (NN protein)) (, ,) (VP (VBN controlled) (PP (IN by) (NP (DT a) (JJ constitutive) (NN promoter)))) (, ,)))) (CC and) (NP (NP (DT the) (JJ chimeric) (NNP TCR)) (, ,) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT a) (JJ trans-activator) (JJ protein-responsive) (NN promoter)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNS tetracyclines))))) (, ,) (NP (DT the) (VBN transfected) (NNP T) (NNS cells)) (VP (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB express) (NP (DT the) (JJ chimeric) (NN receptor)) (PP (IN on) (NP (DT the) (NN cell) (NN surface)))))))) (CC and) (VP (MD could) (VP (VB be) (VP (VBN activated) (PP (IN by) (NP (PRP$ its) (JJ cognate) (NN Ag))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NN IL-2))))))))))) (. .)))
(TOP (S (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNS cells)) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (VBG increasing) (NNS concentrations)) (PP (IN of) (NP (NNS tetracyclines))))))))) (, ,) (NP (NP (NN surface) (NN expression)) (PP (IN of) (NP (DT the) (JJ chimeric) (NN receptor)))) (VP (VBD was) (VP (VBN suppressed) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))))) (, ,) (CC and) (S (NP (DT this) (NN suppression)) (VP (VBD was) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NP (JJ complete) (NN loss)) (PP (IN of) (NP (NP (NN responsiveness)) (PP (TO to) (NP (DT the) (JJ targeted) (NN Ag))))))))))))) (. .)))
(TOP (S (S (NP (NP (JJ Prolonged) (NN suppression)) (PP (IN of) (NP (JJ trans-gene) (NN expression))) (PP (IN for) (NP (QP (IN up) (TO to) (CD 7)) (NNS days)))) (VP (VBD was) (VP (VBN observed) (SBAR (IN after) (S (NP (NN doxycycline)) (VP (VBD was) (VP (VBN removed) (PP (IN from) (NP (DT the) (NNS cultures)))))))))) (, ,) (CC but) (S (S (NP (NP (JJ eventual) (NN recovery)) (PP (IN of) (NP (NN surface) (NN expression)))) (VP (VBD was) (ADJP (JJ complete)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ absolute) (NN time)) (PP (TO to) (NP (NN recovery)))) (VP (VBD was) (ADJP (RB directly) (JJ proportional) (PP (TO to) (NP (NP (DT the) (JJ initial) (NN concentration)) (PP (IN of) (NP (DT the) (NN drug))))))))) (. .)))
(TOP (S (NP (NP (JJ Pharmacologic) (NN control)) (PP (IN of) (NP (JJ trans-gene) (NN expression))) (PP (IN in) (NP (JJ gene-modified) (NNP T) (NNS cells)))) (VP (VP (MD will) (RB not) (ADVP (RB only)) (VP (VB facilitate) (NP (NP (JJ new) (NNS approaches)) (PP (TO to) (NP (NP (DT the) (NN study)) (PP (IN of) (NP (NP (JJ different) (NNS aspects)) (PP (IN of) (NP (NNP T) (NN cell) (NN biology)))))))))) (, ,) (CC but) (VP (MD will) (ADVP (RB also)) (VP (VB provide) (NP (DT the) (NN basis)) (PP (IN for) (NP (JJ new) (NN gene) (NN therapy) (NNS strategies)))))) (. .)))
(TOP (S (NP (JJ Human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (JJ long) (NN terminal) (NN repeat) (NNS quasispecies)) (VP (VBP differ) (PP (IN in) (NP (NP (JJ basal) (NN transcription) (CC and) (JJ nuclear) (NN factor) (NN recruitment)) (PP (IN in) (NP (JJ human) (JJ glial) (NNS cells) (CC and) (NNS lymphocytes)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN generation)) (PP (IN of) (NP (JJ genomic) (NN diversity))) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NN infection)))))) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB affect) (NP (NP (DT all) (NNS aspects)) (PP (IN of) (NP (NP (NNP HIV-1) (NN replication)) (, ,) (PP (VBG including) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ proviral) (NN genome))))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB gain) (NP (NP (DT a) (JJR better) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (JJ long) (NN terminal) (NN repeat) (PRN (-LRB- -LRB-) (NNP LTR) (-RRB- -RRB-)) (NN sequence) (NN diversity))) (PP (IN on) (NP (JJ LTR-directed) (NN gene) (NN expression))) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (NP (NP (DT the) (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-))) (CC and) (NP (JJ immune) (NN system)))))))))))) (, ,) (NP (PRP we)) (VP (VBD amplified) (CC and) (VBD cloned) (NP (NNS LTRs)) (PP (IN from) (NP (NP (JJ proviral) (NN DNA)) (PP (IN in) (NP (JJ HIV-1-infected) (JJ peripheral) (NN blood)))))) (. .)))
(TOP (S (NP (NP (NN Sequence) (NN analysis)) (PP (IN of) (NP (NP (JJ nineteen) (NNS LTRs)) (VP (VBN cloned) (PP (IN from) (NP (NP (CD 2) (NN adult)) (CC and) (NP (CD 3) (JJ pediatric) (NNS patients)))))))) (VP (VBD revealed) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 33) (JJ nucleotide) (NNS changes)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN sequence)) (PP (IN of) (NP (DT the) (NNP LAI) (NNP LTR))))))) (-RRB- -RRB-)) (PP (IN within) (NP (DT the) (JJ 455-bp) (NN U3) (NN region))))))) (. .)))
(TOP (S (NP (NP (JJ Transient) (NN expression) (NNS analyses)) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (JJ neuroglial) (CC and) (JJ lymphocytic) (NN origin)))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT some)) (PP (IN of) (NP (DT these) (NNS LTRs)))) (VP (VBD had) (NP (NP (NNS activities)) (SBAR (WHNP (WDT which)) (S (VP (VBD varied) (ADVP (RB significantly)) (PP (IN from) (NP (DT the) (NNP LAI) (NNP LTR))) (PP (PP (IN in) (NP (NP (NNP U-373) (NNP MG) (NNS cells)) (PRN (-LRB- -LRB-) (NP (DT an) (NN astrocytoma) (NN cell) (NN line)) (-RRB- -RRB-)))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (NNP Jurkat) (NNS cells)) (PRN (-LRB- -LRB-) (NP (DT a) (NN CD4-) (JJ positive) (JJ lymphocyte) (NN cell) (NN line)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (SBAR (IN While) (S (NP (NP (NNS LTRs)) (SBAR (WHNP (WDT which)) (S (VP (VBD demonstrated) (NP (NP (DT the) (JJS highest) (NNS activities)) (PP (IN in) (NP (NNP U-373) (NNP MG) (NNS cells)))))))) (ADVP (RB also)) (VP (VBD yielded) (NP (NP (JJ high) (NNS activities)) (PP (IN in) (NP (NNP Jurkat) (NNS cells))))))) (, ,) (NP (DT the) (NNS LTRs)) (VP (VBD were) (ADVP (RB generally)) (ADJP (RBR more) (JJ active)) (PP (IN in) (NP (NNP Jurkat) (NNS cells))) (SBAR (WHADVP (WRB when)) (S (PP (VBN compared) (PP (TO to) (NP (DT the) (NNP LAI) (NNP LTR))))))) (. .)))
(TOP (S (NP (NP (NNS Differences)) (PP (IN in) (NP (NNP LTR) (NN sequence)))) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS differences)) (PP (IN in) (NP (NN transcription) (NN factor) (NN recruitment))) (PP (TO to) (NP (NP (JJ cis-acting) (NNS sites)) (PP (IN within) (NP (NP (DT the) (JJ U3) (NN region)) (PP (IN of) (NP (DT the) (NNP LTR))))))))) (, ,) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays))))))) (. .)))
(TOP (SINV (PP (IN In) (NP (JJ particular) (, ,) (ADJP (RB naturally) (VBG occurring)) (NN sequence) (NN variation))) (VP (VBD impacted)) (NP (NP (NN transcription) (NN factor)) (VP (VBG binding) (PP (TO to) (NP (NP (DT an) (VBG activating) (NN transcription) (NNP factor/cAMP) (NN response) (NN element)) (VP (VBG binding) (PRN (-LRB- -LRB-) (NP (NNP ATF/CREB)) (-RRB- -RRB-)) (NP (NP (VBG binding) (NN site)) (PRN (-LRB- -LRB-) (VP (VBN located) (PP (IN between) (NP (NP (DT the) (NN LEF-1)) (CC and) (NP (JJ distal) (JJ NF-kappaB) (NN transcription) (NN factor) (VBG binding) (NNS sites))))) (-RRB- -RRB-)) (SBAR (WHNP (IN that)) (S (NP (PRP we)) (VP (VBD identified) (PP (IN in) (NP (NP (JJ previous) (NNS studies)) (PP (IN of) (NP (DT the) (NNP HIV-1) (NNP LTR)))))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP LTR) (NN sequence) (NNS changes)) (VP (MD can) (VP (ADVP (RB significantly)) (VB affect) (NP (NP (JJ basal) (NNP LTR) (NN function) (CC and) (NN transcription) (NN factor) (NN recruitment)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (, ,) (PP (IN in) (NP (NN turn))) (, ,) (VP (VBP alter) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ viral) (NN replication))) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (NNP CNS) (CC and) (JJ immune) (NN system) (NN origin)))))))))))))))) (. .)))
(TOP (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ nuclear) (NN factor) (NNP kappaB) (NN activation)))) (VP (VBZ attenuates) (NP (NN apoptosis) (NN resistance)) (PP (IN in) (NP (JJ lymphoid) (NNS cells)))) (. .)))
(TOP (S (NP (NP (JJ Death-inducing) (NNS ligands)) (PRN (-LRB- -LRB-) (NP (NNS DILs)) (-RRB- -RRB-)) (PP (JJ such) (IN as) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NNP TNFalpha)) (-RRB- -RRB-))) (CC or) (NP (DT the) (JJ cytotoxic) (NN drug) (NN doxorubicin))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB activate) (NP (NP (DT a) (JJ nuclear) (NN factor) (NNP kappaB) (PRN (-LRB- -LRB-) (NNP NFkappaB) (-RRB- -RRB-)) (JJ -dependent) (NN program)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB rescue) (NP (NNS cells)) (PP (IN from) (NP (NN apoptosis) (NN induction)))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP demonstrate) (ADVP (RB here)) (SBAR (IN that) (S (NP (NP (NNP TRAIL)) (PRN (-LRB- -LRB-) (NP (JJ TNF-related) (JJ apoptosis-inducing) (NN ligand)) (-RRB- -RRB-)) (, ,) (NP (DT a) (ADJP (RB recently) (VBN identified)) (NNP DIL)) (, ,)) (ADVP (RB also)) (VP (VBZ activates) (NP (NNP NFkappaB)) (PP (IN in) (NP (JJ lymphoid) (NN cell) (NNS lines))) (PP (IN in) (NP (NP (DT a) (NN kinetic)) (ADJP (JJ similar) (PP (TO to) (NP (NNP TNFalpha)))))))))) (. .)))
(TOP (S (NP (NN NFkappaB) (NN activity)) (VP (VBZ is) (ADJP (JJ independent)) (PP (IN from) (NP (NP (NNP FADD) (, ,) (NNS caspases)) (, ,) (CC and) (NP (NN apoptosis) (NN induction))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NNP NFkappaB) (NN activity))) (PP (IN on) (NP (NP (NN apoptosis)) (VP (VBN mediated) (PP (IN by) (NP (NP (NNP TRAIL)) (, ,) (NP (NNP CD95)) (, ,) (NP (NNP TNFalpha)) (, ,) (CC or) (NP (NN doxorubicin))))))))))) (, ,) (NP (NNP NFkappaB) (NN activation)) (VP (VBD was) (VP (VBN inhibited) (S (VP (VBG using) (NP (NP (DT the) (JJ proteasome) (NN inhibitor)) (NP (NP (ADJP (JJ N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal) (CC or) (JJ transient)) (NN overexpression)) (PP (IN of) (NP (JJ mutant) (NNP IkappaBalpha))))))))) (. .)))
(TOP (S (NP (NP (NN Sensitivity)) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN apoptosis)))))) (VP (VBD was) (VP (ADVP (RB markedly)) (VBN increased) (PP (IN by) (NP (DT these) (NNS treatments))) (PP (IN in) (NP (NN apoptosis) (JJ sensitive) (NN cell) (NNS lines))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (PP (DT both) (PP (IN in) (NP (NN cell) (NNS lines))) (CC and) (PP (IN in) (NP (NP (JJ primary) (NN leukemia) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ resistant) (PP (IN towards) (NP (NP (NN induction)) (PP (IN of) (NP (NN apoptosis))) (PP (IN by) (NP (NP (NNS DILs)) (CC and) (NP (NN doxorubicin))))))))))))) (, ,) (NP (NP (NN antagonization)) (PP (IN of) (NP (NNP NFkappaB) (NN activity)))) (VP (ADVP (RB partially)) (VBD restored) (NP (NN apoptosis) (NN sensitivity))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NNP NFkappaB) (NN activation)))) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ molecular) (NN approach)) (SBAR (S (VP (TO to) (VP (VB increase) (NP (NP (NN apoptosis) (NN sensitivity)) (PP (IN in) (NP (NN anticancer) (NN treatment)))))))))))))) (. .)))
(TOP (NP (NP (NNP HMG) (NN box)) (VP (VBG containing) (NP (NP (NN transcription) (NNS factors)) (PP (IN in) (NP (JJ lymphocyte) (NN differentiation))))) (. .)))
(TOP (S (NP (NP (DT The) (NN identification)) (PP (IN of) (NP (DT the) (JJ mammalian) (JJ sex-determining) (NN gene) (NNP Sry)))) (VP (VBZ has) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN discovery)) (PP (IN of) (NP (NP (DT a) (JJ large) (NN family)) (PP (IN of) (NP (NP (JJ related) (PRN (-LRB- -LRB-) ('' ') (NNP HMG) (NN box) ('' ')) (-RRB- -RRB-)) (NP (NN transcription) (NNS factors)))) (SBAR (WHNP (WDT that)) (S (VP (VBP control) (NP (NP (JJ developmental) (NNS events)) (PP (IN in) (NP (NN yeast) (, ,) (NNP C.) (NNS elegans) (, ,) (NNP Drosophila) (CC and) (NNS vertebrates))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ lymphocyte) (NN differentiation))) (, ,) (NP (JJ several) (NNP HMG) (NN box) (NNS proteins)) (VP (VBP play) (NP (DT a) (JJ decisive) (NN role))) (. .)))
(TOP (S (NP (NN Sox-4)) (VP (VBZ is) (ADJP (JJ important) (PP (IN for) (NP (ADJP (RB very) (JJ early)) (NNP B-cell) (NN differentiation)))) (, ,) (SBAR (IN while) (S (NP (NNP TCF-1/LEF-1)) (VP (VBP play) (NP (DT a) (JJ crucial) (NN role)) (PP (IN in) (NP (JJ early) (NN thymocyte) (NN development))))))) (. .)))
(TOP (S (NP (NN TCF/LEF) (NNS proteins)) (VP (VBP have) (ADVP (RB recently)) (VP (VBN been) (VP (VBN found) (S (VP (TO to) (VP (VB constitute) (NP (NP (DT a) (JJ downstream) (NN component)) (PP (IN of) (NP (DT the) (NNP Wingless/Wnt) (NN signal) (NN transduction) (NN pathway)))))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (VBZ flies))) (, ,) (NP (DT this) (NN pathway)) (VP (VBZ controls) (NP (NN segment) (NN polarity)))) (: ;) (S (PP (IN in) (NP (NNP Xenopus))) (NP (PRP it)) (VP (VBZ controls) (NP (NP (DT the) (NN definition)) (PP (IN of) (NP (DT the) (NN body) (VBZ axis)))))) (. .)))
(TOP (S (NP (NP (NN Deregulation)) (PP (IN of) (NP (DT the) (NN pathway)))) (VP (VBZ occurs) (PP (IN in) (NP (JJ several) (JJ human) (NNS tumors)))) (. .)))
(TOP (S (NP (NP (DT These) (NNS insights)) (PP (IN in) (NP (NP (DT the) (JJ molecular) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NNP TCF/LEF) (NN function))) (PP (IN in) (NP (DT these) (NNS organisms)))))))))) (VP (MD may) (ADVP (RB eventually)) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NP (DT these) (NNP HMG) (NN box) (NNS proteins)) (PP (IN in) (NP (JJ lymphoid) (NN development))))))))))) (. .)))
(TOP (S (NP (NN Loss-) (CC and) (NN gain-of-function) (NNS mutations)) (VP (VBP reveal) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN of) (NP (NP (NNP BSAP)) (PRN (-LRB- -LRB-) (NN Pax-5) (-RRB- -RRB-))))) (PP (IN at) (NP (NP (DT the) (NN start) (CC and) (NN end)) (PP (IN of) (NP (NN B) (NN cell) (NN differentiation)))))) (. .)))
(TOP (NP (NP (NN Pax-5) (NNS codes)) (PP (IN for) (NP (DT the) (NN transcription) (NN factor) (NNP BSAP))) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN expressed) (PP (IN throughout) (NP (NN B) (NN cell) (NN development))) (PP (IN except) (PP (IN in) (NP (ADJP (RB terminally) (VBN differentiated)) (NN plasma) (NNS cells)))))))) (. .)))
(TOP (S (NP (NP (NNP Gene)) (VP (VBG targeting) (NP (NP (NNS experiments)) (PP (IN in) (NP (DT the) (NN mouse)))))) (VP (VBD revealed) (NP (NP (DT a) (NN differential) (NN dependency)) (PP (IN of) (NP (JJ fetal) (CC and) (JJ adult) (NN B-lymphopoiesis))) (PP (IN on) (NP (DT this) (NN transcription) (NN factor))))) (. .)))
(TOP (S (NP (NNP BSAP)) (VP (VBZ is) (VP (VBN required) (PP (PP (IN for) (NP (NP (JJ B-lineage) (NN commitment)) (PP (IN in) (NP (DT the) (JJ fetal) (NN liver))))) (CC and) (PP (IN for) (NP (NP (NN progression)) (PP (IN beyond) (NP (NP (DT an) (JJ early) (JJ pro-B) (NN cell) (NN stage)) (PP (IN in) (NP (NN adult) (NN bone) (NN marrow)))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN characterization)) (PP (IN of) (NP (JJ Pax-5-deficient) (JJ pro-B) (NNS cells)))) (VP (VBD demonstrated) (NP (NP (NP (DT an) (JJ important) (NN role)) (PP (IN of) (NP (NNP BSAP))) (PP (IN in) (NP (NP (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (NNP CD19)))) (, ,) (ADJP (JJ mb-1) (PRN (-LRB- -LRB-) (NP (JJ Ig) (NN alpha)) (-RRB- -RRB-)))) (CC and) (NP (JJ N-myc) (NNS genes))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT the) (JJ developmental) (NN pathway)) (VP (VBG controlling) (NP (JJ VH-to-DHJH) (NN recombination)) (PP (IN at) (NP (DT the) (JJ immunoglobulin) (NN heavy-chain) (PRN (-LRB- -LRB-) (NNP IgH) (-RRB- -RRB-)) (NN locus)))))))) (. .)))
(TOP (S (NP (DT The) (JJ human) (NN PAX-5) (NN gene)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN shown) (S (VP (TO to) (VP (VB participate) (ADVP (RB together)) (PP (IN with) (NP (NP (DT the) (NNP IgH) (NN locus)) (PP (IN in) (NP (DT the) (JJ chromosomal) (NN translocation) (NN t-LRB-9;14-RRB--LRB-p13;q32-RRB-)))))))))) (. .)))
(TOP (S (NP (DT This) (NN translocation)) (VP (VBZ is) (ADJP (JJ characteristic) (PP (IN of) (NP (NP (DT a) (JJ small) (NN subset)) (PP (IN of) (NP (NP (JJ non-Hodgkin) (NNS lymphomas)) (VP (VBG exhibiting) (NP (JJ plasmacytoid) (NN differentiation))))))))) (. .)))
(TOP (S (NP (DT The) (VBN translocated) (NN PAX-5) (NN gene)) (VP (VBZ is) (VP (VBN deregulated) (PP (IN by) (NP (NP (DT the) (NN insertion)) (PP (IN of) (NP (JJ IgH) (JJ regulatory) (NNS elements))) (PP (IN into) (NP (NP (PRP$ its) (CD 5') (NN region)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NN tumorigenesis))) (PP (IN by) (S (VP (VBG interfering) (PP (PP (IN with) (NP (NP (DT the) (NN shut-down)) (PP (IN of) (NP (NN PAX-5) (NN transcription))))) (CC and) (ADVP (RB thus)) (PP (IN with) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NN plasma) (NN cell) (NN differentiation))))))))))))))))))) (. .)))
(TOP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (NNS E-proteins)) (PP (IN in) (NP (NNP B-) (CC and) (NNP T-lymphocyte) (NN development))))) (. .)))
(TOP (S (NP (NP (NNP Department)) (PP (IN of) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ hematopoietic) (NN stem) (NNS cells)))))) (VP (VBZ is) (VP (VBN controlled) (, ,) (PP (IN in) (NP (NN part))) (, ,) (PP (IN by) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ transcriptional) (JJ regulatory) (NNS proteins))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (NP (CD one) (NN class)) (PP (IN of) (NP (JJ helix-loop-helix) (NNS proteins)))) (, ,) (VP (VBN termed) (S (NP (NNS E-proteins)))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN gene) (NN expression))) (PP (IN during) (NP (JJ B-cell) (NN development)))))))) (. .)))
(TOP (S (NP (NP (JJ Recent) (NN analysis)) (PP (IN of) (NP (JJ gene-targeted) (NNS mice)))) (VP (VBZ has) (VP (VBN allowed) (NP (NP (DT a) (JJ direct) (NN assessment)) (PP (IN of) (NP (NP (DT the) (JJ functional) (NNS roles)) (PP (IN of) (NP (JJ several) (NNP E-protein) (NN family) (NNS members))) (PP (IN in) (NP (NN hematopoiesis)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN review))) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT the) (NNS defects)) (PP (IN in) (NP (NP (NNP B-) (CC and) (NNP T-lymphocyte) (NN development)) (PP (IN in) (NP (NNS mice))))) (VP (VP (VBG carrying) (NP (NP (JJ targeted) (NNS mutations)) (PP (IN in) (NP (DT the) (JJ E-protein) (NNS genes))))) (CC and) (VP (VB discuss) (NP (NP (PRP$ our) (JJ current) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (DT these) (NNS proteins)) (PP (IN in) (NP (JJ lymphoid) (NN development)))))))))))) (. .)))
(TOP (S (NP (JJ Oxidative) (NN stress)) (VP (VBZ suppresses) (NP (NP (NN transcription) (NN factor) (NNS activities)) (PP (IN in) (NP (VBN stimulated) (NNS lymphocytes))))) (. .)))
(TOP (S (NP (NP (NNPS Effects)) (PP (IN of) (NP (JJ oxidative) (NN stress))) (PP (IN on) (NP (JJ stimulation-dependent) (NN signal) (NN transduction))) (, ,) (VP (VBG leading) (PP (TO to) (NP (NN IL-2) (NN expression)))) (, ,)) (VP (VBD were) (VP (VBN studied))) (. .)))
(TOP (S (S (NP (VBN Purified) (JJ quiescent) (JJ human) (NN blood) (NN T) (NNS lymphocytes)) (VP (VBD were) (VP (VBN subjected) (PP (TO to))))) (: :) (NP (NP (NP (-LRB- -LRB-) (FW i) (-RRB- -RRB-) (JJ acute) (NN exposure)) (PP (TO to) (NP (NN hydrogen) (NN peroxide)))) (: ;) (NP (NP (PRN (-LRB- -LRB-) (NN ii) (-RRB- -RRB-)) (NN chronic) (NN exposure)) (PP (TO to) (NP (NN hydrogen) (NN peroxide)))) (: ;) (CC and) (NP (NP (-LRB- -LRB-) (NN iii) (-RRB- -RRB-) (JJ acute) (NN exposure)) (PP (TO to) (S (VP (VBG ionizing) (NP (NN radiation))))))) (. .)))
(TOP (S (NP (DT The) (NNS cells)) (VP (VBD were) (ADVP (RB then)) (VP (VBN stimulated) (PP (IN for) (NP (CD 6) (NN h))))) (. .)))
(TOP (NP (NP (NP (JJ DNA-binding) (NNS activities)) (PRN (-LRB- -LRB-) (VP (VBN determined) (PP (IN by) (NP (DT the) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)))) (-RRB- -RRB-)) (PP (IN of) (NP (CD three) (NN transcription) (NNS factors)))) (: :) (NP (NP (NNP NFkappaB) (, ,) (NNP AP-1) (CC and) (NNP NFAT)) (, ,) (VP (VBD were) (VP (VBN abolished) (PP (IN in) (NP (DT the) (NNS lymphocytes))) (PP (IN by) (NP (NP (DT all) (CD three) (NNS modes)) (PP (IN of) (NP (JJ oxidative) (NN stress)))))))) (. .)))
(TOP (S (NP (DT The) (NNS lymphocytes)) (VP (VBD exhibited) (NP (NN lipid) (NN peroxidation)) (PP (ADVP (RB only)) (IN upon) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (DT the) (JJS lowest) (NN level)) (PP (IN of) (NP (NP (NN hydrogen) (NN peroxide)) (VP (VBN used) (PRN (-LRB- -LRB-) (NP (NNP 20) (NNP microM)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP (NP (DT All) (CD three) (NNS modes)) (PP (IN of) (NP (JJ oxidative) (NN stress)))) (VP (VBD induced) (NP (NP (NN catalase) (NN activity)) (PP (IN in) (NP (DT the) (NNS lymphocytes))))) (. .)))
(TOP (S (NP (DT The) (JJ only) (NN exception)) (VP (VBD was) (NP (NN hydrogen) (NN peroxide)) (PP (IN at) (NP (NP (CD 20) (NNP microM)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD did) (RB not) (VP (VB induce) (NP (NN catalase) (NN activity))))))))) (. .)))
(TOP (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (DT that) (: :) (S (NP (NP (PRN (-LRB- -LRB-) (FW i) (-RRB- -RRB-)) (NN suppression)) (PP (IN of) (NP (JJ specific) (NN transcription) (NN factor) (NNS functions)))) (VP (MD can) (ADVP (RB potentially)) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NP (NP (NN exposure)) (PP (TO to) (NP (JJ oxidative) (NN stress)))) (CC and) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (JJ human) (NNS lymphocytes)))))))))))))) (: ;) (S (S (NP (PRN (-LRB- -LRB-) (FW ii) (-RRB- -RRB-)) (NN lipid) (NN peroxidation)) (VP (VBZ is) (ADJP (RB only) (JJ detectable)) (PP (IN in) (NP (JJ human) (NNS lymphocytes))) (PP (IN upon) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (JJ weak) (JJ oxidative) (NN stress)) (SBAR (WHNP (WDT which)) (S (VP (VBZ does) (RB not) (VP (VB induce) (NP (NN catalase) (NN activity)))))))))))) (: ;) (S (S (PRN (-LRB- -LRB-) (INTJ (NN iii)) (-RRB- -RRB-)) (ADVP (RB therefore))) (, ,) (NP (NN transcription) (NN factor) (JJ DNA-binding) (NNS activities)) (VP (VBP are) (ADJP (ADJP (RBR more) (JJ sensitive) (PP (TO to) (NP (JJ oxidative) (NN stress)))) (PP (IN than) (NP (NN lipid) (NN peroxidation))))))) (. .)))
(TOP (S (NP (NN Ro) (CD 09-2210)) (VP (NNS exhibits) (NP (NP (JJ potent) (JJ anti-proliferative) (NNS effects)) (PP (IN on) (NP (VBN activated) (NNP T) (NNS cells)))) (PP (IN by) (S (VP (ADVP (RB selectively)) (VBG blocking) (NP (NNP MKK) (NN activity)))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG using) (NP (NP (JJ high) (JJ throughput) (NN screening)) (PP (IN of) (NP (JJ microbial) (NNS broths))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN identified) (NP (NP (DT a) (NN compound)) (, ,) (VP (VBN designated) (S (NP (NNP Ro) (CD 09-2210)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB block) (SBAR (S (NP (NP (JJ anti-CD3) (VBN induced) (JJ peripheral) (NN blood) (NNP T) (NN cell) (NN activation)) (PP (IN with) (NP (DT an) (NN IC50)))) (VP (SYM =) (NP (CD 40) (NN nM))))))))))))))) (. .)))
(TOP (S (NP (NN Ro) (NN 09-2210)) (VP (VP (VBD was) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB block) (NP (NP (JJ antigen-induced) (NN IL-2) (NN secretion)) (PP (IN with) (NP (DT an) (NNP IC50) (SYM =)))) (NP (CD 30) (NN nM))))))) (, ,) (CC but) (VP (VBD was) (ADJP (ADVP (RB considerably) (RBR less)) (JJ potent)) (PP (IN at) (S (VP (VBG blocking) (NP (NP (JJ Ca2+) (NN flux)) (VP (VBN stimulated) (PP (IN by) (NP (JJ anti-CD3) (NN treatment)))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Ro) (CD 09-2210))))))))) (, ,) (NP (PRP we)) (VP (VP (VBD set) (PRT (RP up)) (NP (NP (DT a) (JJ transient) (NN expression) (NN system)) (PP (IN in) (NP (NNP Jurkat) (NNP T) (NNS cells)))) (S (VP (VBG using) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN reporter) (NN gene) (NNS constructs))))))) (CC and) (VP (VBD showed) (SBAR (S (NP (NP (JJ effective) (NN inhibition)) (PP (IN of) (NP (NP (NN phorbol) (VBD ester/ionomycin-induced) (JJ NF-AT) (NN activation)) (CC and) (NP (NP (JJ anti-CD3) (VBN induced) (NN NF-AT)) (PP (IN with) (NP (NNP IC50))))))) (VP (SYM =) (NP (QP (CD 7.7) (CC and) (CD 10)) (NN nM)) (, ,) (ADVP (RB respectively))))))) (. .)))
(TOP (S (NP (NN Ro) (NN 09-2210)) (VP (VBD was) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB inhibit) (SBAR (S (NP (NP (JJ phorbol) (JJ ester/ionomycin-induced) (NN activation)) (PP (IN of) (NP (NNP AP1))) (PP (IN with) (NP (NNP IC50)))) (VP (SYM =) (NP (FW &lt;) (CD 10) (NN nM)))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (ADVP (RB further)) (VBD showed) (SBAR (IN that) (S (NP (NNP Ro) (CD 09-2210)) (VP (VP (VBD was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NP (JJ c-jun) (VBN induced) (NN expression)) (PP (IN of) (NP (JJ AP1-dependent) (NN reporter) (NNS constructs)))) (PRN (-LRB- -LRB-) (NP (FW IC50) (FW &gt;) (CD 500) (NN nM)) (-RRB- -RRB-)))))))) (, ,) (CC but) (VP (VBD was) (ADJP (JJ able) (S (VP (TO to) (VP (ADVP (RB potently)) (VB inhibit) (NP (NP (JJ ras-induced) (NNP AP1) (NN activation)) (PRN (-LRB- -LRB-) (S (NP (CD IC50)) (VP (SYM =) (NP (CD 20) (NN nM)))) (-RRB- -RRB-)))))))))))) (. .)))
(TOP (S (NP (DT This)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Ro) (CD 09-2210)) (VP (VBD was) (VP (VBG inhibiting) (NP (NP (DT an) (NN activator)) (PP (IN of) (NP (NP (NN AP-1)) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (JJ upstream) (PP (IN of) (NP (NP (ADJP (JJ c-jun) (CC and) (JJ downstream))) (PP (IN of) (NP (NNS ras)))))) (S (VP (VBG signaling)))))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB investigate) (ADVP (RB further))))) (, ,) (NP (PRP we)) (ADVP (RB then)) (VP (VP (VBD purified) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (JJ different) (NNS kinases)) (, ,) (PP (VBG including) (NP (NP (NP (NNP PKC)) (, ,) (NP (NNP PhK)) (, ,) (NP (NNP ZAP-70)) (, ,) (NP (NNP ERK)) (, ,) (CC and) (NP (NNP MEK) (CD 1))) (PRN (-LRB- -LRB-) (NP (DT a) (NNP MKK)) (-RRB- -RRB-)))))))) (, ,) (CC and) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Ro) (CD 09-2210)) (VP (VBD was) (NP (NP (NP (DT a) (JJ selective) (NN inhibitor)) (PP (IN of) (NP (NNP MEK1))) (PP (IN in) (NP (NN vitro)))) (PRN (-LRB- -LRB-) (S (NP (CD IC50)) (VP (SYM =) (NP (CD 59) (NN nM)))) (-RRB- -RRB-)))))))) (. .)))
(TOP (NP (NP (NN Role)) (PP (IN of) (NP (NP (NN GATA-1)) (PP (IN in) (NP (NP (NN proliferation) (CC and) (NN differentiation)) (PP (IN of) (NP (NP (JJ definitive) (ADJP (JJ erythroid) (CC and) (JJ megakaryocytic)) (NNS cells)) (PP (IN in) (NP (NN vivo))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (NNS contributions)) (PP (IN of) (NP (NN GATA-1))) (PP (TO to) (NP (NP (JJ definitive) (NN hematopoiesis)) (PP (IN in) (NP (NN vivo))))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN examined) (NP (NP (NN adult) (NNS mice)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (VP (VBN rendered) (S (ADJP (RB genetically) (JJ defective))) (PP (IN in) (NP (NP (JJ GATA-1) (NN synthesis)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Takahashi) (NNP et) (NNP al)) (, ,) (NP (NNP J) (NNP Biol) (NNP Chem) (CD 272))) (: :) (NP (NP (CD 12611)) (, ,) (NP (CD 1997)))) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP (DT the) (NNP GATA-1) (NN gene)) (VP (VBZ is) (VP (VBN located) (PP (IN on) (NP (NP (DT the) (NNP X) (NN chromosome)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (ADVP (RB randomly)) (VBN inactivated) (PP (IN in) (NP (DT every) (NN cell))))))))))))) (, ,) (NP (JJ heterozygous) (NNS females)) (VP (MD can) (VP (VB bear) (NP (CC either) (NP (DT an) (JJ active) (JJ wild-type) (CC or) (JJ mutant)) (PRN (-LRB- -LRB-) (VP (VBD referred) (PP (TO to)) (PP (IN as) (NP (NN GATA-1.05)))) (-RRB- -RRB-)) (NP (NN GATA-1) (NN allele))) (, ,) (S (ADVP (RB consequently)) (VP (VBG leading) (PP (TO to) (NP (JJ variable) (JJ anemic) (NN severity))))))) (. .)))
(TOP (S (S (NP (DT These) (JJ heterozygous) (JJ mutant) (NNS mice)) (ADVP (RB usually)) (VP (VBD developed) (ADVP (RB normally)))) (, ,) (CC but) (S (NP (PRP they)) (VP (VBD began) (S (VP (TO to) (VP (VB die) (PP (IN after) (NP (CD 5) (NNS months)))))))) (. .)))
(TOP (S (NP (DT These) (JJ affected) (NNS animals)) (VP (VBD displayed) (S (VP (VP (VBN marked) (ADVP (RB splenomegaly))) (, ,) (NP (NN anemia)) (, ,) (CC and) (ADJP (NN thrombocytopenia))))) (. .)))
(TOP (S (S (NP (NNS Proerythroblasts) (CC and) (NNS megakaryocytes)) (VP (ADVP (RB massively)) (VBN accumulated) (PP (IN in) (NP (NP (DT the) (NNS spleens)) (PP (IN of) (NP (DT the) (NNS heterozygotes))))))) (, ,) (CC and) (S (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN neomycin) (NN resistance) (NN gene)) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (DT the) (JJ positive) (NN selection) (NN marker)) (PP (IN in) (NP (NNP ES) (NNS cells))))))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN expressed) (ADVP (RB profusely)) (PP (IN in) (NP (NP (DT the) (ADJP (RB abnormally) (JJ abundant)) (NNS cells)) (VP (VBN generated) (PP (IN in) (NP (DT the) (CD GATA-1.05) (JJ mutant) (NNS females)))))))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD observed) (NP (NP (NNS hematopoiesis)) (PP (IN outside) (PP (IN of) (NP (NP (DT the) (NN bone) (NN marrow)) (PP (IN in) (NP (DT the) (JJ affected) (JJ mutant) (NNS mice)))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (S (SBAR (SBAR (IN that) (S (NP (NP (DT a) (JJ small) (NN number)) (PP (IN of) (NP (NN GATA-1.05) (JJ mutant) (JJ hematopoietic) (NN progenitor) (NNS cells)))) (VP (VBP begin) (S (VP (TO to) (VP (VB proliferate) (ADVP (RB vigorously)) (PP (IN during) (NP (JJ early) (NN adulthood))))))))) (, ,) (CC but) (SBAR (IN because) (S (NP (DT the) (NNS cells)) (VP (VBP are) (ADJP (JJ unable) (S (VP (TO to) (VP (ADVP (RB terminally)) (VB differentiate))))))))) (, ,) (NP (DT this)) (VP (VBZ leads) (S (VP (TO to) (VP (VB progenitor) (NP (NP (NN proliferation)) (PP (IN in) (NP (NP (DT the) (NN spleen)) (CC and) (ADVP (RB consequently)) (NP (NN death)))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (JJ GATA-1)) (VP (NNS plays) (ADJP (JJ important)) (PP (IN in) (NP (NP (NN vivo) (NNS roles)) (PP (IN for) (S (VP (VBG directing) (NP (JJ definitive) (JJ hematopoietic) (NNS progenitors)) (S (VP (TO to) (VP (VB differentiate) (PRT (RP along)) (NP (DT both) (DT the) (ADJP (JJ erythroid) (CC and) (JJ megakaryocytic)) (NNS pathways))))))))))) (. .)))
(TOP (S (NP (DT The) (JJ GATA-1) (JJ heterozygous) (JJ mutant) (NN mouse)) (VP (VBZ shows) (NP (NP (DT a) (NN phenotype)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ is) (ADJP (JJ analogous) (PP (TO to) (NP (JJ human) (JJ myelodysplastic) (NN syndrome))))) (CC and) (ADVP (RB thus)) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (JJ useful) (NN model)) (PP (IN for) (NP (DT this) (NN disorder)))))))))))) (. .)))
(TOP (S (NP (NN Erythropoietin)) (VP (VBZ induces) (NP (NP (JJ tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NNP Jak2) (, ,) (NNP STAT5A) (, ,) (CC and) (NNP STAT5B))) (PP (IN in) (NP (NN primary) (VBD cultured) (JJ human) (JJ erythroid) (NNS precursors))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD examined) (S (VP (VBG signaling) (PP (IN by) (NP (NN erythropoietin))) (PP (IN in) (NP (NP (ADJP (RB highly) (VBN purified)) (JJ human) (NN colony)) (VP (VBG forming) (NP (JJ unit-erythroid) (NNS cells))) (, ,) (VP (VBN generated) (PP (IN in) (NP (NN vitro))) (PP (IN from) (NP (NN CD34-LRB-+-RRB-) (NNS cells))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD found) (SBAR (DT that) (S (NP (NN erythropoietin)) (VP (VBZ induces) (NP (NP (JJ tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NNP Jak2) (, ,) (NNP STAT5A) (, ,) (CC and) (NNP STAT5B)))))))) (. .)))
(TOP (S (NP (NP (JJ Tyrosine) (NN phosphorylation)) (PP (IN of) (NP (JJ Jak2)))) (VP (VP (NNS reaches) (NP (NP (DT a) (NN peak)) (PP (IN around) (NP (CD 10) (NNS minutes))) (PP (IN after) (NP (NN stimulation))))) (CC and) (VP (VBZ is) (ADJP (JJ maximum)) (PP (IN at) (NP (NP (CD 5) (NN U/mL)) (PP (IN of) (NP (NN erythropoietin))))))) (. .)))
(TOP (S (NP (NP (JJ Tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NNP STAT5)))) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (VBN activated) (NNP STAT5))) (PP (TO to) (NP (DT the) (NN nucleus))) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NP (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)) (PRN (-LRB- -LRB-) (NP (NNP EMSA)) (-RRB- -RRB-)) (VP (VBG using) (NP (JJ 32Pi-labeled) (NNS STAT5)) (NP (NP (VBG binding) (NN site)) (PP (IN in) (NP (DT the) (JJ beta-casein) (NN promoter)))))))))))))) (. .)))
(TOP (S (NP (NP (JJ Tyrosine) (NN phosphorylation) (NNP STAT1)) (CC or) (NP (NNP STAT3))) (VP (VBD was) (RB not) (VP (VBN detected) (PP (IN in) (NP (JJ human) (JJ erythroid) (NNS precursors))) (PP (IN after) (NP (NP (NN stimulation)) (PP (IN with) (NP (NN erythropoietin))))))) (. .)))
(TOP (S (S (NP (NP (NNP Crkl)) (, ,) (NP (DT an) (JJ SH2/SH3) (NN adapter) (NN protein)) (, ,)) (VP (VBZ becomes) (VP (VBN coimmunoprecipitated) (ADVP (RB specifically)) (PP (IN with) (NP (NNP STAT5))) (PP (IN from) (NP (JJ erythropoietin-stimulated) (JJ erythroid) (NNS cells)))))) (: ;) (SBAR (IN although) (S (NP (PRP it)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB become) (VP (JJ associated) (PP (IN with) (NP (NNP c-Cbl))) (PP (IN in) (NP (NP (DT the) (NNS studies)) (VP (VBG using) (NP (NN cell) (NNS lines))))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (JJ human) (JJ erythroid) (NNS precursors)) (VP (MD can) (VP (VB be) (VP (VBN expanded) (PP (IN in) (NP (NN vitro))) (PP (IN in) (NP (JJ sufficient) (NNS numbers) (CC and) (NN purity))) (S (VP (TO to) (VP (VB allow) (NP (PRP$ its) (NN usage)) (PP (IN in) (NP (NN signal) (NN transduction) (NNS studies))))))))) (. .)))
(TOP (S (NP (DT This) (NN report)) (VP (VBZ sets) (NP (NP (DT a) (NN basis)) (PP (IN for) (NP (NP (JJ further) (NNS studies)) (PP (IN on) (S (VP (VBG signaling) (PP (IN in) (NP (NP (NN primary) (VBD cultured) (JJ human) (JJ erythroid) (NNS precursors)) (, ,) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBP contribute) (PP (TO to) (NP (NP (PRP$ our) (JJR better) (NN understanding)) (PP (IN in) (NP (NP (DT the) (NN differentiation) (NNS processes)) (PP (IN of) (NP (NP (NNS erythrocytes)) (CC and) (NP (PRP$ their) (NNS precursors)))))))))))))))))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ small) (, ,) (JJ nonpeptidyl) (VBP mimic)) (PP (IN of) (NP (JJ granulocyte-colony-stimulating) (NN factor) (NNP -LSB-)))) (VP (VBP see) (S (NP (NNS commetns)) (ADJP (NNP -RSB-))))))
(TOP (S (NP (NP (DT A) (JJ nonpeptidyl) (JJ small) (NN molecule) (NNP SB) (CD 247464)) (, ,) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG activating) (NP (NP (JJ granulocyte-colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP G-CSF)) (-RRB- -RRB-)))))))) (VP (VP (NN signal) (NP (NN transduction) (NNS pathways))) (, ,) (VP (VBD was) (VP (VBN identified) (PP (IN in) (NP (NP (DT a) (JJ high-throughput) (NN assay)) (PP (IN in) (NP (JJ cultured) (NNS cells)))))))) (. .)))
(TOP (S (PP (IN Like) (NP (NNP G-CSF))) (, ,) (NP (NNP SB) (CD 247464)) (VP (VP (VBD induced) (NP (NP (JJ tyrosine) (NN phosphorylation)) (PP (IN of) (NP (JJ multiple) (VBG signaling) (NNS proteins))))) (CC and) (VP (VBD stimulated) (NP (NP (JJ primary) (JJ murine) (NN bone) (NN marrow) (NNS cells)) (SBAR (S (VP (TO to) (VP (VB form) (NP (NP (JJ granulocytic) (NNS colonies)) (PP (IN in) (NP (NN vitro))))))))))) (. .)))
(TOP (S (NP (PRP It)) (ADVP (RB also)) (VP (VBD elevated) (NP (JJ peripheral) (NN blood) (NN neutrophil) (NNS counts)) (PP (IN in) (NP (NNS mice)))) (. .)))
(TOP (S (NP (NP (DT The) (JJ extracellular) (NN domain)) (PP (IN of) (NP (DT the) (JJ murine) (NNP G-CSF) (NN receptor)))) (VP (VBD was) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP SB) (CD 247464))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT the) (JJ compound)) (VP (NNS acts) (PP (IN by) (S (VP (VBG oligomerizing) (NP (NN receptor) (NNS chains)))))))))))) (. .)))
(TOP (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT a) (JJ small) (NN molecule)) (VP (MD can) (VP (VB activate) (NP (NP (DT a) (NN receptor)) (SBAR (WHNP (WDT that)) (S (ADVP (RB normally)) (VP (VBZ binds) (NP (DT a) (ADJP (RB relatively) (JJ large)) (NN protein) (NN ligand))))))))))) (. .)))
(TOP (S (NP (NNP Thrombopoietin)) (VP (VBZ supports) (PP (IN in) (NP (NN vitro) (JJ erythroid) (NN differentiation))) (PP (IN via) (NP (NP (PRP$ its) (JJ specific) (NN receptor)) (ADJP (NN c-Mpl) (PP (IN in) (NP (DT a) (JJ human) (NN leukemia) (NN cell) (NN line))))))) (. .)))
(TOP (S (NP (NP (NNP Thrombopoietin)) (PRN (-LRB- -LRB-) (NP (NNP TPO)) (-RRB- -RRB-))) (VP (VBZ acts) (PP (PP (IN on) (NP (NP (NN megakaryopoiesis) (CC and) (NN erythropoiesis)) (PP (IN in) (NP (NN vitro))))) (CC and) (PP (IN in) (NP (NN vivo))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD isolated) (NP (NP (DT a) (JJ novel) (NN subline)) (, ,) (NP (NN UT-7/GMT)) (, ,)) (PP (IN from) (NP (NP (DT the) (JJ human) (NN leukemia) (NN cell) (NN line) (NNP UT-7/GM)) (PRN (-LRB- -LRB-) (NP (NNP N.) (NNP Komatsu)) (, ,) (NP (FW et) (FW al.)) (, ,) (NP (NNP Blood)) (, ,) (NP (CD 89)) (: :) (NP (NP (CD 4021-4033)) (, ,) (NP (CD 1997))) (-RRB- -RRB-))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ small) (NN population)) (PP (IN of) (NP (NN UT-7/GM) (NNS cells)))) (VP (ADVP (RB positively)) (VBD stained) (PP (IN for) (NP (NP (NN hemoglobin)) (PRN (-LRB- -LRB-) (NP (NNP Hb)) (-RRB- -RRB-)))) (PP (IN after) (NP (NP (DT a) (JJ 7-day) (NN exposure)) (PP (TO to) (NP (NNP TPO)))))) (. .)))
(TOP (S (NP (NP (QP (JJR More) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (JJ TPO-treated) (NN UT-7/GMT) (NNS cells)))) (VP (ADVP (RB positively)) (VBD stained) (PP (IN for) (NP (NNP Hb)))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NN UT-7/GMT) (NNS cells)))) (, ,) (NP (PRP we)) (VP (VBD examined) (SBAR (WHADVP (WRB how)) (S (NP (NNP TPO)) (VP (VBZ promotes) (NP (NN hemoglobinization)))))) (. .)))
(TOP (S (NP (NNP TPO)) (VP (VBD induced) (NP (NP (NP (JJ tyrosine) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NNP TPO) (NN receptor)))) (CC but) (RB not) (NP (DT the) (NN erythropoietin) (PRN (-LRB- -LRB-) (NNP EPO) (-RRB- -RRB-)) (NN receptor)))) (. .)))
(TOP (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN competition)) (PP (IN between) (NP (NP (NNP TPO)) (CC and) (NP (NNP EPO)))) (PP (IN for) (S (VP (VBG binding) (PP (TO to) (NP (NNP EPO) (NN receptor)))))))) (. .)))
(TOP (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP TPO)) (VP (VBZ has) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN on) (NP (NN hemoglobinization)))) (PP (IN via) (NP (NP (DT a) (JJ specific) (NN receptor)) (PP (IN on) (NP (NN UT-7/GMT) (NNS cells))))))))) (. .)))
(TOP (S (NP (JJ Isoelectric) (VBG focusing)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NNP TPO)) (VP (VBD induced) (NP (JJ fetal) (CC and) (JJ adult) (NNP Hb) (NN synthesis)) (, ,) (SBAR (IN whereas) (S (NP (NNP EPO)) (VP (VBD induced) (NP (ADJP (JJ embryonic) (, ,) (JJ fetal) (, ,) (CC and) (NN adult)) (NN Hb) (NN synthesis))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (PRP$ our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP TPO)) (VP (VBZ has) (NP (NP (DT a) (JJ distinct) (NN action)) (PP (IN on) (NP (NN erythropoiesis)))))))) (. .)))
(TOP (S (NP (NP (NNS Macrophages)) (PP (IN in) (NP (JJ human) (NN atheroma)))) (VP (VBP contain) (NP (NP (NNP PPARgamma)) (: :) (NP (NP (JJ differentiation-dependent) (JJ peroxisomal) (JJ proliferator-activated) (NN receptor) (NN gamma) (PRN (-LRB- -LRB-) (NNP PPARgamma) (-RRB- -RRB-)) (NN expression) (CC and) (NN reduction)) (PP (IN of) (NP (NN MMP-9) (NN activity))) (PP (IN through) (NP (NP (NNP PPARgamma) (NN activation)) (PP (IN in) (NP (NP (JJ mononuclear) (NNS phagocytes)) (PP (IN in) (NP (NN vitro)))))))))) (. .)))
(TOP (S (NP (NNP Mononuclear) (NNS phagocytes)) (VP (VBP play) (NP (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NN atherosclerosis)))) (CC and) (NP (PRP$ its) (NN sequela) (NN plaque) (NN rupture))) (PP (IN in) (NP (NN part))) (PP (IN by) (NP (NP (PRP$ their) (NN secretion)) (PP (IN of) (NP (NP (NN matrix) (NNS metalloproteinases)) (PRN (-LRB- -LRB-) (NP (NNS MMPs)) (-RRB- -RRB-)) (, ,) (PP (VBG including) (NP (NNP MMP-9)))))))) (. .)))
(TOP (S (NP (NP (JJ Peroxisomal) (JJ proliferator-activated) (NN receptor) (NN gamma)) (PRN (-LRB- -LRB-) (NP (NNP PPARgamma)) (-RRB- -RRB-)) (, ,) (NP (NP (DT a) (NN transcription) (NN factor)) (PP (IN in) (NP (DT the) (JJ nuclear) (NN receptor))) (ADVP (RB superfamily))) (, ,)) (VP (VBZ regulates) (NP (NN gene) (NN expression)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ various) (NNS activators)) (, ,) (PP (VBG including) (NP (NP (JJ 15-deoxy-delta12,14-prostaglandin) (NN J2)) (CC and) (NP (DT the) (JJ antidiabetic) (NN agent) (NN troglitazone))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNP PPARgamma))) (PP (IN in) (NP (JJ human) (NN atherosclerosis)))) (VP (VBZ is) (ADJP (JJ unexplored))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP report) (ADVP (RB here)) (SBAR (IN that) (S (NP (NP (NP (NNS monocytes/macrophages)) (PP (IN in) (NP (JJ human) (JJ atherosclerotic) (NNS lesions)))) (PRN (-LRB- -LRB-) (NP (NN n) (SYM =) (CD 12)) (-RRB- -RRB-))) (VP (VBP express) (NP (JJ immunostainable) (NNP PPARgamma)))))) (. .)))
(TOP (S (NP (NP (JJ Normal) (NN artery) (NNS specimens)) (PRN (-LRB- -LRB-) (NP (SYM n) (SYM =) (CD 6)) (-RRB- -RRB-))) (VP (VBP reveal) (NP (JJ minimal) (JJ immunoreactive) (NN PPARgamma))) (. .)))
(TOP (S (NP (NP (NP (JJ Human) (NNS monocytes)) (CC and) (NP (JJ monocyte-derived) (NNS macrophages))) (VP (VBN cultured) (PP (IN for) (NP (CD 6) (NNS days))) (PP (IN in) (NP (ADJP (CD 5) (NN %)) (JJ human) (NN serum))))) (VP (VBD expressed) (NP (NP (NNP PPARgamma) (NNP mRNA)) (CC and) (NP (NN protein))) (PP (IN by) (NP (NP (NP (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction)) (CC and) (NP (JJ Western) (VBG blotting))) (, ,) (ADVP (RB respectively))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNP PPARgamma) (NNP mRNA) (NN expression)) (PP (IN in) (NP (JJ U937) (NNS cells)))) (VP (VBN increased) (PP (IN during) (NP (NN phorbol) (JJ 12-myristate) (CD 13) (JJ acetate-induced) (NN differentiation)))) (. .)))
(TOP (S (NP (NP (NP (NN Stimulation)) (PP (IN of) (NP (NNP PPARgamma))) (PP (IN with) (NP (NN troglitazone)))) (CC or) (NP (NP (JJ 15-deoxy-delta12,14-prostaglandin) (NN J2)) (PP (IN in) (NP (JJ human) (JJ monocyte-derived) (NNS macrophages))))) (VP (VBD inhibited) (NP (NNP MMP-9) (JJ gelatinolytic) (NN activity)) (PP (IN in) (NP (DT a) (JJ concentration-dependent) (NN fashion))) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN by) (NP (NN zymography))))))) (. .)))
(TOP (S (NP (DT This) (NN inhibition)) (VP (VBZ correlates) (PP (IN with) (NP (VBN decreased) (NN MMP-9) (NN secretion))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NNP Western) (VBG blotting))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NNP PPARgamma)) (VP (VP (VBZ is) (ADJP (JJ present) (PP (IN in) (NP (NP (NNS macrophages)) (PP (IN in) (NP (JJ human) (JJ atherosclerotic) (NNS lesions))))))) (CC and) (VP (MD may) (VP (VB regulate) (NP (NP (NN expression) (CC and) (NN activity)) (PP (IN of) (NP (NP (NNP MMP-9)) (, ,) (NP (NP (DT an) (NN enzyme)) (VP (VBN implicated) (PP (IN in) (NP (NN plaque) (NN rupture))))))))))) (. .)))
(TOP (S (NP (NNP PPARgamma)) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (NP (NP (DT an) (JJ important) (NN regulator)) (PP (IN of) (NP (NN monocyte/macrophage) (NN function))) (PP (IN with) (NP (NP (NN relevance)) (PP (IN for) (NP (JJ human) (JJ atherosclerotic) (NN disease))))))))))) (. .)))
(TOP (NP (NP (NP (JJ Peripheral) (NN blood) (NN T) (NNS cells)) (CC and) (NP (NNS monocytes) (CC and) (NN B) (NN cell) (NNS lines))) (VP (VBN derived) (PP (IN from) (NP (NNS patients))) (PP (IN with) (NP (NP (JJ lupus) (JJ express) (NN estrogen) (NN receptor) (NNS transcripts)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (JJ normal) (NNS cells))))))))) (. .)))
(TOP (NP (NP (NNP OBJECTIVE)) (: :) (S (S (VP (TO To) (VP (VB identify) (CC and) (VB characterize) (NP (NN estrogen) (NN receptor) (PRN (-LRB- -LRB-) (NNP ER) (-RRB- -RRB-)) (NNS transcripts))))) (VP (VBN expressed) (PP (IN in) (NP (NP (JJ immune) (NNS cells)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (JJ systemic) (FW lupus) (FW erythematosus)) (PRN (-LRB- -LRB-) (NP (NNP SLE)) (-RRB- -RRB-))) (CC and) (NP (JJ healthy) (NNS donors)))))))))) (. .)))
(TOP (NP (NP (NNS METHODS)) (: :) (S (NP (NP (JJ Peripheral) (NN blood) (NNS monocytes)) (CC and) (NP (NN T) (NNS cells))) (VP (VBD were) (VP (VBN prepared) (PP (IN from) (NP (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NNP SLE)))) (PRN (-LRB- -LRB-) (NP (SYM n) (SYM =) (CD 6)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ healthy) (NNS donors)) (PRN (-LRB- -LRB-) (S (NP (SYM n)) (VP (SYM =) (NP (CD 8)))) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP (NN T) (NNS cells)) (VP (VBD were) (VP (VBN separated) (PP (IN into) (NP (NNP CD4) (CC and) (NNP CD8))))) (. .)))
(TOP (S (NP (DT Some) (NX (NX (NNS monocytes)) (CC and) (NX (NN T) (NNS cells)))) (VP (VBD were) (VP (VBN stimulated) (PP (IN with) (NP (NN estradiol) (, ,) (NNP PMA) (, ,) (CC and) (NN ionomycin))))) (. .)))
(TOP (S (NP (NP (NP (JJ Epstein-Barr) (JJ virus-transformed) (NN B) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (SYM n) (SYM =) (CD 7)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP B) (NN cell) (NNS hybridomas)) (PRN (-LRB- -LRB-) (NP (SYM n) (SYM =) (CD 2)) (-RRB- -RRB-)) (VP (VBN established) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP SLE)) (CC and) (NP (DT a) (JJ healthy) (NN individual))))))))) (VP (VBD were) (VP (VBN used) (PP (IN as) (NP (DT a) (NN B) (NN cell) (NN source))))) (. .)))
(TOP (S (NP (DT These) (NNS cells)) (VP (VBD were) (VP (VBN examined) (PP (IN for) (NP (NNP ER) (NNP mRNA))) (PP (IN by) (NP (ADJP (JJ reverse) (NN transcription)) (VBD nested) (NN polymerase) (NN chain) (NN reaction))))) (. .)))
(TOP (S (NP (NNP Amplified) (NNP cDNA)) (VP (VBD were) (VP (VBN sequenced) (PP (IN by) (NP (JJ standard) (NNS methods))))) (. .)))
(TOP (NP (NP (NNS RESULTS)) (: :) (S (S (PP (IN In) (NP (DT all) (NNS cells))) (VP (VBD tested))) (, ,) (NP (NNP ER) (NNP mRNA)) (VP (VBD was) (VP (VBN expressed) (PP (IN without) (ADVP (RB prior) (PP (IN in) (NP (NN vitro) (NN stimulation)))))))) (. .)))
(TOP (S (NP (NP (JJ Partial) (NNS sequences)) (PP (IN from) (NP (NNS exons) (CD 1-8)))) (VP (VBD were) (ADJP (RB nearly) (JJ identical) (PP (TO to) (NP (NP (DT the) (VBN published) (NN sequence)) (PP (IN of) (NP (DT the) (JJ human) (NNP ER) (NNP mRNA))))))) (. .)))
(TOP (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (JJ notable) (NNS differences)) (PP (IN in) (NP (DT the) (NNP ER) (NNS transcripts))) (PP (IN between) (NP (NP (NNS patients)) (CC and) (NP (JJ healthy) (NNS controls)))))) (. .)))
(TOP (S (NP (NP (JJ Variant) (NN receptor) (NNS transcripts)) (VP (VBG lacking) (NP (NP (NP (NN exon) (CD 5)) (CC or) (NP (NN exon) (CD 7))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (DT the) (NN hormone) (VBG binding) (NN domain))))) (, ,)))) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (DT the) (NNS cells))))))) (. .)))
(TOP (S (NP (NP (JJ Precise) (NN deletion)) (PP (IN of) (NP (DT the) (NNS exons)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (PRP they)) (VP (VBP are) (ADVP (RB alternatively)) (NP (JJ spliced) (NNS transcripts)))))) (. .)))
(TOP (S (SBAR (IN Whether) (S (NP (DT the) (VBN detected) (NNS transcripts)) (VP (VBP are) (VP (VBN translated) (PP (IN into) (NP (JJ functional) (NN receptor) (NNS proteins))))))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN determined)))))) (. .)))
(TOP (SINV (PP (IN In) (NP (NN vitro) (NN stimulation))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NNP ER) (NNP mRNA) (NN expression)))) (. .)))
(TOP (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NNS variants)))) (VP (VBD did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (NN disease) (NN activity)) (CC or) (NP (NN medication)))))) (. .)))
(TOP (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (NNP Monocytes)) (, ,) (NP (NNP T) (NNS cells)) (, ,) (CC and) (NP (NP (NNP B) (NNS cells)) (PP (IN in) (NP (NNS patients))))) (VP (VBP express) (NP (NP (NNS transcripts)) (PP (IN of) (NP (NP (DT the) (JJ normal) (JJ wild) (NN type) (NNP ER)) (CC and) (NP (NP (DT the) (NN hormone) (VBG binding) (NN domain) (NNS variants)) (PP (IN in) (NP (NN vivo))))))))) (. .)))
(TOP (NP (NP (NP (NN Suppression)) (PP (IN of) (NP (NP (JJ human) (JJ anti-porcine) (JJ T-cell) (JJ immune) (NNS responses)) (PP (IN by) (NP (JJ major) (NN histocompatibility) (NN complex) (NN class) (NNP II) (NN transactivator) (NNS constructs)))))) (VP (VBG lacking) (NP (DT the) (JJ amino) (NN terminal) (NN domain))) (. .)))
(TOP (NP (NP (NN BACKGROUND)) (: :) (S (NP (NP (DT The) (NN class) (NNP II) (NN transactivator)) (PRN (-LRB- -LRB-) (NP (NNP CIITA)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (ADJP (JJ bi-) (CC or) (JJ multifunctional)) (NN domain) (NN protein)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ acts) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN activator)))) (CC and) (VP (VBZ plays) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP MHC) (NN class) (NNP II) (NNS genes))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NP (DT a) (VBN mutated) (NN form)) (PP (IN of) (NP (DT the) (JJ human) (NNP CIITA) (NN gene)))) (, ,) (VP (VBG coding) (PP (IN for) (NP (NP (DT a) (NN protein)) (VP (VBG lacking) (NP (DT the) (JJ amino) (NN terminal) (CD 151) (JJ amino) (NNS acids)))))) (, ,)) (VP (VBZ acts) (PP (IN as) (NP (NP (DT a) (JJ potent) (JJ dominant-negative) (NN suppressor)) (PP (IN of) (NP (NNP HLA) (NN class) (NNP II) (NN expression)))))))))) (. .)))
(TOP (S (NP (NNP Porcine) (NNP MHC) (NN class) (NNP II) (NNS antigens)) (VP (VP (VBP are) (NP (NP (JJ potent) (NNS stimulators)) (PP (IN of) (NP (NP (JJ direct) (JJ T-cell) (NN recognition)) (PP (IN by) (NP (JJ human) (NNP CD4+) (NNP T) (NNS cells))))))) (CC and) (VP (VBP are) (, ,) (ADVP (RB therefore)) (, ,) (ADJP (JJ likely) (S (VP (TO to) (VP (VB play) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN rejection) (NNS responses)) (PP (TO to) (NP (NP (JJ transgenic) (NN pig) (NNS donors)) (PP (IN in) (NP (JJ clinical) (NN xenotransplantation)))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD were) (, ,) (ADVP (RB therefore)) (, ,) (ADJP (JJ interested) (PP (IN in) (S (VP (VBG examining) (NP (VBN mutated) (NNP CIITA) (NNS constructs)) (PP (IN for) (NP (NP (PRP$ their) (NN effect)) (PP (IN on) (NP (JJ porcine) (NNP MHC) (NN class) (NNP II) (NN expression)))))))))) (. .)))
(TOP (NP (NP (NNS METHODS)) (: :) (S (NP (NP (JJ Stable) (NNS transfectants)) (PP (IN of) (NP (DT the) (JJ porcine) (JJ vascular) (JJ endothelial) (NN cell) (NN line) (NNP PIEC))) (PP (IN with) (NP (VBN mutated) (NNP CIITA) (NNS constructs)))) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (NNP SLA-DR) (CC and) (NNP SLA-DQ) (NN induction)) (PP (IN by) (NP (JJ recombinant) (NN porcine) (NN interferon-gamma)))))))) (. .)))
(TOP (S (NP (NP (JJ Transient) (NNS transfectants)) (PP (IN of) (NP (NP (DT the) (JJ porcine) (JJ B-cell) (NN line)) (VP (NN L23) (PP (IN with) (NP (DT the) (VBN mutated) (NNP CIITA) (NNS constructs))))))) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP (NP (JJ constitutive) (NNP SLA-DR)) (CC and) (NP (NNP SLA-DQ) (NN expression)))))))) (. .)))
(TOP (S (NP (JJ T-cell) (NN proliferation) (NNS studies)) (VP (VBD were) (VP (VBN performed) (S (VP (VBG using) (NP (ADJP (RB highly) (VBN purified)) (JJ human) (NNP CD4+) (NNP T) (NNS cells)))))) (. .)))
(TOP (NP (NP (NNS RESULTS)) (: :) (S (PP (IN In) (NP (JJ preliminary) (NNS studies))) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (SBAR (DT that) (S (NP (NP (NN transfection)) (PP (IN of) (NP (DT the) (NNP PIEC) (NN line))) (PP (IN with) (NP (JJ full-length) (JJ human) (NNP CIITA) (NNS constructs)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ strong) (NN expression)) (PP (IN of) (NP (NNP SLA-DR) (CC and) (NNP SLA-DQ) (NNS antigens))))) (, ,) (S (ADVP (RB thus)) (VP (VBG establishing) (NP (NP (DT the) (NNS cross-species) (NN effectiveness)) (PP (IN of) (NP (JJ human) (NNP CIITA)))) (PP (IN in) (NP (DT the) (NN pig)))))))))) (. .)))
(TOP (S (NP (DT The) (VBN mutated) (JJ human) (NNP CIITA) (NNS constructs)) (VP (VBD were) (, ,) (ADVP (RB therefore)) (, ,) (VP (VBN tested) (PP (IN in) (NP (DT the) (NN pig))))) (. .)))
(TOP (S (NP (NP (NNP PIEC) (NNS clones)) (VP (ADVP (RB stably)) (VBN transfected) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS constructs))))))) (VP (VBD showed) (NP (NP (ADJP (QP (IN up) (TO to) (CD 99)) (NN %)) (NN suppression)) (PP (IN of) (NP (NP (NNP SLA-DR) (CC and) (NNP SLA-DQ) (NN antigen) (NN induction)) (CC and) (NP (NP (JJ marked) (NN suppression)) (PP (IN of) (NP (NNP SLA-DRA) (NNP mRNA) (NN induction)))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ transient) (NN transfection)) (PP (IN of) (NP (DT the) (JJ porcine) (NNP B-cell) (NN line) (NNP L23)))) (VP (VBD showed) (NP (NP (ADJP (QP (IN up) (TO to) (CD 90)) (NN %)) (NN suppression)) (PP (IN of) (NP (NP (JJ constitutive) (NNP SLA-DR)) (CC and) (NP (NNP SLA-DQ) (NN antigen) (NN expression))))) (PP (IN in) (NP (CD 5-8) (NNS days)))) (. .)))
(TOP (S (PP (IN In) (NP (JJ functional) (NNS studies))) (, ,) (NP (NP (JJ interferon-gamma-stimulated) (NNP PIEC) (NNS clones)) (VP (VBN transfected) (PP (IN with) (NP (DT this) (VBN mutated) (NNP CIITA))))) (VP (VBP construct) (NP (VBN failed) (S (VP (TO to) (VP (VB stimulate) (NP (VBN purified) (JJ human) (NNP CD4+) (NNP T) (NNS lymphocytes))))))) (. .)))
(TOP (NP (NP (NN CONCLUSION)) (: :) (S (NP (VBN Mutated) (JJ human) (NNP CIITA) (NNS constructs)) (VP (VBP are) (NP (NP (JJ potent) (NNS suppressors)) (PP (IN of) (NP (JJ porcine) (NNP MHC) (NN class) (NNP II) (NN expression)))))) (. .)))
(TOP (NP (NP (NN Redox) (NNS signals)) (CC and) (NP (NP (JJ NF-kappaB) (NN activation)) (PP (IN in) (NP (NNP T) (NNS cells)))) (. .)))
(TOP (S (S (VP (VBG Accumulating) (NP (NNS data)) (PP (IN from) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS laboratories))))))) (VP (VBP have) (ADVP (RB recently)) (VP (VBN indicated) (SBAR (IN that) (S (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NN transcription) (NN factor))) (PP (NN NF-kappaB) (PP (TO to) (NP (NP (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NN redox) (NN homeostasis)) (PP (IN of) (NP (NNS cells))))))))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG modulating) (NP (JJ immune) (NN function))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN activation)) (PP (IN of) (NP (NNP NF-kappaB)))) (VP (VBZ has) (VP (VBN been) (VP (VBN recognized) (S (VP (TO to) (VP (VB regulate) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS genes)) (ADJP (JJ necessary) (PP (IN for) (NP (NP (JJ normal) (NNP T) (NN cell) (NNS responses)) (PP (VBG including) (NP (NP (NNP IL-2)) (, ,) (NP (NNP IL-6)) (, ,) (NP (NNP IL-8)) (, ,) (CC and) (NP (JJ several) (NNP T) (NN cell) (NN surface) (NNS receptors)))))))))))))))) (. .)))
(TOP (S (NP (VBN Diminished) (JJ NF-kappaB) (NN activity)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB occur) (PP (IN in) (NP (NNP T) (NNS cells))) (PP (IN with) (NP (NN aging)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (JJ impaired) (NN activation)) (PP (IN of) (NP (NNP NF-kappaB)))) (VP (MD might) (VP (VB occur) (PP (IN during) (NP (JJ cellular) (NN senescence)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS aberrancies)) (PP (IN in) (NP (JJ NF-kappaB) (NN activity)))) (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN immunopathogenesis)) (PP (IN of) (NP (NP (NNS diseases)) (VP (VBG involving) (NP (NP (ADJP (JJ immune) (CC or) (JJ inflammatory)) (NNS processes)) (PP (JJ such) (IN as) (NP (NP (NN atherosclerosis)) (CC and) (NP (NNP HIV-1) (NN infection))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (NNP H2O2)) (CC and) (NP (NP (JJ other) (JJ reactive) (NN oxygen) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNP ROS)) (-RRB- -RRB-))))) (PP (IN as) (NP (NP (DT an) (JJ integratory) (JJ secondary) (NN messenger)) (PP (IN for) (NP (JJ divergent) (NNP T) (NN cell) (NNS signals)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN complicated) (PP (IN by) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (JJ various) (NNP T) (NN cell) (NNS lines)) (CC and) (NP (JJ peripheral) (NN blood) (NN T) (NNS cells))) (VP (VBP differ) (ADVP (RB markedly)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (JJ NF-kappaB) (NN activation)) (VP (VBN induced) (PP (IN by) (NP (JJ oxidant) (NN stress)))))))))))))))) (. .)))
(TOP (S (ADVP (RB Additionally)) (, ,) (NP (NP (VBD proposed) (NNS pathways)) (PP (IN of) (NP (JJ NF-kappaB) (NN activation)))) (VP (VBP have) (VP (VBN been) (VP (VBN based) (PP (IN on) (NP (NP (JJ indirect) (NN evidence)) (VP (VBN provided) (PP (IN by) (NP (NP (NNS experiments)) (SBAR (WHNP (WDT which)) (S (VP (VBD used) (NP (NNS antioxidants)) (S (VP (TO to) (VP (VB inhibit) (NP (JJ active) (NNP NF-kappaB) (NN formation)))))))))))))))) (. .)))
(TOP (S (ADVP (RB Further)) (, ,) (NP (NP (JJ complete) (NN activation)) (PP (IN of) (NP (NNP T) (NNS cells)))) (VP (VBZ requires) (NP (NP (QP (IN at) (JJS least) (CD two)) (NNS signals)) (, ,) (NP (NP (NN one)) (SBAR (WHNP (WDT that)) (S (VP (VBZ stimulates) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ intracellular) (NN calcium)))) (CC and) (NP (NP (NN one)) (SBAR (WHNP (WDT that)) (S (VP (VBZ stimulates) (NP (NP (JJ enzymatic) (NNS processes)) (PP (VBG including) (NP (NNS kinases))))))))))))))) (. .)))
(TOP (S (ADVP (RB Similarly)) (, ,) (NP (JJ substantial) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (JJ full) (NN activation)) (PP (IN of) (NP (NNP NF-kappaB)))) (VP (VBZ requires) (NP (JJ dual) (NNS signals)))))) (. .)))
(TOP (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NP (NNP H2O2)) (CC or) (NP (JJ other) (NNP ROS)))) (S (VP (TO to) (VP (VB induce) (S (S (NP (NP (NNP T) (NN cell) (NNS signals)) (CC and) (NP (NP (JJ functional) (NNS responses)) (PP (IN by) (NP (DT these) (CD two) (NNS mechanisms))))) (VP (VBZ is) (VP (VBN reviewed)))) (CC and) (S (NP (NP (DT the) (JJ specific) (NN response)) (PP (IN of) (NP (NNP NF-kappaB))) (S (VP (TO to) (VP (VB redox) (NP (NP (NNS changes)) (PP (IN in) (NP (NNP T) (NNS cells)))))))) (VP (VBZ is) (VP (VBN examined)))))))) (. .)))
(TOP (S (NP (NNS Data)) (VP (VBP are) (ADVP (RB also)) (VP (VBN presented) (S (VP (TO to) (VP (VB suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN redox) (NN regulation)) (PP (IN in) (NP (JJ NF-kappaB) (NN activation)))) (VP (MD may) (VP (VB be) (ADJP (JJ relevant) (PP (PP (TO to) (NP (JJ immune-related) (NNS diseases))) (CC and) (PP (TO to) (NP (NN aging)))))))))))))) (. .)))
(TOP (S (NP (NNP Ciprofloxacin)) (VP (VBZ induces) (NP (NP (DT an) (JJ immunomodulatory) (NN stress) (NN response)) (PP (IN in) (NP (JJ human) (NNP T) (NNS lymphocytes))))) (. .)))
(TOP (S (NP (NP (NN Exposure)) (PP (IN of) (NP (NNS cells))) (PP (TO to) (NP (JJ adverse) (JJ environmental) (NNS conditions)))) (VP (VBZ invokes) (NP (NP (DT a) (ADJP (RB genetically) (VBN programmed)) (NN series)) (PP (IN of) (NP (NP (NNS events)) (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ specific) (NNS genes)))))))))) (. .)))
(TOP (S (NP (DT The) (JJ fluoroquinolone) (JJ antibiotic) (NN ciprofloxacin)) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB upregulate) (NP (NN interleukin-2) (PRN (-LRB- -LRB-) (NN IL-2) (-RRB- -RRB-)) (NN gene) (NN induction)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN investigation))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN ciprofloxacin))) (PP (IN at) (NP (NP (JJ supratherapeutic) (NNS concentrations)) (PP (IN on) (NP (NP (JJ immediate-early) (PRN (-LRB- -LRB-) (NN &lt;) (CD 2) (NN h) (-RRB- -RRB-)) (NN gene) (NN expression)) (PP (IN in) (NP (JJ primary) (JJ human) (JJ peripheral) (NN blood) (NNS lymphocytes)))))))) (VP (VBD was) (VP (VBN studied) (PP (IN with) (NP (JJ Northern) (NNS blots))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NP (NN IL-2) (CC and) (NN metallothionein) (NN enhancer)) (CC and) (NP (NP (NN promoter) (NNS regions)) (CC and) (NP (NN transcription) (NNS factors) (NNP AP-1) (, ,) (NNP NF-kappaB) (, ,) (CC and) (NNP NF-AT)))))) (VP (VBD were) (VP (VBN analyzed) (PP (IN by) (NP (NP (NP (NN chloramphenicol) (NN acetyltransferase)) (PRN (-LRB- -LRB-) (NP (NNP CAT)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)) (, ,) (ADVP (RB respectively))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN concentration)) (PP (IN of) (NP (NP (NNS c-fos)) (, ,) (NP (JJ c-jun) (, ,) (JJ c-myc) (, ,) (NNP junB)) (, ,) (CC and) (NP (JJ fra-1) (NNS mRNAs))))) (VP (VBD was) (VP (VBN increased) (PP (IN in) (NP (NP (VBN activated) (JJ peripheral) (NN blood) (NNS lymphocytes)) (VP (VBN incubated) (PP (IN with) (NP (NN ciprofloxacin)))))) (PP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (JJ untreated) (NNS controls)))))))) (. .)))
(TOP (S (NP (NNP Ciprofloxacin)) (VP (VBD increased) (NP (NP (NNP CAT) (NN activity)) (PP (IN in) (NP (NP (VBN stimulated) (NNS lymphocytes)) (VP (VBN transfected) (PP (IN with) (NP (NP (NNS plasmids)) (VP (VBG containing) (NP (CC either) (DT the) (NN IL-2) (CC or) (NN metallothionein) (NN enhancer)))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (PP (IN among) (NP (NP (DT the) (NN transcription) (NNS factors)) (VP (VBN tested)))) (, ,) (NP (JJ AP-1) (NN activity)) (VP (VBD was) (VP (VBN increased) (PP (IN in) (S (VP (VBN stimulated) (NP (NP (JJ purified) (NNP T) (NN helper) (NNS lymphocytes)) (VP (VBN incubated) (PP (IN with) (NP (NN ciprofloxacin))) (PP (VBN compared) (PP (TO to) (NP (JJ drug-free) (NNS controls))))))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NN ciprofloxacin)) (VP (VP (VBD increased) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (JJ immediate-early) (NNS transcripts)) (, ,) (NP (JJ enhanced) (NN IL-2)) (CC and) (NP (NN metallothionein) (NN promoter) (NN induction)))))) (, ,) (CC and) (VP (VBD upregulated) (NP (NP (JJ AP-1) (NNS concentrations)) (PP (IN in) (NP (JJ primary) (NNS lymphocytes))))) (, ,) (S (VP (VBG reflecting) (SBAR (S (NP (DT a) (NN program)) (ADVP (RB commonly)) (VP (VBD observed) (PP (IN in) (NP (JJ mammalian) (NN stress) (NNS responses))))))))) (. .)))
(TOP (NP (NP (NP (NNP Recognition)) (PP (IN of) (NP (FW herpes) (FW simplex) (NN virus) (NN type) (CD 2) (NN tegument) (NNS proteins))) (PP (IN by) (NP (NNP CD4) (NNP T) (NNS cells)))) (VP (VBG infiltrating) (NP (JJ human) (JJ genital) (NNS herpes) (NNS lesions))) (. .)))
(TOP (S (NP (NP (DT The) (JJ local) (JJ cellular) (JJ immune) (NN response)) (PP (TO to) (NP (NP (NNS herpes) (NN simplex) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP HSV)) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP (JJ important) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (JJ recurrent) (NNP HSV) (NN infection))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ antiviral) (NNS functions)) (PP (IN of) (S (VP (VBG infiltrating) (NP (JJ CD4-bearing) (NN T) (NNS cells)))))) (VP (MD may) (VP (VB include) (NP (NP (NN cytotoxicity)) (, ,) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ viral) (NN growth)))) (, ,) (NP (JJ lymphokine) (NN secretion)) (, ,) (CC and) (NP (NP (NN support)) (PP (IN of) (NP (JJ humoral) (CC and) (JJ CD8) (NNS responses))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNS antigens)) (VP (VBN recognized) (PP (IN by) (NP (JJ many) (JJ HSV-specific) (NNP CD4) (NNP T) (NNS cells))) (S (VP (VBG localizing) (PP (TO to) (NP (JJ genital) (NN HSV-2) (NNS lesions))))))) (VP (VBP are) (ADJP (JJ unknown))) (. .)))
(TOP (S (NP (NP (NN T) (NNS cells)) (VP (VBG recognizing) (NP (NP (NNS antigens)) (VP (VBN encoded) (PP (IN within) (NP (NN map) (NNS units))) (NP (NP (QP (CD 0.67) (TO to) (CD 0.73))) (PP (IN of) (NP (NNP HSV) (NNP DNA)))))))) (VP (VBP are) (ADVP (RB frequently)) (VP (VBN recovered) (PP (IN from) (NP (JJ herpetic) (NNS lesions))))) (. .)))
(TOP (S (NP (NP (NN Expression)) (VP (VBG cloning) (PP (IN with) (NP (NP (DT this) (NN region)) (PP (IN of) (NP (NNP DNA))))))) (ADVP (RB now)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (NP (NN tegument) (NN protein) (NNP VP22)) (CC and) (NP (DT the) (JJ viral) (NNP dUTPase))) (, ,) (VP (VBN encoded) (PP (IN by) (NP (NNS genes) (NNP UL49) (CC and) (NNP UL50))) (, ,) (ADVP (RB respectively))) (, ,)) (VP (VBP are) (NP (JJ T-cell) (NNS antigens)))))) (. .)))
(TOP (S (NP (NP (JJ Separate) (NNS epitopes)) (PP (IN in) (NP (NNP VP22)))) (VP (VBD were) (VP (VBN defined) (PP (IN for) (NP (JJ T-cell) (NNS clones))) (PP (IN from) (NP (NP (DT each)) (PP (IN of) (NP (CD three) (NNS patients))))))) (. .)))
(TOP (S (NP (NP (NN Reactivity)) (PP (IN with) (NP (NP (DT the) (NN tegument) (NN protein)) (VP (VBN encoded) (PP (IN by) (NP (NNP UL21))))))) (VP (VBD was) (VP (VBN identified) (PP (IN for) (NP (DT an) (JJ additional) (NN patient))))) (. .)))
(TOP (S (NP (CD Three) (JJ new) (NNS epitopes)) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (NP (NNP VP16)) (, ,) (NP (NP (DT a) (NN tegument) (NN protein)) (VP (VBN associated) (PP (IN with) (NP (NNP VP22))))))))) (. .)))
(TOP (S (NP (DT Some) (JJ tegument-specific) (NNP CD4) (NNP T-cell) (NNS clones)) (VP (VBD exhibited) (NP (NP (JJ cytotoxic) (NN activity)) (PP (IN against) (NP (JJ HSV-infected) (NNS cells))))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS herpes) (VBP simplex) (NN tegument) (NNS proteins)) (VP (VP (VBP are) (VP (VBN processed) (PP (IN for) (NP (NP (NN antigen) (NN presentation)) (PP (IN in) (NP (NN vivo))))))) (CC and) (VP (VBP are) (NP (NP (JJ possible) (NN candidate) (NNS compounds)) (PP (IN for) (NP (NNS herpes) (NN simplex) (NNS vaccines))))))))) (. .)))
(TOP (NP (NP (JJ Human) (JJ 15-lipoxygenase) (NN gene) (NN promoter)) (: :) (NP (NP (NN analysis)) (CC and) (NP (NP (NN identification)) (PP (IN of) (NP (NP (NNP DNA) (VBG binding) (NNS sites)) (PP (IN for) (NP (NP (JJ IL-13-induced) (JJ regulatory) (NNS factors)) (PP (IN in) (NP (NNS monocytes))))))))) (. .)))
(TOP (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (JJ transcriptional) (NN control)) (PP (IN of) (NP (JJ 15-LO) (NN expression)))))))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN cloned) (CC and) (VBN sequenced) (NP (DT the) (JJ human) (JJ 15-LO) (NN promoter) (NN region)))) (. .)))
(TOP (S (S (NP (DT The) (JJ 15-LO) (NN promoter)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (DT a) (NNP CpG) (NN island))) (PP (IN at) (NP (NP (DT the) (NN 5'-end)) (PP (IN of) (NP (DT the) (NN gene)))))))) (, ,) (CC and) (S (NP (NN sequence) (NN analysis)) (VP (VBZ reveals) (NP (NP (JJ putative) (ADJP (NNP Sp1) (CC and) (NNP Ap2)) (VBG binding) (NNS site/s)) (CC and) (NP (NP (NN absence)) (PP (IN of) (NP (NNP TATA) (CC or) (NNP CAAT) (NNS motifs))))))) (. .)))
(TOP (S (NP (NNP Transcription)) (VP (VBZ is) (VP (VBN initiated) (PP (IN at) (NP (CD one) (JJ major) (NN site))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NN deletion) (NNS constructs)))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN defined) (NP (NP (DT an) (JJ active) (NN promoter) (NN region)) (PP (IN of) (NP (CD 1056) (NN bp)))))) (. .)))
(TOP (S (NP (JJ Gel-shift) (NNS assays)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (JJ transcriptional) (NN factor)) (PRN (-LRB- -LRB-) (NP (PRP s)) (-RRB- -RRB-))) (VP (VBN induced) (ADVP (RB only)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ IL-13) (NN treatment)) (PP (IN of) (NP (JJ human) (JJ peripheral) (NN blood) (NNS monocytes) (NN bind))) (PP (TO to) (NP (DT the) (JJ 15-LO) (NN promoter) (NN DNA))))))))))) (. .)))
(TOP (S (NP (NP (CD Two) (NNS regions)) (, ,) (NP (NP (NP (NP (NNP DP1)) (PRN (-LRB- -LRB-) (NP (QP (CD -140) (TO to) (CD -92)) (NN bp)) (-RRB- -RRB-))) (CC and) (NP (NNP DP2))) (PRN (-LRB- -LRB-) (NP (QP (CD -353) (TO to) (CD -304)) (NN bp)) (-RRB- -RRB-)) (PP (IN of) (NP (DT the) (NN promoter))))) (VP (VBD were) (ADJP (JJ essential) (PP (IN for) (NP (NP (NN transcription)) (PP (IN in) (NP (NP (NNP HeLa) (NNS cells)) (CC and) (NP (JJ human) (JJ peripheral) (NNS monocytes)))))))) (. .)))
(TOP (S (NP (NNP Hela) (JJ nuclear) (NNS extracts)) (VP (VBD contained) (NP (NP (DT a) (JJ specific) (JJ nuclear) (NN factor)) (PRN (-LRB- -LRB-) (NP (PRP s)) (-RRB- -RRB-)) (VP (VBG binding) (PP (TO to) (NP (NP (JJ 15-LO) (NN promoter) (NN DNA)) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT those)) (VP (VBN derived) (PP (IN from) (NP (JJ IL-13-treated) (JJ human) (JJ peripheral) (JJ monocyte) (JJ nuclear) (NNS extracts))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN fluorescent)) (PP (IN in) (NP (NN situ) (NN hybridization) (PRN (-LRB- -LRB-) (NN FISH) (-RRB- -RRB-)) (NNS results)))) (VP (VBD refined) (NP (NP (DT the) (JJ previous) (NN localization)) (PP (IN of) (NP (CD 15-LO)))) (PP (TO to) (NP (JJ human) (NN chromosome) (CD 17p13.3)))) (. .)))
(TOP (NP (NP (NN Lack)) (PP (IN of) (NP (NP (JJ T-cell-mediated) (NN recognition)) (PP (IN of) (NP (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (JJ pml/RAR-alpha) (JJ hybrid) (NN protein))))))) (PP (IN by) (NP (NP (NNS lymphocytes)) (PP (IN of) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (NNS patients))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ previous) (NNS studies))) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (JJ pml/RAR-alpha) (NN protein))) (, ,) (VP (VBN expressed) (PP (IN by) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (PRN (-LRB- -LRB-) (NNP APL) (-RRB- -RRB-)) (NNS cells)))) (, ,)) (VP (MD can) (VP (VB be) (VP (ADVP (RB specifically)) (VBN recognized) (PP (IN in) (NP (NN vitro))) (PP (IN by) (NP (NP (NN donor)) (PRN (-LRB- -LRB-) (NP (NNP D.) (NNP E.)) (-RRB- -RRB-)) (NP (NP (NNP CD4) (NNP T) (NNS cells)) (PP (IN in) (NP (DT a) (NNP HLA) (NN class) (NNP II) (NNP DR11-restricted) (NN fashion))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP present) (ADVP (RB here)) (NP (NP (DT the) (NNS results)) (PP (IN on) (NP (NP (DT the) (NN recognition)) (PP (IN of) (NP (JJ several) (JJ pml/RAR-alpha) (NNS peptides))) (PP (IN by) (NP (NP (NNP APL) (NNS patients)) (VP (VBG expressing) (NP (NNP HLA) (NNP DR11))))))))) (. .)))
(TOP (S (NP (NP (DT The)) (PP (IN in) (NP (NP (NN vitro) (NN immunization)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NNS lymphocytes))))) (PP (IN from) (NP (NP (CD four) (NNS patients)) (PP (IN in) (NP (NP (NN remission)) (PRN (-LRB- -LRB-) (NP (NNP S.R.)) (, ,) (NP (NNP F.R.)) (, ,) (NP (NNP M.M.)) (, ,) (NP (NNP P.) (NNP G.)) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (NNP BCR1/25)) (, ,) (NP (DT a) (JJ 25-mer) (NN pml/RAR-alpha)) (, ,)))) (VP (VBD did) (RB not) (VP (NN elicit) (NP (NP (CC either) (NP (DT a) (NN polyclonal)) (CC or) (NP (DT a) (JJ clonal) (JJ immune) (NN response))) (ADJP (JJ specific) (PP (TO to) (NP (DT the) (NN peptide))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD generated) (NP (JJ new) (NN donor) (NNP anti-pml/RAR-alpha) (NNP CD4-LRB-+-RRB-) (NNP T-cell) (NNS clones))) (. .)))
(TOP (S (NP (DT These) (NNS clones)) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (PRP$ their) (NN recognition)) (PP (IN of) (NP (NNP BCR1/25))))))) (. .)))
(TOP (S (NP (NP (CD One) (NN clone)) (PRN (-LRB- -LRB-) (NP (NNP C3/5) (, ,) (NNP CD3-LRB-+-RRB-)) (, ,) (NP (NNP CD4-LRB-+-RRB-)) (, ,) (NP (NNP CD8-LRB---RRB-)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN selected) (PP (IN for) (NP (JJ further) (NN analysis))))) (. .)))
(TOP (S (NP (NNP Clone) (NNP C3/5)) (VP (VBD showed) (NP (NP (NP (JJ specific) (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NN cytokine) (-LRB- -LRB-) (NN tumor) (NN necrosis) (NN factor) (NN alpha) (, ,) (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (-RRB- -RRB-)) (NN production)) (SBAR (WHADVP (WRB when)) (S (VP (VBN challenged) (PP (IN with) (NP (NP (JJ autologous) (JJ lymphoblastic) (NN cell) (NNS lines)) (VP (VBN pulsed) (PP (IN with) (NP (JJ peptide) (NNP BCR1/25)))))))))) (. .)))
(TOP (S (NP (CD C3/5) (NNS cells)) (VP (VBD developed) (NP (JJ specific) (NN proliferation) (CC and) (NN cytotoxicity)) (SBAR (WHADVP (WRB when)) (S (VP (VBN challenged) (PP (IN with) (NP (NP (JJ peptide-pulsed) (JJ lymphoblastic) (NN cell) (NNS lines)) (CC and) (NP (NP (JJ peripheral) (NN blood) (NNS lymphocytes)) (PP (IN from) (NP (DT the) (CD four) (NNP DR11-LRB-+-RRB-) (NNP APL) (NNS patients)))))))))) (. .)))
(TOP (S (NP (NP (NNP APL) (NNS blasts)) (, ,) (ADJP (JJ available) (PP (ADVP (RB only)) (IN from) (NP (NNS patients) (NNP F.R.) (CC and) (NNP P.G.)))) (, ,)) (VP (VP (VBD were) (RB not) (VP (VBN lysed) (PP (IN by) (NP (NNP C3/5))))) (CC and) (VP (VBD were) (ADJP (JJ unable) (S (VP (TO to) (VP (RB present) (NP (VB peptide) (NNP BCR1/25)))))))) (. .)))
(TOP (S (NP (NP (NNP Incubation)) (PP (IN of) (NP (NP (NNP APL) (NNS cells)) (PP (IN with) (NP (NNP IFN-gamma)))))) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP (NP (NNP HLA) (NN class) (NNP II) (NNS molecules)) (CC and) (NP (NN recognition))) (PP (IN by) (NP (DT the) (NNP C3/5) (NN clone))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP (NNP APL) (NNS cells)) (VP (VBP do) (RB not) (VP (VB express) (NP (NNP HLA) (NN class) (NNP II) (NNS molecules)))))) (, ,) (NP (PRP we)) (VP (VBD tested) (PP (PP (IN in) (NP (NP (CD two) (NNS donors)) (PRN (-LRB- -LRB-) (NP (NNP D.E.)) (CC and) (NP (NNP C.H.R.))))) (-RRB- -RRB-) (CC and) (PP (IN in) (NP (NNS patients) (NNP S.R.) (CC and) (NNP P.G.)))) (SBAR (IN whether) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ 9-mer) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NNP BCR1/9)) (-RRB- -RRB-))))) (VP (MD would) (VP (VB generate) (NP (DT a) (NNP CD8/HLA) (NN class) (JJ I-restricted) (NN response))))))) (. .)))
(TOP (S (NP (DT No) (JJ peptide-specific) (NNP T-cell) (NN line) (CC or) (NN clone)) (VP (MD could) (VP (VB be) (VP (VBN generated) (PP (IN from) (NP (DT both) (NNS donors) (CC and) (NNS patients)))))) (. .)))
(TOP (S (NP (DT These) (NNS findings)) (VP (VBP are) (VP (VBN discussed) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (JJ possible) (JJ therapeutic) (NNS approaches)) (PP (TO to) (NP (NP (DT the) (NN immunotherapy)) (PP (IN of) (NP (NNP APL))))))))))) (. .)))
